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SUMMARY
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease affecting the 
synovial membranes of multiple joints. Substantial evidence has identified interleukin-1- 
beta (IL-1 p) as a major mediator of this disease. Interaction between T-lymphocytes and 
monocytes controls the production and release of many pro- and anti-inflammatory 
cytokines relevant to RA pathology. A technique was developed to enable the 
investigation of the differential release of IL-lp and its receptor antagonist, IL-lra, by 
monocytes during coculture with T-cells. Freshly isolated T-lymphocytes or monocytes 
from healthy subjects and rheumatoid patients, along with “model” cell lines, were used to 
investigate cytokine release in response to factors affecting either T-cell or monocyte.
Direct cell-cell contact between T-cells and monocytes promoted limited cytokine release, 
but IL-lp release was greatly increased through the action of T-cell produced soluble 
factors. IL-17 was identified as a likely constituent of this soluble factor, strongly inducing 
IL-lp release from monocytes, while CD69 could act as a contributing mediator of the pro- 
inflammatory cell-cell surface interaction.
T-cell lines regularly treated with H2O2 were used to simulate the oxidative stress acting on 
rheumatoid synovial T-cells. These cells exhibited a decreased response to activation with 
a range of stimuli, and also induced less IL-lp release in T-lymphocyte/monocyte 
coculture.
SEA T-cell blasts developed from rheumatoid PBMC induced increased IL-ip release 
from model monocytes relative to healthy blast cells, suggesting a more T-helper 1 like 
phenotype. Differences between cytokine release by PBMC from rheumatoid patients 
receiving different DMARD treatments were also assessed, with PBMC from 
sulphasalazine receiving patients exhibiting a significant shift towards an anti­
inflammatory IL-1 p :IL-1 ra ratio.
The coculture system developed throughout this work was shown to be a highly flexible 
system with a wide range of potential uses, specifically in the analysis of T- 




Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease affecting the 
synovial membranes of multiple joints. A large body of evidence has delineated pro- 
inflammatory cytokines interleukin-lp (IL-lp) and tumour necrosis factor alpha (TNFa) as 
major mediators of this disease. Although released during normal inflammatory immune 
responses, in RA there is evidence of localised continuous over-expression and release of 
IL-ip, contributing to a chronic inflammatory condition.
Cells of the monocyte/macrophage lineage are the primary producers of pro-inflammatory 
cytokines, and the modulation of such cytokine release has been the object of much interest 
to groups investigating RA and similar conditions. Increasing numbers of cytokines with 
both pro- and anti-inflammatory effects have been discovered in recent years, but there is 
also evidence to support the involvement of other mediators, both soluble and membrane- 
bound. In particular, there has been recent interest in the interactions between T- 
lymphocytes and monocyte/macrophages in the rheumatoid synovial joint. The work 
undertaken for this thesis aims to investigate the manipulation of cytokine release as a 
result of T-lymphocyte interactions with monocyte/macrophages, using a range of (RA 
associated) stimuli on the individual cell types.
1.1: RHEUMATOID ARTHRITIS
1.1.1: Aetiology
Rheumatoid arthritis is among the most common inflammatory joint diseases, occurring in 
approximately 1% of the population worldwide, and with a global distribution. RA is 
characterised by recurring episodes of joint inflammation, followed by cartilage and bone 
destruction, which eventually lead to deformities and loss of articular function and 
mobility. There are additional systemic symptoms, including subcutaneous rheumatoid 
nodules, high levels of circulating rheumatoid factors, vasculitis, and a wide range of 
possible complications.
Investigations have determined many possible triggers for the characteristic autoimmune 
response, but the aetiology is still uncertain. A threefold predominance of RA in women
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suggests that hormonal factors might be relevant. Evidence also suggests inappropriate 
triggering and maintenance of an autoimmune response due to recognition of exogenous 
antigens or autoantigens released due to bacterial, mycoplasma or viral infection (Sewell & 
Trentham, 1993). Many possible infectious agents have been implicated, but no specific 
causative agent has yet been reproducibly identified, although there has been recent 
interest in three putative autoantigens, these being the cartilage proteoglycan component 
aggregan, human cartilage gp-39 (HCgp-39) and p78. Aggregan can be found in the 
synovial fluid of RA patients (Lohmander et al., 1993), can initiate inflammatory arthritis 
in murine models (Giant et al., 1987), and exhibited multiple sites capable of binding to 
peptide binding motifs for HLA-DR1 and DR4 (detailed in the next paragraph) (Boots et 
al., 1997). HCgp-39 also gained interest due to its arthritogenic capability in murine 
models (Verheijden et al., 1997), with HCgp-39 mRNA and protein being detected 
expressed on PBMC and in synovial samples and cartilage from RA patients, but not from 
normal subjects (Baeten et al., 1998a/b\ Kirkpatrick et al., 1997). However, there are data 
(utilising specific DR4-antigen binding complexes) suggesting that the major oligoclonal 
CD4+ T-cell expansions in the RA synovium are not specific for either HCgp-39 or the 
older putative autoantigen, collagen type II (Kotzin et al., 2000). Finally, a p78 protein 
with autoantigenic potential was detected in approximately 30% of sera from RA patients. 
When purified, p78 was demonstrated to cross-react and induce proliferation in T-cells 
from 6  out of 10 RA patients, but only 1 out of 13 healthy controls (Panayi et al., 1999), 
with the activated T-cells being preferentially from the Thl subset. This protein was 
identified by mass spectroscopy as immunoglobulin binding protein (BiP), an abundant 
endoplasmic reticulum chaperone protein that regulates protein folding and secretion 
(Buchner, 1996; Davis et al., 1998).
There is also a well-defined genetic connection between the incidence and/or severity of 
RA and an epitope on the MHC class II locus. This so-called “shared epitope” comprises 
amino acids 70-74 of the P-chain on the HLA-DR peptide binding groove, which are 
conserved in the disease-susceptible haplotypes DR1 and DR4 (Gregersen et al., 1987). 
This epitope is present in over 80% of Caucasian RA patients, and strongly supports the 
involvement of T-lymphocyte recognition in RA, either in determining the selection of T- 
cell receptor (TCR) subsets, or in presentation of either exogenous or autoantigenic 
peptides (Feldmann et al., 1996a).
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1.1.2: Pathogenesis
The initial stages in rheumatoid synovial inflammation involve some replication of the 
synovial membrane to form a cellular layer, which thickens primarily due to the 
simultaneous recruitment to this area of large numbers of macrophages, although memory 
T-lymphocytes (CD4+, CD45RO+) are also present in significant numbers, along with 
some plasma cells, dendritic cells and activated fibroblasts. The synovial fluid, acellular 
under normal conditions, becomes populated primarily with neutrophils, but also with 
macrophages, T-lymphocytes, dendritic cells, and desquamated synovial lining cells. This 
influx of mononuclear cells is augmented due to the increase in expression of intracellular 
adhesion molecule-1 (ICAM-1) on the endothelial cells of synovial capillaries, which acts 
as a site of attachment for circulating mononuclear cells (Sewell & Trentham, 1993).
In more advanced, chronic forms of the disease, the pattern of synovial inflammation and 
joint destruction is symmetrical, preferentially involving (but not limited to) the small 
joints of the hands, wrists and feet. In more severe, systemic cases (generally only 
developing in the presence of IgM rheumatoid factors) there are extra-articular 
manifestations of the disease, the most common (in approximately 2 0 % of patients) being 
formation of subcutaneous nodules, often in combination with a systemic vasculitis. These 
nodules are composed of a central necrotic core surrounded by a mantle of cells, consisting 
primarily of macrophages aligned along the boundary with the core. Surrounding this 
mantle is a vascular region that includes areas of capillary proliferation (Palmer, 1995). In 
the most severe cases, symptoms can include lesions of tendons, skeletal muscle, 
peripheral nerves and arteries.
The role of T-lymphocytes in the rheumatoid synovium is an area of substantial 
controversy, and will be covered in more detail in section 1.4. However, it is likely that 
mature memory T-lymphocytes (CD4+/CD45RO+) are capable of triggering several factors 
responsible for rheumatoid symptoms, including cytokine release and immunoglobulin (Ig) 
production by B-cells (Panayi et al., 1992). Rheumatoid factors (classified as 
autoantibodies of (primarily) the IgM type that interact with regions of the Fc portion of 
IgG) have been the subject of extensive investigation by groups studying RA. It has been 
demonstrated that the immunoglobulin production in the synovium of RA patients includes 
anti-type-II-collagen activity, although antibodies to collagen types V, VI and IX are also
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present (Tarkowski et al., 1989; Jasin & Taurog, 1991). The binding of such immune 
complexes to cartilage could however exacerbate the autoimmune response by activating 
complement and triggering further cellular inflammatory responses.
In spite of this, the cytokine profile in the rheumatoid synovial joint is primarily of 
macrophage origin. Substantial quantities of IL-lp, IL-6 , TNFa and 
granulocyte/macrophage-colony stimulating factor (GM-CSF) are present (Di Giovine et 
al., 1988; Haworth et al., 1991; Helle et al., 1991; Houssiau et al., 1988; Saxne et al., 
1988; Xu et al., 1989), while there are only trace quantities of the T-cell cytokines IL-2 
and interferon-y (IFNy) (Firestein et al., 1988; Firestein et al., 1990a). The premise that 
cells of the monocyte/macrophage lineage drive the destruction of both cartilage and bone 
is compatible with both cytokines detected and possible stimulatory action of the memory 
T-cell population. The activity of the mature memory cells prevalent within the synovial 
joint might be due primarily to surface protein interactions, with the cell otherwise in a 
downregulated state (perhaps due to damage from reactive oxygen species), accounting for 
the low levels of T-cell cytokines detected (Panayi et al., 1992). This state might be 
accounted for by the requirement of only low levels of IL-2 (in the presence of high- 
affinity IL-2R), the ongoing production and uptake (by autocrine and paracrine pathways) 
of IL-2, leaving only a small “pool” available for detection, or by genuine effector cells 
being extremely rare (Maurice et al., 1997; Panayi et al., 1992). A recent report (Steiner 
et al., 1999), detected the presence of IL-2, IFN-y and to a lesser extent IL-4 in 0.1-0.3% of 
T-cells in rheumatoid synovial tissue sections, increasing the support for the last of these 
three possibilities.
The primary site of irreversible tissue damage exists at the junction of the synovial 
membrane with cartilage and bone, a macrophage-enriched region of synovial membrane 
referred to as the pannus. Macrophages are present in the normal synovial membrane 
where they perform a standard phagocytic role, eliminating microorganisms and 
scavenging debris from articular structures. In RA, there is substantial recruitment of 
additional macrophages to the synovial layer. The synovial layer undergoes extensive 
alterations in construction, with the free surface becoming highly convoluted with 
substantial deposition of fibrin, proliferation of blood vessels, and development of a degree 
of vasculitis (Palmer, 1995).
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The cells of the pannus migrate over the cartilage and around the bone itself (Allard et al., 
1987), causing erosion primarily due to the actions of matrix metalloproteinases (MMPs), 
enzymes produced by both macrophages and activated fibroblasts in response to pro- 
inflammatory mediators such as IL-lp and TNFa (Vincenti et al., 1994). These enzymes 
are secreted as latent molecules, which are later activated by proteolytic cleavage of the 
pro-peptide domain. Macrophage and fibroblast secreted collagenase (MMP-1) and 
stromelysin-1 (MMP-3), play a major role in the articular destruction, although there is 
also some regulation in the form of specific tissue inhibitors of metalloproteinases (TIMPs) 
(Vincenti et al., 1994). These are also released by macrophages and fibroblasts forming 
the pannus, and irreversibly bind active MMP in a 1:1 ratio, suggesting that an imbalance 
in the production of MMPs and respective TIMPs might be partially responsible for the 
tissue destruction associated with arthritic disease. It is of interest that transforming 
growth factor-p (TGF-p) and IL-10, two anti-inflammatory cytokines produced in the RA 
synovial joint, act not only by inhibiting the production of pro-inflammatory cytokines 
responsible for inducing the release of MMPs, but also by inducing the production of 
TIMPs (Wright et al., 1991; Feldmann et al., 1996b)
Macrophages present in RA synovial tissue express large numbers of HLA class II and 
CD 14 antigens and also show an increased expression of pro-inflammatory cytokines, 
including IL-ip and TNFa (Firestein et al, 1990). In addition to release of MMPs, these 
cytokines induce a range of pro-inflammatory or destructive effects including stimulation 
of cyclooxygenase- 2  (Cox-2) (resulting in increased prostaglandin E2 (PGE2) production), 
bone resorption by osteoclasts, inhibition of proteoglycan synthesis and chemotaxis of both 
macrophages (due to expressed monocyte chemoattractant protein 1 (MCP-1)) and 
neutrophils (Arias-Negrete et al., 1995; Burmester et al, 1997; Koch et al., 1992; Lee et 
al., 1992; Van De Loo et al., 1995)). The increase in ICAM-1 expression, which 
accompanies the thickening of the pannus, is also enhanced by the action of IL-ip, TNFa 
and IFNy. The differential transcription of a range of genes has also been detected in 
activated monocytes from patients with RA, including EL-la, IL-ip, TNFa, IL-6 , IL-8 , 
GM-CSF, macrophage inflammatory protein 2 (MIP-2) and thrombospondin (Barthel et al, 
1996).
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Interestingly, peripheral blood monocytes from rheumatoid patients also show elevated 
levels of these cytokines, and the mean plasma level of IL-1 (detected using IL-1 ELISA) 
has been directly correlated to the disease activity in RA (Eastgate et al., 1988), likely due 
to detection primarily of IL-lp. However, other data suggest that there is no increase in the 
transcription of IL-ip, TNFa or IL- 8  mRNA levels in peripheral blood monocytes from 
rheumatoid patients, and that the increase detected in such cells could be due to partial 
activation of the cells during isolation. This would then imply that the increased levels of 
IL-1 p detected in the serum could be due to direct release from inflamed sites (Rodenburg 
et al, 1998).
There are a variety of substances present in the synovium capable of causing activation of 
monocyte/macrophages. Stimulation of monocytes with rheumatoid synovial fluid results 
in increased transcription of Fey receptors I and in, along with HLA-DR expression 
(Sengupta et al., 1995). However, it is also likely that such activation is not reliant on 
soluble factors, as there is evidence that cell-cell contact between fixed T-cells, or even 
between fragments of T-cell membrane and monocytes can be sufficient to upregulate 
MMP release (Lacraz et al., 1994; Klimiuk et al., 1999). Low levels of IL-12 have also 
been detected in the rheumatoid synovium, and in view of the predominance of the T- 
helper 1 (Thl) subtype of CD4+ T-cells in the rheumatoid joint, may be involved in both 
the early establishment and later maintenance of pro-inflammatory cytokine production 
(Gately et al., 1998; Miossec & Van Den Berg, 1997; Mosmann et al., 1991). The recently 
discovered EL-18, which is upregulated by IL-lp and TNFa, has also been shown to have a 
pro-inflammatory role in RA, acting as a promoter of a Thl-like response, and could 
promote further TNFa production, acting as a possible link between IL-1 P and Thl-like 
cell differentiation (Dayer, 1999; Gracie et al., 1999; Olee et al., 1999).
Monocyte/macrophages are also capable of providing anti-inflammatory signals. 
Differentiated macrophages constitutively express the physiological inhibitor of IL-lp, IL- 
1 receptor antagonist (IL-lra) (Janson et al., 1991; Malyak et al, 1998; Jouvenne et al., 
1998). This molecule has been shown to have strong anti-inflammatory activity, and is 
upregulated by pro-inflammatory cytokines such as IL-1 and GM-CSF. However, in RA, 
there is a shift in the balance of EL-lp/IL-lra to a pro-inflammatory profile, contributing to 
and acting as a marker of chronic disease (Firestein et al., 1994). Both TGF-p and IL-10
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have been detected in the synovial joint and can also act in anti-inflammatory roles, 
although in the case of TGF-P there is uncertainty as to its action, as there is also evidence 
of pro-inflammatory activity by this cytokine (Lotz et al., 1990). Although their presence 
in the rheumatoid synovium has not been confirmed, the effects of EL-4 and IL-13 (or their 
absence) on the modulation of Thl/Th2-like activity must be considered, along with 
resulting consequences for perpetuation of the inflammatory response. This will be 
covered in more detail in a later section (1.4.3).
1.1.3: Hypoxia and Oxidative Stress
One aspect of the rheumatoid synovium that requires consideration is the paradox of a 
hypoxic region in which there are numerous sources of oxidative stress. In the normal 
synovium, the membrane is only 1-2 cells thick, with substantial vasculature. In the 
rheumatoid synovium, the thickening of the pannus is not matched by a similar increase in 
synovial capillaries, leading to a capillary density of approximately one third of the normal 
value (Stevens et al., 1991). The repetitive trauma caused by movement of the joint can 
lead to H2O2 release by neutrophils, exacerbated by hypoxic reperfusion events. Briefly, 
movement compounds the severity of the hypoxic conditions by worsening the blood flow 
to the joint. This may lead to synovial cell redox uncoupling, for example, the conversion 
of xanthine oxidoreductase to the oxidase form, capable of donating an electron to O2 
(upon the restoration of oxygen supply) with the consequent formation of a superoxide 
radical ( (V )  (Allen et al., 1989; Della Corte & Stirpe, 1972). This cycle of exercise 
induced hypoxia followed by restoration of oxygen supply during rest is one of the 
mechanisms involved with the perpetuation of the rheumatoid synovial inflammation.
Both H2O2 and 0 2 *’ are not particularly active as such, although some activities 
contributing to the pathology of RA have been documented. For example, H2O2 is a potent 
stimulator of osteoclastic bone resorption (Bax et al., 1992). However, in the presence of 
transition metal ions (primarily ferric or cupric), these reactive oxygen species (ROS) can 
react to form the highly aggressive hydroxyl radical (OH*), the most damaging of reactive 
oxygen species. Iron is normally compartmentalised intracellularly (in the form of 
ferritin), and in the extracellular environment either bound to lactoferrin or transferrin, or 
intravascularly in haemoglobin. However, iron can become released into the synovium as 
a result of episodes of trauma-associated microbleeding, and catalytic iron salts have been
8
detected in synovial fluid from RA patients (Rowley et al., 1984). These catalyse the 
production of OH* via the Fenton reaction, in which the superoxide anion reduces the iron 
to its ferrous state, followed by the oxidation of the ferrous iron by H2O2 leading to the 
release of a hydroxyl radical (Blake et al., 1989).
The hydroxyl radical is very highly reactive, attacking a wide range of targets linked to a 
number of deleterious effects. Hyaluronic acid in the synovial fluid is attacked, causing its 
depolymerisation and loss of lubricant properties, increasing the friction (and therefore 
mechanical damage) within the joint (Blake et al., 1981). Free radicals are known to cause 
single and double stranded breaks in DNA, along with hydroxylation of constituent bases. 
In addition, ROS directly activate the transcription factor NFkB and early response genes, 
contributing to the synovial proliferation and the activation of circulating peripheral 
mononuclear cells (Tacchini et al., 1995). Hydroxyl radicals can easily attack amino acids, 
and damage to IgG, IgM and IgA could well be involved in the formation of rheumatoid 
factors. Oxidatively denatured proteins could induce an autoimmune HLA-TCR 
interaction, and due to “lacking homology to self’, the release of autoantibodies from B- 
lymphocytes. This suggests how oxidative damage to circulating immunoglobulins could 
act to prolong an otherwise self-limiting inflammatory episode into a persistent event if the 
conditions of oxidative stress were to continue (Fairbum et al., 1993; Lunec et al., 1985; 
Mapp et al., 1995). This situation is not helped by the depletion of anti-oxidant defences, 
including catalase and superoxide dismutase within the synovial joint, and the ascorbate in 
the serum (Blake et al., 1981). There is also evidence linking the depletion of another anti­
oxidant, reduced glutathione (GSH), with the hyporesponsiveness exhibited in synovial T- 
lymphocytes, and that this is mediated via a lowering in the responsiveness of CD3 
mediated signals (Maurice et al., 1997; Maurice et al., 1998).
1.1.4: Treatment of RA
Many of the NSAID, DMARD and glucocorticoid drugs generally prescribed for treatment 
of RA have been reviewed thoroughly elsewhere (Luqmani et al., 1994). The likely modes 
of action of the drug therapies associated with work undertaken for this thesis are outlined 
below, along with summaries of the more recently developed immunological treatments.
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1.1.4.1: Non-steroidal anti-inflammatory drugs (NSAIDs)
NSAIDs are some of the most commonly prescribed drugs worldwide, with approximately 
20% of patients admitted to hospital receiving an NSAID. NSAIDs are normally 
prescribed as treatment during RA, often in combination with a second-line drug. These 
drugs, including such agents as Ibuprofen, Diclofenac, Indomethacin, Naproxen and 
Piroxicam, act primarily to reduce symptoms whilst having limited effect on the 
underlying disease itself. Their principal actions are upon the inflammatory response, 
interfering with production of prostaglandins. This effect is due to inhibition of Cox-1 and 
Cox-2, the enzymes responsible for PG synthesis from arachidonic acid. Cox-1 is a 
constitutive form, responsible for maintenance of PG synthesis in the gastric mucosa, 
platelets and kidney (Funk et al., 1991; Yokoyama & Tanabe, 1989), while the inducible 
Cox-2, which is triggered in response to certain inflammatory stimuli (including IL-1, 
TNFa, LPS, ROS), is thought to contribute to the increase in PG observed in inflamed 
tissues (Arias-Negrete et al., 1995; Feng et al., 1995; Lee et al., 1992). It has been 
hypothesised that the therapeutic effects of NSAIDs are due to inhibition of Cox-2, while 
the side effects are due to unwanted inhibition of the constitutive Cox-1 (Vane, 1994). 
This view has been strengthened following the discovery that NSAIDs that specifically 
inhibit Cox-2 act to reduce pain and inflammation, with reduced side effects affecting the 
gastrointestinal tract (Masferrer et al., 1994; Vane et al., 1998). However, this does not 
simplify the prescription of these drugs to any great degree, as various NSAIDs exhibit 
differing degrees of preference for the inhibition of Cox-1 and/or Cox-2 (Spangler, 1996).
There is evidence to support a range of other modes of action for NSAIDs, including 
effects on leukotriene, superoxide and rheumatoid factor synthesis and lysosomal enzyme 
release. They also act to alter lymphocyte and neutrophil activity, and both enzyme activity 
associated with and transport across the cell membrane (Brooks, P. M., 1993; Brooks, P. 
M. & Day, 1991; Dinarello et al., 1983). In addition, in vitro studies have shown that 
increasing levels of PGE2 can act to downregulate IL-1 synthesis, and that the presence of 
NSAIDs can actually lead to an increase in IL-1 release into culture supernatants 
(Dinarello, 1984).
As mentioned above, NSAIDs are also a common cause of adverse side effects, with the 
potential to cause gastrointestinal effects (such as peptic ulcers or gastric erosion), with
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other possible symptoms including renal damage, nausea, headaches or skin reactions, 
likely due in part to inhibition of Cox-1 (Masferrer et al., 1994; Vane et al., 1998). Given 
the roles of prostaglandins in maintaining gastrointestinal physiology and regulation of 
renal blood flow, these side effects are not surprising, and in cases exhibiting severe side 
effects the NSAID doses are often decreased, and used in conjunction with analgesics such 
as paracetamol (Brooks, P. M.& Day, 1991; Clive & Stoff, 1984).
1.1.4.2: Methotrexate (MTX)
Methotrexate (MTX) is a commonly used disease modifying anti-rheumatic drug 
(DMARD), and is an analogue of folic acid and aminopterin that binds to dihydrofolate 
reductase and thus prevents the reduction of folic acid. It can also interfere with synthesis 
of DNA, RNA and proteins (Segal et al., 1990). Low dose treatment with MTX on a 
weekly basis has been shown to be highly effective in the treatment of RA. It is being used 
more and more in preference to other second line drugs because of its effectiveness and 
low-toxicity/side effects (Kremer and Phelps, 1992; Weinblatt et al., 1992). Investigations 
into the mode of activity of MTX in RA have been hampered by the fact that MTX is 
metabolised in vivo before exerting an effect (Chabner et al., 1985). However, although its 
mode of action is still poorly understood, some aspects of its activity have been 
determined.
The majority of RA patients show rapid clinical remission following treatment with MTX 
(alongside the potential for rapid disease flare following drug discontinuation), which 
suggests an anti-inflammatory mode of action instead of or as well as an 
immunosuppressant mechanism (Kremer et al., 1987; Segal et al., 1990). There are data 
showing inhibitory effects upon the action and release of pro- inflammatory cytokines such 
as IL-1 p, TNFa and IL-8 (Chang et al., 1992; Hu et al., 1988; Seitz et al., 1992), increases 
in release of IL-lra and soluble TNFa receptor (sTNFR p75) (Seitz et a l, 1995), 
reductions in leukotriene B4 synthesis from neutrophils (Sperling et al., 1992), and also 
reductions in synovial gene expression of collagenase (Firestein et al., 1994a). Other 
evidence suggests an increase in adenosine release from connective tissue cells, thus 
inhibiting neutrophil adherence to fibroblasts and endothelial cells (Cronstein et al., 1991). 
Following 6-24 weeks of treatment with MTX, there was a detectable increase in IL-lra
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release from clinically responding patients, alongside either no change or a decrease in IL- 
ip release, resulting in a 4-14-fold increase in the IL-lra:IL-lp ratio (Seitz et al., 1995).
In a separate study (Dolhain et al., 1998), synovial biopsies were obtained from RA 
patients before and after a 16-week course of MTX treatment. There were statistically 
significant decreases in numbers of T-cells, plasma cells, macrophages and proliferating 
cells, and also in the incidence of the cytokines IL-lp and TNFa, and the adhesion 
molecules E-selectin and VCAM-1 in the synovial membrane. Suggested modes of action 
based on these and earlier data included a decrease in proliferation of cells in the 
synovium, or more likely a downregulation of adhesion molecules, reducing the influx of 
cells into the synovium. Given the ability of IL-lp and TNFa to upregulate the expression 
of such markers, it is possible that such changes could be as a result of alterations in 
cytokine release, possibly either due to direct effects upon the macrophages, or indirectly 
by effects upon the regulation of macrophage activation by T-cells. An alternative 
possibility was considered by Hirohata et al. (1999), who demonstrated a decrease in the 
generation of CD14+ cells of monocyte lineage from CD 14* precursors in the presence of 
MTX. The generation of such cells is upregulated in patients with RA, and inhibition of 
this process could certainly have an effect upon pro-inflammatory cytokine production in 
the rheumatoid synovium.
Unfortunately, MTX is also capable of causing a range of side effects, detected in 
approximately 60% of patients. These are generally mild, and only result in 
discontinuation of the therapy in less than 20% of patients treated. Common effects 
include nausea, diarrhoea, stomatitis, headaches and dizziness. There can also be changes 
in the levels of liver enzymes (up to 3-fold), although in cases exceeding this level, 
treatment is usually stopped immediately and restricted to lower doses if MTX therapy is 
resumed. Other less common adverse effects can include rashes, increase in severity of 
rheumatoid nodules, renal deterioration and leucoclastic vasculitis (Clegg et al., 1989; 
Kerstens et al., 1992; Kremer & Lee, 1988; Scully et al., 1991).
1.1.4.3: Sulphasalazine (SPZ)
Sulphasalazine (SPZ) was first synthesised by Professor Nana Svartz in the 1940s, with the 
idea of combining the antibiotic activity of sulphapyridine (SP) with the anti-inflammatory
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action of salicylic acid (Svartz, 1948, cited by Box & Pullar, 1997). At that time, RA was 
believed to have a bacterial aetiology, so this combination seemed ideal for the treatment 
of RA. However, the discovery of cortisone, combined with an unfavourable report, meant 
that SPZ was not used in a widespread manner until included by Amos & McConkey 
(1981) in an open trial, and discovered to have comparable clinical effects to other 
DMARDs including gold, D-Pen and MTX.
Most SPZ (90%) reaches the large intestine before being broken down into SP and 5- 
aminosalicylic acid (5-ASA), of which SP is almost completely absorbed, while almost all 
5-ASA is excreted faecally. Both whole SPZ and SP have been detected in synovial fluid, 
at concentrations slightly lower than those of the drugs in plasma (Farr et al., 1985). As 
with MTX, the specific mode of action of SPZ has yet to be identified. It certainly exhibits 
a bactericidal effect, as demonstrated by a reduction in counts of Clostridium perfringens 
in the gut flora (Neumann et al., 1987). SPZ is a potent inhibitor of 15-prostaglandin 
dehydrogenase (15-PGDH), an important enzyme in the inactivation pathway of 
prostaglandins (Hoult & Moore, 1980), and also of 5- and 15-lipoxygenases, inhibiting the 
release of lipoxygenase products from inflammatory cells and tissues (Bach et al., 1985; 
Sircar et al., 1983; Stenson et al., 1982; Tomhamre et al., 1989). Folate metabolism is also 
inhibited in a similar manner to MTX, although given the lowering of toxicity (with no 
alteration in therapeutic effects) upon supplementation with folic acid, it seems unlikely 
that this is a critical drug mechanism in RA (Morgan et al., 1990).
SPZ has been shown to inhibit a range of actions on inflammatory cells, including the 
production of superoxide, enzyme release and chemotaxis. There are also data 
demonstrating that 5-ASA can act as a potent scavenger of free radicals, including 
superoxide (Carlin et al., 1985; Harvath et a l, 1986; Neal et al., 1987), although given the 
faecal excretion of almost all 5-ASA, this is unlikely to be of substantial therapeutic 
relevance for RA. There is evidence to suggest that SPZ can interact directly with either 
phospholipase C or its associated G-protein to inhibit phosphoinositide metabolism (Carlin 
et al., 1992). In vivo, steady serum levels of 10-15pM SPZ and 120pM SP have been 
determined following 2g/day dosage of SPZ, and these levels are also comparable in the 
synovial fluid (Farr et al., 1985; Smedeg&rd & Bjork, 1995). In vitro, SPZ or SP can 
inhibit both T-cell proliferation (IC50 of 200pM/>400pM, respectively) and activation of 
B-cells (IC50 of 12.5pM/20pM respectively) (Comer & Jasin, 1988; Imai et al., 1994). SPZ
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and SP also inhibit {in vitro) the release of T-cell cytokines including IL-2 (IC50 of 
100jiM/>500|iM respectively) and IFNy and monocyte cytokines IL-lp (IC50 of 200p,M 
SPZ), TNFa (IC50 of 200pM SPZ) and IL-6 (Gronberg, 1994; Remvig & Andersen, 1990). 
However, most of these IC50 values are above the physiological levels of SPZ/SP 
determined in sera. These data are supported by an observed progressive decrease in 
serum levels of IL-ip, TNFa and IL-6 in RA patients treated with SPZ, corresponding to 
improvements in clinical measures of disease activity (Crilly et al., 1995; Danis et al., 
1992). Correlating with the decrease in IL-6, decreases in serum concentrations of IgA and 
IgG have also been observed, along with significant reductions in circulating levels of both 
IgA and IgM rheumatoid factors and IgA anti-gliadin antibodies (Kanerud et al., 1995). 
Recent data also implicates SPZ in the inhibition of IL-12 production from macrophages, 
and thus aiding in suppression of the Thl immune response, which is discussed in a later 
section (1.4.3) (Kang et al., 1999). In addition, SPZ has been recently shown to strongly 
inhibit nuclear factor kappa B (NFkB) activation, a transcription factor capable of rapidly 
activating the transcription of a range of pro-inflammatory cytokines, adhesion molecules 
and chemokines (Wahl et al., 1998).
The side effects of SPZ have been well studied, and consist primarily of minor 
gastrointestinal or central nervous system dysfunctions (generally nausea, although a skin 
rash occurred in 4-5% of patients. There are occasional serious adverse effects including 
agranulocytosis, neutropenia, leucopenia or hepatotoxicity (Farr et al., 1989; Pullar et al., 
1987), although most of these effects were reversible when therapy was withdrawn or 
reduced. Approximately 25% of patients suffer side effects of a serious enough level to 
warrant a withdrawal of treatment, and these generally occur within the first 12 weeks of 
therapy (Box & Pullar, 1997; Donovan et al., 1990).
1.1.4.4: Hydroxychloroquine (HCQ)
Hydroxychloroquine (HCQ) was originally used as an antimalarial compound, but was 
considered for use in rheumatoid disease following improvements in systemic lupus 
erythematosus (SLE). In early tests (Bagnall, 1957, cited by Luqmani et al., 1994), 71% of 
108 RA patients treated with the closely related drug chloroquine showed either 
improvement or remission. Antimalarial drugs are often prescribed during early stages of
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RA, and are usually considered to be somewhat less effective than other DMARDs. HCQ 
is rapidly absorbed into tissue compartments, with between 20-40% being excreted 
unchanged in the urine, the remainder being metabolised. Mechanisms of action that have 
been determined include the inhibition of lysosomal enzymes and inhibition of IL-1 release 
in vivo, and in vitro HCQ has been shown to inhibit polymorphonuclear leucocytes and 
possess possible protective functions for cartilage (Tett et al., 1990). There is also 
evidence to show an inhibitory effect of HCQ on superoxide production by monocytes 
(Hurst et al., 1986)
Although there is incidence of rashes in some subjects (3-10%), which can increase in 
severity to exfoliative dermatitis, the most important side effect of HCQ is the potential for 
retinal damage, although this is considered unlikely at the current recommended doses. 
Treatment with HCQ is usually accompanied by regular visual assessments to enable rapid 
detection of retinopathy should it occur (Tett et al., 1990). In early studies, side effects 
were considered severe enough to warrant withdrawal of therapy in only 3-8% of patients, 
with suppression of joint inflammation in between 50-70% of cases (Bunch et al., 1984; 
Kvien et al., 1985).
1.1.4.5: D-Penicillamine (D-Pen)
Penicillamine is a component of penicillin, and can be prepared from it by acid hydrolysis, 
although the only form available for therapeutic use (D-Penicillamine (D-Pen)) is prepared 
synthetically. It is rapidly absorbed, and is mainly present in the plasma in the form of 
disulphides (approximately 6 8 % of total D-Pen), either penicillamine-cysteine or 
penicillamine-penicillamine. D-Pen was first administered to RA patients to study effects 
on IgM RF, and it was then observed that in addition to the decrease in IgM titre, there 
were also clinical improvements (Jaffe, 1990).
The mechanism of suppression of RA by D-Pen is uncertain. Monocyte accessory function 
(depressed in RA monocytes) was partially restored in patients treated with D-Pen, 
possibly linked to the requirement for free sulphydryl groups on the surface of the 
monocytes (especially as this result could be mimicked with the addition of the simple 
thiol 2-mercaptoethanol to the in vitro culture) (McKeown et al., 1984).
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D-Pen can cause a wide variety of side effects, and these often represent the primary factor 
limiting its use. These can include rashes and mouth ulcers, along with anorexia, nausea, 
vomiting or renal toxicity resulting in proteinuria, although these effects are generally 
controllable with reduced dose. Other more severe side effects observed include effects on 
the neuromuscular system (possibly inducing myasthenia gravis), rheumatoid lung disease, 
and most serious of all, depression of bone marrow activity (reviewed by Jaffe, 1990). 
Due to reduced efficacy in long-term treatment and a high incidence of side effects, use of 
D-Pen has been reduced in recent years in favour of the more effective DMARDs with 
reduced adverse effects.
1.1.4.6: Oral or Intramuscular Gold
Gold compounds have been used extensively in the therapy of RA since 1927, generally 
consisting of monovalent gold stabilised by attachment to a sulphur-containing ligand. It is 
administered either orally or by injection, with injection generally resulting in greater 
efficacy, although oral gold combines milder therapeutic effects with relatively few side 
effects. Gold compounds have a number of actions that could be of pharmacological 
interest. Effects on lymphocytes vary, as the suppression of lymphocyte response to 
mitogens exhibited in RA is restored to normal levels by sodium aurothiomalate (injected), 
but exacerbated by Auranofin (oral) in vivo, and in vitro, both compounds further suppress 
lymphocyte activity (Lorber et al, 1981). Activated lymphocytes are present in increased 
numbers in the blood of patients with RA, and these numbers return to normal upon 
treatment with gold compounds (Wenger et al., 1983).
Treatment with gold compounds also interferes with synthesis of immunoglobulin, leading 
to reductions in levels of rheumatoid factors and other immunoglobulins in the serum (So 
et al., 1984), and as a result of this a reduction in immune complexes. Gold compounds 
accumulate in monocytes and macrophages, contained in vesicles called aurosomes. It is 
considered likely that the observed decrease in lymphocyte activity might be due to 
suppression of monocyte factors responsible for lymphocyte activation, as it can be 
overcome by addition of fresh monocytes not previously exposed to gold compounds 
(Lipsky & Ziff, 1977). There appears to be a protective role against damage caused by 
ROS, as treatment with gold compounds restores the levels of ROS scavenger molecules 
(including GSH) to normal levels, and protects ai-proteinase inhibitor from oxidative
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attack. This polypeptide protects against damage from lysosomal enzymes released by 
inflammatory mediator cells, although gold compounds also act directly to inhibit these 
compounds (such as collagenase, elastase and hyaluronidase), binding to critical 
sulphydryl groups on the enzymes. There are also inhibitory effects on both monocyte 
chemotaxis, and the release of chemokines IL-8  and MCP-1 (Harth et al., 1983; 
Scheinberg et al., 1982).
Documented side effects include rashes, eosinophilia, and proteinuria with occasional more 
severe effects, primarily acute renal failure, pulmonary and gastrointestinal effects. Oral 
gold generally causes fewer side effects, except that diarrhoea is more common with this 
treatment. Severity of side effects generally causes cessation of treatment in 
approximately 14% of patients within 12 months, although 50% of patients are withdrawn 
from the treatment within 4 years, either due to side effects or lack of benefit (reviewed by 
Skosey, 1989). Indeed, one study demonstrated substantial therapeutic effects of gold after 
6  months in 20-35% of patients, but after 12 months only half of these patients showed a 
similar level of response (Champion et al., 1990)
1.1.4.7: Glucocorticoids
Glucocorticoids are prescribed extensively to patients with chronic RA, and can be 
administered either orally for a systemic effect, or intra-articularly for specific localised 
treatment. They are generally prescribed as long-term background therapy, or as short 
courses in combination with the commencement of new DMARD therapy or to act against 
disease flares. A primary example is prednisolone, a synthetic analogue of hydrocortisone 
with 4 times the glucocorticoid activity.
Glucocorticoids exert most of not all of their therapeutic action at the molecular level, first 
binding the intracellular glucocorticoid receptor (Hollenberg et al., 1985), migrating to the 
nucleus and binding specific regulatory sites on DNA, competing with other transcription 
factors such as NFkB. This can then result in alterations in gene expression important in 
the inflammatory process (Boumpas et al., 1993), and inhibit the transcription of many 
cytokines including the pro-inflammatory IL-lp, TNFa and IL-6 . The stimulation by 
glucocorticoids of IkB release, a direct inhibitor of NFkB activity, thus allows 
glucocorticoids to inhibit not only the DNA binding of NFkB, but its initial translocation to
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the nucleus (Auphan et al., 1995). Treatment with low dose prednisolone has been shown 
to significantly lower monocyte expression of the pi- and P2-integrins, FcyR and 
complement receptors (Torsteinsdottir et al., 1999), although this could be as a result of 
downregulation of cytokine release. Glucocorticoid downregulation of adhesion and 
phagocytosis receptors on peripheral monocytes can lead to reduced adhesiveness of 
monocytes to the endothelium, and thus fewer macrophages in the rheumatoid synovium. 
Glucocorticoids can also stimulate the production of lipocortin-1 (also called annexin-1) 
(Goulding et al., 1990), which based on investigation in animal models exhibits a number 
of anti-inflammatory effects (reviewed in Flower & Rothwell, 1994). However, the 
physiological relevance of glucocorticoid lipocortin-1  release is uncertain, except that there 
appears to be a role in negative feedback for neutrophil adhesion to endothelium, released 
following neutrophil adhesion and limiting additional neutrophil binding (Perretti et al., 
1996a/2?), supported by the discovery of receptors for lipocortin on the surface of 
neutrophils and PMBC (Goulding et al., 1996). There is also evidence showing an 
upregulation of IL-IRH expression following glucocorticoid treatment (Colotta et al., 
1993), and that glucocorticoids might act to suppress the induction of Cox-2, with 
corresponding decrease in inflammatory PG synthesis (Breyer, 1999; Masferrer et al., 
1994; Vane et al., 1998).
The adverse effects of glucocorticoid treatment include weight gain, ease of bruising and 
fluid retention, but most importantly an increased susceptibility to infection. As a result of 
this, steroid therapy is generally restricted to short courses of treatment, or where long­
term therapy becomes necessary (some chronic RA patients), restricting the dose to the 
minimum required for a therapeutic effect (Brooks, P. M., 1993).
1.1.4.8: Biological Treatments
More recent treatments for RA include generating antibodies to disease-specific targets, 
with the first clinical trials being carried out using neutralising anti-TNFa antibodies. 
Initial work utilised synovial cell cultures, which when treated with anti-TNFa antibodies 
showed a loss of virtually all IL-1 bioactivity, and also a significant inhibition of GM-CSF 
production (Brennan et al., 1989; Haworth et al., 1991). Since then the therapeutic 
efficacy of this approach has been formally demonstrated in a number of successful
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clinical trials using both a chimeric (mouse x human) mAb (cA2, Infliximab) (Elliott et al., 
1993; Elliott et al., 1994a/b\ Harriman et al., 1999; Rankin et al., 1995) and a fully human 
mAb (D2E7) (den Broeder et al., 1998; Schattenkirchner et al., 1998; van de Putte et al., 
1998). Also in use is a recombinant p75 sTNFR: Fc fusion protein (Etanercept), which 
binds to TNFa preventing the cross-linking of membrane bound TNFR (Franklin, 1999). 
Etanercept has demonstrated significant therapeutic effects in clinical trials, with 60% of 
patients achieving a 50% improvement in RA symptoms according to American College of 
Rheumatology (ACR) criteria (reviewed by Garrison & McDonnell, 1999), although in 
combination with MTX the results were somewhat confused as to any additional 
therapeutic benefit. As a result of the success of anti-TNFa treatments, the signalling 
pathways regulating TNFa production have come under greater scrutiny, with NFkB being 
identified as an essential step in TNFa synthesis (Foxwell et al., 1998).
However, TNFa is not the only therapeutic target being considered for antibody treatment. 
Anti-CD4 antibodies have been used to deplete the T-helper cell populations in RA 
patients, although in some cases the patients who responded successfully to therapy were 
those who exhibited reduced serum levels of IL-1 and TNFa (Homeff et al., 1993), and 
there was often a side effect of CD4 lymphopenia although this did not induce an increase 
in patient mortality (Isaacs et al., 1998). An additional problem was the development of a 
human anti-mouse antibody response (Choy et al., 1998), as a result of which chimeric and 
primatised antibodies were developed, along with localised treatment targeted to the knee 
joint to reduce systemic lymphopenia (Choy et al., 1998; Veale et al., 1999). Another 
study tested the effectiveness of anti-CD4 treatment in conjunction with anti-TNFa 
treatment, and demonstrated a synergistic relationship with regard to the inhibition of IL- 
lp/TNFa expression in joints (Marinova-Mutafchieva et al., 2000).
Alternative investigations into the depletion of T-lymphocytes as a treatment for RA 
utilised NOD-SCID mice engrafted with human rheumatoid synovial tissue, and then 
treated with anti-CD2 antibody. The tissue infiltrating cells were depleted by 80-90%, 
followed by marked decreases in the production of IL-lp (by 70%), TNFa (by 8 6 %) and 
IL-15 (by 84%) mRNA. Transcription of MMP-1 and MMP-2 were also downregulated 
by 72% (Klimiuk et al., 1999). Several other targets have been considered, including TCR 
or HLA-DR1/DR4, CD5 (a co-stimulatory antigen found primarily on T-cells), CD7 (a T- 
lymphocyte transmembrane glycoprotein), CDw52 (a glycoprotein present on all
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lymphocytes and some monocytes), IL- 6  or anti-CD54 (ICAM-1). These suggested 
treatments have generally not proceeded past the animal model stage, or are showing anti- 
IgG responses when used in rheumatoid patients, although certain targets (especially TCR 
and HLA-DR) are being used in clinical trials with RA patients (reviewed by Moreland et 
a l , 1997).
Several cytokines have been considered for possible therapeutic use in RA, and one of the 
most likely candidates is IL-lra, the IL-1 receptor antagonist. IL-lra will be covered in 
more detail later, so only its role as a potential therapeutic agent will be considered here. 
In order to achieve 50% decrease in IL-ip bioactivity, IL-lra needs to be present at 
approximately lOOfold excess to IL-1 p, meaning that IL-lra would need to be administered 
repeatedly at high concentrations (Arend et al., 1990). In one recent double-blind trial 
(Bresnihan et al., 1998) involving 472 patients over 24 weeks, approximately 43% of 
patients showed a positive response according to the American College of Rheumatology 
(ACR) criteria, with only a 5% withdrawal rate from the treatment, generally as a result of 
injection site reactions. Statistically significant improvements were observed in a wide 
range of disease severity markers, including C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), and a number of investigator and patient determined factors.
When the requirement for continual, high level doses of IL-lra is considered, even given 
its efficacy and apparent limited side effects, it becomes apparent that if an alternative 
technique to increase serum concentration of IL-lra could be determined, this could prove 
a more reasonable long-term approach. One possible mechanism would be through the 
administration of other cytokines such as IL-4, IL-10, DL-13, IFNa or TGFp (although 
TGFp has other possible disadvantages, as mentioned earlier). IL-4 and IL-10 have 
already been considered as possible therapies due to their regulation of macrophage 
functions (possibly via Thl/Th2 helper cell function) and efficacy in treating experimental 
arthritides, with several promising trials undertaken in animal models (Allen et al., 1993; 
Kasama et al., 1995; Rocken et al., 1994). A possible method for delivery of these 
cytokines would be through the use of gene therapy, with the goal of increasing local 
expression of anti-inflammatory cytokines or factors in the synovial membrane. Although 
requiring substantial development, initial trials have been performed in rabbit models using 
recombinant IL-lra cDNA using both adenoviral vectors injected directly into the knee 
(Roessler et al., 1993) and retroviral vectors in isolated synovial cells for later
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transplantation (Bandara et al., 1993). When transfected cells were returned to the knee 
joint, biologically active IL-lra was detected within 5 weeks.
1.2: CYTOKINES
As can be determined from the previous sections, there is a complex interplay of cytokine 
activities regulating disease activity in RA. In this section there will be a brief description 
of some of the cytokines involved along with their putative actions in RA. IL-lp and IL- 
lra will be discussed in greater depth as the major cytokines investigated in this thesis. 
Feldmann et al. (1996b) have written a thorough review of the cytokine activities 
associated with RA.
1.2.1: The Interleukin-1 Family
The interleukin-1 family of cytokines comprises distinct but related molecules (2 agonists 
and 1 antagonist) involved in a range of immune and inflammatory responses. For 
example, IL-ip has been implicated in a variety of physiological and pathological activities 
including T-cell stimulation, wound healing, cellular adhesion, cytokine production and 
inflammation. The other members of the IL-1 family, IL-1 a  and IL-lra, share sequence 
homology, hydrophilicity plots and the same receptor sites (Dower et al., 1986; Eisenberg 
et al., 1990). The genes for all 3 members of the IL-1 family, as well as for IL-1 receptors 
(IL-1R) types I and II have been localised to the long arm of chromosome 2. In normal 
health, there is evidence to suggest a role for IL-1 in embryonic development, due to IL-1 
expression in the forming placenta, although studies utilising gene knockouts in mice for 
IL-lp, IL-ip converting enzyme (ICE) and IL-1 receptor I (IL-1RI) have shown normal 
ovulation, fertilization and implantation. As both EL-la and IL-ip are potent pro- 
inflammatory cytokines, with carefully regulated production and activation (especially IL- 
lp), it is perhaps unsurprising that there has been extensive research regarding the role of 
IL-1 in disease (reviewed by Arend, 1993; Dinarello, 1996).
Both IL-1 a and IL-1 p are translated as intracellular precursors with molecular masses of 
approximately 31kDa each (pro-IL-la and pro-EL-ip) and possess relatively low sequence 
homology (30-40%). Neither precursor possesses a leader sequence, and so they are 
released independently of the endoplasmic reticulum/golgi network (Eisenberg et al., 1990;
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March et al., 1985). Pro-IL-la exhibits binding to the IL-1R in both the precursor state 
and mature 17.5kDa form, and remains largely cell-associated, with the small 
concentrations detected extracellularly likely due to release from damaged cells, or due to 
calpain-mediated cleavage of the membrane-bound pro-IL-la (Kobayashi et al., 1990). 
Pro-IL-ip requires processing to its active 17.5kDa peptide by the highly selective protease 
ICE (also called caspase 1) before obtaining any substantial biological activity, at which 
time it is rapidly secreted (Black et al., 1989; Hazuda et al., 1988; Hazuda et al., 1989; 
Mosley et al., 1987). Since pro-IL-lp is only found intracellularly, and mature IL-ip is 
generally found extracellularly, it is reasonable to expect a direct link between the 
intracellular cleavage of the cytokine and its active release.
The IL-1 receptor family consists of a number of related receptor molecules, although not 
all of these molecules bind IL-la, IL-1 P or IL-lra. IL-1RI is an 80kDa protein, found 
primarily on T-cells and fibroblasts, although present in low levels on most cells, while IL- 
1RD is a 6 8 kDa protein found mainly on neutrophils and B-cells (Chizzonite et al., 1989; 
Sims et al., 1989). Recent data have identified the IL-1R as members of an LL-l/Toll-like 
receptor superfamily, effectively describing an additional 5 receptors with sequence 
homology to the IL-1R (Belvin & Anderson, 1996).
IL-1RI acts as the primary effector receptor, triggering the rapid induction of NFkB in 
response to binding with IL-1. There is no TATA or CAAT box in the IL-1RI gene 
promoter, suggesting a housekeeping function, as it is continually expressed at low levels, 
although 2 AP-1 binding domains provide a possible method of upregulation of 
transcription (Ye et al., 1993). In addition, very few IL-1RI sites require occupation in 
order to transmit a biological signal, due to efficient amplification of signal transduction 
(Akahoshi et al., 1988). There is evidence to suggest that IL-IRH acts as a decoy receptor, 
as there is no triggering of NFkB induction when bound to IL-1 (Colotta et al., 1993; Sims 
et al., 1993). In addition, IL-lra was found to bind strongly to the type I receptor, but not 
to the type II receptor (Stylianou et al., 1992).
There is an additional important member of the IL-1R family, the 6 6 kDa IL-1 accessory 
protein (IL-1R AcP), which forms complexes with IL-1RI and either IL-la or IL-lp (but 
not IL-lra). IL-1RI exhibits a higher affinity for EL-1 p when associated with IL-1R AcP, 
and antibodies to IL-1 R AcP which block binding to IL-1 RI also block IL-lp binding and
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signal transduction, suggesting that the active IL-1R complex consists of at least 2 subunits 
(Greenfeder et al., 1995). Other members of the IL-1R family include IL-1 receptor- 
related protein (IL-lRrp), accessory protein-like receptor (AcPL) and T1/ST2, although 
none of these binds IL-1 as ligand. However, a potential ligand has been discovered for 
T1/ST2 capable of eliciting a signal via the p38 MAP kinase, and there is evidence that IL- 
lRrp may be the IL-18 receptor, and AcPL the corresponding accessory protein (Bom et 
al., 1998; Kumar et al., 1995; Pamet et al., 1995; Torigoe et al., 1997).
The genes of IL-la, IL-lp and IL-lra show differential expression, with the IL-ip gene 
possessing a TATA box although the IL-la gene does not (Arend, 1993; Shirakawa et al.,
1993). IL-lp is regulated by at least 2 different signalling pathways, as demonstrated by 
differential induction with LPS or the phorbol ester phorbol-12-myristate- 13-acetate 
(PMA). Differences exist between the kinetics of this activation, with LPS causing rapid 
expression, rising to a peak at 2h before declining to low levels after 5h, while PMA 
induced a consistent increase in IL-lp mRNA reaching and maintaining a steady plateau 
after 7h. Stimulation with LPS provokes a transient expression of IL-1 p mRNA, while 
stimulation with PMA gives rise to a more stable, non-transient population of mRNA, due 
to a much longer i\n of the stabilised mRNA, and the action of a transcriptional inhibitor 
(which can in turn be inhibited by the action of cycloheximide) on the LPS induced 
expression (Fenton et al., 1988),
IL-ip gene transcription has been extensively investigated in response to LPS stimulation 
as an immediate and potent inducer of IL-lp release from monocytes (Dinarello, 1992). 
As a result of this, a wide range of transcription factors have been determined to have 
effects upon IL-lp gene transcription. NFkB induces IL-lp transcription, binding to a 
consensus sequence site in the upstream regulatory region, and in addition further regulates 
transcription through interaction with an upstream non-consensus cyclic AMP (cAMP) 
response element (CRE) (Cogswell et al., 1994). The nuclear factor designated as being 
required for transcription of the IL- 6  gene (NF-IL6 ) is also important for EL-1 p gene 
expression (Shirakawa et al., 1993), as is a separate CRE-binding element (CREB) 
(Tsukada et al., 1994), a LPS and IL-1 induced STAT-like factor (Signal Transducers and 
Activators of Transcription) (Tsukada et al., 1996a/b), and the macrophage, neutrophil and 
B-cell specific nuclear transcription factor PU.l, which binds 6 bp upstream from the 
TATA motif (Buras et al., 1995). Regulation of transcription of IL-lp (and IL-la) mRNA
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by IL-lp itself is also mediated by the nuclear factor Oct-1, and results in an increase in 
stable mRNA levels in thymic stromal cells (Tseng & Schuler, 1998). Complement 
component C5a also acts as an inducer of IL-lp transcription, although without additional 
stimulus (such as LPS or IL-1) there is no translation of gene product (Schindler et al., 
1990a).
In contrast, due to its lack of leader sequence, IL-la generally remains unprocessed and 
either cytosolic or membrane associated, although there is evidence to show release due to 
cell damage during severe disease (Schindler et al., 19906; Wakabayashi et al., 1991). IL- 
lp is able to overcome this restriction due to the proteolytic activity of ICE.
IL-lp is initially synthesised as a 31kDa precursor peptide, requiring conversion into its 
17.5kDa active form by the highly selective proteinase ICE (Black et al., 1989; Hazuda et 
al., 1989). ICE was originally identified as a result of its sequence homology to ced-3, a 
pro-apoptotic gene product of Caenorhabditis elegans, and along with the other members 
of the caspase family is capable of inducing cellular apoptosis through the cleavage of 
intracellular structural and regulatory proteins (Alnemri et al., 1996), although it can also 
exhibit anti-apoptotic activity in inflammatory neutrophils through the action of IL-ip 
(William et al., 1998). The active enzyme is a heterodimer, consisting of a lOkDa and a 
20kDa subunit, which are derived by autoproteolysis from a single 45kDa or 43kDa 
proenzyme (Kostura et al., 1989; Yamin et al., 1996). As ICE is expressed constitutively, 
it is likely that the primary mode of regulation of ICE activity is control of this 
autoproteolytic cleavage of pro-enzyme leading to active forms, although an active 
inhibitor of ICE activity has been demonstrated in vascular smooth muscle cells 
(Schumann et al., 1998; Schonbeck et al., 1997; Thomberry, 1994; William et al., 1998). 
LPS is one stimulus capable of inducing ICE activity in addition to increasing pro-IL-lp 
transcription.
ICE acts to cleave the pro-IL-ip molecule specifically between the aspartic acid and 
alanine residues 116 and 117, thus releasing the 153 amino acid COOH terminal that 
constitutes the active cytokine (Black et al., 1989; Kostura et al., 1989). ICE activity has 
been detected in both monocytes and the human monocytic cell line THP-1, although 
additional stimulation is required (for example, LPS) for IL-1 p release (Miller et al., 1993; 
Schumann et al., 1998). The mRNA for the enzyme has also been detected in a range of
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non-monocytic cell types including T-cells, B-cells and neutrophils, but as only monocytes 
and THP-1 cells contain easily detectable levels of IL-lp mRNA, the enzyme may also act 
on alternative substrates (Cerretti et al., 1992; Thomberry et al., 1992). There is more 
recent evidence that demonstrates that ICE is required for the production of the mature 
form of the distant IL-1 family member, IL-18 (Ghayur et al., 1997).
The activity of mature IL-lp, once released, is regulated by several mechanisms, including 
the IL-1RE decoy receptor, soluble EL-Ira (sIL-lra), and effects of EL-1 itself upon the IL- 
1RI receptor. The IL-1 RE receptor, which can occur in soluble or membrane bound forms, 
is the predominant IL-1R expressed on the cell surface and acts as a molecular trap for EL- 
1, thus inhibiting its activity. The expression of IL-1 RE can be augmented by the action of 
IL-4 and glucocorticoids (Colotta et al., 1993). IL-lra (which is covered in detail later in 
this chapter) competes with active IL-1 for IL-1RI sites. There is also a rapid 
downregulation of IL-1 binding capability on target cells following exposure to EL-1, 
which is restored, and then surpassed (to a 2-fold level) over 48h, with the upregulation of 
IL-1R expression being at least partially due to the action of PGE2 (Akahoshi et al., 1988).
The first signalling event triggered by IL-1 following ligand-receptor binding is the ligand 
induced formation of the IL-1RI/IL-1R AcP complex, followed by the recruitment of the 
adaptor protein MyD8 8  to the complex (Greenfeder et al., 1995; Huang et al., 1997; Muzio 
et al., 1997; Wesche et al., \991a/b). This then enables association and phosphorylation 
of the EL-lR-associated kinase (IRAK), which then leaves the receptor complex and 
interacts with TRAF6  (Cao et al., 1996; Croston et al., 1995; Kanakaraj et al., 1998). This 
IRAK-TRAF6  interaction then triggers kinase cascades leading to the activation of IkB 
kinases and c-Jun NH2-terminal kinases (INK), which phosphorylate inhibitor-kappa-B 
(IkB, the inhibitor of NFkB) and c-Jun, respectively. This “tagging” of IkB labels it for 
destruction by proteasomes, enabling the subsequent activation of NFkB (Baeuerle, 1998). 
IRAK is also an essential constituent of IL-1 induced activation of mitogen-activated 
protein (MAP) kinases and the p38 MAP kinase. The heavily phosphorylated IRAK 
undergoes a steady degradation by proteasomes, which coupled with the constant low level 
of both phosphorylated and unphosphorylated IRAK suggests a steady resynthesis, 
phosphorylation and degradation of the kinase (Kanakaraj et al., 1998; Yamin & Miller,
1997). There is also evidence to link the activation of phosphatidylinositol 3-kinase
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(PI3K) to the ligation of IL-1 RI, as stimulation of cells with IL-1 causes rapid translocation 
of PI3K from the cytoplasm to the nucleus (Bavelloni et al., 1999).
IL-1 can act on a diverse range of cell types, and can cause a wide range of effects. It can 
stimulate the proliferation and differentiation of T-cell, B-cells and fibroblasts, while 
inducing proteolysis, bone resorption and breakdown of cartilage, all associated with RA 
(reviewed by Dinarello, 1996). Indeed, the concentration of IL-lp in the plasma of 
rheumatoid patients has been directly correlated to disease severity (Eastgate et al., 1988). 
This, coupled with the recently proven efficacy of IL-lra as a therapeutic agent (Bresnihan 
et al., 1998) provides substantial evidence as to the importance of IL-1 activity in this 
disease. Inflammatory actions include stimulating the release of prostaglandins, 
chemokines and proteolytic enzymes (reviewed by Durum et al., 1985; Newton, 1990). 
Although (pro-)EL-la is retained by the cell (and so likely to have a minor role in 
mediating an inflammatory signal), there is still evidence for IL-la functioning as an 
autocrine growth factor, acting as an intracellular messenger in certain cell types (Zubiaga 
et al., 1991; Zuniga-Pfliicker et al., 1995). IL-lp meanwhile exhibits a diverse range of 
biological activity including both systemic and localised effects, changes in immune 
responses and regulatory effects on cells and tissues (reviewed by Dinarello, 1996). The 
basis for this range of activity is due to effects of IL-lp on the expression of various genes 
and surface receptors, often by either initiating transcription or stabilising mRNA. This 
includes the ability of both IL-la and IL-1 p to increase expression of the IL-1 family of 
genes.
IL-1 is also responsible for the upregulation of other inflammatory cytokines, lymphocyte 
growth factors, chemokines, colony-stimulating factors and mesenchymal growth factor 
genes. Inducible nitric oxide synthase (iNOS), type-2 cyclooxygenase (Cox-2) and type-2 
phospholipase A2 (PLA2) are all highly specialized enzymes that are closely regulated by 
IL-1. The products of these enzymes (NO, prostaglandins, leukotrienes and platelet- 
activating factor) are all potent pro-inflammatory mediators, and can prolong the effect of 
IL-1 on the cell as well as mediating many of the biological effects associated with IL-1 
(Kunz et al., 1994; Miihl et al., 1994). There is also a suppression of a number of 
housekeeping genes, including albumin and cytochrome p450, possibly as a response to 
infection, allowing upregulation of immune defences while conserving energy by
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downregulating genes non-essential for the immune response (Beuscher et al., 1987; 
Ghezzi et al., 1986; Ramadori et al., 1985).
Effects on surface receptors are an important regulatory mechanism of IL-1 activity, with 
both increases and reductions of a large number of receptors in a wide range of cells. In 
the first case this is self-regulatory, with increased expression of the IL-1RII receptor, and 
a decrease in the stability of mRNA coding for IL-1RI. There is also downregulation of 
the p55 TNF-receptor (p55TNFR) in response to IL-lp, due to both a suppression of gene 
expression and shedding of the receptor (Brakebusch et al., 1994; Holtmann & Wallach, 
1987), although there is also an upregulation in expression of the p75TNFR. There is 
increased expression of the genes and surface receptors E-selectin (ELAM) and ICAM-1, 
FcR (except FcyRHI), IFNy receptors and TGFp receptors, along with many others too 
numerous to detail here. In the same manner, IL-1 downregulates the surface expression or 
receptor binding of PGE2, CD4 on lymphocytes, PDGF receptors, and fibroblast growth 
factor (FGF) receptors, amongst others (Dinarello, 1996).
As a final comment in this section, IL-lp is capable of synergising with a number of 
factors, including bradykinin, IL-6 , a number of growth factors (CSF, FGF, PDGF, EGF 
and TGFa) and TNFa (Dinarello, 1996). Of perhaps the most interest with regard to RA is 
the synergy with TNFa, another important pro-inflammatory and regulatory cytokine, from 
which one important result is a further increase in PGE2 production from fibroblasts 
(Brakebusch et al., 1994; Holtmann & Wallach, 1987). The mechanism for this synergy is 
unclear, although there is evidence demonstrating that both IL-lp and TNFa receptors 
trigger responses through the same MAP kinase kinase kinase (MAPKKK), designated 
NFkB inducing kinase or NIK (Baeuerle, 1998). This could then enable such synergy to 
occur through an additive stimulation of NFkB activation.
1.2.1.1: IL-1 receptor antagonist (IL-lra)
An IL-1 specific inhibitor was originally detected in cultures of human monocytes grown 
on a substrate of immune complexes or IgG, with similar activity being detected in the 
urine of patients with fever or myelomonocytic leukaemia (Arend et al., 1985; Balavoine 
et al., 1986). Human IL-lra was later isolated from the supernatants of monocytes
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cultured on IgG, from the U937 myelomonocytic cell line when pre-treated with PMA and 
cultured with GM-CSF, and from PMA-differentiated THP-1 cells (Bienkowski et al., 
1990; Carter et al., 1990; Hannum et al., 1990). The production of IL-1 p and IL-lra is 
differentially regulated, with both IL-lp and IL-lra production stimulated by LPS, while 
IgG stimulates only IL-lra production (Arend et al., 1991). A wide range of stimuli can 
act to induce IL-lra release, including (in addition to those mentioned above) IL-1, IL-2, 
EL-3, IL-4, IL-6 , IL-10, EL-13, TGFp, IFNa, IFNy and direct contact with T-lymphocytes 
(Th2 phenotype). Of these, the most potent in vitro are adherent IgG, LPS, EL-4 and GM- 
CSF, although this may not be the case in vivo (reviewed by Arend et al., 1998). EL-Ira is 
inducible in most cells types, although an intracellular form has been observed in intestinal 
epithelial cells that is transcribed constitutively (Haskill et al., 1991). Considering the wide 
range of cytokines and other stimuli that control EL-Ira release, it is likely that IL-lra plays 
an important role in many inflammatory and immune responses.
EL-Ira exists in 3 primary structural isoforms, a secreted 17kDa form (sEL-lra) and both 
18kDa and 16kDa intracellular forms (icIL-lral and icEL-lrall respectively). The 17kDa 
and 18kDa forms arise from differential transcription of the same gene, with the 16kDa 
form occurring as a result of alternative translation of sEL-lra mRNA (Malyak et al., 
1998a/b). The sIL-lra precursor possesses a leader sequence, and so is cleaved and 
secreted normally, whilst the intracellular forms do not. While both sEL-lra and icEL-lral 
possess equal efficacy for the inhibition of EL-1 activity, icIL-lraEI is approximately 5-fold 
less effective at binding EL-1R (Arend et al., 1998; Black et al., 1989; Hannum et al.,
1990).
Investigation of the transcriptional regulation of IL-lra has determined separate 5’ 
regulatory regions for the 18kDa and 17kDa forms. The promoter region for sEL-lra 
possesses one inhibitory LPS response element (LRE), and an additional 3 positive- 
response binding sites (LRE1, LRE2, LRE3)(Smith et al., 1994). Of these, one has been 
identified as a binding site for NFkB (LRE1), while a second site binds PU.l (essential for 
LPS induced secretion), although binding site consensus sequence data suggest a second 
binding site for PU. 1, overlapping the NFkB site, and competing for binding with not only 
NFkB, but with the transcription factor GABP (Smith et al., 1998). A STAT6  binding site 
in LRE3 mediates EL-4 induction of EL-lra production (Ohmori et al., 1996).
28
The incidence of increased EL-Ira release in rheumatoid disease has been well 
documented. Raised levels of plasma IL-lra have been detected in patients with juvenile 
arthritis (De Benedetti et al., 1995; Prieur et al., 1987), polymyositis (Gabay et al., 1994), 
SLE (Suzuki et al., 1995) and RA (Chikanza et al., 1995). RA patients exhibited a lower 
IL-lra to IL-lp ratio than patients suffering from osteoarthritis or osteomyelitis, which 
suggests that there may be a deficiency in IL-lra production from rheumatoid patients 
(Chikanza et al., 1995). This is supported by the observation that in patients showing 
clinical improvement in response to MTX or gold, there was an increase in IL-lra 
production (and corresponding increase in EL-Ira to EL-ip ratio) from peripheral blood 
monocytes (Seitz et al., 1995; Seitz et al., 1996; Shingu et al., 1995).
EL-Ira has also been detected at raised levels in the synovial fluid of patients with RA, 
although soluble IL-1RI may have obscured the results obtained with ELISA. It is thought 
that neutrophils may be the primary source of EL-Ira in synovial fluid, although the EL-Ira 
to EL-ip ratio for these cells is less than for peripheral blood neutrophils (Arend et al., 
1994; Beaulieu & McColl, 1994; Malyak et al., 1993). Although EL-lra mRNA and 
protein are localised to macrophages in the sublining and perivascular synovial tissue, 
cultures of rheumatoid synovial tissue show a significantly reduced IL-lra to EL-lp ratio 
(Firestein et al., 1992; Firestein et al., 19946; Fujikawa et al., 1995; Chomarat et al., 
1995). EL-lra production in these cultures was enhanced with the addition of EL-4, EL-10 
or EFNy, consistent with similar results observed in macrophages, so this would suggest 
that while the potential exists for substantial EL-lra release from synovial tissue, the actual 
quantities of EL-lra released are insufficient to overcome the effects of EL-1 (Chomarat et 
al., 1995, Seitz et al., 1994). It has been estimated that IL-lra is required at 10-100-fold 
excess compared to the concentration of active IL-lp to reduce IL-lp activity by 50% 
(Arend et al., 1990).
1.2.2: Tumour Necrosis Factor Alpha (TNFa)
The pro-inflammatory cytokine TNFa is of major importance in the pathogenesis of RA. It 
is considered to be the dominant regulator of EL-lp production (inducing IL-lp release to 
similar levels as LPS), and shares many of the biological actions of EL-ip, often leading to
29
an increased effect due to synergy between the two cytokines. TNFa also stimulates 
production of the pro-inflammatory cytokines GM-CSF, IL- 6  and IL-8 , and induces an 
upregulation of HLA-DR antigen and IL-2R expression on T-lymphocytes, leading to an 
increase in the efficiency of antigen presentation (Brennan et al., 1989; Butler et al., 1995; 
Feldmann et al., 1996; Haworth et al., 1991). In rheumatoid patients, there can also be an 
activation of synovial fibroblasts leading to increased secretion of collagenase and 
prostaglandins, and stimulation of osteoclasts resulting in bone resorption (Bertolini et al., 
1986).
TNFa is produced as a 26kDa propeptide, and is induced by a wide range of stimuli, 
including EL-1, IFNy, LPS and mitogens. Its active form in solution is as a trimer 
consisting of 17kDa subunits, although a small proportion (approximately 1-2% in the 
propeptide form) can possess biological activity as a transmembrane protein (Dayer & 
Fenner, 1992; Vilcek & Lee, 1991). There are 2 distinct TNF receptors (TNFR), of 55kDa 
and 75kDa length, transmembrane proteins that are distributed differentially between cell 
types, enabling the promotion of distinct biological responses (Loetscher et al., 1991; 
Schall et al., 1990; Tartaglia et al., 1991). The extracellular fragments of these receptors 
can be shed, and these soluble TNFR can then act to inhibit the activity of TNFa 
(Engelmann et al., 1989; Seckinger et al., 1988). The production and activity of TNFa can 
be inhibited by EL-4, as demonstrated in rheumatoid synovial cell cultures (Miossec et al., 
1992), although this can also cause increases in transmembrane TNFR expression (Cope et 
al., 1993). IL-10 is also an active inhibitor of TNFa activity, as the treatment of synovial 
cell cultures with anti-IL-10 antibody enhanced both IL-1 and TNFa production, whilst the 
addition of exogenous IL-10 to these cultures reduced TNFa production by 50% (Katsikis 
et al., 1994)
TNFa is found in over 50% of rheumatoid synovial fluids, often from patients with active 
disease, or producing rheumatoid factors (Dayer & Fenner, 1992; Di Giovine et al., 1988; 
Saxne et al., 1988; Tetta et al., 1990; Westacott et al., 1990; Yamagata et al., 1988). 
TNFa was also detected in over 50% of rheumatoid synovial samples, localised primarily 
to the macrophages and synovial lining cells (Chu et al., 1991). Although having little 
effect when injected alone, TNFa acts to exacerbate the inflammatory response caused by 
IL-1 when injected into rabbit knee joints (O’Byme et al., 1990). Recent evidence has
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suggested a possible mechanism for its synergy with IL-1 to the triggering of NIK 
(described in 1.2.1), although by a different signalling route through TRAF2 (Baeuerle,
1998).
However, the pivotal role of TNFa in RA pathogenesis gained significant acceptance 
following the creation of transgenic mouse models, expressing modified human TNFa 
(Keffer et al., 1991). These mice rapidly developed an erosive arthritis, although it is not 
understood why this was the only primary pathology, as the TNFa was expressed in all 
tissues. However, treatment with neutralising anti-TNFa antibody was sufficient to 
prevent the onset of symptoms. This arthritis was lymphocyte independent (Feldmann et 
al., 1996), and therapy with a neutralising antibody to IL-1 RI was also protective (Probert 
et al., 1995). Considering that in human rheumatoid synovial cultures, TNFa is the 
primary stimulus for IL-1 production (Brennan et al., 1989), it seems likely that in the 
animal model at least, the pro-arthritic effects of TNFa are mediated via IL-lp (Feldmann 
et al., 1996). In addition, there has been substantial success using a range of anti-TNFa 
antibodies to treat RA in a range of clinical trials, described in more detail in section 
1.1.4.8 (Charles et al., 1999; Feldmann et al., 1996; Maini et al., 1997; Maini et al., 1999; 
Taylor et al., 1997).
1.2.3: Other Pro-Inflammatory Cytokines
Granulocyte-macrophage colony stimulating factor (GM-CSF) normally acts as a growth 
factor for monocytes as part of haemopoiesis, but can also activate mature monocytes and 
macrophages. There is evidence suggesting a contribution to the pathogenesis of RA, due 
to its induction and maintenance of HLA class II expression on RA synovial cells. In 
addition, it may possess other modes of actions, as it can augment neutrophil mediated 
cartilage degradation (Alvaro-Garcia et al., 1989; Alvaro-Garcia et al., 1991; Kowanko, 
1991).
Interleukin 6  (EL-6 ) does not exhibit pro-inflammatory properties in the same manner as 
EL-1 or TNFa, but can stimulate proliferation and differentiation of B-cells, contributing to 
the inflammatory effect via the production of rheumatoid factors and autoantibodies. It can 
also stimulate haemopoietin-1 activity and can activate T-cells, although there is evidence 
to show that it can provide a regulatory role by suppressing the transcription of IL-lp and
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TNFa (Hirano et a l, 1992; Schindler et al., 1990c). A major role of IL- 6  is the induction 
of the acute phase response (APR). The APR is induced in response to inflammation or 
tissue damage, and is characterised by an increase in plasma concentration of a range of 
functionally diverse acute phase proteins produced primarily by the liver, but also by 
intrestinal epithelial cells. These proteins, which include LPS binding protein and serum 
amyloid A, act to increase host defences and control inflammation (Gangloff & Goyert, 
1999; Vreugdenhil et al., 1999).
Of recent interest is IL-17 (initially termed CTLA-8 ), a (CD4+, CD45RO+) T-cell derived 
cytokine produced spontaneously from RA synovial explant cultures (Chabaud et al.,
1999), for which the receptor is ubiquitously expressed (Yao et al., 1995). It is interesting 
to note that this is a T-cell derived cytokine detected in a region where certain other T-cell 
derived cytokines (including EL-4 and IFNy) have been difficult to detect (Firestein et al., 
1990; Miossec et al., 1990).
There is evidence demonstrating EL-17 stimulation of IL-lp and TNFa production from 
human macrophages, and both ICAM-1 expression and chemokine production from human 
keratinocytes (Albanesi et al., 1999; Jovanovic et al., 1998). Other evidence shows 
stimulation of IL-6 , IL-8 , GM-CSF and PGE2 release from human fibroblasts (Fossiez et 
al., 1996; Yao et al., 1995), and the ability to induce differentiation and maturation of 
dendritic cell progenitors, as demonstrated by increases in surface expression of CD 11c, 
costimulatory molecules (CD40, CD80 and CD8 6 ), and MHC class II antigens 
(Antonysamy et al., 1999). There have also been observed increases in EL-ip and TNFa 
production in human chondrocytes (along with upregulation of both iNOS and Cox-2 
genes), alongside signalling events via the ERK1, ERK2, JNK and p38 MAPKs, 
suggesting that IL-17 mediates its actions in chondrocytes (at least) via the MAPK and 
NFkB pathways (Shalom-Barak et al., 1998). In addition, it has been demonstrated that 
IL-17 release from T-cells is actually from a Thl (and ThO) subset, and that Th2 cells are 
unable to produce EL-17 (Aarvak et al., 1999a). When it is considered that T-cells in the 
rheumatoid synovium are primarily of Thl phenotype (Miltenburg et al., 1992), it is likely 
that IL-17 possesses a role in regulation of macrophage activity by T-cells.
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IL-18, as previously mentioned, is a distantly related member of the IL-1 family, with 
related (but not cross-reactive) receptors and receptor accessory proteins, which also 
requires ICE for cleavage, maturation and secretion. There is a body of evidence 
demonstrating the regulatory activity of this cytokine, including induction of IFNy and IL- 
8 production, along with inhibition of IL-10 production (Ushio et al., 1996). Other 
research performed in chondrocytes has demonstrated induction of iNOS, Cox-2, IL- 6  and 
stromelysin gene expression (Olee et al., 1999), and also the possible involvement in the 
development and modulation of the Thl cytokine response (Gracie et al., 1999; Novick et 
al., 1999). Based upon this wide range of (primarily) pro-inflammatory actions, it is 
considered likely that IL-18 plays a significant role in a number of disease states, including 
RA (reviewed by Dayer, 1999).
1.2.4: Other Anti-Inflammatory Cytokines
Transforming growth factor p (TGFp) is a multifunctional cytokine that exhibits both 
stimulatory and inhibitory effects upon a range of cell types (Massague, 1987). It also 
possesses immunosuppressive effects, inhibiting T-cell proliferation and cytokine release 
(Kehrl et al., 1986a; Ranges et al., 1987). It can inhibit B-cell proliferation and the release 
of many isotypes of immunoglobulins, although it stimulates the release of IgA and IgG2 
(Coffman et al., 1989; Kehrl et al., 1986b). In addition, TGFp inhibits cytokine 
production, HLA class II antigen and adhesion molecule expression in monocytes (Chantry 
et al., 1989). However, TGFp is present in significant quantities in the rheumatoid 
synovium without any abatement of symptoms (exogenous TGFp added to synovial cell 
cultures in vitro had no additional effect) (Brennan et al., 1990), either indicating a lack of 
anti-inflammatory effect, that the maximal effect had already occurred, or that, as the cells 
were already activated, TGFp could have no additional effect. The situation is complicated 
by the apparent ability of TGFp to mediate both pro- and anti-inflammatory effects. For 
example, if  injected locally into the joints of normal rats, it induced rapid leukocyte 
infiltration and synovitis, while introduction of anti-TGFp antibodies into the joints of rats 
with arthritis lessened the existing inflammation (Allen et al., 1990; Wahl et a l, 1993). 
Alternatively, TGFp can inhibit the induction of metalloproteinases while stimulating the 
synthesis of type I and type XI collagen (Khalil et al., 1989; Lafyatis et al., 1989). As a 
result of this, the role of TGFp in RA is not clearly defined.
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Interleukin 4 (IL-4) is an important cytokine with regards to the progress of RA, but 
because of its absence, as IL-4 production has only been detected from a small (0.1%- 
0.3%) proportion of T-cells within the rheumatoid synovium (Steiner et al., 1999). It is 
capable of inhibiting LPS-induced release of PGE2 and pro-inflammatory cytokines from 
both human monocytes and synovial cell cultures, and so for some time was considered as 
a possible therapy for use in RA (Brennan et al., 1995; Essner et al., 1989; Hart et al., 
1989). IL-4 can also act to inhibit the production of superoxide in macrophages 
(Abramson & Gallin, 1990). In addition, IL-4 is capable of increasing release of sEL-lra, 
and can upregulate the expression of the “decoy receptor” IL-IRH (Colotta et al., 1993; 
Marie & Cavaillon, 1997). The other important role of IL-4, which may have some 
bearing on RA, is its role as a modulator of Th2 response, which will be discussed in a 
later section (1.4.3).
Interleukin-10 (IL-10) was previously known as cytokine synthesis inhibitory factor, and is 
abundantly expressed in the rheumatoid joint with an immunoregulatory role (Katsikis et 
al., 1994). Its synthesis is enhanced by the actions of PGE2 and NO (Benbemou et al.,
1997). There is a growing body of evidence supporting the role of IL-10 as an anti­
inflammatory agent, as its neutralisation with anti-ELlO antibodies leads to significant 
increases in IL-lp, TNFa, and macrophage inflammatory proteins (MIP-la and MIP-2) 
(Kasama et al., 1995). The downregulation of IL-lp release is mediated via CD40 and the 
CD40 protein tyrosine kinase (PTK) signalling pathway, and is synergistic with the effects 
of IL-4 (Poe et al., 1997). However, despite the wide range of anti-inflammatory actions 
of IL-10, and its presence in the rheumatoid synovial joint, its actions are not sufficient to 
control the inflammatory processes occurring there.
1.3: MONOCYTE/MACROPHAGES
As can be determined from the previous section, monocyte/macrophages may not be the 
final effector cells causing chronic inflammation and joint destruction in RA. However, 
they are certainly major contributors to perpetuation of the inflammatory condition through 
the release of the pro-inflammatory cytokines IL-lp and TNFa, and the imbalance between 
IL-ip and IL-lra release. As the regulation of monocyte activation and subsequent 
cytokine release is one of the major foundations of this thesis, this next section will
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describe the differentiation and development of the monocyte/macrophage cell lineage, 
followed by details of some of the possible roles of the cells in RA, and major stimuli 
causing activation of the cells.
1.3.1: Monocyte-Macrophage Cell Lineage
The differentiation from pluripotent stem cell to mature macrophage, and indeed the 
differentiation from stem cell to any of the range of potential cell types is still not 
completely understood, although in recent years a significant number of relevant cytokines 
have been identified. This development takes place in the bone marrow, and begins with 
the self-perpetuating pluripotent stem cells, which give rise to all blood cell types through 
a process of simultaneous lineage commitment, differentiation and proliferation (reviewed 
by Socolovsky et al., 1998). A wide range of cytokines act upon the process of cell 
differentiation, including (in the case of monocyte/macrophages) IL-3, IL-6, GM-CSF, 
stem cell factor (SCF) and macrophage colony stimulating factor (M-CSF) (Clark & 
Kamen, 1987; Metcalf, 1992). From pluripotent stem cell, cell differentiation in the bone 
marrow is first via CFU-GEMM (colony forming unit -  granulocyte-erythroid-monocyte- 
megakaryocyte), then to CFU-granulocyte-macrophage (CFU-GM), then to a monoblast 
and pro-monocyte stage which undergo several cell divisions before release into the 
bloodstream (Figure 1.1). The THP-1 cell line used extensively throughout these studies 
initially represents immature cells of the human monocyte/macrophage lineage (at the non- 
CD 14 expressing monoblast stage), requiring differentiation with 1,25-dihydroxyvitamin 
D3 (l,25(OH)2D3) in order to express surface markers of a more mature population (for 








Figure 1.1: Monocyte-Macrophage Cell Lineage
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Once released into the bloodstream, it is generally believed that these cells do not divide 
further, instead circulating for up to 5 days before binding to adhesion molecules, 
infiltrating their eventual location in the tissue and differentiating into macrophages (Hume 
et al, 1983). Even at this stage, these cells still maintain a substantial potential to 
differentiate, as depending on the tissue or organ infiltrated, or cytokine triggers due to 
immune responses, cells can differentiate into Kupffer cells in the liver, synovial 
macrophages, or osteoclasts, capable of contributing to bone destruction in RA (Burmester 
et al., 1997; Watrous & Andrews, 1989). In addition, in the presence of GM-CSF and IL- 
3, TNFa is capable of inhibiting macrophage differentiation, instead guiding the cell 
towards a dendritic cell type, specialised antigen-presenting cells (APCs) (Reid et al., 
1992; Sallusto & Lanzavecchia, 1994; Thomas & Lipsky, 1994). In RA, under conditions 
of inflammation, differentiation of infiltrating monocytes by inflammatory mediators can 
lead to the formation of granulomas consisting of epithelial and giant cells in both the 
synovial tissue and especially in rheumatoid nodules (Burmester et al., 1997).
Based on a number of recent papers utilising transgenic expression of the bcl-2 anti- 
apoptotic protein in a range of progenitor cells in growth-factor deficient hosts (Akashi et 
al., 1997; Lagasse & Weissman, 1997; Maraskovsky et al., 1997; Socolovsky et al., 1997), 
there is an alternative hypothesis regarding cell differentiation in the bloodstream. This 
suggests that progenitor cells are already “primed” with a course of differentiation and 
target tissue, and that growth factors are able to target specific receptors on the cells to 
deliver a survival signal rather than a signal for differentiation (Socolovsky et al., 1998), 
resulting in an enriched population based upon the growth factors provided. However, 
further investigation of this aspect is beyond the scope of this report.
Further evidence regarding differential activation or maturation of monocytes in RA can be 
obtained from their expression of surface adhesion proteins. Circulating monocytes from 
RA patients possess upregulated surface expression of the P2-integrin CD 11/CD 18 
complexes (especially CD 1 lb/CD 18 (CR3)), which act as receptors for the adhesion 
molecules ICAM-1, ICAM-2 and ICAM-3 present on activated endothelium in either 
constitutive or inducible forms (Liote et al., 1996). Increased levels of E-selectin and 
ICAM-1 have been detected in the synovial capillaries of RA patients, especially in areas 
of chronic inflammation such as the pannus (Veale et al., 1993). Rheumatoid monocytes 
also express increased levels of very late antigen-4 (VLA-4) and VLA-5, involved in
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adhesion to vascular cell adhesion molecule 1 (VCAM-1) and fibronectin (Elices et al., 
1990; Hemler, 1990). This can then facilitate the increased binding and infiltration of cell 
tissue characteristic of the inflamed rheumatoid synovial joint.
One primary role of macrophages is the phagocytosis of large particles (involving FcR and 
complement receptors), followed by lysosomal fusion and degradation and presentation via 
MHC class n. Activation of the cells via Fc receptors will be discussed in more detail 
later. (An alternative “coiling” phagocytosis can occur, in which a processus from the cell 
coils around the matter to be engulfed, and the matter is degraded intracellularly without 
the use of lysosomes. Such matter is believed to be processed for presentation via MHC 
class I) (Rittig et al., 1992; Rittig et al., 1994). The presentation of autoantigens (such as 
type II collagen, proteoglycan or heat-shock proteins) to synovial T-cells is one possible 
mechanism by which monocyte/macrophages contribute to the perpetuation of the 
inflammatory conditions in the synovium (Moots & Wucherpfennig, 1998; Nepom & 
Erlich, 1991), although confirmation of an exact (auto) antigen is proving elusive. In 
addition to the expression of MHC class n, the proteins CD40, CD54, CD80, CD8 6  (Liu et 
al., 1996; Ranheim & Kipps, 1994) and ICAM-3 (El-Gabalawy et al., 1994) have been 
detected on the surfaces of synovial macrophages. These surface proteins are responsible 
for functions during antigen recognition referred to as signal 2 , necessary for signal 1 
(MHC-antigenic epitope-TCR interaction) to trigger an effective response. In the absence 
of signal 2, the T-cell response actually results in tolerance to that particular antigen 
(Kinne et al., 1997). Perhaps a more important question in this regard, given the range of 
potential antigens or autoantigens available, would be to determine whether T-cells in the 
rheumatoid synovium are capable of responding to such signals, especially in chronic RA. 
This question, and the conflicting evidence regarding the activity of T-cells in the RA 
synovial joint, will be addressed in more detail later (section 1.4).
Although their precise role in the perpetuation of RA is still to be defined, 
monocyte/macrophages do exhibit a range of characteristics that suggest a substantial 
involvement. In RA, macrophage populations are enriched not only in the synovium, but 
also in the pannus, associated with areas of joint destruction (Klareskog et al., 1982; 
Palmer, 1995). The intensity of macrophage infiltration correlates directly with both the 
clinical activity of the disease and articular damage (Mulherin et al., 1996; Soden et al.,
1991). The cytokine profile in the rheumatoid synovium is predominantly macrophage
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produced (examined in section 1 .2 ), and there is increased production of both prostanoids 
and cytokines by both macrophages and peripheral monocytes (Firestein et al., 1990; Hahn 
et al., 1993; Seitz & Hunstein, 1985), along with an increase in phagocytic activity by 
peripheral monocytes (Steven et al., 1984).
Of recent interest has been the discovery that HC gp39 is expressed and secreted from 
peripheral-blood derived macrophages during differentiation from monocyte to 
macrophage. HC gp39 has also been detected at increased levels in both the blood and 
synovium of RA patients (Kirkpatrick et al., 1997). Although this provides a new marker 
of disease activity (not only RA, but also osteoarthritis, joint injury and others (Hakala et 
al., 1993; Johansen et al., 1993)), and is genetically well conserved from both mouse and 
Drosophila, its biological function has not yet been determined.
1.3.2: Mechanisms of Monocyte/Macrophage Activation
In this section several mechanisms of monocyte/macrophage differentiation and activation 
will be discussed. The interaction of both pro- and anti-inflammatory cytokines plays an 
important regulatory role in the progression of rheumatoid disease. The activation of 
monocyte/macrophages resulting in the release of various cytokines is therefore a major 
factor affecting the eventual outcome of the (auto-) immune response. There are obviously 
a number of factors in the synovial environment capable of activating 
monocyte/macrophages, as stimulation of macrophages with synovial fluid results in 
increased transcription of FcyRI and FcyRm as well as HLA-DR expression (Burmester et 
al., 1997; Sengupta et al., 1995).
LPS has been widely used as a classic potent inducer of IL-1 production, and so will be 
described carefully in terms of monocyte activation. Also included in some detail will be 
l,25(OH)2D3, used as a differentiating agent to drive the immature monocytic cell line 
THP-1 into a more mature phenotype, the triggering of FcR involved in responses to 
immune complexes or immunoglobulins and an outline of a number of other factors with 
some relevance to monocyte activation in RA. Interactions between T-cells and 
monocytes, either by cell-cell contact or through soluble mediators, will be covered in a 
later section (1.5).
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1.3.2.1: Bacterial Lipopolysaccharide (LPS)
Lipopolysaccharide (bacterial endotoxin) is a complex glycolipid present in the outer 
membrane of all gram-negative bacteria, and is a potent activator of a variety of cell types. 
It acts by inducing myeloid and non-myeloid cells to express a variety of genes coding for 
proteins that bring about the physiological changes associated with septic shock. 
Essentially, this syndrome is characterised by hypotension leading to inadequate blood 
supply to organs, followed by potential organ failure and, often, death (Cohen & Glauser, 
1991; Glauser et al., 1991). It consists of a repeating oligosaccharide chain linked to a 
hydrophilic polysaccharide core which is in turn attached to a hydrophobic domain called 
Lipid A. Studies involving Lipid A suggest that a significant proportion (if not all) of the 
biological actions of LPS are due to Lipid A, as synthetic Lipid A possesses full endotoxic 
activity (Rietschel et al., 1994; Takada & Kotani, 1989).
1.3.2.1.1: LPS Surface Receptor Interactions
The understanding of LPS signalling increased greatly with the discovery and cloning of 
lipopolysaccharide binding protein (LBP), a 60kDa glycoprotein and type-1 (IL-l/TNFa 
inducible) acute phase protein (Grube et al., 1994; Schumann et al., 1996; Su et al., 1994). 
LBP binds LPS (most likely at a 1:1 ratio) within the Lipid A portion of the molecule, and 
is a member of a family of lipid carrier proteins, capable of transporting amphipathic 
molecules in aqueous environments (Wright et al., 1990; Ulevitch & Tobias, 1994). LBP 
has been determined as being highly important for the binding of LPS to its primary 
receptor, membrane-bound CD 14 (mCD14), by assisting the association of LPS with 
CD 14 without which LPS signal transduction does not occur (except at high concentrations 
of LPS) (Wright et al., 1990).
CD 14 is a 53-55kDa glycoprotein expressed either on the surface of mature 
monocyte/macrophages (mCD14) or as a soluble form (sCD14) released into the serum 
(Frey et al., 1992; Wurfel et al., 1994). Membrane-bound CD 14 is not a transmembrane 
protein, and cannot by itself transduce cytoplasmic signals, leading to substantial research 
investigating the identity of the transmembrane proteins responsible for signal 
transduction. It is bound to a glycosylphosphatidylinositol (GPI) anchor, and acts as a 
receptor for LBP-bound LPS (Wurfel et al., 1994). This has been demonstrated by the
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proteolysis of monocyte CD 14 with human leukocyte elastase, resulting in inhibition of 
LPS-mediated cell activation, although this inhibition could be overcome with the addition 
of high concentrations of LPS (Le-Barillec et al., 1999). The binding between CD 14 and 
LPS, and subsequent internalisation of LPS has been linked to both the activity of LBP and 
the size of LPS aggregate involved, with larger aggregates and presence of LBP resulting 
in an increased rate of internalisation (Kitchens & Munford, 1998).
In addition to its role as LPS receptor, mCD14 has been shown to facilitate attachments to 
both activated endothelial and T-cells, although the physiological significance of this is 
unknown (Beekhuizen et al., 1991; Lue et al., 1991). It can act as a receptor for other 
bacterial and mycobacterial cell membrane constituents (generally involving lipoproteins, 
and independent of the action of LBP) (Bernardo et al., 1998; Giambartolomei et al., 1998; 
Wooten et al., 1998), and also acts as a receptor mediating the phagocytosis of apoptotic 
cells, without provoking the release of pro-inflammatory cytokines (Devitt et al., 1998).
The exact role of the GPI in signal transduction of LPS is uncertain. It has been 
demonstrated (using transfectants) that transmembrane forms of CD 14 are equally as 
capable of successfully binding LPS leading to LPS-induced activation of the cell as GPI- 
bound CD 14. However, anti-CD 14 antibody-induced cross-linking resulted in no 
detectable effect on the transmembrane form, but initiated a rapid calcium mobilisation 
signal from the GPI-bound CD 14, involving the actions of phospholipase C and protein 
tyrosine kinases (PTKs), suggesting perhaps importance of the GPI-CD14 in alternative 
signalling functions (Pugin et al., 1998).
The source of sCD14 is uncertain, although several possibilities have been considered, 
including release from GPI due to the actions of IFNy or phospholipase D (Metz et al.,
1994). An alternative possibility is direct secretion from myeloid lineage cells (or perhaps 
from an extra-myeloid source) (Feams et al., 1994). The functions of sCD14 are not as 
well defined, although there is some evidence suggesting possible actions of the protein. 
One role involves facilitating the activation of endothelial and epithelial cells in response 
to low levels of LPS, as these cells do not express mCD14 (Frey et al., 1992; Pugin et al., 
1993; Schumann et al., 1996). The involvement of LBP in this is uncertain, although it is 
certainly beneficial in vitro, and seems to be required for the activation of endothelial cells
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in serum (Pugin et al., 1993). There is also evidence to suggest an ability of sCD14 to 
activate monocytes in the absence of LPS, although this would be inhibited in 
physiological situations by the presence of an uncharacterised plasma factor (Landmann et 
al., 1998). It is possible that sCD14 acts as a shuttle molecule, facilitating the transfer of 
LPS to either high-density lipoprotein or into lipid bilayers (Vasselon et a l,  1997). Other 
evidence appears to suggest no significant role in activation of cells possessing GPI-CD14, 
and that in certain situations the action of sCD14 may be inhibitory (Haziot et al., 1994; 
Kitchens & Munford, 1998).
It has been determined that an additional protein distinct from the GPI-CD14 complex is 
required for the transduction of LPS signalling, and that this factor is protease sensitive 
(Vasselon et al., 1997). The Toll-like receptors (TLRs) were recently identified on the 
basis of their similarity to the Toll transmembrane receptor in Drosophila, and also share 
sequence homology with the intracellular portion of the EL-1R (Rock et al., 1998). Recent 
work has identified Toll-like receptor 4 (TLR4) as capable of inducing NFkB in a dose- 
and time-dependant fashion, in response to stimulation with CD14-LPS complexes (Chow 
et al., 1999). In addition, this signal is inhibited by E5531, a potent lipid A analogue that 
acts as an antagonist of LPS-induced activation. It is believed that E5531 antagonises LPS 
activity at its cell-surface receptor, and in the transfected system used the only protein that 
can account for the transmission of the LPS signal is TLR4. These data strongly suggest 
that TLR4 may be the essential transmembrane mediator of the LPS signal.
Endogenous inhibitors of LPS signalling have been discovered, in addition to the possible 
actions of sCD14 outlined above. Phosphatidylinositides are capable of binding to mCD14 
(utilising the action of LBP), and inhibit monocyte activation by preventing the binding of 
LPS, providing a possible modulatory mechanism for the LPS response (Wang et al.,
1998). Tissue factor pathway inhibitor (TFPI) is a plasma protease inhibitor that plays an 
important role in feedback inhibition of the coagulation cascade. It can be found 
associated with lipoproteins, stored in platelets, or associated with endothelium (prior to 
release by the action of heparin)(Novotny et al., 1991). However, in addition to the 
anticoagulant effect, a decreased IL- 6  response was observed when used in baboons to 
treat septic shock (Creasey et al., 1993). Subsequent investigations demonstrated an 
ability of TFPI to bind to LPS in vivo, preventing interaction with both LBP and CD 14 
(Park et a l, 1997).
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As mentioned earlier, there is a certain level of CD 14-independent signalling (in the 
presence of high concentrations of LPS), in which a number of receptors have been 
implicated. For example, it has been demonstrated that LPS can induce the production of 
acute phase proteins (including LBP) in CD 14 deficient mice (Haziot et al., 1998), and that 
the Lps gene product (identified as TLR4 by Poltorak et al., 1998) is required for this 
induction (Chow et al., 1999). A number of alternative receptors have been considered, 
including the complement receptor complexes CD 1 lb/CD 18 (CR3) and CD 11 c/CD 18 
(CR4). Although neither CR3 nor CR4 was found to be essential for the induction of 
NFkB and TNFa by LPS, there is evidence to suggest that CR3 can act as a CD 14- 
independant signalling molecule, as shown by LPS inhibition of anti-CR3 mAb binding, 
and anti-CR3 mAb binding leading to induction of inducible nitric oxide synthase (iNOS) 
and NO production in macrophages (Matsuno et al., 1998; Medvedev et al., 1998). The 
acetylated low-density lipoprotein receptor is also capable of acting as a receptor for LPS 
(Granowitz et al., 1993).
1.3.2.1.2: LPS-induced Signal Transduction Pathways
A significant number of signal transduction pathways have been implicated in the 
transmission of the LPS signal, and would appear to form a complex system regulating 
further gene transcription. These signals are generally alike in that they result in the 
activation of transcription factor NFkB, and subsequent expression of pro-inflammatory 
cytokine genes.
A primary route of LPS signal transduction is via the mitogen-activated protein kinases 
(MAPKs), including the extracellular signal-regulated kinases (ERKs), and the stress 
activated kinases c-Jun N-terminal kinase (JNK) and p38 (Hambleton et al., 1996; 
Weinstein et al., 1992; Weinstein et al., 1993), which when phosphorylated can translocate 
to the nucleus and upregulate transcription factor activity. LPS is capable of increasing 
ceramide release from the cell membrane (probably due to induction of sphingomyelinase 
cleavage of sphingomyelin) (MacKichan & DeFranco, 1999), and this can potentially 
activate JNK kinase via the MAPK kinase kinase (MEKK) TAK-1, and MAPK kinase 
MKK4 pathway (Sanghera et al., 1996). However, although successful in inducing JNK, 
treatment with C2-ceramide analogue did not result in activation of p38 or ERK
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(MacKichan & DeFranco, 1999). Other data suggest the involvement of the protein 
tyrosine kinases (PTKs), as the use of herbimycin A (a general PTK inhibitor) along with 
more specific PTK inhibitors was able to block MAPK phosphorylation and inhibit LPS- 
induced biological responses (Han et al., 1993; Weinstein et al., 1992). However, the Src- 
family PTKs Hck, Fgr and Lyn are not involved, or are at least non-essential for LPS 
signal transduction (Meng & Lowell, 1997).
Alternative data have implicated phosphatidylinositol-3-kinase (PI3K), activation of 
phospholipase D (PLD) and stimulation of protein kinase C (PKC) as intermediates in the 
LPS signalling pathway (Herrera-Velit & Reiner, 1996). Further investigation (Procyk et 
al., 1999) resulted in linking of this to ERK activation, with a proposed pathway as 
follows: Stimulation of (as yet to be determined) PTK by LPS results in activation of 
PI3K, followed by activation of PLD by both PTKs and PI3K. Phosphatidic-acid 
phosphohydrolase and PLD combine to produce diacylglycerol (DAG), a specific activator 
of DAG-sensitive PKC, which activates the MAPK kinase (MEK) and ERK cascade by an 
indeterminate route (Figure 1.2). It is considered unlikely that Raf-1 is involved in the 
activation of MEKs by LPS, as LPS-induced ERK activation in the BAC-1.2F5 
macrophage cell line was shown to be Raf-1 independent (Buscher et al., 1995).
GPI-Linked CD 14
C ______ LPS Extracellular
Cell Membrane
PTK PI3K Intracellular\ r /PLD ^  DAG______ ^  PKC .  MEK
Figure 1.2: PI3K Mediated LPS Signalling MAPK
There is also evidence linking the activation of NFkB following LPS stimulation with the 
IL-1R signalling pathway. TLR4 and IL-1R are both members of the IL-l/TLR 
superfamily, and experiments utilising dominant negative mutants for the IL-1R signalling 
pathway demonstrated that mutants without MyD88, IRAKI, ERAK2 and TRAF6 showed 
reduced induction of NFKB-luciferase activity in response to either IL-1 or LPS (Zhang et 
al., 1999). The greatest inhibition was observed with double negative NIK mutants, 
perhaps indicating this as an important step in the LPS signalling cascade.
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One interesting observation is that the blockade of NFkB activity by excess IkB is able to 
completely inhibit pro-inflammatory cytokine expression in response to LPS. However, 
the same blockade has only a small inhibitory effect on anti-inflammatory cytokines 
released following LPS stimulation (Bondeson et al., 1999). This indicates a range of 
mechanisms regulating pro- and anti-inflammatory effects, even in response to a single 
stimulus. This also suggests that blockade of NFkB, or preventing its activation, might 
prove an effective therapy for the treatment of chronic inflammatory diseases.
An indication of the differential signals that can be transmitted in response to LPS 
stimulation is the induction of iNOS, with corresponding NO production. As mentioned 
earlier in this section, stimulation via PI3K may be one route leading to the activation of 
ERKs. However, under conditions of LPS stimulation, specific inhibition of PI3K by the 
fungal metabolite wortmannin (or the synthetic inhibitor LY294002) results in stimulation 
of iNOS activity, while exhibiting no effect upon the induction of NFkB via MAPKs (Park 
et al., 1997). Indeed, the induction of NFkB was also shown to be essential for the 
induction of iNOS (Pahan et al., 1999). This may prove relevant in light of the discovery 
that the stimulation of IL-8  production by LPS is enhanced in the presence of reactive 
oxygen species, which were also shown to enhance the activation of the nuclear factors 
NFkB and AP-1 in human astrocyte cell line U373 (Tanaka et al., 1997). It has also been 
reported that both H2O2 and NO can activate Ras, a membrane-bound guanine nucleotide- 
binding protein that acts as a link between tyrosine kinase activation and downstream 
signalling events, including the MAPK cascade (Lander et al., 1995; Lander et al., 1996).
1.3.2.2: 1,25-Dihydroxyvitamin D3
The steroid hormone 1,25-dihydroxyvitamin D3 (l,25(OH)2D3) is the active metabolite of 
Vitamin D3, is produced exclusively in the kidney, and was originally considered a major 
physiological regulator of mineral metabolism in humans. It facilitates calcium absorption 
from the intestine, mobilises calcium from bone, and may have a role in renal reabsorption 
of calcium (reviewed Ross et al., 1994). It was later discovered that a receptor for the 
steroid (VDR) was present intracellularly in neoplastic cell lines, and that treatment with 
l,25(OH)2D3 could inhibit proliferation and differentiate the cells towards a more classic 
monocytic morphology. The VDR was then identified on monocytes and activated
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lymphocytes, suggesting an immunomodulatory role of l,25(OH)2D3 (Prowedini et al., 
1983). Since then, VDR has been detected in a wide range of cell types, including 
intestinal and colonic enterocytes, osteoblasts, parathyroid cells, distal renal cells and 
keratinocytes (reviewed Ross et al., 1994). Of particular importance to the field of pro- 
inflammatory cytokine studies was the discovery that l,25(OH)2D3 was capable of 
stimulating myeloid cells to preferentially differentiate along a monocyte/macrophage 
lineage. This property has been demonstrated in both mouse and human models, and in the 
case of the human pro-monocytic cell line U937 has been shown to upregulate IL-1 release 
in response to preconditioned T-cell derived medium (Abe et al., 1981; Amento et al., 
1984; Bar-Shavit et al., 1983). Confirmation of this differentiation-inducing action of 
l,25(OH)2D3 was obtained in both normal and leukaemic myeloid stem cells, driving the 
cells towards a monocyte/macrophage lineage (Koeffler et al., 1984). This technique is 
now used routinely in the study of pro-inflammatory cytokine activity, especially when 
using pro-monocytic cell lines, in which it induces an increase in CD l ib  and CD 14 
expression, and an increase in pro-inflammatory cytokine release (IL-1 (3, TNFa, IL-6 ) in 
response to additional stimulation (Chizzolini et al., 1997; Landmann et al., 1998; Vey et 
al., 1992). The mechanism controlling this differentiation is believed to be primarily due 
to effects on gene expression, and includes upregulation of PKC transcription (Obeid et al.,
1990), increased turnover of sphingomyelin (Okazaki et al., 1989) and increased 
expression of calcium binding proteins (Roth et al., 1993).
A number of other immunomodulatory or immunosuppressant roles have been determined 
for l,25(OH)2D3 of which a major effect appears to be the regulation of lymphocyte 
activity. Interestingly, the VDR appears to be present only on activated T-cells (Prowedini 
et al., 1983). The action of l,25(OH)2D3 inhibits the transcription and secretion of IL-2 and 
the transcription of IFNy in the T-helper (Th) lymphocyte population (Rigby et al., 1984; 
Rigby et al., 1987), while inhibiting the generation of cytotoxic T-cells (Merino et al.,
1989). The progression of relapsing encephalomyelitis (a mouse model of multiple 
sclerosis) was blocked by l,25(OH)2D3, with some of this effect due to increased 
transcription of IL-4 and TGFp (Cantoma et al., 1996; Cantoma et al., 1998). There is 
also a suppressive effect on immunoglobulin production by B-lymphocytes, although this 




There are two primary classes of Fc receptor (FcR), those responsible for transport of Ig 
across tissues to sites of action, and those present on the surfaces of effector cells, 
responsible for the induction of a range of biological responses when triggered by Ig or 
more usually, Ig-antigen immune complexes. It is this last class that has direct relevance 
to the activation of monocyte/macrophages. Within this class, specific FcR exist for each 
Ig subtype, these being FcaR (IgA), Fc5R (IgD), FceR (IgE), FcyR (IgG) and FcpR (IgM) 
(Fridman, 1991; Hulett & Hogarth, 1994). Of the above, only FcyR and FceR have been 
characterised in any detail, and of these only FcyR is directly relevant to 
monocyte/macrophage activity, FceR being present primarily on mast cells and basophils, 
and mediating the allergic response (Sutton & Gould, 1993).
The FcyRs mediate a range of activities, including phagocytosis (engulfing of microbial 
particles), endocytosis (similar to phagocytosis, but involving fragments <lpm  in 
diameter), the release of inflammatory mediators and the regulation of B-cell activation 
and antibody production (van de Winkel & Anderson, 1991). Endocytosis (as opposed to 
phagocytosis) provides a more efficient mechanism for the presentation of antigen to MHC 
class II molecules (Amigorena et al., 1992)
The FcyR family is divided into three subsets, these being FcyRI (CD64), FcyRH (CD32) 
and FcyRIII (CD 16). These designations generally refer to the a chain of the receptor 
complex, which comprise the Ig binding domains. Within each of these subsets exist 
several isotypes of the a chains, also including the potential for soluble receptors as well as 
membrane bound, by virtue of differential transcription or cleavage of membrane bound 
receptors (Fridman, 1991; Galon et al., 1995). They are all members of the 
immunoglobulin superfamily (as are most FcR), as opposed to the few that possess a more 
lectin-like structure (Raghavan & Bjorkman, 1996). Most FcyR a-chains (primarily FcyRI 
and FcyRIII) require association with a transmembrane y-chain (or possibly ^-chain) for 
signal transduction, although in certain cases the y-chain is also required for stability of the 
FcyR (Ernst et al., 1993; Raghavan & Bjorkman, 1996). These show homology to the £- 
chain associated with the CD3/TCR receptor complex, and share a common signalling
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motif consisting of a twice repeated YxxL sequence flanking 7 variable residues, which are 
designated immunoreceptor tyrosine-based activation motifs (ITAMs) (Cambier et al.,
1994). These then trigger signal transduction via activation of PTKs including members of 
the src, syk and tec families, followed by a number of other signalling cascades involving 
MAPK and PI3K (reviewed by Daeron, 1997). FcRs that do not trigger cell activation 
have no associated ITAM, such as FcyRHIB, which contributes to cellular activation 
through association with other FcR, or FcyRIIB, which possesses a single inhibitory YxxL 
motif designated immunoreceptor tyrosine-based inhibition motif (ITIM) (Daeron et al.,
1995).
FcyRI (CD64) is present primarily on monocytes, neutrophils, granulocytes and 
macrophages (Hulett & Hogarth, 1994; van de Winkel & Anderson, 1991). It binds 
monomeric IgG with high affinity, and as such can trigger effector responses at low IgG 
concentration, mediating phagocytosis and endocytosis when triggered by cross-linked 
antigen-IgG (Davis et al., 1995). Following internalisation, receptor-ligand complexes are 
retained in intracellular compartments and degraded (Harrison et al., 1994), and although 
this could potentially lead to presentation of antigen via MHC class II complexes, there is 
some doubt as to whether this occurs via this receptor (Raghavan & Bjorkman, 1996).
FcyRH (CD32) is distributed widely among the cells of the immune system, binding 
monomeric IgG with low to negligible affinity, reacting instead with aggregated IgG 
present in immune complexes (Hulett & Hogarth, 1994; van de Winkel & Anderson,
1991). There is evidence suggesting the requirement of the y-chain for signal transduction, 
although only in the FcyRUA and FcyRKC, with FcyRIIB possessing an ITIM motif in the 
cytoplasmic region. However, FcyRUA and C possess a single ITAM-like motif in their 
own cytoplasmic domain, which might render this unnecessary (Qiu et al., 1990). In either 
case, FcyRILA and C would then mediate conventional signalling via ITAMs following 
receptor cross-linking.
FcyRm (CD 16) is expressed primarily on macrophages, neutrophils and mast cells, and is 
the only FcR on NK cells. It is also a low affinity receptor, binding IgG immune 
complexes. There are 2 a chain genes identified, one coding for a protein with a 
polypeptide transmembrane region and a short cytoplasmic domain (FcyRIILA), and the
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other coding for an a-chain which is anchored to the membrane via a GPI linkage 
(FcyRIHB), and is expressed mainly in neutrophils (Hulett & Hogarth, 1994; van de 
Winkel & Anderson, 1991). FcyRIHA binds immune complexes and triggers signal 
transduction via an associated y-chain and associated IT AMs, while FcyRHIB binds 
complexes but does not induce a signal, although it is believed to cooperate with FcyRH to 
enhance responses such as phagocytosis (Daeron et al., 1994; Nagarajan et al., 1995).
Activation of FcR that signal via IT AMs leads to 2 primary biological events, these being 
cell activation and internalisation. FcyRI mediate ADCC by monocytes and macrophages, 
inducing superoxide production and the secretion of inflammatory cytokines, and including 
the activation of NFkB (Tsitsikov et al., 1995). FcyRUA also trigger NFkB activity in 
monocytes, triggering through the same signalling pathways as y-associated ITAMs 
(Tsitsikov et al., 1995). Cross-linking of FcyRIILA is also able to stimulate TNFa 
secretion in monocytes, of interest in RA as it is specifically expressed in the synovium 
(Abrahams et al., 1998).
FcR with ITAMs also internalise the cross-linking ligands, either by endocytosis or by 
phagocytosis (in phagocytic cells only). FcyRI and FcyRIHA mediate endocytosis and 
phagocytosis in an IT AM dependent manner, with endocytosis resulting in enhanced 
antigen presentation in MHC class II expressing cells (Amigorena et al., 1992), as did 
FcyRUA when expressed in macrophages. Phagocytosis requires phosphorylation of the 
IT AM, with corresponding phosphorylation of syk PTK during the process (Darby et al.,
1994). There is also evidence implicating a Ca flux during the phagocytic process, 
required for phagocytosis via FcyRUA at least (Edberg et al., 1995)
1.3.2.3: Other Inducers of Monocyte Activation
Phorbol-12-myristate-13-acetate (PMA) and other phorbol esters trigger signalling 
cascades primarily due to their capacity to act as analogues of diacylglycerol, and as such 
activate PKC (Sharkey & Blumberg, 1985). This can then promote the phosphorylation of 
a wide range of proteins and peptides, induce ICAM-1 expression, or potentiate the cells 
towards a signal following additional stimulus (Dean et al., 1994; Kurosaka et al., 1998). 
Phorbol esters have also been used, in much the same manner as l,25(OH)2D3, to
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differentiate early myeloid progenitor cells into a more mature form (Pedron et al., 1995). 
For example, pre-treatment of pro-monocytic THP-1 cells with PMA can potentiate the 
induction of pro-inflammatory cytokine transcription (IL-1 P and IL-8 ) and expression (IL- 
8 ) when later stimulated via the phagocytosis of apoptotic cells of the murine CTLL-2 cell 
line (Kurosaka et al., 1998).
Calcium flux, induced for example by the calcium ionophores ionomycin or A23187, can 
also be used to activate monocytes. For example, the incubation of isolated human 
monocytes with A23187 results in stimulation of IL- 8  mRNA transcription to levels 
comparable to LPS stimulation (Wilson et al., 1993). There is also involvement of calcium 
flux in the monocyte-lineage differentiation and maturation process, as isolated peripheral 
blood myeloid-lineage cells cultured with ionomycin or A23187 downregulated CD 14 
expression, acquired dendritic cell morphology, and expressed increased levels of MHC, 
costimulatory molecules and CD83, a dendritic cell surface protein (Czemiecki et al.,
1997), although when repeated using fractionated populations of cells, the purified 
monocytes (CD14+) were shown to respond only marginally to the ionophore stimulus, 
apart from a strong upregulation of ICAM-1 expression .
Cell adherence to a surface, containing for example fibronectin or laminin, is also 
sufficient to cause activation of monocytes, and in vivo often coincides with the ongoing 
maturation process. This signal is mediated via the signal transducer and activator of 
transcription 1 (STAT1), and can result in steady increases in ICAM-1 and FcyRI, although 
this increase can be prevented by the addition of TGFp (Coccia et al., 1999).
1.4: T-LYMPHOCYTES
The role of T-lymphocytes in RA has been debated at considerable length, with arguments 
over their importance ranging from minimal to vital for the initiation and ongoing 
progression of inflammation. This section will provide an overview of T-lymphocytes and 
their actions with relevance to RA, beginning with a brief overview of T-lymphocyte cell 
lineage, followed by the primary effectors of T-cell activation, and finally taking a look at 
the controversy regarding the role of T-lymphocytes in RA.
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1.4.1: T-Lymphocyte Differentiation
Pluripotent stem cells in the bone marrow give rise to lymphoid stem cells that migrate to 
the thymus. In the thymus, immature CD4+/CD8+ precursor thymocytes are used to 
generate phenotypically and functionally mature CD4+/CD8' or CD47CD8+ cells via a 
mechanism k n o w  as positive selection (Marrack & Kappler, 1997). An essential step 
during this maturation process is an interaction between the apTCR receptor complex on 
the immature thymocytes and MHC molecules (class I or II), determining whether 
maturation proceeds to the CD8 + or CD4+ lineage respectively (von Boehmer, 1996), after 
which they are released into the bloodstream. Upon cell activation, the CD45 isotype 
expressed on the cell surface is altered from the nai’ve, high molecular weight CD45RA to 
the low molecular weight CD45RO of the “memory T-cell” (Akbar et al., 1988; Deans et 
al., 1992). CD45RO+ T-lymphocytes are the phenotype preferentially recruited into the 
rheumatoid synovium (Sewell & Trentham, 1993).
1.4.2: T-Lymphocyte Activation 
1.4.2.1: TCR/CD3 and CD28 Signalling
T-lymphocytes in vivo require at least 2 signals for complete activation, these being an 
antigen signal via the TCR/CD3 complex (Signal 1) and a costimulatory signal via CD28 
(Signal 2) (June et al., 1994). Cross-linking of the TCR/CD3 complex occurs via 
MHC/antigen complexes, while triggering of CD28 occurs via the cell surface proteins 
CD80 (B7.1) or CD8 6  (B7.2) on the surface of APCs (June et al., 1994). In vitro, this 
mechanism has been simulated by using immobilised anti-CD3 and anti-CD28 antibodies 
(Levine et al., 1997), or through incubation with bacterial superantigen in the presence of 
endogenous APCs or Chinese hamster ovary cell (CHO) transfectants expressing HLA- 
DR4 and CD80 (McLeod et a l , 1998).
Activation via the TCR/CD3 complex triggers multiple signalling pathways including the 
recruitment and activation of src PTKs (Park et al., 1991). The signalling cascades 
triggered include those via phospholipase Cy (PLCy), which is responsible for the release 
of inositol-1,4,5-triphosphate (IP3) and DAG (Perlmutter et al., 1993). DAG, as mentioned 
earlier, then activates several isoforms of PKC, leading to the triggering of the MAPK
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signalling pathway (Buscher et al., 1995), while IP3 acts to mobilise intracellular Ca2+ 
stores (Weiss et al., 1984). However, in the absence of co-stimulatory signals, the end 
result is generally T-cell anergy or apoptosis. Thus the co-stimulatory signal determines 
whether the antigen presentation signal activates or deactivates subsequent immune 
responses (Mueller et al., 1989).
CD28 ligation acts as a positive stimulus for T-cell proliferation and IL-2 production, in 
the presence of an associated TCR signal (June et al., 1994). There is also an upregulation 
of IL-4, IL-8 , IL-3, IFNy and GM-CSF, and elements of the IL-2R (Guinan et al., 1994) 
with activation of PI3K isoforms and IL-2 release (Kapeller & Cantley, 1994). Surface 
expression of the P chemokine receptors CCR1, CCR2 and CCR5 are downregulated 
following CD28 ligation (Carroll et al., 1997). Triggering of CD28 also acts as a potent 
anti-apoptotic signal, although this is due at least in part to the induction of apoptosis 
inhibitor proteins such as Bcl-2 by IL-2 (Akbar & Salmon, 1997; Lu et al., 1997). 
Although there is evidence suggesting that other factors associated with T-cell activation 
can associate with PI3K (via the src kinases fyn and lck), such as the TCR/CD3 complex 
or IL-2R, activation via these pathways appears to be 4-5-fold less effective that that via 
CD28 (Prasad et al., 1994).
Downstream targets of the PI3K include the p70/85 s6  kinase (p70s6K), a ubiquitous 
mitogen activated serine-threonine kinase essential for continued proliferation following 
mitogen stimulation (Downward, 1994; Weng et al., 1995). Inhibition of p70s6K by 
rapamycin (which inhibits the effects of CD28 induced p70s6K activation) results in 
interruption of downstream signals responsible for the downregulation of IkB activity (Lai 
& Tan, 1994; Pai et al., 1993), suggesting that CD28, via p70s6K, may be able to 
upregulate NFkB activity. Another possible target for CD28 activated PI3K is the 
transcription factor AP-1, which requires triggering of both TCR and CD28 signalling 
pathways (Rincon & Flavell, 1994). AP-1 transcriptional activity is regulated by c-jun and 
c-fos gene transcription, and is under the regulation of the ERKs and JNK, respectively, 
suggesting PI3K triggering of the MAPK cascade. This is supported by the role of rac (a 
small, ras-related GTP-binding protein) as both a downstream regulator of PI3K activity 
(Hawkins et al., 1995) and as an upstream regulator of JNK activation (Coso et al., 1995). 
Specific PKC isoforms (8 , e, r| and Q triggered by products of PI3K (D-3 phosphoinositol
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lipids) are also capable of triggering MAPK cascades via ras itself, with PKCe (for 
example) being implicated in AP-1 and nuclear factor of activated T-cells (NFAT-1) 
induction (Kapeller & Cantley, 1994; Rao, 1994; Toker et al., 1994). Activation of the p38 
MAPK occurs in purified T-lymphocytes, but is dependant on solely the action of CD28 
(activation of the TCR is not required) (Schafer et al., 1999).
Also of importance in the co-stimulatory signal is cytotoxic-T-lymphocyte associated 
antigen 4 (CTLA-4), a high affinity receptor for B7 molecules that competes with CD28 
for ligand binding (Linsley & Golstein, 1996). CTLA-4 surface expression is highly 
activation dependent, with the receptor only becoming present on the surface of activated 
cells, and even then only at a low level (2-3% of CD28 expression). There is evidence to 
support a downregulation of IL-2 production and thus inhibition of proliferation due to 
CTLA-4 signalling (Krummel & Allison, 1996). This is supported by work utilising 
CTLA-4 knockout mice, which die rapidly of a lymphoproliferative disease, the effects of 
which are reduced substantially through the addition of soluble CTLA-4-IgG (Tivol et al., 
1997; Waterhouse et al., 1995).
1.4.2.2: Superantigen
As an alternative method of triggering CD3 mediated signalling, a method used in vitro is 
the addition of superantigens, a group of highly immunostimulatory proteins of bacterial or 
viral origin. In contrast to conventional antigen presentation, superantigens interact as 
unprocessed proteins outside the MHC class II binding groove on APCs (Dellabona et al., 
1990). The superantigen binds and activates all T-lymphocytes expressing specific Vp 
chains, resulting in vigorous T-cell proliferation, production of cytokines and stimulation 
of cytotoxic activity (Choi et al., 1990). APCs are required not only for the provision of 
MHC molecules to “present” the superantigen, but also to provide costimulatory signals 
via CD28 if complete T-cell activation is required (Lando et al., 1993). However, in the 
absence of APCs, superantigens alone are capable of inducing both anergy and 
proliferation (Cornwell & Rogers, 1999).
Staphylococcal enterotoxins (SE) are a group of superantigens sharing structural and 
functional homology, with a molecular mass of about 25kDa, and that number at least 10 
members (A-J, and toxic shock syndrome toxin-1 (TSST-1)) (Nilsson et al., 1999). The
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binding sites for the various SEs vary significantly, especially considering their similarity. 
For example, SEB binds to a site on the a-chain of MHC class n, while SEA binds to 2 
separate sites, a high affinity site on the P-chain (requiring co-ordination with a Zn ion), 
and a low affinity site on the a-chain with similarities to the SEB binding site, with both 
SEA sites required for functional activity (Dowd et al., 1996; Hudson et al., 1995). 
Further evidence suggests that the potency of SEA as a superantigen results from the 
simultaneous cross-linking of 2 MHC class II molecules, and the ligation of both SEA 
binding sites as a result (Tiedemann & Fraser, 1996).
1.4.2.3: Phorbol Ester/Calcium Flux
Members of the phospholipase family are responsible for progression of a number of 
signalling pathways, by the release of IP3 triggering calcium flux (Weiss et al., 1984), and 
PKC activation due to the release of DAG (Buscher et al., 1995). PLCy at least is involved 
directly in the transmission of the TCR/CD3 signal (Perlmutter et al., 1993). In vitro, this 
signal (and corresponding activation of T-cells) has been partially simulated through the 
use of phorbol esters (such as PMA and phorbol-12, 13-dibutyrate (PDBu)) and agents 
capable of triggering calcium flux (such as calcium ionophores ionomycin and A23187), 
thus mimicking the action of DAG and IP3 respectively (Berry et al., 1989; Truneh et al., 
1985). This can then lead to increased responsiveness to IL-2 via upregulation of high 
affinity IL-2R, and an upregulation of IL-2 release, in combination with a substantial 
proliferative response (Stoeck et al., 1987).
Additional data have determined that the full activation of NFkB in T-cells requires the 
combined action of a calcium-mobilising and PKC-activating signal. Stimulation with 
calcium mobilising agents activates either none or a small proportion of cellular NFkB, and 
PMA alone is likewise only a weak inducer of NFkB activity. However, simultaneous 
stimulation with these factors results in a strong NFkB activation signal (Baeuerle & 
Henkel, 1994). In spite of this, it seems unlikely that triggering T-cell activation by 
simulating the action of the phospholipases alone will have the full effect on T-cell 
activation as triggered by the combination of TCR/CD3 and CD28.
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1.4.2.4: Lipopolysaccharide (LPS)
LPS, in addition to its effects upon the activation of monocyte/macrophages, is also a 
potent stimulator of human T-cell proliferation and of Th-1 associated cytokines, although 
this requires the presence of viable monocytes. Replacement with paraformaldehyde-fixed 
monocytes or a mixture of monocyte-derived cytokines was unable to support LPS 
stimulated T-cell proliferation (Mattem et al., 1994). Further investigation revealed that 
this interaction was MHC independent, but required the action of costimulatory signals via 
CD80, and also required membrane CD 14 expression on the monocytes (Mattem et al.,
1998).
1.4.2.5: Oxidative Stress and Antioxidants
There is somewhat confused evidence regarding the effect of oxidative stress and 
antioxidants upon T-cell proliferation and activation. Early studies involving the addition 
of antioxidants observed the inhibition of T-cell proliferation, IL-2R expression and IL-2 
production, although suppression of IL-2 production was not consistent over all groups 
studied (Chaudhri et al., 1988; Novogrodsky et al., 1982). This was combined with data 
demonstrating the activation of lymphocytes by low concentrations of H2O2 (Finazzi-Agro 
et al., 1980). However, there is also evidence to suggest a downregulation of the CD3£- 
chain expression due to the action of H2O2 (Kono et al., 1996), presumably demonstrating 
the inhibitory effects of increased H2O2 concentration. Alternative data demonstrate that 
addition of either the antioxidant GSH or its precursor, N-acetyl-L-cysteine (NAC) results 
in promotion of synthesis and turnover of IL-2 receptors, IL-2 production and T-cell 
proliferation, or that decreases in GSH can lead to inhibition of these events (Fischman et 
al., 1981; Maurice et al., 1997).
More recent data have determined specific roles for ROS in signal transduction. A more 
detailed study of the effects of low concentrations of H2O2 detected increases in 
intracellular PKC activity, followed by the activation of MAPK and p70s6K, although this 
activation was not wholly PKC dependent (Whisler et al., 1995). ERK2, a member of the 
MAPK signalling cascade, is responsive to oxidative signalling during lymphocyte 
activation (Goldstone & Hunt, 1997). Pre-treatment with buthionine sulphoximine (BSO), 
a specific inhibitor of GSH synthesis, inhibited the stimulation of calcium mobilisation
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without significantly affecting other aspects of TCR-initiated signal transduction, while 
stimulation with TNFa only triggered significant tyrosine phosphorylation in GSH- 
depleted cells (Staal et al., 1994). This would suggest that GSH and other antioxidants 
play a role in mitigating inflammatory reactions. However, although there is evidence 
implicating both oxidants and antioxidants at several stages of signal transduction, there 
are also data that demonstrate that these effects may be specific to certain cell types 
(Brennan & O’Neill, 1995), and so any effects observed on signal transduction need to be 
given careful consideration before any conclusions are drawn.
1.4.2.6: CD69 Surface Receptor
During the activation of T-lymphocytes, a specific cell surface receptor is expressed, 
designated CD69. It is expressed as an early activation marker, induced rapidly 
(transcription within 30-60 minutes and declining within 4-6 hours) upon ligation of the 
TCR (Cohen, 1993), with surface expression within 2-3 hours, declining with a fi/2 of 
24hours upon removal of the stimulus (Muller & Kyewski, 1992). Important events 
required for CD69 expression are the activation of Ras, generally due to activation of PKC 
and a calcium flux (D’Ambrosio et al., 1994; Muller et al., 1993). CD69 expression 
discriminates between MHC dependent and independent stages of thymocyte selection, 
with expression marking the end of requirement for MHC involvement in the maturation 
process (Hare et al., 1999). An exact role for CD69 in RA has not been determined, 
although there is circumstantial evidence to suggest a link to RA pathogenesis (Marzio et 
al., 1999). It has been identified as a stimulatory receptor for NK cells, promoting 
cytotoxic effects (Borrego et al., 1999) and also as an inducer of the pro-inflammatory 
cytokine IL-15 in rheumatoid synovial lymphocytes (Ortiz et al., 1999), but as yet no 
putative ligand for CD69 has been proposed.
1.4.3: T-helper 1/T-helper 2 (Thl/Th2) Cell Balance
T-helper (CD4+) lymphocytes were first separated into 2 distinct subsets in 1985 and 
defined with regard to their profile of cytokine release and function capabilities (Mosmann 
et al., 1986). They are all previously primed memory (CD45RO) cells and thus derived 
from the naive CD4+ T-cells released from the thymus (Constant & Bottomley, 1997). 
Initial studies in murine models determined that the presence of Thl and Th2 subsets
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corresponded to ongoing cell-mediated and humoral immune responses respectively 
(Mosmann & Sad, 1996), although Thl/Th2 cells were also identified in other species, 
including humans (Romagnani, 1994). There is substantial evidence to suggest a role for 
Thl/Th2 cell balance in RA, and this will be mentioned in more detail in a later section 
(1.4.4).
Thl cells release a cytokine profile consisting of IFNy and IL-2, and as such are considered 
to promote a pro-inflammatory response, while Th2 cells release IL-4, IL-5, IL-6 , IL-10 
and IL-13 (promoting an anti-inflammatory response), although as new cytokines are 
defined, these lists will almost certainly grow (Constant & Bottomley, 1997). For 
example, the recently discovered IL-17 has been associated with Thl response (Aarvak et 
al., 1999a), as has IL-18 (Barbulescu et al., 1998). There is also a third subset, ThO, that 
produces a mixture of these cytokine profiles and as such could form a precursor group 
(Firestein et al., 1989), although there is evidence to suggest this might be due to merely a 
mixed population of CD4+ cells (Openshaw et al., 1995).
The differentiation of Thl cells occurs in response to a combination of IL-12 and IFNy. 
The role of IFNy is the inhibition of Th2 outgrowth, while IL-12 directly augments Thl 
differentiation whilst possessing no inhibitory effects upon Th2 (reviewed by Seder & 
Paul, 1994). This last observation appears strange, as one function of IL-12 is the 
upregulation of IFNy production by T-cells, suggesting a hierarchy of cytokine interactions 
in which IL-12 may be more easily affected by the actions of other cytokines. Th2 cell 
differentiation is primarily under the control of IL-4, with higher doses suppressing the 
differentiation of IFNy producing cells. In addition, the inclusion of anti-IL-4 antibody is 
capable of completely abrogating the development of Th2 cells, suggesting that IL-4 is 
essential for Th2 differentiation (Hsieh et al., 1992; Swain et al., 1994). Both IL- 6  and 
PGE2 have also been implicated in Th2 responses, IL- 6  by stimulating low levels of IL-4 
production from naive T-cells (Rincon et al., 1997), and PGE2 by inhibiting both the 
release of IL-12 from dendritic cells and the release of IFNy from T-cells (Hilkens et al.,
1997). In the absence of IL-4 and IL-12, it has been demonstrated that treatment with IL-2 
and anti-CD28 antibody can trigger naive cells towards a Th2 phenotype, although cells 
triggered in this manner differentiated towards Thl if additional TCR signals were 
provided. However, although the Th2 cells prepared in this manner would alter their
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phenotype in response to IL-12, the Thl cells remained unresponsive to exogenous IL-4 
(Moriggl e ta l., 1998).
In addition to the production and release of a range of cytokines, Thl and Th2 cells 
differentially express the receptors for a range of chemokines. Thl cells express CCR2, 
CCR.5 and CXCR3, with CCR1 and CXCR5 expressed on a specific subset of cells, 
enabling the binding of (among others) RANTES, MIP-la, MIP-lp and MCPs 1-4. Th2 
express CCR2, CCR3 and CCR4, with a subset of cells expressing CXCR5, providing 
receptors for the binding of RANTES, MCPs 1-4 and eotaxin (reviewed Sallusto et al.,
1998).
The Jak-STAT pathway, which mediates very rapid transduction of a signal into the 
nucleus, is responsible for activating cellular responses associated with Thl/Th2 cytokines. 
The Janus kinases (Jaks) consist of at least 4 PTKs, designated Jakl, Jak2, Jak3 and Tyk2, 
of which 3 are ubiquitously expressed, while Jak3 is present constitutively in NK cells and 
thymocytes, and is inducible in T-cells, B-cells and myeloid cells (reviewed by Leonard & 
O’Shea, 1998).
Jaks are activated following high affinity binding of a variety of cytokines to their 
multimeric cell surface receptors, with between 1 and 3 Jaks being activated depending on 
the ligand. Receptor ligation results in the formation of receptor dimers or oligomers, 
leading to activation of associated Jak(s). These then recruit and tyrosine phosphorylate 
signal transducers and activators of transcription (STATs), after which the STATs undergo 
dimerisation (forming either homo- or hetero-dimers). The activated STAT dimers then 
translocate to the nucleus, whereupon they bind to specific DNA sequences in the 
promoters of target genes (reviewed by Pellegrini & Dusanter-Fourt, 1997).
STATs are proteins consisting of between 750-850 amino acids, possessing a common and 
highly complex structural organisation (for example, 24 exons in the STAT2 gene), and a 
carboxy-terminal region showing significant diversity (Hou et al., 1994; Zhong et al., 
1994b). At least 8  genes have been identified that code for STATs, of which 7 are human 
and one found in Drosophila. STAT1 and STAT2 were identified as being involved in 
IFN signalling (Schindler & Darnell, 1995), with STAT3 being identified as an acute phase 
reactive factor activated by IL- 6  (Zhong et al., 1994a). STAT4 was identified through
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homology to STAT1 and is activated by IL-4 (Yamamoto et a l, 1994; Zhong et al., 
1994b), STAT5a and STAT5b are triggered by IL-3, GM-CSF and LL-5 (Azam et al.,
1995) and STAT6  was purified as a transcriptional factor involved in IL-4 responses 
(Quelle et al., 1995). These are by no means the only ligands activating STAT proteins, 
with a range of other cytokines, growth factors and receptor tyrosine kinases implicated in 
the activation of 1 or more STATs (reviewed by Schindler & Darnell, 1995), however in 
the context of the Thl/Th2 balance, the important triggers are IL-4 and IL-12, which are 
activators of STAT6  and STAT4 respectively.
STAT4 and STAT6  deficient murine models have been used to elucidate further the 
specificity of IL-4 and IL-12 signalling. There was marked impairment of IL-12 responses 
in STAT4 deficient mice, including an inability to upregulate IFNy production or stimulate 
proliferation (Kaplan et al., 1996; Thierfelder et al., 1996). There was a corresponding 
abrogation of IL-4 responses in mice lacking STAT6 , including failure to activate a 
number of inducible genes coding for cell surface proteins including MHC class II 
antigens, CD23 (FcsRII) and the IL-4R a-chain (Shimoda et al., 1996; Takeda et al.,
1996). T-cells from STAT6  deficient mice were also unable to differentiate into Th2 cells 
in response to IL-4 in vitro (Grusby, 1997). Further work, utilising double STAT4/STAT6 
deficient mice, was able to determine that Thl differentiation is possible by a STAT4- 
independent route, whereas Th2 differentiation requires the presence of STAT6 , and that 
isolated T-cells produced significant amounts of IFNy when activated in vitro (Kaplan et 
a l, 1998).
Corresponding research in using isolated human cells or cell lines has determined that the 
interactions in human cells appear to be a lot more complex than in the murine models. 
Many of the results initially observed in murine models have been repeated in human T- 
lymphocytes, although often with the discovery of complications. For example, in human 
T-lymphocytes there is evidence demonstrating the activation of STAT4 in response to IL- 
12, but this can also result in activation of STAT3 and/or STAT5 as well (Ahn et al., 1998; 
Jacobson et al., 1995). STAT4 has also been shown to be activated in T-cells following 
binding of IFNa (Cho et al., 1996). It has been demonstrated that EL-4 activation of 
STAT6  results in production of IL-4 and the closely related EL-13, but that in activated Th2 
cells this can occur in the absence of IL-4 (Huang et al., 1997), and also that a STAT6
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response element in the EL-4 gene promoter can be activated following stimulation with 
either IL-4 or EL-13 (Yu et al., 1998).
There have been several reviews challenging the “classic” view of Thl/Th2 differentiation 
into specific subsets, suggesting that such an inflexible framework overlooks the 
possibility of a more adaptable structure, and could well be resulting in an 
oversimplification of the system (Allen & Maizels, 1997; Kelso, 1995). As an alternative, 
it is suggested that factors affecting Thl/Th2 phenotype are actually skewing the 
population of cells towards a certain profile of cytokine release, and that either in the 
absence of a continuing stimulus or the addition of opposing stimuli, populations of cells 
could be reverted towards the opposing phenotype. This proposal is supported by a 
number of clinical conditions requiring both Thl and Th2 effects for successful resolution 
of the immune response, and also by the realization that Thl and Th2 represent the 
extremes of the cytokine production profiles, and that (as in the ThO subset) there are many 
examples of cells secreting combinations of “T hl” and “Th2” cytokines (reviewed in 
Kelso, 1995). This does not mean that the Thl/Th2 paradigm is of no use when 
considering disease states, merely that it is important to be aware that a range of responses 
is possible.
1.4.4: Role of T-Lymphocytes in RA
The importance of T-cells in RA pathogenesis has been debated for over a decade, with a 
review of the initial arguments for and against T-cells as primary coordinators of RA 
presented in 2 papers (Firestein & Zvaifler, 1990; Panayi et al., 1992). Since then, there 
have been a number of developments clarifying aspects of the arguments both for and 
against, but the degree of importance of T-cells in RA is still uncertain. In this section I 
will attempt to summarise the data regarding the role of T-lymphocytes in RA, with a view 
to addressing the underlying controversy as to their significance.
The likelihood of T-cells providing major stimuli for RA progression in the rheumatoid 
synovium was considered low for a number of reasons. Firstly, most articular T-cells were 
small and quiescent, with <1% of synovial DNA synthesis occurring in the lymphocyte 
population (Nykanen et al., 1986), along with very low levels of T-cell derived cytokines 
in the rheumatoid synovium (Bergroth et al., 1989). The early theories regarding T-cell
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involvement required the infiltration into the synovium of a homologous subset of specific 
antigen reactive T-cells, for which there was little evidence (Duby et al., 1989; Keystone et 
al., 1988), and in addition, infiltrating CD4+ cells required to mediate antigen recognition 
and stimulate antibody production were localised mainly in the perivascular space, separate 
from the B-cells requiring these signals (Ishikawa & Ziff, 1976). Both isolated synovial 
and peripheral T-cells from rheumatoid patients showed poor response to mitogens, recall 
antigens or exogenous IL-2 (Allen et al., 1995; Emery et al., 1988; Verwilghen et al.,
1990). These “anergic” cells are often found in excess in patients suffering severe disease, 
although paradoxically these patients also seem to respond well to T-cell depletion therapy 
(Homeff et al., 1991).
The identification of genetic susceptibility to RA or to more severe RA, followed by the 
“shared epitope” hypothesis, provided a framework explaining the predisposition of certain 
HLA-DR subtypes to rheumatoid disease. The hypothesis proposes that variations in the 
hypervariable region of MHC class II molecules lead to the selection of peptide fragments, 
which when presented via TCR select CD4+ cells predisposed to autoimmune activity 
(Gregersen et al., 1987). This would then relegate the role of T-cells to mediator of the 
autoimmune response, specifically selected due to a more fundamental fault in MHC 
presentation, although once activated, T-cells can also express MHC class II molecules and 
act as effective APCs (Bamaba et al., 1994).
There is also a substantial body of evidence suggesting or directly implicating T-cells in 
the immune response in the synovial joint. T-lymphocytes present in the rheumatoid 
synovium express surface markers of both long-term (CD45RO, HLA-DR) and recent 
(CD69, IL-2R (CD25) -  on a minority of cells only) activation, fundamental to the view 
that RA is a result of T-cell immune responses to antigens in the joint (Afeltra et al., 1997; 
Harris, 1990; Janossy et al., 1981). Plasma cells in the synovium produce as much IgG as 
peripheral lymph nodes (Schroder et al., 1996), supporting the view that the synovial 
membrane is a highly active immunological site, with T-cells stimulating B-cell Ig release. 
More recent applications of immunohistochemistry to examine tissue sections from 
rheumatoid synovium samples revealed expression of T-cell derived cytokines EL-2, IFNy 
and (to a lesser extent) IL-4 in a small proportion of the T-cell population (0.1-0.3%), 
primarily CD4+, in the perivascular areas (Steiner et al., 1999). There is also evidence to
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demonstrate the stimulation of TNFa release from monocytes in response to IL-2 (or IL- 
15) stimulated T-cells, in an antigen-independent manner (Mclnnes et al., 1997; Sebbag et 
al., 1997). Release of TNFa and IL- 6  from a small proportion of synovial T-cells was also 
observed (Steiner et al., 1999). In addition, it has been determined that the production of 
pro-inflammatory cytokines IL-ip, TNFa and IL-15 along with MMP-1 and MMP-3 in the 
rheumatoid synovium is highly dependent on the presence of T-cell derived signals 
(Klimiuk et al., 1998).
This argument that only a very small proportion of T-cells are required to exert an effect in 
RA is strengthened by the observation that small numbers of T-cells stimulate further 
immune responses in other diseases (for example, tuberculoid leprosy and multiple 
sclerosis (Modlin et al., 1988; Sun et al., 1991)). A non-specific mechanism of 
heterologous T-cell infiltration has been determined, in which memory T-cells enter 
inflammatory sites (including those in RA) due to upregulation of adhesion markers such 
as VCAM-1 on endothelial cells (Postigo et al., 1992), which is also linked to Thl 
expression of specific chemokine receptors (discussed later in this section) (Bonecchi et 
al., 1998). Of this infiltrate, only a minority of cells are likely to respond to any (auto)- 
antigens present (Panayi et al., 1992; Ziff, 1991), providing an excess of anergic cells, and 
this small number of active T-cells present (expressing the IL-2R) also corresponds to the 
limited numbers of cells releasing IFNy and IL-2 (Firestein & Zvaifler, 1990; Smolen et 
al., 1996). It is therefore a distinct possibility that that the auto-reactive T-cells might be 
only a small proportion of these active cells, but still of sufficient number to maintain the 
chronicity of the reaction or restimulated disease flares in RA (Panayi et al., 1992).
There is a recent proposition that Thl/Th2 ratio might be of prognostic value in assessing 
the severity of RA (van der Graaff et al., 1998). This study attempted to link the ratio of 
Thl/Th2 in peripheral blood to the outcome of disease after 9 months of DMARD 
treatment. Although a positive correlation was determined, there were a number of 
potential weaknesses in the reasoning, including measurement of only IL-4 versus IFNy, 
and taking no account of the possible presence of ThO cells, for example. There was also 
no apparent link between Thl/Th2 ratios and initial disease severity, but all patients were 
selected for similar levels of disease severity, severely reducing the range of such an 
indicator (Prevoo et al., 1995). In spite of this, there has been significant research
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implicating Thl/Th2 balance in the pathogenesis of RA. Several studies have 
demonstrated a shift towards Thl cells as determined by cytokine profiles and chemokine 
receptors present on T-cells isolated from rheumatoid synovial joints, often accompanied 
by an increase in the proportion (relative to Thl) of Th2 cells in the peripheral blood due to 
preferential tissue infiltration by Thl cells (Brauer et al., 1996; Dolhain et al., 1996; Qin et 
al., 1998; Yin et al., 1997). Additional work has correlated this increase in peripheral Th2 
(and associated increase in synovial Thl) with an increase in disease severity, as 
determined by ESR, CRP and radiographic joint destruction (van der Graaff et al., 1999; 
van Roon et al., 1997).
There are also data suggesting that Th2 differentiation in response to IL-4 is impaired in 
RA patients (Skapenko et al., 1998). This is supported by the detection of elevated levels 
of Thl cytokine mRNA in PBMC from RA patients (Schulze-Koops et al., 1995), which 
would also opposes earlier measurements of peripheral blood Th2 cells. However, this 
increased level of Thl cytokines was not related (in this study) to either Thl or Th2 cells 
numbers, and so a simple increase in cytokine transcription from Thl cells (or indeed, 
overall T-cell cytokine transcription) could account for this whilst accommodating the 
previous data, especially as an increase of IFNy mRNA was also detected. The relevance 
of Thl/Th2 balance in RA is strengthened by data demonstrating an inhibition of synovial 
Thl cell induced pro-inflammatory activity upon addition of exogenous IL-4 (van Roon et 
al., 1995), and an increase in IL-lra transcription mediated by IL-4 (Ohmori et al., 1996). 
The presence of the IL-4-like cytokine IL-13 in the rheumatoid synovium has been shown 
to be at very low levels relative to other cytokines (Woods et al., 1996).
The Thl promoting cytokine IL-12 meanwhile has been detected at significantly increased 
levels in synovial tissue from RA patients, with secretion of IFNy inhibited upon the 
addition of IL-12 depleting antibodies (Morita et al., 1996; Morita et al., 1998; Sakkas et 
al., 1998). Also, when added exogenously (as part of cancer treatment), IL-12 caused 
serious exacerbation of an existing RA condition (Peeva et al., 2000), confirming the 
capability of IL-12 to provoke an inflammatory reaction. CD4+ depleting antibodies 
showed only limited beneficial effects in the treatment of several autoimmune diseases 
including RA (Choy et al., 1992; Moreland et al., 1993), SLE (Hiepe et al., 1991) and MS 
(Lindsey et al., 1994). This was later discovered to be because the antibody preferentially
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depleted both naive and IL-4 producing cells in circulation, but had little effect upon the 
activated IL-12 and IFNy producing Thl cells (Rep et al., 1997).
1.5: T-LYMPHOCYTE/MONOCYTE COCULTURE
There are a wide range of immunological mechanisms requiring cell-cell surface 
interactions, including antigen-presentation, the activation of B-cells by direct cell-cell 
contact with T-cells (Clark et al., 1994; Parker, 1993), and recent evidence showing cell- 
surface-mediated 2-way interactions between B-cells and monocytes (Kienzle & Von 
Kempis, 2000; Langstein et al., 1998). There has been a substantial body of research 
investigating the interactions between T-cells and monocytes, focussing in recent years 
upon the direct cell-cell contact between the 2 cell types. In the rheumatoid synovium, 
tissue damage occurs in the perivascular regions where the T-cells and monocytes are in 
close contact, suggesting cell surface mediated mechanisms might be responsible for 
instigating inflammation and tissue destruction (Burger & Dayer, 1998; Firestein et al., 
1992; Firestein et al., 1994).
Early work in this field concentrated on the production of membrane bound IL-1 (IL-la) 
from murine macrophages in response to incubation with isolated T-cells, including T-cells 
incubated with a protein synthesis inhibitor emetine, demonstrating induction due to both 
T-cell cytokines and surface interactions (Weaver & Unanue, 1986). The study also 
introduced the capability of fixed macrophages to induce macrophage-stimulating cytokine 
production from T-cells. This study was expanded, and using Thl and Th2 clones it was 
shown that during antigen presentation mRNA was produced for both IL-la and IL-lp, 
and that the T-cell cytokine release was greater from Thl cells (Weaver et al., 1989). 
Further work (Landis et al., 1991) utilising human monocytes demonstrated that cell-cell 
contact with anti-CD3 mAh activated T-cells could trigger IL-1 mRNA production (within 
1-12 hours), but T-cells fixed with paraformaldehyde or treated with emetine were unable 
to stimulate IL-lp release. Soluble factors produced from activated T-cells were also able 
to induce EL-1 mRNA, but with a greater delay before transcription (>12 hours).
CD40 and CD40 ligand (CD40L, CD 154) are responsible for interactions between T-cells 
and B-cells, resulting in B-cell proliferation and antibody production. Wagner Jr. et al.
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(1994) proposed that as CD40 was also expressed on monocytes, CD40/CD40L 
interactions could be involved in stimulation of IL-1 synthesis. A monoclonal blocking 
antibody to CD40L was able to reduce monocyte IL-1 synthesis in response to membranes 
from anti-CD3 mAb activated T-cells, and a monoclonal activating CD40 IgM was able to 
induce resting monocytes to synthesise IL-1. This idea was opposed however by the 
observation that l,25(OH)2D3 differentiated THP-1 cells responded to stimulation with 
phytohaemagglutinin (PHA)/PMA activated, fixed T-cells with production of IL-1 p, TNFa 
and IL-6 , but did not express CD40 (Burger & Dayer, 1998; Vey et al., 1991). Also, Hut- 
78 cells (a T-lymphocytic cell line) were able to induce cell signalling in isolated 
monocytes by cell-cell contact, but did not express CD40L (Gauchat et al., 1993; Gazbar et 
al., 1990). Alternative data have suggested L-selectin as a possible surface receptor 
mediating these interactions. Jurkat cells express CD2 associated to carbohydrate 
molecules containing N-linked sialic acid, which induce TNFa secretion by direct cell-cell 
contact with monocytes, supported by data using both inhibitors and alternative ligands for 
L-selectin (Putz and Mannel, 1996). However, the carbohydrate residues associated with 
CD2 are characteristic of tumour cells, differing somewhat from those expressed in normal 
cells, and so might not be relevant for normal T-cell interactions. Other surface molecules 
that have been implicated in T-lymphocyte monocyte interactions include CD69 and 
lymphocyte function associated antigen 1 (LFA-1, CD 11 a/CD 18 complex) (Manie et al., 
1993). Using a Jurkat and THP-1 coculture system, it was demonstrated that anti-CD3 Ab 
stimulated Jurkats induced IL-1 from THP-1 cells through cellular contact, in a manner 
independent of Fc receptors. LFA-1 was shown to be involved, although most likely in 
mediating initial interaction, while antibodies to CD69 inhibited IL-1 production by 40- 
50%, suggesting a role in cell-cell mediated signalling (Manie et al., 1993). In 
experiments using isolated T-cells and THP-1 cells, antibodies against CD69, CD 11 a, 
CD l ib  (part of CR3) and C D llc (part of CR4) exhibited some inhibition of contact- 
activation, but this was a partial inhibition at best (Isler et al., 1993; Vey et al., 1992).
The induction of monocyte EL-1 p and TNFa release following cell-cell contact with fixed, 
PHA/PMA activated T-cells was confirmed using isolated human monocytes in addition to 
differentiated THP-1 cells (Li et al., 1995; Vey et al., 1992). Additional experiments also 
detected release of MMPs from monocytes or THP-1 cells cultured with fixed T-cells (or 
T-cell membranes) activated with either PHA/PMA or anti-CD3 mAb (Lacraz et al., 1994; 
Miltenburg et al., 1995). Release of TIMP was also detected from THP-1 cells when
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incubated with PHA/PMA activated, fixed T-cells or T-cell membranes, although not when 
using T-cells activated with anti-CD3 mAb. Providing additional relevance to RA, 
Rezzonico et al. (1998) demonstrated that in addition to the above effects, direct T-cell 
contact to fibroblasts or synoviocytes led to inhibition of synthesis of collagen types I and 
ID, partially due to the effects of T-cell membrane associated IFNy, TNFa and IL-la.
There has also been evidence linking T-lymphocyte/monocyte cell-cell contact with the 
release of both IL-lp and IL-lra. This study (Vey et al., 1997) showed cell-cell contact 
from activated, fixed T-cells or cell membranes stimulating both IL-lp and IL-lra 
production from THP-1 cells, and that inhibition of serine/threonine phosphatases by 
okadaic acid resulted in further upregulation of IL-1 p, while downregulating IL-lra 
release. An interesting aspect of this study was the incubation of freshly isolated T-cells 
with freshly isolated monocytes, together or separated by a porous membrane. 
Unstimulated T-cells had no significant effect, activated T-cell soluble factors (when 
separated from the monocytes by a porous membrane) induced a small increase in IL-lp 
and a substantial increase in IL-lra release, whilst coculturing the cells together resulted in 
great increases in both IL-lp and IL-lra, although substantially greater for EL-1 p release.
The other major factor implicated in differing levels of cytokine release from monocytes is 
the Thl/Th2 phenotype of the stimulating T-cells. Using Thl and Th2 derived clones, 
activated using either PMA/PHA or anti-CD3 and anti-CD28 antibodies, it was 
demonstrated that Thl cells induced higher levels of IL-1 p and lower levels of IL-lra than 
Th2 cells (Chizzolini et al., 1997). IL-lp production due to Thl stimulation corresponded 
to IFNy production by the Thl cells, but was not affected by neutralisation of IFNy, while 
IL-lra production induced by Th2 cells corresponded to IL-4 release, and was partially 
inhibited by IL-4 neutralisation. This supports the theory that the high proportion of Thl 
cells in the rheumatoid synovium may be at least partially responsible for the propagation 
of the chronic inflammatory response. Figure 1.3 displays the release of substances from 
monocyte/macrophages in response to T-cell derived stimuli, which Figure 1.4 outlines 



























Figure 1.3:T-Lymphocyte/Monocyte Interactions: Monocyte-Derived Factor 
Release Following T-Lymphocyte-Derived Stimulus
T-Lymphocvte


























Figure 1.4: Primary T-Lymphocyte and Monocyte Surface Proteins Potentially 
Involved in T-Lymphocyte/Monocyte Interactions
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1.6: THE AIMS OF THE STUDY
Pro-inflammatory cytokines have been implicated in the instigation and progression of the 
chronic inflammatory conditions present in rheumatoid synovium. IL-ip plays a pivotal 
role in the immune and inflammatory processes leading to tissue destruction in RA, but the 
underlying mechanisms controlling the continuous monocyte induction and resultant 
release of IL-lp and other pro-inflammatory mediators remain unclear. Following release, 
IL-1 P activity is regulated by the production of the specific receptor antagonist IL-lra, and 
also by IL-1 RE decoy receptors and their substantial expression in relation to the signal 
transducing receptor IL-1RI. Increased understanding of the factors regulating IL-1 
production and release could provide significant advances towards the development of 
therapy for both RA and other inflammatory conditions. The primary aim of this study 
was therefore to investigate the balance between IL-lp and IL-lra production and activity, 
with a view to manipulation of this balance in favour of an anti-inflammatory response.
There has been substantial interest in the induction of monocyte cytokine release following 
T-lymphocyte/monocyte interactions. Activation of both the T-cells and monocytes with a 
range of standard stimuli was shown to have differential effects upon the cytokine profile 
released. A range of potential surface markers and soluble factors have been investigated, 
and evidence implicating these factors in the release of either pro- or anti-inflammatory 
cytokines has been obtained. However, the mechanisms behind these cell-cell interactions 
(both direct contact and cytokine mediated) are still somewhat unclear, although there is a 
considerable body of data linking T-lymphocyte/monocyte interactions to the release of IL- 
lp and IL-lra. Based upon this information, the second aim of this study was to develop 
working models of T-lymphocyte/monocyte interactions based upon both freshly isolated 
cells and cultured cell lines. The design of these models would enable the investigation of 
different methods of activation on both T-lymphocytes and monocyte/macrophages, and 
would also enable investigation of differences between direct cell-surface mediated 
interactions and those due to the action of soluble factors. Once developed, these models 
could then be used in additional experiments to investigate the effects of various factors 
acting upon either T-cells or monocytes, and the effect of these manipulations on IL-ip 
and EL-Ira release.
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As mentioned above, the regulatory factors modifying the balance between IL-ip and IL- 
lra are still poorly defined. Immunomodulatory cytokines such as IL-4, IL-10, IL-12, IL- 
17 and IFNy all exhibit effects upon either T-cell or monocyte behaviour including 
stimulation of other cytokines, and indeed some (IL-4, IFNy) have been directly implicated 
in the regulation of IL-1 p or IL-lra release from monocyte/macrophages. Thl/Th2 
lymphocytes have been shown to possess differential effects upon monocyte cytokine 
release, by both cytokines and direct cell-cell contact, especially relevant considering the 
prevalence of Thl-like cells in the rheumatoid synovium. Different methods for the 
activation of T-lymphocytes (for example, PMA/PHA and anti-CD3 mAb) stimulate 
different profiles of release of cytokine and pro-inflammatory mediators from monocytes. 
In addition, given the substantial presence of ROS in the rheumatoid synovium combined 
with the ability of ROS to stimulate or regulate T-lymphocyte intracellular signalling (for 
example, induction of ERK2), it is not inconceivable that through manipulation of T-cell 
activation, ROS could have a considerable effect upon monocyte cytokine release. As 
such, an additional goal of this study was to investigate a range of factors that could affect 
monocyte release of IL-lp and IL-lra during RA, including cell surface proteins, soluble 
factors, oxidative stress, and Thl/Th2 ratio.
The other potential use of the coculture system would be to investigate the differing effects 
of T-lymphocytes and/or monocytes isolated from rheumatoid patients, in comparison with 
those from healthy controls. Such investigations could aid in highlighting potential 
differences in T-cell or monocyte activation (with regard to cytokine release and surface 
marker expression) and corresponding induction of monocyte-derived cytokines, with a 
view to potential targets for treatment of RA. In addition, the mechanisms of action of a 
number of the DMARDs in use today have not been fully characterised, and further 
understanding of the modes of action of these drugs could help to improve their effective 
use. Such information could enable the existing drugs to be more appropriately prescribed 
for specific symptoms/conditions, or provide a better understanding of the modes of action 
when considering multi-DMARD therapy, a common approach in current RA treatment. 
Thus, the final aim of the study was to characterise differences between T-cells and 
monocytes from healthy and rheumatoid subjects, with regard to the induction of monocyte 
IL-lp and IL-lra release. In addition, an attempt would be made to determine any
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difference in IL-1 p and IL-lra release from coculture systems including monocytes or T- 





Unless noted otherwise, all routine chemicals were purchased from Sigma Chemical 
Company Ltd. The constituents of buffers and growth media are detailed in Appendix 1. 
All tissue culture media were purchased from Gibco BRL technologies, with the exception 
of foetal bovine serum, which was purchased from Sigma Chemical Company Ltd.
2.1.1: Antibodies
Hybridomas were obtained from the American Type Culture Collection 
(ATCC)(Rockville, Maryland USA), and maintained by colleagues within the laboratory. 
These included anti-CD2 (OKT11), CD3 (OKT3), CD8  (UCHT-4), CD25 (HB8784), 
CD69 and HLA-DR4 (L243). The anti-CD 14 (UCHM-l) hybridoma was a kind gift to D. 
M. Sansom from P. Beverley (Jenner Institute, Compton UK) The purified antibodies from 
these hybridomas were a kind gift from D. M. Sansom. The anti CD-19 antibody (BUI2) 
was a kind gift to D.M. Sansom from I. MacLellan (University of Birmingham UK). The 
anti-CD80 antibody (BB1) and the anti-CD28 antibody (9.3) were kind gifts to D. M. 
Sansom from P. Linsley (Bristol-Myers Squibb, Seattle USA). Goat anti-mouse IgG, anti­
mouse IgG(F(ab) ’2 specific) FITC and isotype matched control mouse IgG2b-kappa 
(MOPC141) were purchased from Sigma Chemical Company Ltd. Mouse anti-human IL- 
4, IL-12 and IL-17 blocking antibodies were purchased from R&D Systems Ltd. 
Antibodies for ELISA of IL-lp and IL-lra were purchased from R&D Systems Ltd. Total 
human IgG was prepared by colleagues within the laboratory and was a kind gift from J. A. 
Baugh.
2.1.2: Cytokines
Recombinant human IL-lp, EL-Ira and IL-17 were purchased from R&D Systems Ltd. 
Recombinant human EL-4 and IL-12 were a kind gift from D. M. Sansom.
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2.1.3: Cell lines
The human monocytic cell line THP-1 was obtained from the European Collection of 
Animal Cell Cultures (ECACC). The human T-lymphocytic cell lines Jurkat (J16) and H9 
were obtained from the ATCC. CHO and COS-7 cells were a kind gift from D. M. 
Sansom.
2.1.4: Transfected cells
Chinese hamster ovary (CHO) cells stably transfected with human cDNA encoding CD80, 
Human Leukocyte antigen HLA-DR4 or both were a kind gift from D. M. Sansom. COS-7 
monkey fibroblast cells stably transfected with human cDNA encoding CD69 were a kind 
gift from J. A. Baugh.
2.1.5: General equipment
Tissue culture plastics were purchased from Fahrenheit Laboratory Supplies Ltd. Cell 
culture was performed in a laminar flow hood (Class II) using sterile laboratory technique. 
Incubation of cell lines, for either routine maintenance or assays was carried out in a 5% 
CO2 humidified incubator (Gallenkamp) kept at 37°C. All PBMC and monocyte cell 
manipulations were performed in polypropylene tubes to prevent loss of cells through 
adherence. When recovery of monocytes after incubation was required, sterile 
polypropylene tubes were used (14ml polypropylene Falcon tubes). Cells were counted 
using a Neubauer haemocytometer. Centrifugation of cell cultures was carried out in 
polypropylene tubes (14ml/50ml Falcon tubes) using a Beckinson GS-1592 bench top 
centrifuge with a S4180 rotor.
FACS analysis was performed on a Becton Dickinson FACStar Plus, using a lOOmW, 
488nm argon laser, with light being channelled by a 520nm±20 filter (FL-1) and a 
580nm±20 filter (FL-2).
An Ultraspec II spectrophotometer (LKB Biochrom) was used to perform the biochemical 
Na,K-ATPase assay. ELISA and BioRad assay (protein determination) plate readings
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were performed on a Dynatech MR5000 spectrophotometer. Proliferation assays were 
harvested using a 96-well plate harvester (Packard), and measured using a p Liquid 
Scintillation Top Counter (Packard).
EMSA nuclear extractions were carried out in 1.5ml polypropylene Eppendorf tubes, with 
sample centrifugation in a Biofuge Fresco (Heraeus Instruments, Germany) at 12,000g. 
EMSA protein separation was carried out in SE400 or SE600 Electrophoresis units (Hoefer 
Scientific Instruments, San Francisco USA).
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2.2: GENERAL METHODS
2.2.1: Basic Tissue Culture
All cell cultures were initiated from frozen stocks held in liquid nitrogen at Bath. Cell 
stocks were defrosted rapidly in a waterbath at 37°C, and washed three times in warm 
(37°C) medium to remove any residual DMSO before transfer to culture flasks.
J-16, H9 and THP-1 cell lines (and derivatives) were maintained in RPMI 1640, 
supplemented as shown in Appendix 1. J-16 cells were maintained between 0.3x106 ml' 1 
and 2xl06 ml"1, while THP-1 and H9 cells were maintained between 0.3x106 ml' 1 and 
lxlO6 ml"1. Cells were harvested on occasion for storage under liquid nitrogen to replenish 
stocks.
Chinese hamster ovary (CHO) and COS-7 cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM), modified as indicated in Appendix 1. Both CHO and COS-7 
cells were passaged every 3-4 days once the cultures had reached confluence. Culture 
medium was removed by aspiration, and the adherent cells washed once with sterile PBS 
before the addition of 1ml trypsin-EDTA (Gibco BRL technologies). Cells were then 
incubated for 5 minutes at 37°C to allow trypsinisation of the cell-flask interface before the 
cells were dislodged by gentle tapping of the culture flask. At this point, fresh medium 
was added to inactivate the trypsin, and the cells either harvested for further use or split at 
approximately a 1:10 dilution in fresh medium for continued growth. Cells were harvested 
on occasion (at the sub-confluent stage) for storage under liquid nitrogen to replenish 
stocks.
2.2.2: Cell Membrane Fixation
Cells utilised for membrane-bound stimulations were fixed prior to use with 0.025% 
glutaraldehyde. This process enables the surface bound molecules to interact with other 
cell types, whilst preventing production of soluble factors or further proliferation. To this 
end, cells were washed 3 times with sterile PBS, counted and the resuspended in 0.025% 
glutaraldehyde for 3 minutes at room temperature (1ml glutaraldehyde for every 5 million
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cells). Cells were then washed a further 3 times in culture medium to prevent any 
carryover of glutaraldehyde into further cell cultures.
2.2.3: Liquid N2 Cell Storage
Cells for storage in liquid N2 were first pelleted by centrifugation at 500g, and resuspended
7 1to a density of 1x10 cells ml" in culture medium containing 40% FCS. Cell suspension 
(lml) was then mixed with 1ml of culture medium containing 20% DMSO in a 2ml 
cryovial (Nalge Nunc International, Denmark), and frozen at -80°C overnight before 
transfer into liquid N2 storage.
2.2.4: Isolation of peripheral blood mononuclear cells (PBMC)
Patients were selected for the clinical studies from two distinct groups attending the 
RNHRD (Royal National Hospital for Rheumatic Diseases, Bath, UK), those with 
suspected early stage RA (Early Synovitis, ES), and those with chronic sero-positive RA, 
along with healthy controls. In addition, selected patients were being prescribed either 
non-steroidal anti-inflammatory drugs only (NSAIDs) or disease modifying anti-rheumatic 
drugs (DMARDs) in addition to NSAIDs. Patients who had received any steroid treatment 
within the previous 3 months were excluded from the study.
Peripheral blood samples were taken with informed consent from patients by venepuncture 
into EDTA vacutainers by trained hospital staff. The quantity of blood obtained (20ml) 
generally provided sufficient PBMC for all assays to be performed. Samples were diluted 
1:1 with sterile PBS before layering onto 15ml Lymphoprep (1.077g ml' 1 density gradient, 
Nycomed), in 50ml polypropylene tubes. Samples were then centrifuged at 350g for 30 
minutes at room temperature. After centrifugation, the upper plasma layer was removed 
by aspiration, and the PBMC harvested from the layer remaining above the Lymphoprep 
into warm RPMI. The cells were then centrifuged at 350g for 10 minutes to remove any 
trace of lymphoprep, and washed twice more in RPMI before a portion was transferred to a 
haemocytometer to determine cell numbers.
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2.2.5: Establishment and maintenance of T-cell blast cultures from PBMC
Freshly prepared PBMC (3-5x106 ml'1) were stimulated with staphylococcal enterotoxin A 
(SEA, lOng ml"1), which binds to HLA-DR molecules on the surface of antigen presenting 
cells (APC) within the PBMC population, such as monocytes, macrophages and B-cells. 
These APC also provide the co-stimulatory molecules required for T-cell activation, in 
synergy with SEA. The activated T-cell blasts were cultured (37°C, humidified 5% CO2) 
for up to 9 days before use, with additional medium being added every 2-3 days to 
maintain the culture at a density of between 2-4x106 m l'1. If additional cycles of 
stimulation were required, this was performed on day 7. CHO cells stably transfected with 
the costimulatory CD80 protein (B7.1), were incubated with SEA for 4 hours before 
membrane fixation as described earlier. These were then added to the culture (in fresh 
medium) at a ratio of 1 CHO: 5 T-cell blasts, and incubated as above. Blast cultures were 
also prepared from PBMC or purified T-cells stimulated with combinations of phorbol 
ester (PMA or PDBu) and ionomycin, or with anti-CD3 antibody (either plastic adhered or 
IgG aggregated) and fixed CHO-B7.1 cells.
2.2.6: Isolation of T-lymphocytes from PBMC
Freshly isolated PBMC (5xl06 ml'1) suspended in RPMI were placed in 9cm polystyrene 
Petn dishes (Falcon), maximum 5x10 cells per plate, and incubated at 37°C for 1 hour, 
during which time any monocyte-macrophages present adhered to the plastic surface. The 
remaining cells were then transferred into 15ml round-bottomed polypropylene tubes 
(Falcon), centrifuged at 350g for 5 minutes, and the medium removed by aspiration. The 
resultant cell pellet was resuspended in 500pl anti-CD 14 (UCHM-1) antibody, 500pl anti- 
HLA-DR4 (L243) antibody and lOOpl anti-CD 19 (BUI2) antibody, and incubated at 4°C 
for 1 hour on a slow rotary mixer. (If purely CD4+ T-cells were required, 500pl anti-CD8 
(UCHT-4) antibody was also added at this stage). All antibody stock solutions were at a 
concentration of lpg/ml in RPMI. Cells were then washed 3 times in RPMI with 
centrifugation at 350g, and resuspended in 500pl RPMI and lOOpl of Sheep anti-mouse 
IgG Dynabeads (Dynal A.S., Oslo, Norway). Cells were then incubated at 4°C for 1 hour 
on a slow rotary mixer, after which RPMI (5ml) was added. The cells were then negatively 
selected by repeated exposure to a magnetic field (3 cycles) to remove the beads and
76
attached cells, with the remaining (unattached) T-lymphocytes being transferred to a clean 
tube after each exposure. A portion (10pl) of the remaining cell suspension was then 
transferred to a haemocytometer to determine cell numbers, and the purity of the T-cell 
preparation determined through flow cytometry.
2.2.7: Isolation of monocyte-macrophages from PBMC
Several methods were considered for the preparation of purified monocytes throughout 
these studies, primarily adherence selection and immuno-magnetic selection utilising 
magnetic beads. The most efficient system assessed, in both time and yield, was the 
Miltenyi Monocyte Negative selection kit (Miltenyi Biotec GmbH, Germany), using a 
Variomacs magnet and LS+ columns and adapter.
PBMC were washed in buffer (PBS supplemented with 10% autologous serum, 0.5% BSA 
and 2mM EDTA, then degassed), and then resuspended in fresh buffer to a total volume of 
60pl per 107 cells. 20pl of FcR blocking reagent and 20pl of Hapten-Antibody cocktail 
were added per 107 cells and incubated for 5 minutes at 6-12°C. The cells were the washed 
twice in buffer and resuspended as before. FcR blocking reagent was added again as were 
20pl of anti-hapten microbeads per 107 cells. The cells were then incubated at 6-12°C for 
15 minutes, then washed, resuspended in 500pl of buffer and loaded onto a buffer treated 
column. Negatively selected monocytes were washed through the column with buffer and 
retained, with purity assessed by flow cytometry (routinely >90% CD14+).
2.2.8: Proliferation assay: 3H-Thymidine Incorporation
T-cells were suspended at 4xl05 ml' 1 in fresh RPMI and aliquotted (lOOpl) in triplicate 
into round-bottomed 96 well plates (Falcon). To these were added lOOjLtl of various stimuli, 
including glutaraldehyde fixed CHO or CHO-B7 cells (lxlO 5 m l'1), PMA (0.5ng/ml) with 
or without ionomycin (lpM), and anti-CD3 (2pg/ml) with lOpg/ml anti-mouse IgG 
(causing antibody aggregation) and incubated for 48 hours. At this point H-thymidine 
(specific activity 6.7 Ci/mmol) was added (1 pCi/well), and the cells incubated for a further 
18 hours before being harvested onto 96 well glass fibre filter plates (Packard) using a 
Packard 96 well harvester. 3H-thymidine incorporation into the cellular DNA was then
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assayed using p liquid scintillation. This is therefore an indirect measure of cell 
proliferation.
2.3: Na,K-ATPase Assay
This biochemical assay measures the regeneration of enzymatically hydrolysed ATP by 
linking it to the oxidation of NADH, as shown below.
Mg2*, Na+, NR,*
ATP ----------------------------------► ADP + Pi
ATPase
Phosphoenolpyruvate + ADP ------------- ► ATP + Pyruvate
Pyruvate Kinase
Pyruvate + NADH -► Lactate + NAD+
Lactate Dehydrogenase
Cells to be assayed were washed twice in PBS, and resuspended at a density of lx l0 6 cells 
ml"1 (cultured cell lines) or 2.5x106 cells ml' 1 (PBMC). Triplicate 200pl samples were 
incubated at 4°C (on ice) for 30 minutes in the presence or absence of 200pM ouabain. In 
the meantime, the assay cocktail (Appendix 1) was prepared with addition for 250pM P- 
NADH, 0.1% saponin (filter sterilised) and 1.2 units/ml of both lactate dehydrogenase and 
pyruvate kinase, and then incubated at 37°C for 30 minutes. 0.1% saponin was then added 
to each sample, mixed gently, and incubated for 5 minutes on ice to allow for membrane 
permeabilisation to occur. The assay was initiated by the addition of 800pl of assay 
cocktail to each cell sample, and the change in absorbance (340nm) at 37°C monitored 
over time. A calibration curve was also constructed with the addition of ADP (0, 10, 20, 
40, 80, 160pM) in the absence of cells, allowing the determination of specific ATPase 
activity in each sample. The subtraction of values obtained in the presence and absence of 
ouabain allowed the determination of the Na,K-ATPase activity present.
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2.4: FACS analysis
2.4.1: Determination of cell surface m arker expression
Cell staining was achieved by incubating 2xl05 cells in 50pl primary antibody (lpg/ml in 
RPMI) for 30 minutes at 4°C. Cells were then washed with PBS, and the cells incubated 
with 50pl FITC-conjugated F(ab) 52 specific anti-mouse IgG (7pg/ml in RPMI), detecting 
any (bound) primary antibody still present. As a control, cells were also analysed after 
having been incubated with the secondary antibody alone.
2.4.2 Annexin V apoptest
This assay is based upon the “membrane-flip” which occurs during apoptosis, externalising 
phosphatidyl serine (Martin et al., 1995) which can be detected through its binding to 
annexin-V. Briefly, after experimental stimulation, 3xl05 cells were washed in ice cold 
PBS and resuspended in lOOpl HEPES buffer containing 2pl annexin-FITC reagent, and 
2pg/ml propidium iodide (PI), a nuclear stain used to determine membrane integrity in 
combination with FACS analysis. After incubation at room temperature for 10 minutes, 
cells were diluted 1:5 in HEPES buffer and analysed by flow cytometry, with annexin- 
FITC visualised as FL-1 fluorescence and PI staining as FL-2 fluorescence. Displaying 
FL-1 against FL-2 allowed distinction between apoptotic cells (FL-1+, FL-2') and necrotic 
cells (FL-1+, FL-2*).
2.S: Establishment of oxidant stress tolerant cell lines 
2.5.1: FACS analysis of H2O2 tolerance
To assess initial H2O2 tolerance before treatment, and also to determine any increase in 
H2O2 tolerance after treatment, cells were washed twice in PBS and resuspended in serum- 
free RPMI (Appendix 1), at lxlO6 ml"1. 1ml aliquots were transferred to capped 6 ml 
polypropylene FACS tubes and treated with a range of concentrations of H2O2 (lpM  to 
lOmM, dependent on cell type), before being incubated at 37°C for 2 hours. At this point, 
lOOpl of FCS was added per tube, and the cells incubated for a further 18 hours. Cells 
were then washed twice in PBS and resuspended in 500pl, to which was added 20pl PI
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(50pg/ml stock), and the cells analysed with flow cytometry (FL-2), using % PI uptake as 
an indication of cell death.
2.5.2: Treatment of cells with H2O2
J16 and H9 T-lymphocyte cell lines were washed twice in PBS and resuspended in serum- 
free RPMI at a density of lx l0 6 ml*1. Cells were then treated with H2O2 at a concentration 
determined by their tolerance (generally a concentration causing over 60% cell death), and 
incubated at 37°C for 2  hours. After this time, cells were harvested by centrifugation 
(350g, 5 minutes) and resuspended in an equal volume of RPMI. After 18 hours 
incubation, cell numbers and survival were determined using trypan blue exclusion on a 
haemocytometer. This protocol was repeated every 2-3 weeks, depending on recovered 
cell numbers, with increasing doses of H2O2. H2O2 tolerant cell lines produced using this 
method were designated HJ16 and HH9, respectively.
2.5.3: Reduced glutathione (GSH) assay
Cells were washed twice and resuspended in PBS at lx l0 6 ml"1. 500|il aliquots of cell 
samples were sonicated (3 five second pulses, 8-10Hz) to disrupt the cell membranes. 
500pl of assay cocktail (Appendix 1) was immediately added to both sonicated samples 
and GSH standards (0, 2, 4, 8 , 16 and 30pM), and the samples left to develop fluorescent 
adduct for 10 minutes at room temperature, protected from light. Samples were then 
measured on a fluorimeter, with a 1cm light path, and excitation wavelength 395nm, 
emission wavelength 470nm. A standard curve was constructed, and GSH levels in cell 
samples determined (per lxlO6 cells).
2.6: Thl/Th2 cell differentiation 
2.6.1: Cell culture and stimulation
PBMC were isolated from normal volunteers, and in certain cases the T-lymphocytes 
isolated. These cells were then stimulated with SEA (PBMC), CD3/B7, or PDBu/I (T- 
cells) either as a control culture or with the addition of IL-12 and anti IL-4 (Thl) or IL-4 
and anti IL-12 (Th2). After 8-9 days of blast culture, the cells were either restimulated or 
utilised further.
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2.6.2: Electrophoretic Mobility Shift Assay (EMSA)
2.6.2.1: Preparation of nuclear extract
All centrifugation was carried out in a bench top microfuge (12,500g) at room temperature 
unless otherwise stated, and samples stored on ice in 1.5ml polypropylene Eppendorf 
tubes. Cells (typically between 0.5-lxl07) were pelleted and washed once in 1.5ml ice cold 
PBS. Cells were then pelleted, and resuspended in 400pl Buffer A (Appendix 1), before 
being left on ice for 10 minutes for the cells to swell. Cells were then vortexed for 10 
seconds, centrifuged for 10 seconds, and the supernatants discarded. The pellet was 
resuspended in 60-100pl cold Buffer C (volume dependent on original cell count), and the 
cells incubated on ice for 20 minutes. Samples were then centrifuged for 2  minutes at 4°C 
to remove cellular debris, and the supernatants transferred to fresh Eppendorf tubes before 
being snap-frozen in liquid N2 and transferred to storage at -80°C. Protein concentrations 
of the nuclear extracts were then determined using the BioRad DC protein assay.
2.6.2.2: BioRad DC Protein Assay
A range of standard concentrations of BSA (0.1, 0.2, 0.5, 1.0, 2.0mg/ml) was prepared in 
Buffer C (Appendix 1). 5pi of samples and standards were then pipetted, in duplicate, into 
a flat-bottomed 96-well microtitre plate. 25pi reagent A (including 2% solution S) was 
then added to each well, followed by 200pl of solution B. The plate was then left for 15 
minutes while colour developed, before the absorbance (760nm) of each well was read on 
a microtitre plate reader (MR5000, Dynatech). A standard curve was constructed, and 
used to determine the protein concentration of each sample.
2.6.2.3: 32P oligonucleotide labelling
Oligonucleotide (STAT4, STAT6 , NFkB, AP-1) 2.5pl
PNK buffer (5x) (Promega) 5pi
y ATP (Redivue, Amersham) 2.5pi
T4 Polynucleotide Kinase (Promega) 1.5pi
Milli-Q H20  13.5pl
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A reaction mixture was prepared as indicated above, and incubated at 37°C for 10 minutes. 
The reaction was then stopped by the addition of lpl 0.5M EDTA, and diluted to a total 
volume of 50pl with TE buffer (Appendix 1). Oligonucleotides corresponding to STAT4 
and STAT6  consensus DNA binding sequences were obtained from Gibco BRL, and the 
sequences are detailed below.
STAT4: s’ CTAGGCGTGGCTTTCCCGGAATCCTTGAG 3’ 
STAT6: 5’ GTCTGATTTCACAGGAACATTTTA 3’ 
2.6.2.4: Determination of P incorporation
Duplicate samples (1 jllI) of labelled oligonucleotide were transferred onto separately 
labelled pieces of glass filter paper, and allowed to dry. 1 piece of filter paper was then 
washed for 5 minutes in 0.5M Na2HP0 4  (pH 6 .8 ), with the buffer discarded and replaced 
twice for a total of 3 wash cycles. This phase stripped the filter of any non-specifically 
bound yATP. The filter was then washed a further 2 times in Milli-Q H2O as a rinse. The 
second filter was then added, and both filters washed in ethanol (99.5%), dried, and 
transferred to a 24 well plate (Packard) for p scintillation counting. The ratio of 
specifically bound yATP to total yATP (measured as CPM) was generally >60% if the 
reaction was successful.
2.6.2.5: Gel shift/Supershift
A sample of each nuclear extract (12pl, 0.5mg/ml) in buffer C was mixed with 6 pi of 
binding mix (Appendix 1) in 0.5ml polypropylene Eppendorf tubes, and incubated at room 
temperature for 10 minutes. 2pi of 32P-labelled oligonucleotide (40,000CPM total) was 
then added to each tube, and the sample incubated for a further 2 0  minutes at room 
temperature. 5 pi of 6 % w/v loading dye was added to a buffer C control to act as a 
marker. Samples were then loaded onto a 5% non-denaturing polyacrylamide gel 
(Appendix 1), and the gel run in 0.5% TBE for approximately 2 hours at a constant voltage 
of 150V. The gel was then fixed with 10% v/v methanol, 10% v/v glacial acetic acid and
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5% v/v glycerol, before drying on filter paper and autoradiography. Exposure of the film 
was generally for 24 hours, with increased exposure time if required.
Supershift assays were carried out as above, apart from an additional incubation step pre- 
loading, in which 2pl of anti-STAT4 or STAT6  antibody was added per 20pl sample (as 
appropriate) and incubated for 30 minutes at room temperature before loading onto the gel. 
Anti-STAT4/STAT6 antibodies were obtained from Autogen Bioclear, and were supplied 
as 200pg IgG in 1ml PBS including 0.1% sodium azide and 0.2% gelatin.
2.6.3: FACS analysis
Activated cells were stained using CCR3 or CCR5 as primary antibodies, and then 
subjected to FACS analysis, to determine any shift in Thl/Th2 characteristics.
2.7: T-cell/monocyte interactions and cytokine production 
2.7.1: THP-1 differentiation
In order to use THP-1 cells as a model for monocyte/macrophages, they first needed to be 
differentiated with 1,25-dihydroxy vitamin D3 (l,25(OH)2D3). In a resting state, THP-1 
cells express CD 14 poorly, and show little response to LPS. THP-1 cells were washed 
once in RPMI and resuspended at 0.5xl06 ml"1. l,25(OH)2D3 (lOnM) was then added, and 
the cells incubated for 48hr at 37°C before use. Differentiation was confirmed through 
flow cytometry, with differentiated populations routinely showing >60% CD14+ cells.
2.7.2: T-cell/T-cell line activation
The effects of activation of T-lymphocytes and J-16 cells when used in monocyte coculture 
were investigated, with T-cells being activated with CD3/B7 ligation or phorbol esters and 
ionomycin (as outlined in section 2.2.8.1). T-cell activation was assessed through tritiated 
thymidine incorporation and by detection of activation surface markers through flow 
cytometry. T-lymphocytes and J-16 cells were suspended at lxlO 6 cells ml"1 in RPMI, and 
incubated with treatments for 18hr at 37°C. Before coculture, T-cell activation was 
assessed by measuring surface CD69 expression.
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2.7.3: Basic T-cell/monocyte coculture technique
Coculture experiments were assembled in 96 well U-bottomed plates, with all treatments 
carried out on duplicate samples. All cells were suspended in RPMI-1640 with 10% FCS.
Monocytes were suspended at initial densities of either lx l0 6 cells ml"1 (l,25(OH)2D3 
treated THP-1 cells) or 2xl06 cells ml"1 (PBMC/purified monocytes), giving final culture 
concentrations of 5x10s cells ml' 1 and lxlO6 cells ml' 1 respectively, of which lOOpl were 
added to each well.
T-lymphocytes (purified T-lymphocytes, T-cell blasts, J16/H9 cell lines) were suspended 
at an initial concentration of 5xl06 cells ml'1, giving a final concentration of 2.5xl06 cells 
ml' 1 of which lOOpl were added to each well.
Cells were then incubated for 48 hours, after which the plate was centrifuged in a plate 
spinner (350g, 10 min), with the supernatants harvested into a sterile 96-well plate and 
stored at -80°C until use.
2.8 Enzyme Linked Immunosorbant Assay (ELISA)
ELIS As were performed to determine IL-1 p or IL-lra content of coculture supernatants. 
Briefly, the wells of flat-bottomed 96-well plates (Nunc Maxisorb II immunoplates) were 
coated with 50pl of monoclonal primary antibody suspended in (mouse anti-human IL-ip 
IgG at 17.5pg/ml or mouse anti-human IL-lra IgG at 60pg/ml, diluted in 0.05M carbonate- 
bicarbonate buffer, pH9.6), and incubated at 4°C for 18 hours. Wells were washed once 
with PBS-Tween (PBS containing 0.05% Tween 20) and then blocked for 90 minutes with 
300pl per well of PBS containing 1% BSA and 5% sucrose. Plates were then washed 3 
times with PBS-Tween, and either used immediately or sealed and stored at 4°C until use 
(within 1 week). Standard dilutions of cytokine were added to the plate in duplicate wells 
(IL-lp at 0-2000pg/ml or IL-lra at O-lOOOOpg/ml) to allow the plotting of a standard curve, 
and test coculture supernatants also added to duplicate wells at a dilution of 1:3 with fresh 
RPMI, before the plates were sealed and incubated at 4°C for 18 hours. Plates were again
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washed 3 times in PBS-Tween, and 50jol of biotinylated secondary antibody added to each 
well (goat anti-human IL-lp IgG or goat anti-human IL-lra IgG at lpg/ml, diluted in tris- 
saline buffer (pH7.3) containing 0.1%BSA). Plates were sealed and incubated for 2 hours 
at 25°C, washed 3 times in PBS-Tween, and 50jj1 of streptavidin-HRP (horseradish 
peroxidase) at lpg/ml diluted in tris-BSA buffer added to each well. After a further 30 
minutes incubation, plates were washed thoroughly 4 times with PBS-Tween, and pounded 
dry. OPD substrate (50pl, Sigma FAST o-phenylenediamine dihydrochloride tablets) was 
then added to each well and the plates incubated at 25°C in darkness for 30-60 minutes, 
before the reaction was stopped with the addition of 50pl 0.5M H2SO4, and absorbance 
read at 490nm.
2.9 Statistical analysis
All data are generally presented as mean ± standard error (SEM) where sample numbers 
are sufficient. Statistical significance was tested using either Mann-Whitney U-test (non­
paired data) or Wilcoxon signed-rank test (paired data) as appropriate.
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CHAPTER 3
Development of a T-Lymphocyte/Monocyte Coculture System to 
Investigate Monocyte Cytokine Release
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3.1: INTRODUCTION
The aim of the experiments reported in this chapter was to capitalise on a model system 
being developed within the laboratory to study T-lymphocyte induced cytokine release by 
monocytes, with a view to gaining insight into possible interactions within the rheumatoid 
synovial joint. The potential applications of such a system are immense, and indeed the 
uses to which it has already been put form only a small proportion of the manipulations 
possible. Development of model monocytes and T-lymphocytes within the system could 
then be used to investigate factors acting upon each cell type specifically, influencing the 
release of pro- and anti-inflammatory cytokines by the monocyte. It would also be 
possible to substitute isolated T-lymphocytes or monocytes from rheumatoid arthritis (RA) 
patients into the system, and compare their effect with leucocytes isolated from healthy 
controls in response to the same range of stimuli.
Data collected in this study examine the effect of a range of factors upon monocyte 
cytokine production, specifically interleukin (IL)-lp, its receptor antagonist (IL-lra), and 
the balance between the two. Data were obtained using a coculture system based upon 
that developed by J-M Dayer et al., who demonstrated the production of cytokines from 
THP-1 cells when stimulated by activated T-cells (Vey et al., 1997). The technique and 
development of coculture are introduced in section 1.5.
In order to obtain inducible IL-lp release from the pro-monocytic cell line THP-1, cells 
required differentiation with l,25(OH)2D3 for 48 hours before use (J.A.Baugh, personal 
communication; Vey et al., 1997), and all THP-1 cells used in this study were 
differentiated in this manner. Differentiated THP-1 cells were washed thoroughly before 




3.2.1: Successful differentiation of THP-1 cells with l,25(OH)2D3 is demonstrated by 
an upregulation of surface marker CD14
THP-1 cells have been shown to possess little response to LPS, but it has been reported 
that 1,25-dihydroxy-vitamin D3 (l,25(OH)2D3) can be used to differentiate the cells along 
the monocyte/macrophage pathway. This results in an increase in expression of CD 14, a 
monocyte surface marker and also receptor for LPS, which was therefore used as an 
indication of successful THP-1 differentiation. All samples of THP-1 cells treated with 
l,25(OH)2D3 were tested for CD 14 expression, to ensure that the cells would demonstrate 
a reaction to LPS, and cultures exhibiting reduced CD 14 expression after differentiation 
were discarded. Although a pre-monocytic cell line, THP-1 cells remained non-adherent in 
culture, even when treated with l,25(OH)2D3, and so activation of the cells due to surface 
adherence was not a significant concern.
THP-1 cells were washed once in fresh RPMI, resuspended at a concentration of 5xl05/ml 
in RPMI, supplemented with lxlO ' 8 M l,25(OH)2D3, and incubated for 48h. The cells 
were then washed three times in PBS before being resuspended in fresh RPMI. Cells were 
then analysed for CD 14 surface expression using flow cytometry. The results overleaf 
(Figure 3.1) are representative of routine testing.
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Figure 3.1: Determination of THP-1 differentiation using anti-CD14 antibody.
Determination of THP-1 differentiation due to l,25(OH)2D3, measured as the level 
of FL-1 fluorescence due to binding of FITC conjugated secondary antibody to 
CD 14 specific primary antibody, detected with flow cytometry.
Panel A: Dot plots demonstrating increase in FL-1 fluorescence (with anti-CD 14 
antibody) due to l,25(OH)2D3 differentiation (indicative of routine testing).
Panel B: Histograms of FL-1 fluorescence, without/with anti-CD14 antibody.
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3.2.2: Differential LPS induction of IL-lp and IL-lra production by THP-1 cells in 
J16 coculture
It was important to determine baseline production of IL-ip and IL-lra by THP-1 cells 
alone and with J16 cells in the coculture system, as this would provide a marker against 
which any differential effects could be compared. The intention was to use the J16 cells as 
standard model T-cells in the coculture system, given the ease of expanding and 
manipulating this cell line in culture. In addition, the effect of standard concentrations of 
LPS on the above combinations would need to be determined, to determine appropriate 
concentrations of LPS to be used later to amplify IL-ip production.
J16 cells were incubated for 48h, and the cells and culture medium harvested for addition 
to coculture. Differentiated THP-1 cells were then incubated in the absence or presence of 
J16 cells or supernatant (to detect any soluble factors constitutively released by the J16 
cells), and with 2 concentrations of LPS for 48h before determination of cytokine levels in 
the coculture supernatants (displayed in Figure 3.2).
IL-lp production by THP-1 cells is stimulated to a limited degree by J16 cells and 
supernatant from 48h J16 cultures, but the quantities produced are almost negligible when 
compared to the induction of EL-lp by LPS. LPS induces IL-ip and IL-lra production in a 
dose dependent manner from THP-1 cells alone, with J16 supernatant having little or no 
effect. However, J16 cells appear to synergise to a limited extent with LPS to induce IL-ip 
production. The most noticeable effect however is the apparent ability of J16 cells to 
almost halve the baseline IL-lra production of THP-1 cells, and also to prevent any effect 
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Figure 3.2: Effect of LPS on IL-lp/ IL -lra production by THP-1 cells.
Panel A: IL-ip production by THP-1 cells in 48hr culture, either alone, or cocultured 
with J16 cells/J 16 culture supernatant, and stimulated with LPS. (n=6 ±sem)
Panel B: As Panel A, except indicating IL-lra production.
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3.2.3: Investigation of J16 activation by PDBu/ionomycin and J16 cell fixation on 
THP-1 cytokine production.
J16 cells had been shown to provide a limited stimulus to THP-1 cells, resulting in a small 
increase in IL-ip production (and perhaps a slightly larger increase by synergising with 
LPS), and also eliminating any LPS effect on IL-lra production. However, for use as a 
model T-cell, it would be preferable if  the cells could provide an increased induction of IL- 
ip. In order to investigate possible methods of cell activation, proliferation studies were 
carried out on J16 cells stimulated with CD3/B7, PDBu and PDBu in combination with 
ionomycin.
Unlike freshly isolated, unstimulated T-cells, the J16 cell line actually proliferates at a 
substantial rate, and factors routinely used to induce T-cell activation (and proliferation) 
often cause a significant reduction in the proliferative response of J16 cells, while still 
causing an upregulation in standard markers of T-cell activation. One such marker is 
CD69, one of the earliest markers to increase in expression after T-cell activation, reaching 
a peak well within 24h, with expression declining slowly over the course of several days. 
CD69 expression has been recorded throughout these studies as a marker of T-cell 
activation.
Neither CD3/B7 nor PDBu caused any detectable change in J16 proliferation, but the 
combination of PDBu with a calcium flux induced by ionomycin resulted in a substantial 
decrease in J16 proliferation (with CD69 data confirming that an activation event had 
occurred). In addition, it would be of great interest to investigate whether the effects upon 
cytokine production were due to the interaction of surface markers between the monocyte 
and T-cell, or due to the action of soluble factors released from the J16 cells.
Based upon these data, J16 cells were activated (18h) with PDBu/ionomycin, and both 
resting and activated J16 cells were used to stimulate THP-1 cells in the coculture system. 
In addition, resting and activated J16 cells were fixed using 0.025% glutaraldehyde (which 
kills the cell while “fixing” the cytoplasmic membrane and associated surface markers) to 
aid in determining any effect of the J16 surface markers alone on cytokine production by 
the THP-1 cells, and also any effect of the absence of any interaction between the cells 
based upon soluble factors.
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Production of EL-1 p by THP-1 cells is enhanced to a limited degree by coculture with 
activated J16 cells (compared with unstimulated J16 cells), especially in synergy with 
lower concentrations of LPS (Figure 3.3). The stimulation of IL-lp production by the 
higher concentration of LPS could well be masking any effect of the activated J16 cells. 
Regarding IL-lra production however, activation of the J16 cells had little effect upon the 
negation of the LPS effect, except perhaps restoring some production at the higher dose of 
LPS.
Fixation of the unstimulated J16 cells had limited effect on IL-lp production, leading to a 
reduced effect when in synergy with the highest concentration of LPS. On the other hand, 
fixed J16 cells have reduced ability to prevent LPS stimulation of IL-lra production, and 
also enhance IL-lra release to a small extent, (although given the low sample numbers this 
result should not be accorded too much significance). However, there are indications that 
soluble factors released from the J16 cells might be involved in the induction of EL-lp 
release and the inhibition of the release of IL-lra.
Activated J16 cells, when fixed, are less effective in their ability to stimulate IL-ip 
production, showing limited increases (if any) over baseline THP-1 cytokine production. 
However, there is a suggestion that the LPS might restore some induction of EL-Ira, and a 
possible increase over baseline THP-1 IL-lra production, although again it is uncertain 




















1 8 0 0
1 6 0 0








7 0 0 0
6 0 0 0
5 0 0 0
4 0 0 0










F J16 J 1 6 *
□  Ctrl
°  0 .1 p g / m l  LPS




□  0.1 p g / m l  LPS
□  1 p g /  ml LPS
FJ1 6'
Figure 3.3: Effect of activation (PDBu/I) and J16 cell fixation on IL-lp/ IL -lra 
production by THP-1 cells.
Panel A: IL-lp production by THP-1 cells in 48hr culture, either alone, or cocultured with 
J16 cells (* indicates previous 18hr PDBu/I activation, F indicates cell fixation before 
addition), and stimulated with LPS. (n=6 ±sem)
Panel B: As Panel A, except indicating IL-lra production. (n=3)
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3.2.4: Comparison of cytokine production from isolated monocytes and PBMC in
the basic coculture system.
In addition to using THP-1 cells as a model monocyte in the coculture system, it was 
intended that freshly isolated monocytes or peripheral blood mononuclear cells (PBMC) 
could be substituted into the system, and the modulation of their cytokine production 
investigated. It was therefore important to ensure that the cells could be used effectively in 
the system, and would respond to the same stimuli as the THP-1 cells. In addition, the 
technique for isolation of purified monocytes from PBMC, while effective, was both costly 
and time consuming, and if isolated PBMC could be used instead this would greatly 
improve the ease of throughput of samples.
As demonstrated with CD 14 staining and FACS analysis of both PBMC and purified 
monocyte samples, it is easy to identify the monocyte population by their increased size 
(FSC), granularity (SSC) and high levels of CD14 expression (Figure 3.4). This also 
provides us with a simple technique to determine monocyte purity after isolation. Isolated 
monocytes were typically of greater than 95% purity (as judged by CD14 expression, 
Figure 3.5).
The primary aim of this experiment was to determine if the patterns of cytokine production 
by PBMC and monocytes were similar. The actual quantities of cytokines produced were 
likely to be greater from the monocytes (due to the reduced proportion of monocytes in the 
PBMC), but if  similar patterns of cytokine release in response to standard stimuli were 
obtained, it would be likely that PBMC could act as an acceptable replacement for purified 
monocytes.
Isolated PBMC and purified monocytes were incubated for 48h in coculture with both 
unfixed and fixed unstimulated J16 cells. The cells were also stimulated with two 
concentrations of LPS to induce greater levels of cytokine production. Initial coculture 
experiments had led to the discovery that lower concentrations of LPS were required to 
induce IL-lp/IL-lra production from PBMC/monocytes than from THP-1 cells, and this 
was factored into the experiment, with LPS concentrations being lowered by a factor of 
one hundred.
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An initial overview of the results matches closely the expected outcome, although as these 
are the results from a single experiment, only a little weight can be attributed to the 
outcome. PBMC and purified monocytes exhibit similar patterns of response to fixed and 
unfixed J16 cells when stimulated with LPS, although the actual amounts of cytokine 
released are generally greater from the purified monocytes (Figure 3.6).
In comparison with THP-1 cells, the baseline IL-lp production of LPS stimulated PBMC 
and monocytes is greatly increased (between 2-5 fold), and the same is true to an even 
greater extent when considering the interaction of the freshly isolated cells with unfixed 
J16 in synergy with LPS. It is important to emphasize that whereas J16 cells do not induce 
great increases in IL-lp release from THP-1 cells, they do induce substantial increases in 
IL-lp release from PBMC and isolated monocytes. However, the general pattern in 
response to the stimuli remains the same, as fixed J16 also show little (if any) effect upon 
IL-ip production above that induced by LPS alone. This again suggests an important role 
for J16 produced soluble factors in the induction of IL-ip release from monocytes. The 
IL-lra results are more difficult to interpret, although again the pattern of response to 
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Figure 3.4: Demonstration of monocyte staining with anti-CD14 antibody.
Panel A: Dot plot demonstrating forward scatter (FSC) against side scatter (SSC) for 
control and UCHM-1 bound PBMC samples. Region R1 indicates monocyte 
population (n=l).
Panel B: Histograms indicating FL-1 fluorescence without/with anti-CD 14 antibody, 
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Figure 3.5: Determination of monocyte purity using anti-CD14 antibody.
Determination of isolated monocyte purity, measured as the level of FL-1 
fluorescence due to binding of FITC conjugated secondary antibody to CD 14 
specific primary antibody, detected with flow cytometry.
Panel A: Histogram of FL-1 binding, without/with anti-CD 14 antibody.
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Figure 3.6:Comparison of PBMC and monocyte coculture cytokine production. 
Panel A: IL-1 (3 production by PBMCs or monocytes in 48hr coculture, alone or with 
unstimulated J16 cells (unfixed or fixed), and stimulated with LPS (n=l).
Panel B: As Panel A, except indicating IL-lra production.
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3.2.5: Comparison of THP-1 cytokine production induced by purified T-cells, SEA T-
cell blasts and cultured PBMC cells.
In the same way that both THP-1 and PBMC were to be used as model monocytic cells in 
the coculture system, it was also an intention to substitute a more “realistic” T-cell for the 
J16 cell line in some coculture experiments. Three sources of T-cells were investigated, all 
initially from PBMC. Cultured PBMC themselves (3 and 6 day cultures in RPMI) were 
included, as the crude PBMC preparation includes approximately 50% T-cells. T- 
lymphocytes were purified with a negative selection protocol using a mouse anti-human 
antibody cocktail and sheep anti-mouse IgG coated magnetic beads (detailed in section 
2.2.6). Isolated PBMC were also stimulated with SEA (3 and 6 day cultures), causing 
expansion of the T-cell population specifically.
The primary problem in obtaining an easily prepared T-cell suitable for inclusion into the 
coculture system was ensuring the exclusion of all monocytes. As shown in the previous 
experiment (Figure 3.6), purified monocytes, especially when stimulated with LPS, could 
produce sufficient quantities of cytokines (especially EL-ip) to interfere with the 
experimental data being collected. In this experiment (and in any related experiment 
conducted later), controls containing “T-cells” but no THP-1 cells (replaced with medium) 
were included in the coculture experiment, so that any residual production of cytokines 
from the T-cell preparation could be determined.
Purity of the isolated T-cells was assessed using CD3 staining, and the technique available 
found to be quite unsatisfactory -  only a 76% purity was obtained, and the cytokine 
production from the T-cell sample alone was quite substantial. Monocytes also seemed to 
survive quite successfully in 3 and 6 day PBMC culture, with significant carry-over of 
cytokine production. SEA blasts, which were intended to produce a consistent population 
of T-cells and exhibited little carry-over of cytokine releasing monocytes, offered the most 
convenient method for the production of T-cells for use in the coculture system. In 
addition, (when adjusted for background cytokine production), unfixed day 3 SEA blasts 
induced EL-1(3 release from THP-1 cells to a far greater extent than that achieved by 
resting, purified T-cells, while still retaining a distinct synergistic response to LPS. Fixed 
SEA cells also induced a greater release of EL-lp than either fixed PBMC or T-cells,
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perhaps allowing a better investigation of the effect of any surface markers on IL-lp 
production.
Both purified T-cells and day 3 PBMC displayed a strong induction of IL-lra production 
(and an even stronger synergy with LPS), while SEA blasts only induced a 2-3fold 
increase in IL-lra release from THP-1 cells which was not affected by LPS (in a similar 
manner to J16 cells) (Figure 3.7). Fixing day 3 SEA blasts caused a reduction in IL-lra 
release compared to unfixed blasts (Figure 3.8), but the cells retained the ability to 
synergise with LPS, while fixing T-cells and PBMC severely reduced their stimulation of 
IL-lra release and any synergy with LPS.
Based upon these data, it was decided that SEA blasts would be examined further as 
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Figure 3.7: Direct Comparison of unfixed T-cells, SEA blasts and PBMCs in THP-1 
coculture.
Panel A: IL-lp production by THP-1 cells in 48hr coculture, with unfixed purified T-cells, 
SEA blasts or cultured PBMCs, stimulated with O.lpg/ml LPS. (Results adjusted for basal 
cytokine production of (Non-THP-1) cells)(n=l).
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Figure 3.8: Direct Comparison of fixed T-cells, SEA blasts and PBMCs in THP-1 
coculture.
Panel A: IL-lp production by THP-1 cells in 48hr coculture, with fixed purified T-cells, 
SEA blasts or cultured PBMCs, stimulated with 0.1pg/ml LPS (n=l).
Panel B: As Panel A, except indicating IL-lra production.
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3.2.6: Cytokine production of THP-1 cells in coculture with SEA blasts
With SEA blasts confirmed as the model T-cells, it was important to confirm the ability of 
the technique to produce consistent results. SEA blasts were going to be isolated from 
blood taken from a range of healthy volunteers, so there was the potential for significant 
variation to occur. As such, SEA blasts were sampled from blast culture at 3 and 6 days, 
and used in coculture (either unfixed or fixed) with THP-1 cells, some of which were 
stimulated with LPS. SEA blasts were also incubated without THP-1 cells, as a control for 
residual cytokine production from any monocytes remaining in the preparation. Values 
obtained from these cultures were subtracted from coculture samples containing unfixed 
SEA blasts.
Unfixed SEA blasts were able to induce both IL-lp and IL-lra release from THP-1 cells 
(Figure 3.9), and also synergised with LPS to induce much greater release of IL-lp (but not 
IL-lra). Fixed SEA blasts alone induced negligible EL-ip production from THP-1 cells, 
and only a small (if any) increase in IL-lra release, although in both cases there was 
synergy with LPS leading to an increase above basal cytokine release (which was more 
marked with EL-Ira). There was still residual cytokine release from the blast cell 
preparations themselves, although this did not seem to be affected by LPS, and was not of 
sufficient quantity to alter the results involving unfixed SEA blasts.
The only other point of interest was that between 3 and 6 days, the SEA blasts were 
reduced in their capacity to stimulate cytokine release from THP-1 cells, although after 6 
days there was still considerable stimulation of cytokine release and synergy with LPS.
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Figure 3.9: Effect of SEA Blasts (day3/6) on IL-lp/IL -lra production by THP-1 cells. 
Panel A: IL-1 p production by THP-1 cells in 48hr coculture with normal SEA Blasts (3 or 
6 day), stimulated with O.lpg/ml LPS. (n=6 ±sem) Including controls with no THP-1 cells 
added, and THP-1 cells alone.
Panel B: As Panel A, except indicating IL-lra production. (n=5 ±sem)
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3.2.7: Comparison of cytokine production from THP-1 cells in coculture with J16 
cells and SEA blasts.
It is important to consider carefully the differences between the two model T-cells being 
used -  the T-cell blasts and the J16 cell line. Essentially, the J16 cells, even when 
activated with PDBu/ionomycin, are very poor inducers of cytokine release from THP-1 
cells when compared to SEA blasts. However, there are some parallels that can be drawn, 
and in the same manner that J16 can effectively induce substantial levels of IL-lp release 
from PBMC, THP-1 cells can be induced to release substantial quantities of IL-lp when 
cultured with SEA blasts.
Both cell types induce IL-1 P production from THP-1 cells and synergise with LPS to 
further increase this IL-lp production (Figure 3.10). This is also true, although to a lesser 
extent, when the “T-cells” are fixed. It is interesting to note again that the most important 
factors relevant for IL-lp release appear to be soluble factors, especially given the decrease 
in IL-1 P release when the SEA blasts are fixed (being reduced to similar levels to the fixed 
J16 cells). A possible constituent of this soluble factor is investigated further in Section 
4.2.
When considering IL-lra release however (Figure 3.11), there appears to be little synergy 
between lymphocytes and LPS, except in the case of fixed SEA blasts. Unfixed SEA blasts 
are effective at stimulating IL-lra production, while unfixed J16 cells are unable to 
stimulate IL-lra release, and even inhibit LPS-induced release from THP-1 cells. Both 
fixed blasts and J16 induce very little (if any) IL-lra release from THP-1 cells, although 
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Figure 3.10: J16 and SEA blast induction of IL-lp production by THP-1 cells.
Panel A: IL-1P production by THP-1 cells in 48hr coculture, stimulated with 0.1pg/ml 
LPS, and cocultured with J16 cells (unstimulated, or activated with PDBu (0.5 ng/ml) and 
ionomycin (lpM )). (n=4-6 ±sem)
Panel B: As Panel A, except THP-1 cells were cocultured with SEA blasts (Day 3/6).
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Figure 3.11: J16 and SEA blast induction of IL -lra production by THP-1 cells. 
Panel A: IL-lra production by THP-1 cells in 48hr coculture, stimulated with O.lpg/ml 
LPS, and cocultured with J16 cells (unstimulated, or activated with PDBu (0.5 ng/ml) and 
ionomycin (lpM )). (n=4-6 ±sem)
Panel B: As Panel A, except THP-1 cells were cocultured with SEA blasts (Day 3/6).
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3.2.8: SEA blast culture timecourse -  Effects on cytokine production by THP-1 in 
coculture
If SEA blasts were to be used extensively as model T-cells in the coculture system, it was 
important to understand the blast culture better, with a view to the cells effects on the 
coculture system at various stages throughout the blast culture. SEA blasts were cultured 
for 6 days, with daily sampling into coculture with THP-1 cells. Portions of the SEA blasts 
were also fixed before coculture, and some incubated without THP-1 cells to determine 
any residual production of cytokines from surviving monocytes. Residual cytokine release 
from the blasts was deducted from the total cytokine production of the coculture samples 
containing unfixed cells, as appropriate. Cells were also stained with anti-CD69 and 
analysed using flow cytometry to obtain a measure of the state of activation of the blasts.
Unfixed SEA blasts were able to stimulate IL-ip and IL-lra release throughout the 6-day 
timecourse (Figure 3.12). IL-ip release was reduced over the first 3 days of culture, but 
had reached a steady state by day 3. The addition of LPS had a stabilising effect, with 
there being little change over time in the EL-lp induction due to blasts and LPS, except for 
a possible increase on day 2. IL-lra induction decreased over the first 3 days, both in the 
absence and presence of LPS, but after this point there was a steady increase throughout 
the remainder of the experiment, which was more marked in the presence of LPS.
Fixed SEA blasts (Figure 3.13) were still able to induce IL-ip release, although at a greatly 
reduced level when compared to the unfixed cells (around 10-fold decrease), and only in 
combination with LPS. Addition of LPS to the coculture induced an increase in IL-lp 
induction peaking on day 3, with a slow, steady reduction thereafter, approaching the basal 
IL-ip production of LPS-induced THP-1 by day 6. Fixed SEA blasts had little effect upon 
the induction of IL-lra unless in combination with LPS, which caused a slight increase in 
IL-lra induction between days 2 and 4.
There was a significant residual release of IL-lp from SEA blasts sampled on day 1 of the 
blast culture (Figure 3.14). This required controlling for, in order to determine IL-ip 
release from the THP-1 cells alone. However, from day 2 of the blasts culture onwards, 
residual IL-lp production reduced substantially, and was virtually negligible by day 4 of 
the blast culture. Although it was prudent to retain a control for this residual cytokine
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production in continuing experiments, using SEA blasts from cultures of at least 2-day 
duration would eliminate the risk of it having a severe effect.
During the blast culture, CD69 expression of the SEA blasts rose to between 40-50% on 
days 1-3 of the blasts culture, then decreased to around 20% on day 4, after which there 
was a slow but steady decrease for the remainder of the timecourse studied (Figure 3.15). 
Based upon these results, and the requirement to reduce as far as possible any cytokine 
production from residual monocytes, it was decided that the use of day 3 blasts would be 
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Figure 3.12: Effect of SEA blast culture duration on IL -ip /IL -lra production by 
THP-1 cells in coculture.
Panel A: IL -lp production by THP-1 cells in 48hr coculture with unfixed SEA blasts 
(timecourse), stimulated with 0.1 jug/ml LPS. Values adjusted for SEA blast cytokine 
production. (n=6 ±sem)
Panel B: As Panel A, except indicating IL-lra production.
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Figure 3.13: Effect of SEA blast culture duration on IL -lp/IL -lra production by 
THP-1 cells in coculture (fixed SEA blasts).
Panel A: IL-1 (3 production by THP-1 cells in 48hr coculture with fixed SEA blasts 
(timecourse), stimulated with O.lpg/ml LPS. (n=6 ±sem)
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Figure 3.14: Effect of SEA blast culture duration on IL -ip /IL -lra production. 
Panel A: IL-1 (3 production by SEA blasts in 48hr culture (timecourse), stimulated with 
0.1pg/ml LPS. THP-1 baseline shown for reference.(n=6 ±sem)
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Figure 3.15: Timecourse of CD69 expression during SEA blast culture
Change in CD69 expression during SEA blast culture timecourse, measured by increase 
in FL-1 fluorescence due to binding of anti CD69 antibody, determined by flow 
cytometry. (n=3-4 ±sem)
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3.2.9: PDBu/ionomycin-induced blast culture timecourse -  Effects on cytokine
production by THP-1 cells in coculture
PDBu/ionomycin was to be extensively used as a means of activation of J16 cells for use in 
the coculture. The use of a phorbol ester and ionomycin (specifically PMA) is also a 
standard method for the activation/blasting of T-cells. PMA was not used in these studies, 
as it was important to have no carry-over of phorbol ester into the coculture system, where 
it could have considerable effect upon the monocytes as well as the T-cells used. PMA is 
considered to be quite a lipophilic molecule, while PDBu can be far more easily removed 
from cells with repeated washing. In light of this, it was considered prudent to investigate 
the blasting effect of PDBu/ionomycin on T-cells, and also as a comparison to SEA blasts 
in the coculture system.
Unfixed PDBu/I blasts (Figure 3.16), in both the absence and presence of LPS, show a 
similar pattern of IL-1 p induction to the SEA blasts, although of a reduced magnitude. In 
the absence of LPS, there is an initial induction of IL-ip release from THP-1 cells, 
although this then decreases steadily until a plateau is attained around day 3 of culture. In 
the presence of LPS, there is considerable induction of IL-1 p release from THP-1 cells, 
which peaks at around day 2, then decreases slightly to form a plateau, in much the same 
manner as with the SEA blasts. There is certainly induction of IL-lra production, but due 
to variability of the results it is difficult to determine any pattern, other than a steady 
induction of IL-lra at around the 10,000pg/ml concentration, which is unaffected to any 
great degree by the addition of LPS.
Fixed PDBu/I blasts (Figure 3.17) also show similar patterns of IL-1 p release from THP-1 
cells to the fixed SEA blasts. There is no discernible induction of IL-1 p release by fixed 
PDBu/I cells unless in combination with LPS, when the induction peaks by day 2, and then 
decreases steadily, approaching basal LPS-induced levels of IL-lra release from THP-1 
alone by day 5-6. In this case, overall levels of IL-1 p induced were very similar to those 
induced by the SEA blasts. Fixed PDBU/I blasts did not have any effect upon IL-lra 
production from THP-1 cells, regardless of the presence or absence of LPS. The exception 
to this was when using blasts from day 6 of the blast culture, in which case there was 
limited induction of IL-lra, which was again LPS independent.
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As with SEA blasts, PDBu/I blast cultures retained some residual IL-1 p production (Figure 
3.18), although less than that of the SEA blasts, and this had also decreased to negligible 
values by day 3 of culture. However, of more interest was the IL-lra release from PDBu/I 
blasts. This increased from a baseline level of 10,000 pg/ml on days 1-3 of culture to 
around 30,000pg/ml by day 6, in the presence or absence of LPS. This seems to imply that 
although both the methods of blast culture induce LL-ip to similar patterns, there are 
definite functional differences between them. In PDBu/I culture at least, either the 
monocytes are not dying (but merely becoming inactive in their production/release of IL- 
1P), or perhaps there is IL-lra release from the T-cells.
CD69 expression throughout the course of the PDBu/I blast culture (Figure 3.19) mirrored 
the general pattern exhibited by SEA blasts cultures. However, the expression of CD69 
was much more comprehensive, with almost 90% expression on days 2 and 3 of the culture 
(compared to 40-50% with SEA blasts). This higher level of expression was matched with 
a more rapid decrease in CD69 expression after this point, with CD69 expression 
decreasing rapidly on days 4 to 6, until reaching an expression o f less than 10% on day 6 
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Figure 3.16: Effect of PDBu/I blast culture duration on IL -lp /IL -lra production by 
THP-1 cells in coculture.
Panel A: IL-ip production by THP-1 cells in 48hr coculture with unfixed PDBu/I blasts 
(timecourse), stimulated with O.lpg/ml LPS. Values adjusted for SEA blast cytokine 
production. (n=4 ±sem)
Panel B: As Panel A, except indicating IL-lra production.
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Figure 3.17: Effect of PDBu/I blast culture duration on IL -ip/IL -lra production by 
THP-1 cells in coculture (fixed PDBu/I blasts).
Panel A: IL-lp production by THP-1 cells in 48hr coculture with fixed PDBu/I blasts 
(timecourse), stimulated with O.lpg/ml LPS. (n=4 ±sem)
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Figure 3.18: Effect of PDBu/I blast culture duration on IL-l(3/IL-lra production. 
Panel A: IL-1 (3 production by PDBu/I blasts in 48hr culture (timecourse), stimulated with 
0.1|ig/ml LPS. THP-1 baseline shown for reference.(n=4 ±sem)
Panel B: As Panel A, except indicating IL-lra production.
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Figure 3.19: Timecourse of CD69 expression during PDBu/ionomycin blast culture
Change in CD69 expression during PDBu/ionomycin blast culture timecourse, measured 
by increase in FL-1 fluorescence due to binding of anti CD69 antibody, determined by 
flow cytometry. (n=2)
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3.2.10: Cytokine production by THP-1 cells in coculture with CD69 COS-
transfectants.
Continuing experiments were to investigate the interactions between cells in a coculture 
system, including the possible actions and interactions of surface molecules and released 
soluble factors. One such surface molecule is CD69, which exhibits rapid (within 2 hours) 
upregulation of surface expression with T-cell activation, and yet its receptors and any 
regulatory interactions it performs are poorly understood.
COS-7 cells that had been stably transfected with human CD69 (COS-69 cells) had been 
recently produced within the laboratory, and were made available for the investigation of 
the effect of the CD69 surface marker on induction of cytokine release from THP-1 cells. 
COS-69 cells were incubated with anti-CD69 antibody and analysed with flow cytometry 
to determine CD69 expression. COS-69 cells were then fixed with 0.025% glutaraldehyde, 
washed thoroughly, and added to cultures containing THP-1 cells and LPS. After 48h of 
coculture, cytokine release was assessed in culture supernatants using sandwich ELISA.
As can be seen from Figure 3.20, there is substantial expression of CD69 on the COS-69 
cells, with CD69 present on almost 50% of the cells.
There was little increase in IL-lp release with COS-69 cells alone (Figure 3.21). However, 
these initial results suggest that CD69 is able to act in synergy with LPS to induce 
considerably greater levels of IL-lp than the controls containing untransfected COS-7 
cells. There did not appear to be any significant differences in IL-lra release. COS-7 cells 
themselves also induced IL-ip release in synergy with LPS, although to a lesser extent. 
This could be due to COS cells expressing surface molecules with some homology to 
human surface adhesion molecules, with non-specific interactions or adhesion leading to 
weak activation of the THP-1 cells.
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Figure 3.20: Determination of COS-69 cell CD69 expression.
Determination of COS-69 expression of CD69, measured as the level of FL-1 
fluorescence due to binding of FITC conjugated secondary antibody to CD69 
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Figure 3.21: IL-lp/ IL -lra  production by THP-1 cells in coculture with CD69 
transfcctants.
Panel A: IL-ip production by THP-1 cells in 48hr coculture (LPS stimulated) with COS 
cells (control and CD69 transfectants). (n=2)
Panel B: As Panel A, except indicating IL-lra production.
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3.3: SUMMARY
The aim of the work detailed in this chapter was to develop the coculture system, for 
further study of a range of standard stimuli acting upon both T-lymphocytes and 
monocytes. In order to use the technique to facilitate further investigation of factors 
relevant to RA, it was first necessary to standardise both the model T-lymphocytes and 
monocytes to be used in coculture, and any manipulations or stimuli that could be used to 
improve the discriminatory power of the procedure.
The cell lines used as model T-lymphocytes and monocytes were Jurkat J16 cells and pro- 
monocytic THP-1 cells, respectively. THP-1 cells had been previously used in coculture 
(Vey et al.t 1997), requiring differentiation with l,25(OH)2D3 before use, and routine 
testing of CD 14 expression was carried out to ensure that successful differentiation had 
occurred. J16 cells exhibited limited stimulatory ability in coculture with THP-1 cells, 
stimulating EL-ip release to a small degree and inhibiting IL-lra release, while activation 
of J16 cells with PDBu/ionomycin resulted in a slight increase in IL-lp release. Fixing of 
the J16 cells decreased the potential to stimulate IL-1 p release from THP-1 cells, and 
restored a degree of the previously inhibited IL-lra release, suggesting a soluble factor 
might be partially responsible for both stimulation of IL-lp and inhibition of IL-lra 
release.
In addition to cell lines, freshly isolated cells were used in the coculture system. PBMC 
and purified monocytes were compared, demonstrating similar patterns of response to 
coculture with unfixed and fixed J16 cells, in combination with LPS. As a result of this, 
PBMC were used in further coculture experiments, removing the requirement for the time- 
consuming monocyte purification process. It was also noted that J16 cells stimulated IL- 
ip release from PBMC much more effectively than from THP-1, perhaps as a result of 
deficiency in THP-1 surface receptors.
Freshly isolated T-cells, SEA cultured T-cell blasts and cultured PBMC were considered as 
potential model T-cells. Day 3 SEA blasts stimulated IL-ip release from THP-1 cells to a 
greater extent than either freshly isolated T-cells or cultured PBMC. Both fresh T-cells 
and day 3 cultured PBMC stimulated substantial IL-lra release from THP-1 cells, although
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SEA blasts were still able to induce modest levels of IL-lra release. There was however 
significant background IL-lp release from both the T-cell and PBMC cells.
On the basis of these initial data, SEA blasts were used in coculture experiments on day 3 
and 6 of culture to assess the consistency of data (as SEA blast cultures would be 
developed from a range of healthy volunteers), and also cultured over a full 6-day 
timecourse, with samples transferred into coculture with THP-1 cells on a daily basis. 
Patterns of response were consistent between blast cultures from different individuals, 
based on responses to LPS, with both fixed and unfixed SEA blasts from day 3 or 6 of 
blast culture. Unfixed SEA blasts induced both IL-ip and IL-lra release from THP-1 cells 
throughout the culture, decreasing towards day 6. Fixed blasts induced very little IL-lp 
release, but could induce lower levels of IL-lra in combination with LPS. After day 2 of 
culture, background IL-ip release from SEA blast cultures had fallen to negligible levels. 
It is unlikely that this was due to death of monocytes remaining in the blast culture, as 
background IL-lra release was still detected. CD69 expression of the culture was also 
recorded as an indication of the state of activation of the cells, rising to a peak after 2-3 
days and declining gently throughout the rest of the culture. It was decided to use SEA 
blasts from days 3 and 6 of blast cell culture as model “activated” T-cells for the coculture 
system, based on the stimulation of IL-lp and IL-lra release, consistency of response to 
SEA blasts from differing individuals and also on the reduction in “background” IL-lp 
release.
In parallel to the SEA culture timecourse, a similar experiment was performed using 
PDBu/ionomycin stimulated cells. CD69 expression on these cells differed from that in 
SEA cultures, rising steadily over the first 3 days of culture, stabilising until day 4, and 
then decreasing rapidly. Generally, the release of IL-1 p and IL-lra from THP-1 cells 
cocultured with PDBu/ionomycin blasts was lower than that from SEA blasts. Although 
there was little difference between the pattern of IL-1 P release due to unfixed SEA or 
PDBu/ionomycin blasts, THP-1 cultured with PDBu/ionomycin blasts did not show the 
considerable inhibition of IL-lra release evident in THP-1 cultured with SEA blasts. Fixed 
blasts of either type were unable to induce more than a slight increase in IL-lp release 
from (LPS) untreated THP-1 cells, while SEA blasts synergised more effectively with LPS 
than PDBu/ionomycin blasts to induce IL-lp release. Fixed SEA blasts were also more 
effective, when in combination with LPS, at inducing IL-lra release from THP-1 cells
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between days 2-4, although intriguingly fixed PDBu/ionomycin blasts from day 6 of blast 
culture were able to induce substantial IL-lra release (independent of LPS), likely due to 
the induction of delayed-response surface proteins (or perhaps downregulation of 
previously induced surface proteins). Basal IL-ip release from both blast types had 
dropped to low levels by day 3, and while basal IL-lra release from SEA blasts varied 
around 2000pg/ml (similar to THP-1 baseline release), IL-lra release from 
PDBu/ionomycin blasts started at an initial level of lOOOOpg, and from day 4 onwards 
increased steadily to approximately 30000pg/ml on day 6 (independent of LPS). This 
shows that cells (probably monocytes) still present in the PDBu/ionomycin blast culture 
are capable of significant IL-lra release, and supports the theory that the decrease in IL-lp 
release is due to a downregulation in production or release as opposed to death of the 
monocytic population. It is apparent from the differences between these results that 
activation of T-cells via SEA and PDBu/ionomycin trigger different responses within the 
T-lymphocyte, resulting in differential induction of pro- and anti-inflammatory signals in 
the monocyte.
LPS was used throughout these experiments as an inducer of IL-lp release, capable of 
stimulating substantial increases in IL-lp release from model monocytes either alone or in 
synergy with unfixed or fixed T-cells. The lower dose (0.1pg/ml) seems capable of 
inducing additional EL-ip, while still enabling the detection of effects due to other factors. 
The IL-lra release in response to LPS is more variable. With THP-1 and J16 cells, there is 
a slight increase in the induction of IL-lra only when the J16 cells are fixed, a situation 
repeated when SEA blasts are used with THP-1 cells. However, there is no synergy for the 
induction of IL-lra when LPS is included with COS-69 cells. The effect of LPS on PBMC 
(and monocyte) IL-lra release is uncertain, with apparent induction of EL-Ira in the 
presence of unfixed J16, and inhibition in the presence of fixed J16. Nevertheless, LPS 
was used throughout the following experiments to increase the magnitude of differences in 
IL-ip release, and understanding of IL-lra release due to addition of LPS could be 
investigated further using these cocultures.
Data contained in this chapter demonstrate that surface proteins present on T-lymphocytes 
possess limited capability to induce IL-lp or IL-lra release from a range of different model 
monocytes. The use of a transfectant cell line containing CD69 implies that the induction 
of IL-lp from THP-1 during coculture could be related to CD69 expression. However, a
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substantial amount of the data collected demonstrates that live T-lymphocytes are capable 
of inducing far greater quantities of cytokine release than fixed cells alone. This suggests 
either that a soluble factor produced by T-cells is a major stimulus for cytokine release, 
that there is a requirement for synergy between soluble and surface factors to induce 
substantial cytokine release, or that 2-way interactions are required between T-lymphocyte 
and monocyte (surface or soluble factor mediated), leading to alteration of soluble factor 
and surface protein expression, before cytokine-inducing signals are triggered.
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CHAPTER 4
Investigation and Manipulation of T-Lymphocyte Actions 
within the Coculture System
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4.1: CHAPTER INTRODUCTION
A wide range of factors affecting either monocyte or T-cell can act to manipulate 
monocyte cytokine release following interactions with T-lymphocytes in the rheumatoid 
synovium, and experiments performed and detailed in this chapter investigate a number of 
these factors. These are:
1) The effect of long-term exposure of T-lymphocytes to reactive oxygen species,
2) The action of a putative constituent of T-lymphocyte produced soluble factor, IL- 
17,
3) Na,K-ATPase, a physiologically important transmembrane enzyme with 
demonstrated indirect effects upon both calcium signalling and pro-inflammatory 
cytokine release, and
4) Thl and Th2 cells, and the relative proportions and effects of each in the RA 
synovium.
4.2: DIFFERENTIATION AND CHARACTERISATION OF T-CELL LINES 
TOLERANT TO OXIDATIVE STRESS
4.2.1: INTRODUCTION
The rheumatoid synovial joint is in a hypoxic state, a situation that is exacerbated upon 
exercise, with a rise in intra-articular pressure leading to a temporary cutting off of 
synovial perfusion. This leads to uncoupling of synovial cell redox reactions, including the 
conversion of xanthine dehydrogenase into the oxidase form. When the joint is rested, 
restoration of the blood supply (reperfusion) enables xanthine oxidase to donate electrons 
to O2, with the resultant formation of superoxide radicals (O2*). Iron ions (that enter the 
joint due to exercise-inflicted microbleeding) can then act as catalysts for the conversions 
of O2** and H2O2 into the highly reactive *OH.
There is also evidence to suggest that this build-up of free radicals within the rheumatoid 
joint leads to depletion of anti-oxidant defences such as a-tocopherol, ascorbate and 
reduced glutathione. Reduced levels of glutathione have been demonstrated in rheumatoid 
synovial T-cells, and also in the erythrocytes of RA patients. With the depletion of these
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anti-oxidant defences, enzymes that contribute to the safe removal of free radicals (such as 
superoxide dismutase and catalase) could well be insufficient to compensate for the 
increased levels of H2O2, 0{~  or *OH. All of these data would suggest that cells present in 
the rheumatoid synovium are under constant levels of oxidative stress (detailed in section 
1.1.3).
There is extensive data investigating the state of T-lymphocytes in the rheumatoid 
synovium, suggesting death, total inactivity or low levels of activity, including evidence 
that reduction in anti-oxidant defences might be responsible for the hyporesponsiveness to 
T-lymphocytes in RA (Maurice et al., 1997; Maurice et al., 1998). In order to investigate 
any effects on T-cells of long-term exposure to oxidative stress, an attempt was made to 
generate T-lymphocytic cell lines through regular exposure of the cells to oxidative stress 
(in this case, increasing concentrations of hydrogen peroxide). These cell lines were then 
characterised with regard to (among other things) their tolerance of oxidative stress, 
resistance to apoptosis, cell surface phenotype, proliferation and induction of cytokine 
release from monocytic cells.
4.2.2 RESULTS
4.2.2.1: Generation of oxidative stress tolerant cell lines and determination of H2O2 
tolerance.
J16 cells were treated with hydrogen peroxide at increasing concentrations, from an initial 
50pM to a final concentration of 3mM, with 2-3 weeks between treatments to enable 
recovery of cell numbers. These oxidative-stress tolerant J16 cells were designated HJ16. 
In the same manner, H9 cells were treated with hydrogen peroxide, from an initial 30pM to 
a final treatment concentration of 250pM. These oxidative-stress tolerant H9 cells were 
designated HH9. The J16 possessed greater initial tolerance of exposure to hydrogen 
peroxide, and this continued throughout the progress of the work, as the J16 cells became 
steadily more resistant to increasing doses of hydrogen peroxide, whereas it proved 
difficult to substantially improve the tolerance of H9 cells to this particular stress.
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Proliferation of the oxidative stress tolerant cells was assessed utilising tritiated thymidine 
incorporation (48 hours, with H-thymidine added for the final 18 hours), following 4 
hours of pre-incubation with a range of concentrations of hydrogen peroxide (in serum-free 
RPMI). Although an indirect measure of cell proliferation, this technique could be used to 
determine any relative changes in the proliferation of the peroxide-tolerant cells in 
comparison to the “parent” cell culture when exposed to hydrogen peroxide.
As a more routine technique for assessing the extent of hydrogen peroxide tolerance, cells 
were incubated with hydrogen peroxide for 4 hours (in serum-free RPMI), and then for a 
further 20 hours (in RPMI + 10% FCS). 50pl of the vital stain propidium iodide (50pg/ml) 
was then added, and uptake of the stain (indicative of cell necrosis) assessed using flow 
cytometry.
As can be seen from Figure 4.1, there is no significant difference between the basal 
proliferation of J16 and HJ16 cells. Incubation with 100pM H2O2 has little effect upon the 
proliferation of HJ16 cells, but decreases the proliferation of the non-tolerant J16 cells by 
approximately 50%. Increasing the concentration of H2O2 to ImM effectively reduces 
proliferation of J16 cells to zero, and reduces the proliferation of the HJ16 cells to around 
50% of the untreated total, with lOmM H2O2 reducing the proliferation of both cells lines 
to negligible levels. This would seem to suggest that the HJ16 are able to survive at a 
concentration of H2O2 approximately ten times higher than their original cell line.
The routine assessment of H2O2 tolerance by flow cytometry (Figure 4.2) also 
demonstrates a definite increase in H2O2 tolerance in the HJ16 line. LD50 for J16 is 
approximately IOOjiM, which increases to approximately ImM for HJ16 cells. This again 
demonstrates a tenfold increase in the concentration of H2O2 to which the HJ16 cells are 
tolerant. In contrast, the HH9 cells (which were only exhibiting small increases in 
tolerance to H2O2) show little difference to the H9 cell line, except perhaps a small 
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Figure 4.1: Effect of hydrogen peroxide on J16/HJ16 proliferation.
J16/HJ16 proliferation (48h, determined by 3H-thymidine incorporation) on incubation 
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Figure 4.2: Hydrogen peroxide induced death of H20 2 tolerant cell lines.
Panel A: Death of J16/HJ16 cells incubated with various concentrations of hydrogen 
peroxide for 4 hours, then cultured for a further 20 hours. Cell death was measured 
as an increase in FL-2 fluorescence due to uptake of propidium iodide by necrotic 
cells, determined by flow cytometry. (n=l, indicative of routine testing)
Panel B: As Panel A, except using H9/HH9 cells.
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4.2.2.2: Surface m arker expression of J16 and HJ16 cells
Interaction between T-lymphocytes and monocytes is facilitated by both soluble factors 
and interaction between cell surface markers. In addition to general characterisation of the 
generated cell line, any changes in the expression of surface markers on the H^C^-tolerant 
cells could be worth further investigation in the light of modulation of monocyte cytokine 
production.
The FACS data overleaf (Figure 4.3) indicate the mean fluorescent index (MFI) of cells 
stained for a range of T-cell activation markers. The only surface markers exhibiting a 
statistically significant change were CD3 and CD69. Also displayed are typical FACS 
plots for CD3 and CD69 expression on both J16 and HJ16 cells. This demonstrates that the 
decrease in CD3 MFI is due to a general downwards regulation of CD3 over the entire 
population of cells, as opposed to, say, the loss of CD3 on a specific proportion of cells. 
Likewise, the increase in MFI on CD69 stained HJ16 is also due to an overall upregulation 
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Figure 4.3: Differences in surface marker expression between J16/HJ16 cells. 
Panel A: Determination of cell surface marker expression, measured as the level 
of FL-1 fluorescence due to binding of FITC conjugated secondary antibody to 
marker specific primary antibodies, detected with flow cytometry. (n=4-8 ±sem,
* indicates p<0.05 with Mann-Whitney U-test)
Panel B: Shift in fluorescence due to CD3 and CD69 staining o f J16/HJ16 cell 
populations relative to background fluorescence.
4.2.2.3: J16 and HJ16 proliferation in response to PDBu and ionomycin
Activation of J16 cells results in an increase in CD69 expression, but also leads to a 
substantial decrease in cell proliferation, perhaps linked to the considerable rate at which 
the cells are proliferating in normal cell culture. While characterising the HJ16 H2O2- 
tolerant cell line, it was considered important to ensure that the cells were proliferating at a 
similar rate to the “parent” cell line, and also to determine whether the cells responded in a 
similar manner to the basic activation stimuli used in the coculture system. Proliferation of 
the two cell lines was determined by H-thymidine incorporation using “resting” cells, and 
cells treated with PDBu (0.5ng/ml) and PDBu in combination with ionomycin (lpM). The 
results are displayed in Figure 4.4.
Basal proliferation of both the J16 and HJ16 cell lines was at a similar rate, and there 
appeared to be little change to either when stimulated with PDBu alone. However, 
whereas the J16 cells responded to PDBu/ionomycin treatment with a substantial (60%) 
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Figure 4.4: Comparison of J16/HJ16 proliferation in response to PDBu and ionomycin.
J16/HJ16 proliferation (48h, determined by 3H-thymidine incorporation) in response to PDBu 
(0.5ng/ml) and PDBu/ionomycin (lpM ). (n=3)
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4.2.2.4: Induction of apoptosis in oxidative-stress tolerant cell lines.
In addition to being a primary mediator of oxidative stress in the rheumatoid synovial joint, 
hydrogen peroxide is also a well-categorised trigger of apoptosis. It has already been 
demonstrated that HJ16 cells possess significantly increased tolerance to hydrogen 
peroxide induced death, and this could be due in part to an overall increase in the cells 
ability to survive apoptotic signals. CH11 is a widely used anti-Fas antibody, capable of 
inducing programmed cell death through cross-linking CD95 (Fas).
Annexin V staining is a technique used to distinguish between apoptotic and necrotic death 
by flow cytometry, in combination with the vital stain propidium iodide (PI). Phophatidyl 
serine (PS) is externalised during the membrane “flip” which occurs during the early stages 
of apoptosis. Annexin V then binds the PS, detected by an increase in FL-1 fluorescence, 
but as the cell membrane integrity is still intact at this stage, there is no increase in FL-2 
fluorescence. If cell death is occurring due to necrosis, (with corresponding loss of 
membrane integrity), then the cells stain with both Annexin V and PI, with corresponding 
increase in both FL-1 and FL2 fluorescence.
Cells from the J16, HJ16, H9 and HH9 cell lines were incubated for 4 hours with CH11 
anti-Fas antibody (lOng/ml), and tested for apoptosis or necrosis using the standard 
Annexin V protocol with flow cytometry. Results are displayed (Figure 4.5/4.6, Panel A) 
as dot plots of fluorescence intensity for FL-1 (Annexin V binding) against FL-2 (PI 
incorporation). Live cells are present in the lower left (LL) quadrant, apoptotic cells in the 
lower right (LR) quadrant, necrotic cells in the upper right (UR) quadrant and cell debris in 
the upper left (UL). In addition, comparative histograms were plotted (Panel B) showing 
Annexin V binding to both untreated and CHI 1 treated cells for all 4 cell lines tested.
These results indicate that the J16 cells being studied are themselves quite resistant to 
apoptosis induction, with only a 15% shift of cells from the healthy to the apoptotic 
populations. However, the HJ16 cells showed an increase in their resistance of apoptosis, 
with only a 2-3% increase in apoptotic cells. There was no increase above 1-2% in 
necrotic cells in either cell population, indicating that the increases present were due to 
apoptosis alone.
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In contrast, the H9 cell line exhibited a substantial susceptibility to CH11 induced 
apoptosis, with approximately 45% of the overall cell population shifting from a healthy to 
an apoptotic state. The stressed HH9 cells, while only exhibiting a slight increase in their 
overall resistance to H2O2 induced cell death, showed increased resistance to CH11 
induced apoptosis, with only 15% of the cells shifting to an apoptotic state upon incubation 
with CH11. Again, there was little, if any, increase in necrotic cells in either population. 
This is not quite as substantial a shift as it seems however, when set against the 
background levels of apoptotic cells present in the two cultures, with only 10% of the H9 
cells undergoing apoptosis, but almost 30% of the HH9 cells in an apoptotic state in 
normal culture. This raises questions about the short to mid-term recovery of the HH9 
cells from the regularly applied H2O2 induced oxidative stress, especially when compared 
with the background levels of apoptosis in the J16 and HJ16 cell lines, which are both 
between 12-16%.
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Figure 4.5: Susceptibility of J16/HJ16 cells to CH11 anti-Fas antibody.
Cells were treated with CHI 1 anti-Fas antibody (lOng/ml), and incubated for 24hrs. 
Cells were then analysed for Annexin V binding (FL-1) indicating apoptosis and 
propidium iodide incorporation (FL-2) indicating necrosis using flow cytometry 
(figures indicative of n=3)
Panel A: Quadrant designation is as follows: LL: live cells, LR: apoptotic cells, 
UR: necrotic cells, UL: cell debris.
Panel B: Indicates Annexin V binding relative to CHI 1 untreated cells.
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Figure 4.6: Susceptibility of H9/HH9 cells to CH11 anti-Fas antibody.
Cells were treated with CHI 1 anti-Fas antibody (lOng/ml), and incubated for 24hrs. 
Cells were then analysed for Annexin V binding (FL-1) indicating apoptosis and 
propidium iodide incorporation (FL-2) indicating necrosis using flow cytometry 
(figures indicative of n=3).
Panel A: Quadrant designation is as follows: LL: live cells, LR: apoptotic cells,
UR: necrotic cells, UL: cell debris.
Panel B: Indicates Annexin V binding relative to CHI 1 untreated cells.
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4.2.2.5: Determination of reduced glutathione (GSH) content of HJ16 and HH9 cells
Experiments involving the HJ16 and HH9 cell lines have concentrated primarily on cell 
responses, especially survival, proliferation or response to apoptotic signals. Given the 
increased tolerance of the HJ16 cells to oxidative stress, an effort was made to elucidate 
some of the mechanisms behind this increased resistance.
Reduced glutathione (GSH) is an important constituent of the intracellular antioxidant 
defences, acting to scavenge or reduce the toxic effects induced by free radicals. Reduced 
levels of GSH have been detected in the red blood cells of patients with RA, probably 
related to disease activity. There are a number of studies that have investigated the 
implications of changes in the intracellular glutathione concentrations.
T-lymphocytes isolated from the synovial fluid of RA patients have been shown to contain 
a specific and significant reduction in GSH concentration when compared to T- 
lymphocytes isolated from peripheral blood (which in turn, showed negligible difference 
compared to peripheral blood T-lymphocytes from healthy subjects). Similarly, it was 
shown that in both healthy and RA T-lymphocytes (synovial and peripheral blood), 
artificially increasing and decreasing intracellular GSH concentrations had a similar effect 
upon cell proliferation in response to CD3/CD28 stimulus (Maurice et al., 1997; Maurice 
et al., 1998).
An inherited glutathione deficiency in sheep (a reduction of approximately 80% in sheep 
red blood cells) appears to correspond with a significantly lower intracellular concentration 
of potassium (Tucker & Kilgour, 1969). Interestingly enough, studies in the rat suggested 
a correlation between total glutathione content and Na,K-ATPase activity, with increasing 
concentrations of glutathione corresponding to higher Na,K-ATPase activity and vice versa 
(Haddock et al., 1995). At this point it should be noted that under normal conditions, the 
proportion of total glutathione in the oxidised state is generally very small (concentrations 
reported in rat heart between 1-3%, in perfused rat liver at <0.05%), although this ratio can 
change rapidly under oxidative stress conditions.
A reduced glutathione assay was developed utilising the formation of a fluorescent adduct 
between GSH and monochlorobimane (mBCl). GSH content of J16, HJ16, H9 and HH9 
cell lines was assayed, utilising a separate standard calibration curve with each experiment.
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GSH content was plotted for HJ16 and HH9 cells as the percentage increase compared to 
the respective unstressed cell line (Figure 4.7).
The HJ16 cell line shows a substantial increase in GSH content relative to J16 cells. 
However, the HH9 cell line exhibits little, if any increase in GSH concentration above that 
of the H9 cell line. In comparison, the HJ16 cell line shows a statistically significant 
increase in GSH concentration compared with the HH9 cells, which agrees with the altered 
sensitivity of HJ16 cells to H2O2. It would appear from these results that the increased 
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Figure 4.7: Intracellular reduced glutathione (GSH) content of HJ16 and HH9 cells. 
Panel A: Representative standard calibration curve from GSH assay (repeated for each 
experiment).
Panel B: Difference in intracellular GSH between HJ16 and HH9 cells, expressed as 
percentage GSH content relative to unstressed J16 and H9 cells respectively. (n=6-10 ±stdev, 
*** indicates p<0.005 for HJ16 cells versus HH9 cells, using Mann Whitney U-test).
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4.2.2.6: Determination of total and Na,K-ATPase activity of J16 and HJ16 cells.
The adaptation of HJ16 cells to increased tolerance against oxidative stress has led to a 
range of changes in cell physiology and function, including increased concentration of 
GSH and resistance to induction of apoptosis. In particular, the cells appeared to have a 
differing proliferative response to PDBu in combination with ionomycin, suggesting 
possible changes in calcium signalling within the cell. The Na,K-ATPase plays an
I 2 1
important role in the maintenance of low intracellular sodium levels, and by Na /Ca 
exchange, an indirect effect upon intracellular calcium levels. It has been widely accepted 
that submitting cells to oxidant stress causes an increase in intracellular Ca2+ concentration 
(Bruce & Elliott, 1998; Hoyal & Forman, 1996; Mapp et al., 1995; Sweiry et al., 1999). In 
addition, there is evidence demonstrating an inhibition of Na,K-ATPase activity in the 
presence of ROS or following depletion of GSH (Guzman et al., 1995; Kowluru & 
Kowluru, 1992; Kurella et al., 1995).
The total and ouabain resistant ATPase activities of J16 and HJ16 cells (along with THP-1 
as a separate control) were determined, and Na,K-ATPase activity calculated as the 
difference between the two. Values were plotted for each cell line as nmol ADP produced 
per hour per 106 cells, and also for the Na,K-ATPase as the percentage of the total ATPase 
activity (Figure 4.8).
There was some difference observed between J16 and HJ16 as far as total ATPase activity 
was concerned, with an observed (although not statistically significant) increase in overall 
activity of approximately 25% in the HJ16 cells. There was also a similar increase in 
Na,K-ATPase between J16 and HJ16, although again not statistically significant. 
However, there was no increase in Na,K-ATPase as a percentage of total ATPase activity 
in the HJ16 cell line, perhaps suggesting an overall upregulation of cellular metabolism as 
opposed to a specific increase in Na,K-ATPase expression.
Of additional interest is the fact that the pro-monocytic THP-1 cell line exhibited not only 
an overall higher ATPase activity than the T-cell lines, but also that a far greater proportion 
of the total ATPase (20% compared to 10% in the T-cell lines) was due to Na,K-ATPase 
activity.
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Figure 4.8: Comparison of THP-1, J16 and HJ16 ATPase activity 
Panel A: Total ATPase and Na,K-ATPase activity of THP-1, J16 and HJ16 cells. Na,K- 
ATPase activity was calculated as the total ATPase activity inhibited after incubation with 
2mM ouabain. (n=7-19 ±stdev)
Panel B: Na,K-ATPase activity of THP-1, J16 and HJ16 cells, expressed as the percentage 
of total ATPase. (n=7-19 ±stdev).
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4.2.2.7: Comparison of cytokine production from THP-1 cells in coculture with J16
and HJ16 cells.
The increased tolerance of HJ16 cells to H2O2 induced oxidative stress also had a range of 
other effects upon the HJ16 cells. In order to determine whether any of these changes had 
altered the HJ16 cell line interactions with monocytes, J16 and HJ16 cells were compared 
in their ability to induce cytokine release from THP-1 cells. Cocultures were set up with 
and without activation of the T-cells (with PDBu/ionomycin as described previously), 
fixation of the T-cells with glutaraldehyde, and in the presence or absence of LPS. After 
48 hours of coculture, supernatants were harvested and analysed for cytokine release using 
ELISA.
Unactivated, unfixed HJ16 in the absence of LPS induced increased IL-lp release from 
THP-1 cells when compared to the production induced by J16 cells (Figure 4.9), and this 
was also the case with fixed J16, even in the presence of LPS. However, the unfixed J16 
cells interacted more effectively with LPS than the HJ16 to induce IL-ip release. One 
unusual result here is the increased EL-1 P release from THP-1 cells stimulated with fixed 
HJ16 cells in the presence of the high concentration of LPS, which is in fact greater than 
that induced by unfixed cells. (It must be considered that J16 cells are not generally strong 
inducers of EL-1 p release from THP-1 cells, so this might be an effect of changes in surface 
phenotype of the HJ16 cells, perhaps having increased effect as a side-effect of the fixation 
procedure). There was very little difference between the unactivated J16 and HJ16 cells 
with regard to induction of IL-lra release, with both suppressing IL-lra release by 
approximately 50%, and the removal of this suppression with fixed J16/HJ16 cells.
When activated T-cells were included in the coculture (Figure 4.10), there was a similar 
effect to the unfixed cells, with J16 cells responding more effectively in the presence of 
LPS. In addition, with both T-cell lines there was a slight overall increase in the levels of 
IL-ip release induced. When activated cells were fixed, there was also little difference 
between the cell lines, except that the fixed HJ16 cells were more severely reduced in their 
ability to induce IL-lp than the J16 cell line. IL-lra induction varied little between the 
activated cell lines, except that activation lead to a modest increase in the ability of both 
cell lines to induce EL-Ira in synergy with LPS. In the absence of LPS, activation had no
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effect upon the HJ16 cells induction of IL-lra from THP-1, whereas activated J16 cells 
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Figure 4.9: J16 and HJ16 induction of IL-lp/ IL -lra production by THP-1 cells in 
coculture.
Panel A: IL-1 (3 production by THP-1 cells in 48hr coculture, with unstimulated 
unfixed/fixed J 16 or HJ16 cells, stimulated with LPS. (n=4-5 ±sem)





















1 8 0 0
1 6 0 0










E  J 1 6
□  H J16





Unfixed* Unfixed*  
+ 0 . 1 ^ g / m l  + 1 ^ g / m l L P S  
LPS
□  H J16
□  T H P -1 Only
rfiYini ~TI.il
Rxed* R xed* R xed*
+ 0 .1 j x g /m l  + 1 n g / m l L P S  
LPS
8 0 0 0
6 0 0 0




Unfixed* Unfixed*  
+ 0 .1  ^ig/ml  
LPS
Unfixed*
+1 n g / m l  LPS
R x e d ’ R x ed *  
+ 0 .1  n g / m l  
LPS
R xed*
+ 1 n g /m l  LPS
Figure 4.10: Activated J16 and HJ16 induction of IL-1(3/ IL -lra  production by 
THP-1 cells in coculture.
Panel A: IL-lp production by THP-1 cells in 48hr coculture, with unfixed/fixed J16 or 
HJ16 cells (PDBu(0.5ng/ml) and ionomycin (lpM ) activated (18hr)), stimulated with 
LPS. (n=4-5 ±sem)
Panel B: As Panel A, except indicating IL-lra production.
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4.2.3: SUMMARY
The aim of this work was to generate cell lines using long-term exposure to a source of 
oxidative stress, and then characterise the cells obtained. Of the two cell lines used, the 
J16 cell line (HJ16) exhibited increased tolerance to oxidative stress, as demonstrated by 
sustained proliferation and resistance to cell death following treatment with H2O2. The H9 
cell line (HH9), although showing signs of a proportion of cells with slight increased 
tolerance to oxidative stress, did not show significant increases in survival following 
treatment with H2O2.
In addition to greater resistance to H2O2 induced death, HJ16 cells were also resistant to 
CH11 Fas ligand induced apoptosis, and exhibited reduced membrane expression of CD3 
and increased expression of CD69. Whereas the proliferation of J16 cells was reduced 
following incubation with PDBu/ionomycin, similarly treated HJ16 cells showed no 
changes in proliferation. HJ16 cells also possessed greater intracellular GSH than J16 
cells, which could contribute towards the cells increased tolerance to oxidative stress.
In the absence of LPS, both unfixed and fixed HJ16 cells generally induced greater EL-lp 
release from THP-1 cells than J16 cells, although still at low levels (~200pg/ml). This 
could imply that, in the absence of additional triggering stimuli, T-lymphocytes subjected 
to long-term oxidative stress can act in a more pro-inflammatory manner than normal. 
There was little difference between J16 and HJ16 in the presence of LPS, except that fixed 
HJ16 were able to synergise more effectively with LPS to induce EL-1 p release from THP- 
1 cells. Following activation of the J16 and HJ16 cells with PDBu/ionomycin, both cell 
lines induced slightly greater IL-lp when unfixed, and slightly less IL-lp when fixed, and 
when unfixed also inhibited IL-lra release to a greater extent. However, there were no 
major differences between activated cell lines with regard to induction of IL-lra release 
from THP-1 cells
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4.3: INVESTIGATION OF INTERLEUKIN-17 (IL-17) AS A COMPONENT OF 
THE T-LYMPHOCYTE PRODUCED SOLUBLE FACTOR
4.3.1: INTRODUCTION
It is clear from earlier data (Figures 3.3, 3.6, 3.9-3.11) that unfixed J16/SEA blasts are far 
more effective inducers of EL-lp release than the corresponding fixed cells. This 
difference is not found for IL-lra production, where fixed T-cells are often more 
stimulatory for THP-1 cells. The most likely explanation is the release from T-cells of a 
soluble factor/cytokine able to promote EL-lp production by monocytes/THP-1 cells, and it 
was considered likely that one element of this pro-inflammatory soluble factor could be EL- 
17 (section 1.2.3).
4.3.2: RESULTS
4.3.2.1: Soluble mouse IgG2b acts in synergy with LPS to induce IL-lp release from 
PBMC.
One experiment planned was to deplete EL-17 from the coculture using mouse anti-human 
EL-17 antibody. However, one discovery during these experiments that required careful 
controls to compensate for, was that the mouse IgG itself possessed a pro-inflammatory 
effect, and could in fact synergise with LPS to induce considerable IL-lp production 
(Figure 4.11). As with all experiments utilising isolated PBMC from several control 
volunteers, there was a significant level of variation between the absolute levels of 
cytokines produced. There is however a visible pattern, with addition of mouse IgG2b to the 
coculture resulting in approximately a twofold increase in release of EL-ip, although there 
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Figure 4.11: Effect of mouse IgG2b on IL-ip/ IL -lra production by PBMC.
Panel A: IL-1P production by PBMC in 48hr coculture, stimulated with LPS and treated 
with mouse IgG2b (n=4 ±sem).
Panel B: As Panel A, except indicating IL-lra production.
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4.3.2.2: Comparison between mouse and human IgG induction of cytokine release 
from PBMC
One interesting development at this stage was the apparent ability of mouse IgG to elicit a 
pro-inflammatory response from PBMC. In the rheumatoid synovial joint the IgG present 
includes anti-IgG, leading to the formation of immune complexes, and these rheumatoid 
factors have often been associated with more severe forms of the disease. It was therefore 
interesting to compare the data obtained from incubation with mouse IgG, to additional 
data obtained while studying the effect of human IgG on PBMC cytokine production 
(displayed in context in chapter 5).
PBMC were incubated for 48 hours with either mouse IgG2b, or with human whole IgG, 
and the supernatants harvested and assayed for cytokine content as described earlier. 
PBMC exposed to mouse IgG2b were incubated with a range of concentrations of mouse 
IgG2b in solution in the culture media. In a separate experiment, PBMC were cultured with 
two concentrations of human IgG adsorbed onto the surface of plastic 96-well plates.
Human IgG is capable of eliciting a dose-dependent increase in EL-lp release from PBMC, 
with values for the higher concentration approaching statistical significance (Figure 4.12), 
and while the same might be occurring for mouse IgG, there is substantial variation and 
very low IL-lp production from these samples. Although an overall higher concentration 
of human IgG (as opposed to mouse IgG2b) is required to promote increased cytokine 
production from PBMC, it is uncertain as to the exact proportion of IgG which actually 
adsorbed to the surface of the plastic, so no direct comparison can be drawn in this case. In 
addition, it should be considered that the mouse IgG is in solution, whilst the human IgG 
was plastic-bound, which may have affected interactions with the PBMC.
In comparison to IL-lp production, mouse IgG2b had no effect upon IL-lra release from 
PBMC at the concentrations studied (Figure 4.13). However, plastic-bound human IgG 
induced a statistically significant dose-dependent increase in IL-lra release from PBMC. 
This suggests that there are distinct differences between either the effect of mouse and 
human IgG, or perhaps between aggregated IgG in solution, and IgG adsorbed onto plastic 
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Figure 4.12: Comparison of the effect of human IgG and mouse IgG2b on IL-113 
production by PBMC.
Panel A: IL-1 (3 production by PBMC in 48hr coculture, treated with human IgG 
(n=10 ±sem).
Panel B: As Panel A, except treated with mouse IgG2b (n=4 ±sem).
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Figure 4.13: Comparison of the effect of human IgG and mouse IgG2b on IL -lra 
production by PBMC.
Panel A: IL-lra production by PBMC in 48hr coculture, treated with human IgG (n=12 
±sem; ** indicates p<0.01, *** indicates p<0.005 for Wilcoxon signed-rank test).
Panel B: As Panel A, except treated with mouse IgG2b (n=4 ±sem).
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4.3.2.3: Changes in cytokine production by THP-1/PBMC incubated with IL-17
It was considered (based on available literature) that one pro-inflammatory element of the 
soluble factor responsible for increased IL-lp production by THP-1/PBMC was likely to 
be IL-17. In order to confirm any effect of IL-17 upon the induction of further pro- 
inflammatory cytokines from monocytic cells, THP-1 cells and PBMC were incubated for 
48h with recombinant human IL-17 (rhIL-17) at a range of concentrations, alone or in 
combination with LPS. Culture supernatants were harvested and cytokine release 
measured as outlined previously. The change in IL-lp release compared to untreated cells 
(with or without LPS as appropriate) was calculated and plotted overleaf (Figure 4.14).
PBMC showed little response to rhIL-17 without additional stimulus unless the 
concentration of rhIL-17 was very high (lOOng/ml). In contrast to this, the concentration 
required to induce a substantial increase in IL-lp release in synergy with LPS was at least 
10,000 times smaller. This synergy also appeared to increase in a dose-dependent manner 
until O.lng/ml rhIL-17, after which the release of additional IL-lp reached a plateau. 
Although LPS was required to synergise with rhIL-17 to induce a substantial increase in 
IL-1 p release (at lower concentrations of rhIL-17), there was no further increase in IL-lp 
release when using the higher concentration of LPS. There was no discernible pattern or 
significant effect of rhIL-17 upon EL-Ira release by PBMC (data not shown).
THP-1 cells stimulated with rhIL-17 showed little, if  any, increase in IL-1 p release in the 
absence of LPS. However, rhIL-17 in synergy with LPS is able to induce a significant 
increase (p<0.05) in IL-ip release, in a dose-dependent manner with respect to both rhEL- 
17 and LPS. This dose-dependent effect is more marked with the higher dose of LPS, as 
with O.lpg/ml LPS the increase plateaus at lng/ml rhIL-17, whereas with lpg/ml LPS the 
dose dependent effect continues up to lOng/ml rhIL-17 (with an additional twofold 
increase in IL-ip release). There was also no discernible pattern or significant effect of 
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Figure 4.14: Effect of rhIL-17 on IL-ip production.
Panel A: Change in IL-1 (3 production in PBMC culture (48hr) stimulated with LPS in 
response to increasing doses of rhIL-17. (n=3). Average basal PBMC production of 
IL -lp (pg/ml): 21 (Ctrl), 2670 (1 ng/ml LPS), 3259 (lOng/ml LPS)
Panel B: As Panel A, except with THP-1 cells. (n=6 ±sem) Average basal THP-1 
production of IL-ip (pg/ml): 43 (Ctrl), 210 (0.1 ng/ml LPS), 556 (1 ng/ml LPS).
(* indicates p<0.05 for total IL-1 P production versus controls containing no rhIL-17, 
using Wilcoxon signed-rank test).
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4.3.2.4: The effect of IL-17 depletion with anti IL-17 antibody on cytokine release in 
THP-1 coculture with J16 cells or culture supernatant
Having determined that IL-17 is capable of eliciting a pro-inflammatory reaction from both 
THP-1 and PBMC, the next step was to attempt to disrupt this signal in the coculture 
system. To this end, THP-1 cells were incubated in coculture for 48 hours with both J16 
cells and J16 culture supernatant, in the presence of LPS and a range of concentrations of 
mouse anti-human IL-17 IgG. Control cultures were also performed for all conditions, 
replacing anti IL-17 antibody with mouse IgG2b as an isotype matched control. As a result 
of the pro-inflammatory effects of mouse IgG2b determined earlier, data demonstrating the 
effects of anti IL-17 IgG on cytokine release are displayed as changes relative to levels 
detected in paired control cultures containing matching concentrations of mouse IgG2b-
Once again, there was a considerable degree of variation in the results, although in spite of 
this there were still patterns, which can be interpreted with care. In the presence of J16 
cells (Figure 4.15), increasing concentrations of anti IL-17 reduce IL-lp release from THP- 
1 cells, a pattern which is independent of the concentration of LPS (although presence of 
LPS does affect overall values, due to the synergy between LPS and IL-17 demonstrated 
earlier). In the same fashion, increasing the concentration of anti IL-17 causes a significant 
increase (p<0.05) in the release of IL-lra from THP-1 cells. It is also interesting to note 
that the pattern of decrease in IL-lp release is mirrored by a pattern of increase in IL-lra 
release, suggesting an overall shift towards a more anti-inflammatory action of the 
monocytes.
In experiments including J16 culture supernatant with THP-1 cells (Figure 4.16), 
essentially the same patterns are present. Increasing concentrations of anti IL-17 lead to 
decreases in IL-ip release and significant (p<0.05) increases in IL-lra release by THP-1 
cells. In addition, in the absence of J16 cells, the LPS effect upon IL-lra production is 
restored, supporting earlier data suggesting that IL-17/LPS synergy is dose dependent with 
regard to both factors. It is also not surprising that given the substantial ability of J16 cells 
(compared to supernatant) to inhibit IL-lra production, that in cocultures containing 
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Figure 4.15: Effect of anti IL-17 antibody on IL -ip /IL -lra production by THP-1 cells in 
J16 coculture.
Panel A: Change in IL -lp production by THP-1 cells (versus isotype matched IgG controls) in 
J16 coculture (48hr) stimulated with LPS, in response to anti IL-17 antibody. (n=5-6 ±sem). 
Average basal THP-1 production of IL-lp with J16 cells (pg/ml): 56 (Ctrl), 384 (0.1 pg/ml 
LPS), 862(1 pg/ml LPS).
Panel B: As Panel A, except indicating IL-lra production. Average basal THP-1 production of 
IL-lra with J16 cells (pg/ml): 852 (Ctrl), 1010 (O.lpg/ml LPS), 1055 (1 pg/ml LPS).











□  0 .1  n g /m l  LPS
□  1 n g /  ml LPS
<  - 1 5 0  j 
-200 ; 
- 2 5 0  {  
- 3 0 0  -
3 5 0 0  
3 0 0 0  |  
2 5 0 0  
2 0 0 0
ct 1 5 0 0
Q.
2 1000
<  5 0 0
0




□  0 . 1 n g / m l  LPS 
n  I n g / m l  LPS
10
[ a n t i  IL-1 7 ] ( n g /  ml )
IIIIII
0 . 5 10-1°00 ^
[ a n t  i IL-1 7 ]  ( n g /  ml )
Figure 4.16: Effect of anti IL-17 antibody on IL-lp/IL -lra production by THP-1 cells 
cultured with J16 supernatant.
Panel A: Change in IL-1 (3 production by THP-1 cells (versus isotype matched IgG controls) 
cultured with J16 supernatant (48hr) stimulated with LPS, in response to anti IL-17 antibody. 
(n=7 ±sem) Average basal THP-1 production of IL-lp with J16 supernatant (pg/ml): 8 (Ctrl), 
182 (0.1 pg/ml LPS), 590 (1 pg/ml LPS).
Panel B: As Panel A, except indicating IL-lra production. Average basal THP-1 production of 
IL-lrawith J16 supernatant (pg/ml): 1039 (Ctrl), 1427 (0.1pg/ml LPS), 1406 (lpg/ml LPS).
(* indicates p<0.05 for samples versus IgG matched controls, using Wilcoxon signed-rank test).
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4.3.2.5: The effect of IL-17 depletion with anti IL-17 antibody on cytokine release 
from PBMC
PBMC are, to a certain degree, a coculture system with both the T-lymphocytes and 
monocytes required already present. T-cells are also capable of releasing a wide range of 
cytokines, v/hether resting, activated or isolated from patients with active disease 
(Mosmann et al., 1991; Romagnani, 1994). After investigating the effects of depletion of 
IL-17 in the THP-1 culture system, the next step in determining the role of IL-17 as a 
soluble factor affecting monocyte cytokine release was a similar experiment using PBMC.
Freshly isolated PBMC in the absence or presence of LPS were incubated for 48 hours 
with a range of concentrations of mouse anti-human IL-17. Paired control cultures were 
also prepared as previously mentioned (Section 4.2.2.1), substituting isotype matched 
mouse IgG2b for anti IL-17 antibody, and the data displayed as the change in cytokine 
release relative to levels detected in these control cultures (Figure 4.17).
It was difficult to determine any effect of IL-17 depletion on unstimulated PBMC, as the 
baseline production of IL-ip was simply too low to enable any changes to be accurately 
measured. However, when PBMC cultures including LPS were treated with anti IL-17 
antibody, there was a distinctive decrease in EL-1 p release, which was dose-dependent at 
lower concentrations, reaching a plateau at around 5pg/ml anti IL-17. Although LPS was 
required for significant IL-lp production, there seemed to be no additional effect with 
increased concentration of LPS. There was considerable variation within the IL-lra 
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Figure 4.17: Effect of anti-IL-17 antibody on IL -lp/IL -lra production by PBMC. 
Panel A: Change in IL-1 (3 production (versus isotype matched IgG controls) in PBMC 
culture (48hr) stimulated with LPS, in response to increasing doses of anti IL-17 antibody. 
(n=4 ±sem). Average basal PBMC production of IL-lp (pg/ml): 9(Ctrl), 2092 (lng/ml 
LPS), 2672 (lOng/ml LPS)
Panel B: As Panel A, except indicating IL-lra production. Average basal PBMC 
production of IL-lra (pg/ml): 3730 (Ctrl), 4325 (lng/ml LPS), 4774 (lOng/ml LPS).
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4.3.3: SUMMARY
The mouse IgG2b used as a control in this experiment shows some induction of IL-lp in 
synergy with LPS, but apart from comments in the literature regarding HAMA (human 
anti-mouse antibody) reaction (Choy et al., 1998), no previous work could be obtained 
regarding the effects of mouse IgG triggering of human FcR, or other inflammatory 
responses. Mouse IgG2b controls were incorporated into experiments in order to assess 
collected data with regard to this pro-inflammatory response. However, in the absence of 
LPS, mouse IgG2b induced little IL-ip, and were not used at concentrations comparable to 
those at which human IgG induced IL-1 p release.
Exogenous rhIL-17 induces substantial increases in IL-1 p release from PBMC even at low 
doses, and at higher concentrations can induce an increase in EL-1 p release even in the 
absence of LPS. This is also the case for IL-lp release from THP-1 cells, in which the data 
collected were statistically significant (p<0.05) in many cases, although only in the 
presence of LPS. There was no consistent change in IL-lra following addition of rhIL-17.
It had been previously demonstrated that T-lymphocytes produced IL-17 in the rheumatoid 
synovium, that addition of exogenous IL-17 to synovial tissue samples could induce IL-6, 
and that a blocking anti-IL-17 antibody could inhibit IL-6 release (Chabaud et al., 1999). 
In addition, IL-17 could induce IL-lp and TNFa release from isolated macrophages 
(Jovanovic et al., 1998), strengthening the data collected for this report. Would interfering 
with the IL-17 signal in a coculture system downregulate the release of these cytokines? 
Using THP-1 cells cocultured with J16 cells or J16 culture supernatant, there was a 
downward trend in the induction IL-lp release with increasing concentrations of anti-IL-17 
antibody, although even with internal controls for the inflammatory activity of mouse 
IgG2b, this effect could still have masked the trend to some extent. Interestingly, 
increasing concentrations of anti-IL-17 antibody also induced statistically significant 
(p<0.05) increases in the induction of IL-lra release, somewhat surprising given that 
addition of rhIL-17 had no effect on IL-lra release from THP-1 cells. When anti-IL-17 
antibody was added to isolated PBMC, it was difficult to detect any effect due to the 
antibody except in the presence of LPS, although there were slight decreases in IL-1 p in 
the absence of LPS. In the presence of LPS, there was substantial inhibition of IL-17
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release that was dose-dependent at lower concentrations of anti-IL-17 antibody. There was 
no discemable pattern to the effect of anti-EL-17 antibody on IL-lra release from PBMC.
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4.4: MODULATION OF Na,K-ATPase IN THP-1 CELLS
4.4.1: INTRODUCTION
Na,K-ATPase is an important membrane protein, responsible for maintaining an ion and 
electrical gradient across the plasma membrane. Ouabain binding to and subsequent 
inhibition of the Na,K-ATPase leads to an increase in the intracellular Na+ concentration, 
which then causes an increase in the Ca2+ concentration due to Na+/Ca2+ exchange. 
Ouabain has also been shown to induce inhibition of proliferation of human T- 
lymphocytes, and also to potently upregulate IL-ip production in human monocytes (Foey 
et al., 1996; Matsumori et al., 1997; Walev et al., 1995). This last effect was also 
mimicked through use of A23187, a calcium ionophore that enhances transport of divalent 
cations (primarily calcium) across the plasma membrane (Matsushima & Oppenheim, 
1985). A decrease in Na,K-ATPase activity has been detected in erythrocyte membranes 
from rheumatoid patients (Testa et al., 1987). It was thought important, especially 
considering further work to be performed upon rheumatoid cells, to determine any effect of 
modulating the activity of Na,K-ATPase in the coculture system.
4.4.2: RESULTS 
4.4.2.1: Effect of pre-incubation with ouabain on cytokine release from THP-1 cells, 
alone or in coculture with J16 cells.
THP-1 cells were incubated for 30 minutes with a range of concentrations of ouabain. The 
cells were then washed thoroughly and incubated with LPS for 48 hours, either alone or in 
coculture with J16 cells, before the supernatants were assayed for cytokine release.
LPS stimulated THP-1 cells showed a slight increase in IL-lp release (Figure 4.18), but no 
real change in release of IL-lra apart from an increase with O.lnM ouabain, which was not 
maintained with increased concentrations of the toxin. There was a sharp decrease in both 
IL-lp and IL-lra release from THP-1 cells incubated with lpM  ouabain, almost certainly 
due to toxic effects upon the cells.
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THP-1 cells in coculture with J16 cells (Figure 4.19) also showed slight increases in IL-lp 
release in the presence of ouabain. However, ouabain appeared to have a dose-dependent 
inhibitory effect upon IL-lra release from cells stimulated with LPS, especially at the 
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Figure 4.18: Effect of ouabain on IL-1(3/ IL -lra  production by THP-1 cells.
Panel A: IL-1 (3 production by THP-1 cells in 48hr culture,stimulated with LPS. (THP-1 
cells preincubated for 30 minutes with various concentrations of ouabain). (n=2)
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Figure 4.19: Effect of ouabain on IL-lp/ IL -lra  production by THP-1 cells in J16 
coculture.
Panel A: IL-1 (3 production by THP-1 cells in 48hr coculture with J16 cells, stimulated 
with LPS. (THP-1 cells preincubated for 30 minutes with various concentrations of 
ouabain). (n=2)
Panel B: As Panel A, except indicating IL-lra production.
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4.5: THE EFFECT OF MODULATION OF Thl/Th2 BALANCE IN T- 
LYMPHOCYTES
4.5.1: INTRODUCTION
One area of T-cell monocyte interaction that warranted further investigation was the 
investigation of the Thl/Th2 balance in the T-cell population, and any effect this might 
have on the monocyte cytokine release in coculture. The intention was to attempt to 
manipulate the Thl/Th2 profile of purified T-cells, but in order to determine whether any 
attempted shift had been successful, some method of determining the Thl or Th2 
characteristics of the cell population would have to be developed. One possible technique 
that could be used in this manner was to use an electrophoretic mobility shift assay 
(EMSA) to detect early activation events associated with a Thl or Th2 phenotype. 
Alternatively, the expression of the Thl/Th2 specific surface markers CCR3 and CCR5 
could be used to determine any shift towards a Thl or Th2 phenotype.
4.5.2: RESULTS
4.5.2.1: Induction of STAT4 and STAT6  expression by PDBu/ionomycin
Signal transducers and activators of transcription (STATs) are well-characterised 
substrates of the Janus kinases (Jaks), and are early members of a range of intracellular 
signalling cascades. Of these, STAT4 and STAT6 are of particular interest, as they are 
specifically activated by Thl or Th2 associated cytokines. The signal induced by IL-4 has 
been shown to be STAT6 dependent, with STAT6 specifically recruited to only the IL-4 
and IL-13 receptors (IL-13R being related to IL-4R). It might therefore be possible to 
utilise this protein as a marker of a Th2 response. In the same manner, IL-12 induces 
production of IFNy, a primary event in the development of a Thl response. As IL-12 
specifically activates STAT4, it might be possible to measure STAT4 to provide an 
indication of a Thl response.
J16 cells were activated with PDBu/ionomycin for a range of time periods, and nuclear
T9extracts prepared. These extracts were then incubated with P-labelled oligonucleotides of
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STAT4 or STAT6 consensus binding sequences before being visualised using 
polyacrylamide gel electrophoresis (PAGE) and autoradiography.
As can be seen, incubation of J16 cells with PDBu/ionomycin is able to induce bands 
detectable by STAT4 and STAT6 binding consensus sequences (Figure 4.20). A number 
of these bands appear to be constitutively expressed, and may in fact represent non-specific 
binding of the oligonucleotides. However, in each case a single band is induced, providing 
a weak signal after about 2 hours, which then becomes more evident with increasing time.
Having determined that it was possible to induce STAT4/STAT6 specific binding proteins 
with PDBu/ionomycin, it was also important to determine that these bands were in fact
99STAT4 and STAT6. This was achieved by competing out the P-labelled oligonucleotide 
with unlabelled oligonucleotide, and also through utilising anti-STAT antibodies in a 
supershift experiment.
J16 cells were activated with PDBu/ionomycin, and nuclear extracts prepared. These 
extracts were then initially incubated with P-labelled oligonucleotides as before, but then 
for 15 minutes with excess unlabelled oligonucleotide (same sequence), excess unlabelled 
oligonucleotide (unrelated sequence -  in this case for AP-1), and either anti-STAT4 or 
anti-STAT6 antibody respectively. Due to problems with the antibody, nuclear extracts 
were also incubated with the anti-STAT antibody for 30 minutes or 18 hours, in both cases 
immediately before incubation with the labelled oligonucleotides.
Once again, incubation with PDBu/ionomycin caused the visualisation of a single 
inducible band on the gel with both STAT4 and STAT6 (Figure 4.21). Incubation with 
excess unlabelled STAT4 or STAT6 oligonucleotide (respectively) erased the band (and 
reduced to a certain extent the intensity of the constitutive bands), though excess unrelated 
oligonucleotide had no apparent effect upon the bands.
Anti-STAT4 antibody had little discernible effect when added post-oligonucleotide, 
although there is perhaps a very slight weakening in band intensity with the anti-STAT4 
antibody. However, in both cases, incubation with the antibody for 30 minutes or 18 hours 
before the addition of the labelled oligonucleotide resulted in a substantial reduction in 
band intensity in both the induced band and, to a certain extent, the constitutive bands as
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well. This therefore suggests that the EMSA protocol can be used to visualise induced 
STAT and STAT6. In addition, it is possible that the constitutive bands might be the 
singular forms of the STAT proteins, and the induced band the activated dimer/oligomer 






Figure 4.20: Timecourse of STAT4/STAT6 induction by PDBu/ionomycin. 
Panel A: Nuclear extracts from J16 cells after activation with PDBu/ionomycin for 
various time periods (visualised with 32P-labelled STAT4 binding oligonucleotide 
using gel shift). (Indicative of 3 experiments).
Panel B: As Panel A, except using STAT6 binding oligonucleotide.
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Figure 4.21: STAT4/STAT6 Gel Shift/Super Shift
Panel A: Nuclear extracts from purified T-cells activated with PDBu/ionomycin (4h) 
(unless identified as unstimulated), incubated with 32P-labelled STAT4 binding 
oligonucleotide. Samples treated with cold oligo (STAT4 and unrelated) or anti- 
STAT4 antibody (after, 30 minutes before, or 18h before addition of oligo). 
(indicative of 4 experiments)
Panel B: As Panel A, except using STAT6 oligonucleotide and anti-STAT6 antibody.
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4.5.2.2: Induction of STAT4 and STAT6 in CD8" SEA blasts cultured in Thl/Th2 
promoting conditions.
PBMC were isolated from healthy volunteers, incubated with mouse anti-human CD8 
antibody and the CD8+ cells depleted through the use of magnetic beads coated with anti­
mouse IgG. The depletion of CD8+ cells was an attempt to simplify the system, removing 
the cytotoxic T-lymphocytes while retaining the CD4+ T-helper cells. The remaining cells 
were then cultured for 9 days with SEA, either as controls or in the presence of Thl 
promoting or Th2 promoting conditions (IL-12/anti IL-4 antibody or IL-4/anti IL-12 
antibody respectively). After 5 and 9 days, cells were harvested and stimulated with either 
IL-4 or IL-12 for 30 minutes before the preparation of nuclear extracts. These extracts 
were then incubated with 32P-labelled STAT4 or STAT 6 consensus sequence 
oligonucleotides and visualised using EMSA, as previously mentioned.
It was generally very difficult to determine any differential effects between cells incubated 
with IL-4 or IL-12, in terms or either STAT4 or STAT6 induction. There was certainly a 
continuous low level of STAT4 and STAT6 induction in all cultures (most likely a side 
effect of the SEA blast procedure). The most obvious difference occurs with STAT6 
expression, in which the day 9 culture incubated with IL-4 shows reduced STAT6 
expression when left unstimulated, but this is probably due to the SEA blast culture cells 
advancing towards a resting state.
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Figure 4.22: STAT4/STAT6 induction in SEA blasts incubated with 
IL-4/IL-12
Panel A: Nuclear extracts from SEA blasts incubated with either IL-4 or IL- 
12 for 5 or 9 days, and then restimulated with IL-4 (4) or IL-12 (12) for 30 
minutes(visualised with 32P-labelled STAT4 oligonucleotide using gel shift). 
(Indicative of 3 experiments)
Panel B: As Panel A, except using STAT6 oligonucleotide.
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4.5.2.3: Incubation of SEA or CD3/B7 blasts in Thl/Th2 promoting conditions.
PBMC were isolated from healthy volunteers, and cultured for 6 days with either SEA or 
aggregated anti-CD3 IgG and fixed CHO-B7 transfectants (CD3/B7 stimulation), either as 
controls or under Thl promoting conditions (IL-12/anti EL-4 antibody) or Th2 promoting 
conditions (EL-4/anti EL-12 antibody). After this time, cells were harvested and washed for 
use in coculture with THP-1 cells. In addition, cells were retained from each culture for 
FACS analysis.
CCR3 is the designation given to the eotaxin receptor, a surface marker that has been 
shown to have greatly increased expression on cells with a Th2 phenotype. CCR5 (another 
chemokine receptor) has been demonstrated to be upregulated on cells with a Thl 
phenotype. It was therefore hoped that these surface markers could be used to give an 
indication of the level of Thl or Th2 differentiation within the treated populations of T-cell 
blasts. Cells from the treated blast cultures were incubated with mouse anti-human CCR3 
or mouse anti-human CCR5 antibody, followed by anti-mouse FITC, and the cells 
analysed using flow cytometry.
Cells from the blast cultures were split into 2 samples, and 1 sample of each fixed with 
gluteraldehyde. Cells were then incubated in coculture with THP-1 cells in the absence or 
presence of LPS for 48 hours, and any cytokine release into the supernatants determined by 
ELISA.
It proved extremely difficult to determine any differences at all in CCR3 or CCR5 
expression between the cultures, as unlike the surface markers investigated up to this point, 
expression of both CCR3 and CCR5 was almost negligible. However, in occasional 
samples, there was indication of an increase in CCR5 expression. Such an example is 
displayed overleaf (Figure 4.23), but it should not be taken as indicative of the general 
situation, merely that it was possible to obtain such a shift in occasional samples.
Overall, the results from these experiments were disappointing. The EL-lp and IL-lra 
release from THP-1 cells stimulated with these “Thl and Th2 differentiated cells” 
generally showed little change, either negative results or at best, inconclusive. However, 
as with the CCR data, there were occasional experiments that showed some indication of
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the expected changes, with “T hl” cells inducing greater concentration of IL-1 P release and 
reduced IL-lra release.
The cocultures using SEA blasts show some interesting patterns (Figure 4.24). With 
unfixed cells, the “Thl-treated” cells produce slightly more IL-lp than either the “Th2- 
treated” cells or the control culture, the difference being the most pronounced when the 
cells are cultured in the absence of LPS. Interestingly, the fixed cells also show this 
pattern, although in this case requiring the amplification of IL-1 P release brought about by 
synergy with LPS. In the main, these trends are small, although there is some evidence 
that with increased numbers some statistically significant increases might be present.
These patterns are mirrored in the production of IL-lra, with an increase in IL-lp generally 
also showing a decrease in IL-lra. The IL-lra production of THP-1 cells induced with 
unfixed “Thl-treated” T-lymphocytes is reduced, to an extent that is almost statistically 
significant even with only n=4. Results with fixed T-lymphocytes show a different pattern 
to those with unfixed cells, inducing a slight increase in levels of IL-lra production while 
showing little difference between treated or control cultures, although there was a greater 
increase in IL-lra induction with the highest dose of LPS.
Although some “Thl-treated” T-lymphocytes displayed expected traits (induction of 
increased IL-lp and decreased IL-lra release), the cells treated with “Th2” inducing 
conditions did not display the related expected tendencies. Indeed, especially when 
inducing THP-1 cells stimulated with LPS, such cells appeared to induce effects similar to 
those of the “Thl-treated” cells, although generally of lesser magnitude. Only in the 
absence of LPS, or when fixed T-lymphocytes were used, did the “Th2-treated” cells 
induce reduced quantities of IL-lp in comparison to control and “T h l” cultures.
T-lymphocyte cultures stimulated with CD3/B7 showed completely different patterns of 
differentiation (Figure 4.25). Unlike SEA blasts, these cells generally showed a reduced 
ability to stimulate IL-lp release if treated with either Thl or Th2 promoting conditions, 
and also showed this trend with regards to IL-lra release as well. These patterns were also 
followed when the cells were fixed. It would appear that differentiation of T-lymphocytes 
with cytokines can promote a range of different effects depending on the proliferative 
signals provided.
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Also presented is Figure 4.26, which is displayed to demonstrate that in specific, individual 
cases there was substantial alteration of the T-lymphocytes’ ability to induce IL-lp as 
appropriate to a Thl or Th2 phenotype (although the trend with IL-lra induction is less 
clear). This is the same sample used earlier to demonstrate the occasional shift evidenced 
in CCR5 expression with LL-12/anti IL-4 incubation (Figure 4.23).
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Figure 4.23: CCR3/5 surface expression on "Thl/Th2" differentiated SEA blasts
SEA blasts cultured with IL-4 and anti IL-12 antibody or IL-12 and anti IL-4 antibody 
(day 6 of culture). Histograms indicate FL-1 fluorescence, either background (filled 
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Figure 4.24: Day 6 SEA blasts differentiated with IL-4/anti IL-12 or IL-12/anti IL-4. 
Panel A: IL-1 (3 production by THP-1 cells in 48hr coculture stimulated with LPS, with 
SEA blasts (6 day) preincubated with IL-4/anti IL-12 IgG or IL-12/anti IL-4 IgG. (n=4 
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Figure 4.25: Day 6 CD3/B7 blasts differentiated with IL-4/anti IL-12 or IL-12/anti IL-4. 
Panel A: IL-1 p production by THP-1 cells in 48hr coculture stimulated with O.l^ig/ml LPS, 
with CD3/B7 blasts (6 day) preincubated with IL-4/anti IL-12 IgG or IL-12/anti IL-4 IgG.
(n=3)




















9 0 0 0  j 
8 0 0 0  : 
7 0 0 0  I- 
6 0 0 0  ; 
5 0 0 0  4  
4 0 0 0  





10000  ; 
8 0 0 0  |  
6 0 0 0  





□  IL -4 /a n ti IL-12
□  IL-12 / anti IL-4














□  IL -4 /a n ti IL-12
□  IL-12 /an ti IL-4 













Figure 4.26: Day 6 SEA blasts (example) differentiated with IL-4/anti IL-12 or 
IL-12/anti IL-4 .
Panel A: IL-1 p production by THP-1 cells in 48hr coculture stimulated with 0.1 pg/ml LPS, 
with SEA blasts (6 day) preincubated with IL-4/anti IL-12 IgG or IL-12/anti IL-4 IgG.(n=l) 
Panel B: As Panel A, except indicating IL-lra production.
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4.5.3: SUMMARY
Two methods were tested in an attempt to detect differences between Thl and Th2 
differentiated cells. Although both methods appeared to be working correctly, it generally 
proved difficult to detect any differences between the differentiated cells except in a few, 
specific cases. In the case of STAT4 and STAT6, it would appear that induction of T-cell 
blast proliferation with SEA results in the continual stimulation of a low level o f STAT4 
and STAT6 induction, making it difficult to detect any differences in STAT4 or STAT6 
induction due to the effects of Thl or Th2 promoting cytokines. CCR3 and CCR5 
expression were more successful at determining a change in Thl/Th2 phenotype in a 
specific few cases, although even in these samples there was only a slight shift in CCR5 
expression.
Differences were also apparent between T-cells blast cultures stimulated with SEA or 
CD3/B7. It would appear that when stimulated with SEA, incubation with either cytokine 
protocol caused increases in EL-ip induction from THP-1 cells, while cultures stimulated 
with CD3/B7, cytokine treatment resulted in a slight decrease in IL-ip induction from 
THP-1. In both cases, both cytokine treatments reduced IL-lra release from THP-1. SEA 
blasts incubated in pro-Thl conditions did induce greater IL-lp release from THP-1 cells 
than the other SEA blasts, most markedly in the absence of LPS, and in the presence of 
LPS also induced the least IL-lra, but in most of these cases the differences in cytokine 
release were small.
In summary, it was very difficult to detect a consistent Thl or Th2 shift, with any effects 
observed generally being small and irreproducible. This held true for STAT analysis, CCR 
expression and cytokine release during coculture. As a result of this, it was decided not to 
pursue this line of experimentation further. It is quite possible that human T-cells are 
difficult to drive towards a Thl or Th2 phenotype, or perhaps that the duration of the 
incubation was too short to have any detectable effect in most cases. It should however be 
noted that in a few specific samples, successful induction of a Thl phenotype, detected by 
CCR5 expression, could be observed, and that these cells then induced greater IL-ip 
release from THP-1 cells than matched Th2 or control groups.
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CHAPTER 5




The immunology of rheumatoid arthritis has been studied extensively using both model 
systems and isolated cell types, with investigation of cytokines released (Brennan et al., 
1995; Feldmann et al., 1996), the involvement of a Thl over a Th2 T-cell phenotype 
(Miossec & van den Berg, 1997), roles of neutrophils (Edwards & Hallett, 1997) and 
monocytes (Arend & Dayer, 1995; Liote et al., 1996). However, there is still a great deal 
that is not known or confirmed about the disease. The mechanisms of action of many of 
the second-line drugs in widespread use today have still to be determined, and the 
relevance of the T-cell in the synovial joint is still uncertain. Release of IL-1 p and TNFa 
from monocyte/macrophages has been confirmed as a primary cause of inflammation 
within the synovial joint, but many of the mechanisms controlling monocyte cytokine 
release are still being investigated.
Total and Na,K-ATPase of both normal and rheumatoid cells was determined, as part of 
the experiments detailed in this chapter. The Na,K-ATPase is an integral membrane 
protein found in the cell membrane of all higher eukaryotes, and is responsible for 
pumping 3 Na+ out of the cell whilst pumping 2K+ ions in, utilising ATP as the driving 
force. It is responsible for maintaining both ionic and electrochemical gradients across the 
plasma membrane (Lingrel & Kuntzweiler, 1994). It has been demonstrated that there is 
an impaired Na,K-ATPase on rheumatoid mononuclear cells and erythrocytes, and that this 
inhibition of Na,K-ATPase activity can be simulated through use of a thiol-blocker (p- 
hydroxymercuriphenylsulphonate (pHMPSA)) (Maubach et al., 1993; Testa et al., 1987). 
When intracellular [K+] is depleted, or the activity of the Na,K-ATPase inhibited (by the 
specific inhibitor, ouabain), there is induction of pro-inflammatory cytokine release (IL-lp, 
TNFa and IL-6) from mononuclear cells (Foey et al., 1996; Matsumori et al., 1997; Walev 
et al., 1995). The biochemical ATPase assay could therefore be used to further investigate 
Na,K-ATPase activity on rheumatoid mononuclear cells, to complement this earlier work 
and the data on IL-lp/IL-lra production detailed later in the chapter.
It is important to note that in this chapter, J16 cells are used as a model T-cell to stimulate 
PBMC, and THP-1 cells are used as model monocytes to measure stimulatory effects of 
SEA T-cell blasts. While J16 cells only provide a minimal stimulus to THP-1 cell cytokine
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release, both cell lines acted well in their roles as model cell types when 
stimulated/cocultured with “normal” cells. It is also important to be aware that PBMC 
(Section 5.2.3.2) were only stimulated with PDBu/ionomycin activated, fixed J16 cells (as 
opposed to unfixed). These experiments were carried out as part of a larger study for 
Pharmacia Upjohn, investigating the effects of breakdown products of sulphasalazine on 
PBMC cytokine release when exposed to several stimuli (including culturing with fixed, 
activated J16 cells), the larger part of which will not be covered in this thesis.
The primary aim of the experiments in this chapter was to use isolated PBMC and T-cells 
from rheumatoid patients to investigate the interactions between rheumatoid T- 
lymphocytes and monocytes, and to determine the effects of both the rheumatoid condition 
and several standard disease modifying anti-rheumatic drugs (DMARDs) upon the cells’ 
ability to either induce or release pro- and anti-inflammatory cytokines.
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5.2: RESULTS
5.2.1: Comparison of ATPase activity of healthy and rheumatoid PBMC
Both total ATPase and Na,K-ATPase were determined for PBMC isolated from healthy 
subjects and rheumatoid patients. Na,K-ATPase is directly involved in a whole range of 
homeostatic cell functions, including maintenance of electrical and chemical gradients, 
and modulation of intracellular Na+ (and indirectly Ca2+) levels. As such, the Na,K- 
ATPase could have significant effects upon cellular signalling through the indirect effects 
upon Ca concentration (which acts as a secondary messenger in a range of cellular 
signalling pathways). In combination with work investigating the relationship between 
ouabain (specific inhibitor of the Na,K-ATPase) and increases in IL-ip release, there is 
certainly an argument for further investigation of the activity of the Na,K-ATPase in 
rheumatoid cells. Total ATPase activity can also be considered, to a certain extent, as an 
indication of overall cellular metabolism (ATP utilisation).
PBMC were isolated from healthy controls and rheumatoid patients, which were 
subdivided into early synovitis (ES) and chronic rheumatoid arthritis (RA) groups. Early 
synovitis patients were receiving NSAIDs only, while RA patients selected for this study 
were all receiving methotrexate and NSAIDs. The ATPase activity (both total and Na,K- 
ATPase) was determined for all samples using the biochemical ATPase assay in the 
presence or absence of ouabain (Section 2.3). Values were plotted as total ATPase and 
Na,K-ATPase activity for all three groups, and also Na,K-ATPase as a percentage of total 
ATPase activity. CD 14 expression of PBMC samples was also measured using flow 
cytometry, to determine the proportion of monocytes present, since macrophages have 
higher ATPase activity than lymphocytes, and could therefore influence the overall levels 
detected. In order to confirm this, matched samples of PBMC, purified monocytes and 
purified T-lymphocytes were also utilised in the ATPase assay.
There is a highly statistically significant (p<0.005) increase in total ATPase activity in 
both of the rheumatoid groups compared to the normal controls, with almost a doubling of 
total ATPase in evidence (Figure 5.1). There was also an obvious increase in Na,K- 
ATPase activity in both rheumatoid groups, which also proved to be statistically significant 
for the ES samples versus healthy controls (p<0.05), an increase over the healthy controls
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of approximately 50% (Figure 5.2). However, in spite of this increase in both overall 
ATPase and Na,K-ATPase activity, there was only a small (2%) decrease in Na,K-ATPase 
as a percentage of the total, for the RA group only.
Experiments comparing isolated PBMC, purified monocytes and purified T-lymphocytes 
(Figure 5.3) show significant (p<0.05) increases in both the total ATPase and Na,K- 
ATPase activities in monocytes relative to paired PBMC samples. T-lymphocytes exhibit 
significantly less (p<0.05) total ATPase activity than PBMC.
This could suggest that any increase in Na,K-ATPase activity is not due to any specific 
changes in the sodium pump regulation, but possibly due to an overall upregulation of 
cellular ATP utilisation, upregulation of cellular activation or different proportions of cell 
types in the PBMC population. However, there were no significant differences between 
the proportions of cells expressing CD14 in healthy, ES or RA groups (Figure 5.4).
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Figure 5.1: Total and Na,K-ATPase activity of healthy and patient group PBMC.
Total ATPase and Na,K-ATPase activity of healthy, early synovitis (ES) and rheumatoid 
arthritis patient (RA) PBMC, determined using the biochemical ATPase assay, with and 
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Figure 5.2: Na,K-ATPase activity of healthy and patient group PBMC.
Na,K-ATPase activity of healthy, early synovitis (ES) and rheumatoid arthritis patient 
(RA) PBMC, determined using the biochemical ATPase assay, with and without 
ouabain (200pM). (n=l 1-23 ±sem, * indicates p<0.05, against normal samples using 
Mann-Whitney U-test).
Panel A: Calculated Na,K-ATPase activity.
Panel B: Na,K-ATPase activity expressed as a percentage of total ATPase activity.
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Figure 5.3: Total and Na,K-ATPase activity of healthy PBMC, monocytes and 
T-lymphocytes
Panel A: Total ATPase activity for matched samples of isolated PBMC, purified 
monocytes and purified T-lymphocytes, determined using the biochemical ATPase 
assay (n=6±stdev, * indicates p<0.05 versus PBMC using Wilcoxon signed-rank 
test)
Panel B: As Panel A, except for Na,K-ATPase activity.
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Figure 5.4: CD14 surface expression of PBMC from healthy and patient groups
Percentage CD 14 expression on PBMC from healthy controls, early synovitis (ES) and 
rheumatoid arthritis patients (RA), determined by flow cytometry (n=6-13±sem)
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5.2.2: Differences in cytokine release by THP-1 cells induced by rheumatoid SEA 
blasts cultured from patients receiving different drug therapies
As mentioned earlier, the mechanisms of action of many of the DMARD class of drugs 
have yet to be fully elucidated. Work was initially focussed on patients being treated with 
sulphasalazine (SPZ) due to the acquisition of related funding from Pharmacia Upjohn. 
However, patients from the RNHRD (Royal National Hospital for Rheumatic Diseases) 
clinics were generally prescribed one (or more) of a range of DMARDs, and this seemed 
an ideal opportunity to investigate further the possible mechanisms for the actions of 
various DMARDs. The experiments performed in this section primarily investigate the 
effect of the various drug therapies on rheumatoid T-cell activity in the coculture system. 
(Section 5.2.4 will deal with the effect of such therapies on the corresponding cytokine 
release of rheumatoid monocytes).
Blood samples were obtained with informed consent from healthy subjects and sero­
positive RA patients attending clinics at RNHRD. Patients had generally been receiving 
single DMARD therapy for at least 3 months, and had not received any steroidal therapy 
for a similar time period. DMARDs studied were methotrexate (MTX), sulphasalazine 
(SPZ), D-penicillamine (D-Pen) and hydroxychloroquine (HCQ). RA patients receiving 
NSAJD therapy alone were also included in the study as a disease positive control.
In an attempt to standardise the state of T-cells from healthy and rheumatoid arthritis 
patients, and also to reduce any carry-over of monocytes into the THP-1 coculture, SEA T- 
cell blast cultures (Section 2.2.5) were produced from freshly isolated PBMC before 
inclusion in coculture experiments with THP-1 cells. In addition, samples were also set up 
including LPS as an added stimulus for IL-lp release from THP-1 cells. Controls 
containing SEA blast cells alone were used to determine any residual cytokine release, and 
these values were also used to adjust values determined from cocultures containing THP-1 
cells and unfixed SEA blasts. This was to ensure cytokine concentrations measured were 
due specifically to cytokine release from THP-1 cells, or increases due to the interactions 
between the cell types.
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As an indication of cell activation, CD69 expression of SEA blast cultures was routinely 
assessed for each timepoint (Figure 5.5). There was substantial expression o f CD69 (35- 
40% CD69+ cells) on day 3 in both healthy and rheumatoid cultures, which had decreased 
by day 6 to approximately 15% expression. Although there was some limited variation 
between rheumatoid and healthy samples, no significant differences in CD69 expression 
were observed.
Most of the patients from whom blood samples were obtained were receiving MTX or SPZ 
therapy, and these were investigated and compared together as the predominant therapies 
being prescribed at the clinic. Smaller numbers of patient samples were available for the 
other drugs (HCQ, D-Pen), so these have been displayed separately, although there are still 
some interesting results observed in samples from patients receiving these drugs. 
Although oral and intramuscular gold are still used as a therapy for RA, no samples from 
patients receiving these treatments were available during this study.
In summary, rheumatoid blasts are initially capable of inducing (or indeed, generating 
themselves) greater amounts of IL-ip release than healthy blasts, but this ability decreases 
more rapidly than in healthy cells. This is also true to a lesser extent when the SEA blasts 
are fixed before addition to the coculture. In addition, rheumatoid SEA blasts induce less 
IL-lra release from THP-1 cells than healthy SEA blasts.
5.2.2.1: Samples from patients treated with methotrexate or sulphasalazine
SEA blasts (day 3) from all samples induced substantial release of IL-lp from THP-1 cells, 
with MTX and SPZ cells inducing approximately 50% and 100% more than the healthy 
and NSAID samples (Figure 5.6). The addition of LPS caused a 3-4 fold increase in IL-lp 
release, and also made differences between the samples less obvious as all blasts induced 
similar amounts of IL-ip release, with NSAID samples inducing the most and MTX the 
least. Fixed day 3 SEA blasts from the MTX and SPZ groups were capable of inducing 
very small amounts of IL-lp release from THP-1 cells, but these levels were virtually 
negligible unless LPS was added to the coculture. Fixed healthy and NSAID blasts did not 
induce any detectable levels of IL-lp release above basal from THP-1 cells. Comparing 
this to the EL-lp release induced by unfixed blasts, this again demonstrates the importance
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of either a soluble factor or active interaction between the cell types to induce IL-lp 
release. With the addition of LPS, there was more easily detectable release of IL-lp, 
although there was little evidence of any difference between the various sample groups. 
Basal IL-lp release from 3-day MTX blasts, although low, was substantially greater than 
that from healthy or NSAID blasts. The addition of LPS had no observable effect upon IL- 
lp  release from healthy blasts, although both NSAID and SPZ groups exhibited increased 
release of IL-ip and MTX blasts released approximately 50% greater amounts of IL-lp 
than either of these groups of samples.
SEA blasts (day 3) from all groups were also able to induce substantial amounts of IL-lra 
release from THP-1 cells, although healthy SEA blasts were able to induce greater release 
than any of the disease groups. Of the patient groups, MTX samples were able to induce 
the most IL-lra release, a result that became slightly more marked upon the addition of 
LPS to the cocultures. However, LPS had little (if any) overall effect on IL-lra release, and 
this observation could well be due to sample variation. Fixed SEA blasts did not induce 
any additional IL-lra release from THP-1 cells except in the presence of LPS. With the 
addition of LPS, 3-day healthy and NSAID blasts induced approximately a 200% increase 
in IL-lra release from THP-1 cells, while MTX and SPZ blasts could only induce a 100% 
increase in EL-lra release. Basal IL-lra release from 3-day SEA blasts was similar for all 
groups (slightly lower than THP-1 basal release), except for the NSAID group, which 
exhibited almost double the IL-lra release of the other samples. Although the overall basal 
levels of IL-lra release decreased slightly with the addition of LPS, this had no effect on 
this pattern of results.
As shown in Figure 5.7, by day 6 of SEA blast culture, all groups were reduced in their 
ability to induce IL-lp release, although this was most marked in the NSAID and MTX 
groups. Also, all disease groups (NSAID, MTX, SPZ) showed considerably reduced 
ability to synergise with LPS for the induction of IL-ip release (<45%), whereas SEA 
blasts from healthy subjects still induced levels of IL-ip release that were only slightly 
reduced (-80% release) from the day 3 blast cultures. The fixed healthy blasts from day 6 
SEA blast culture had retained the ability to induce similar release of EL-ip to the 3-day 
culture, but the three disease groups had all exhibited a reduction in their induction of IL- 
lp release from THP-1 cells. Of the disease groups, those from SPZ blasts could still 
induce levels approaching those of the healthy blasts, while MTX cells induced less IL-lp
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and the NSAID group could induce no additional release of IL-lp above basal THP-1 
release (with LPS). As expected, blasts from 6-day SEA cultures possessed virtually no 
residual release of IL-ip.
Blasts from 6-day cultures also induced substantial IL-lra release, although reduced (by 
25-30%) when compared to release induced by day 3 blasts. Interestingly, in the absence 
of LPS, blasts from the MTX group maintained their induction of IL-lra release at levels 
very similar to those of the healthy groups, while cells from the NSAID and SPZ groups 
induced levels of IL-lra that were about 25% lower. Again, the addition of LPS had no 
apparent effect on IL-lra release, except that blasts from NSAID patients exhibited 
increased induction of IL-lra release to levels comparable to those induced by healthy and 
MTX blasts. Fixed day 6 blasts did not increase THP-1 basal IL-lra release in the absence 
of LPS, but could induce IL-lra release from THP-1 cells in the presence of LPS, but there 
was little difference between the sample groups. 6-day blasts were still capable of releasing 
low levels of IL-lra, with healthy blasts releasing the most, although SPZ, and especially 
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Figure 5.5: CD69 expression of healthy/RA SEA blasts (grouped by drug therapy)
Percentage CD69 expression of SEA blasts cultured from healthy /RA subjects, at day 3 
and day 6 of blast culture (n=2-8±sem). (Day 0 values for healthy cells were 12±5%, for 
RA were 16±3%, values for HCQ Day6 unavailable).
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Figure 5.6: Comparison of Day3 healthy/RA SEA blasts (grouped by drug therapy) 
on IL -lp /IL -lra production by THP-1 cells.
Panel A: IL-lp production by THP-1 cells in 48hr coculture with healthy/RA SEA blasts 
(3 day, grouped according to drug therapy, unfixed or fixed), stimulated with O.lpg/ml LPS. 
(n=3-8 ±sem) Unfixed values adjusted for basal SEA blast cytokine production (No THP-1) 
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Figure 5.7: Comparison of Day6 healthy /RA SEA blasts (grouped by drug therapy) 
on IL-l|3/IL-lra production by THP-1 cells.
Panel A: IL-lp production by THP-1 cells in 48hr coculture with healthy/RA SEA Blasts 
(6 day, grouped according to drug therapy, unfixed or fixed), stimulated with O.lpg/ml LPS. 
(n=3-8 ±sem) Unfixed values adjusted for basal SEA blast cytokine production (No THP-1) 
Panel B: As Panel A, except indicating IL-lra production.
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5.2.2.2: Samples from patients treated with D-penicillamine or hydroxychloroquine
SEA blasts from patients treated with D-Pen and HCQ displayed some similarities to cells 
from other disease groups in their patterns of induction of IL-lp and IL-lra release from 
THP-1 cells, but also exhibited some interesting differences. Unfortunately, the numbers 
of samples available from these patient groups were severely limited, but nevertheless 
some intriguing patterns were in evidence from these data. Data involving day 3 SEA 
blasts are displayed in Figure 5.8, while data from day 6 SEA blasts are shown in Figure 
5.9.
Unfixed, 3-day SEA blasts from patients treated with D-Pen and HCQ showed 2 extremes 
of induction of DL-ip release. Blasts from patients treated with D-Pen showed very little 
ability to induce IL-ip release from THP-1 cells, while blasts cultured from patients treated 
with HCQ induced the highest release of IL-lp of all groups (approximately 300% of the 
release induced by the healthy and NSAID control groups). The additional release upon 
addition of LPS to the coculture masked the effect with the HCQ blasts, which induced 
similar levels to the other control and disease groups, but the IL-lp release induced due to 
D-Pen blasts was still severely reduced. Fixed SEA blasts (day 3) from D-Pen and HCQ 
groups were able to induce a very small release of IL-lp from THP-1 cells, although 
certainly more than patients treated with NSAIDs, and slightly more than blasts from the 
other two disease groups. As with the data from the other disease groups, addition of LPS 
increased the overall release of IL-lp in all groups, but in this case the release from both 
HCQ and D-Pen groups was slightly more than from the other disease groups, or the 
controls. Residual IL-ip release from day 3 HCQ blasts was comparable to those obtained 
from other disease group blasts, while the residual IL-lp release from D-Pen blasts was 
substantially more than that obtained from any other set of samples, and this difference 
was only magnified with the addition of LPS.
<r
IL-lra release from THP-1 cells induced with day 3 HCQ and D-Pen SEA blasts was 
surprising when compared to the results from the other disease groups. Based on data from 
the NSAID, MTX and SPZ rheumatoid groups, IL-lra induction was generally similar to 
or lower than that induced by the healthy blasts (perhaps slightly greater with MTX blasts). 
However, these initial results indicate that IL-lra induction by blasts from patients treated 
with HCQ or D-Pen are actually similar to or higher than the release induced by healthy or
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NSAID blasts. There appeared again to be little significant effect of LPS upon induction 
of IL-lra release. IL-lra release induced by fixed day 3 HCQ blasts appeared to follow the 
general pattern set by the other disease groups (compared to healthy and NSAID controls), 
in that there was very little induction of IL-lra release from THP-1 cells, and this only 
increased slightly in response to LPS (to a lesser degree in fact than the other disease 
groups). This maintenance of IL-lp release from day 3 D-Pen blasts was also in evidence 
with regard to IL-lra release from these cells. Whereas residual EL-Ira release from HCQ 
blasts was comparable with blasts from the MTX and SPZ groups, blasts from patients 
treated with D-Pen were capable of releasing large quantities of IL-lra, similar to those 
released from THP-1 cells induced with unfixed blasts.
When using day 6 HCQ blasts there was little induction of IL-lp, although the D-Pen 
blasts were able to maintain the low (but still increased) level of IL-ip release induced at 
day 3. With the addition of LPS, HCQ and D-Pen samples exhibited similar results to the 
other disease groups, inducing far less IL-lp release than the healthy blasts. Fixed 6-day 
SEA blasts from HCQ and D-Pen groups exhibited an overall reduction in induction of IL- 
ip  release, with the healthy blasts best retaining the ability to induce IL-ip over the 
duration of the blast culture. The IL-ip release from day 6 HCQ blasts had decreased to 
negligible levels (similar to MTX and SPZ samples), but the release from day 6 D-Pen 
blasts was still several magnitudes greater than that from THP-1 cells.
As with 3 day SEA blasts, 6-day blasts from HCQ and D-Pen patients induced greater 
levels of EL-Ira release from THP-1 than not only other rheumatoid samples, but also 
healthy and NSAID sample groups. Fixed day 6 HCQ blasts exhibited similar effects to 
the SPZ and MTX blasts, inducing very little additional IL-lra release from THP-1 cells. 
However, the fixed D-Pen blasts were capable of inducing greater levels of IL-lra release 
than either the control or other rheumatoid groups, a factor which was even more 
distinctive with day 6 blasts, and also in evidence with the addition of LPS (in both cases). 
IL-lra release from day 6 HCQ blasts had reduced to low levels, but day 6 D-Pen blasts 
were still releasing quite substantial quantities of IL-lra. Even allowing for the small 
sample numbers (n=2), in combination with the data above, this would seem to suggest a 
survival or retention of activity of monocytes in the D-Pen blast culture not seen in the 
other samples.
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Figure 5.8: Comparison of Day3 healthy/RA SEA blasts (grouped by drug therapy) 
on IL-ip/IL -lra production by THP-1 cells (additional data).
Panel A: IL-1(3 production by THP-1 cells in 48hr coculture with healthy/RA SEA Blasts 
(3 day, grouped according to drug therapy, unfixed or fixed), stimulated with 0.1pg/ml LPS. 
(n=2-5 ±sem) Unfixed values adjusted for basal SEA blast cytokine production (No THP-1) 




0  H ealthy  
□  NSAIDs 
°  D-Pen  
H HCQ
a  ThP-1 Only
8 0 0 0
O)
a 6 0 0 0
4 0 0 0
2000




2  8 0 0 0
6 0 0 0




1 6 0 0 0  _













No THP-1 No THP-1 
+L PS
0  H ealthy  
□  NSAIDs 
H D-Pen  
Q HOQ
0  THP-1 O nly
N o T H P -1 No THP-1 
+L PS
Figure 5.9: Comparison of Day6 healthy/RA SEA blasts (grouped by drug therapy) 
on IL -ip/IL -lra production by THP-1 cells (additional data).
Panel A: IL-1P production by THP-1 cells in 48hr coculture with healthy/RA SEA blasts 
(6 day, grouped according to drug therapy, unfixed or fixed), stimulated with O.lpg/ml LPS. 
(n=2-5 ±sem) Unfixed values adjusted for basal SEA blast cytokine production (No THP-1) 
Panel B: As Panel A, except indicating IL-lra production.
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5.2.3: Factors influencing cytokine release by rheumatoid PBMC cultured from
patients receiving different drug therapies
This section contains the complementary experiments to those detailed in section 5.2.2. 
Whilst the data included there concentrated primarily upon the involvement of the 
rheumatoid T-cell in the induction of cytokine release from “standard” monocytes (i.e. 
THP-1 cells), this section focuses on cytokine release from the rheumatoid monocyte. 
Specifically, the experiments investigated any differences between the levels of cytokines 
released from rheumatoid monocytes isolated from patients treated with the various 
DMARD therapies outlined earlier in this chapter, in part with regard to stimulation of the 
monocytes with a “standard” T-cell (PDBu/ionomycin activated, fixed J16).
PBMC were isolated from blood samples obtained from sero-positive RA patients with 
informed consent. Patient groups and suitability were determined as outlined in section 
5.2.2. In order to determine any differences in response of the different drug therapy 
groups to standard stimuli, PBMC from all groups ( lx l0 6 cells/ml final concentration) 
were incubated for 48 hours, either in RPMI medium alone, or with one of several stimuli. 
Stimuli used were PDBu/ionomycin-activated fixed J16 cells (final concentration 
2.5xl06/ml), whole human IgG adsorbed onto plastic (25 and 50pg/ml) and LPS (1 and 
lOng/ml). Cytokine release was then determined in the supernatants by use of ELISA.
5.2.3.1: Basal cytokine release from rheumatoid PBMC
As can be seen from Figure 5.10, basal release of IL-lp from both healthy and rheumatoid 
cells was uniformly low. Although there was a substantial degree of variation between 
samples, healthy cells released the greatest quantities of IL-lp. Of the disease groups, only 
MTX released more EL-ip than the NSAID controls, with SPZ and HCQ groups releasing 
very small and negligible quantities respectively. Interestingly, these results are generally 
mirrored by the results for the release of IL-lra, in that NSAID and SPZ PBMC (lower for 
IL-lp release) exhibited higher IL-lra release, while healthy and MTX PBMC released 
lower levels of IL-lra. The only exception to this are PBMC from patients treated with 
HCQ, which while releasing lower levels of IL-lra than other sample groups, also 
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Figure 5.10: Basal IL -ip/IL -lra production by PBMC from patients and controls. 
Panel A: IL-lp production by PBMC in 48hr culture, from healthy controls and patient 
groups (n=3-21 ±sem where possible).
Panel B: As Panel A, except indicating IL-lra production.
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5.2.3.2: Cytokine release from rheumatoid PBMC stimulated with activated, fixed
J16 cells
J16 cells were incubated with PDBu (0.5ng/ml) and ionomycin (lpM) for 18 hours, 
washed thoroughly and fixed with glutaraldehyde before addition to the PBMC coculture. 
Although activated, fixed J16 cells had limited effects stimulating cytokine release from 
THP-1 cells, the effects upon PBMC were more extensive, possibly due to the generally 
greater basal cytokine release of PBMC compared to THP-1.
Addition of activated, fixed J16 to healthy PBMC caused a 100% increase in IL-lp release 
(much greater than with THP-1 cells), while the NSAID PBMC coculture showed over a 
300% increase in IL-ip release compared to PBMC alone (Figure 5.11). SPZ cells 
exhibited a similar increase to the NSAID disease control cells, but MTX cells responded 
dramatically to the stimuli provided by the activated, fixed J16 cells, with over a tenfold 
increase in IL-lp release. HCQ PBMC, in which no basal IL-lp release was detected, also 
failed to release any detectable IL-lp when stimulated with J16 cells.
All PBMC samples showed increases in IL-lra release in response to the addition of 
activated, fixed J16 cells. However, the increases were overall in line with the basal IL-lra 
release from the specific sample groups. In proportion to the basal release, healthy cells 
showed the least response, with an increase of approximately 60% over basal IL-lra 
release. The NSAID cocultures, which possessed the greatest basal release of IL-lra, 
increased this release by approximately 100%. Although an increase of approximately 
200% was in evidence in MTX cocultures upon the addition of J16 cells, the overall IL-lra 
release was still lower than in NSAID samples. SPZ PBMC showed the greatest response 
to J16 cells, with an IL-lra release approximately 40% greater than from the NSAID 
disease control group (which exhibited a similar basal release to SPZ PBMC), perhaps not 
surprising given their lower response in terms of IL-lp release. HCQ PBMC also 
demonstrated a significant response to the addition of J16 cells, with a 3-4-fold increase in 
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Figure 5.11: Activated, fixed J16 stimulated IL -ip/IL -lra production by PBMC from 
patients and controls.
Panel A: IL-lp production by PBMC (from healthy controls and patient groups) in 48hr 
coculture with PDBu/I activated (18hr), fixed J16 cells. (n=3-21 ±sem where possible) 
Panel B: As Panel A, except indicating IL-lra production.
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5.2.3.3: Cytokine release from rheumatoid PBMC stimulated with human IgG
Human IgG (25 and 50 pg/ml) suspended in bicarbonate buffer (pH 9.6) was added to U- 
bottomed 96 well plates (50pl/well) and incubated at 4°C for 18 hours, at which point the 
wells were washed twice with PBS before use. The data from these experiments is 
displayed in Figure 5.12.
Healthy cells showed negligible response to 25pg/ml IgG, but responded strongly to 
50pg/ml with a 100% increase in IL-lp release. This response was mirrored with the 
NSAID sample, although at a lower overall level or IL-lp release. Given the low values of 
IL-lp release throughout this experiment, most differences are likely to be due to reduced 
quantitative discrimination of the ELISA at these concentrations. The only other 
substantial increases over basal IL-ip release are from the SPZ PBMC, which react to IgG 
with a large increase IL-ip release. It may be interesting to note that the HCQ PBMC, 
previously unresponsive with regards to EL-lp release, appear to have been induced to 
release IL-lp (although still at very low levels) in the presence of IgG.
In comparison with the overall low release of EL-lp in response to IgG, there were quite 
extensive increases in IL-lra release throughout the sample groups. Healthy PBMC 
responded the least, with approximately a 2-fold increase in IL-lra release, and similar 
effects were observed with the NSAID PBMC, these having slightly greater overall release 
of IL-lra. All of the DMARD treated patient groups showed greater responses, both in 
terms of the total IL-lra release, and as a proportion of basal release, especially the SPZ 
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Figure 5.12: IgG stimulated IL-lp/ IL -lra production by PBMC from patients and 
controls.
Panel A: IgG stimulated IL-lp production by PBMC (from healthy controls and patient 
groups) in 48hr culture. (n=3-21 ±sem where possible)
Panel B: As Panel A, except indicating IL-lra production.
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5.2.3.4: Cytokine release from rheumatoid PBMC stimulated with LPS
When isolated PBMC were cultured with LPS, all sample groups showed substantial 
increases in IL-lp release (Figure 5.13). The healthy cells showed the lowest increase of 
all the groups, and even so exhibited almost a 20-fold increase in IL-lp release, with little 
difference between the two concentrations of LPS. The rheumatoid PBMC exhibited far 
greater release of IL-lp than the healthy cells, but still varied widely between PBMC from 
patients receiving different drug therapies. The NSAID and HCQ groups demonstrated IL- 
ip release that was approaching double that of the healthy PBMC with the highest dose of 
LPS, and the MTX and SPZ groups released even greater levels of IL-1 p.
In comparison to the disease group PBMC, LPS had little effect upon the IL-lra release of 
healthy cells, with a decrease in IL-lra release of approximately 20%. In contrast to this, 
the addition of LPS to NSAID PBMC resulted in an increase in IL-lra release of between 
50 and 80%. There were similar increases in IL-lra release in all rheumatoid cell groups, 
although given the variation involved between samples, it is unlikely that there was a 
significant dose dependent effect between the two concentrations of LPS used. Again, the 
increase in EL-Ira release showed some relation to the basal EL-Ira release of the PBMC in 
the different groups, with the MTX and HCQ cells releasing levels of IL-lra slightly lower 
than that of the NSAID group. The largest release of IL-lra from the SPZ cells, ranging 
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Figure 5.13: LPS stimulated IL-lp/IL -lra production by PBMC from patients and 
controls.
Panel A: LPS stimulated IL-1 (3 production by PBMC (from healthy controls and patient 
groups) in 48hr culture. (n=3-21 ±sem where possible).
Panel B: As Panel A, except indicating IL-lra production.
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5.3: CONSOLIDATION OF COCULTURE DATA
The experiments detailed in this chapter attempted to draw two main comparisons, 
between healthy and rheumatoid cells, and between healthy cells/NSAJOD disease controls 
and rheumatoid cells from patients receiving different DMARD therapies. The following 
sections combine the previous data focussing upon general trends and specific differences.
The ratio of IL-ip to IL-lra release is another method used to assess pro- or anti­
inflammatory tendencies in cell populations. As mentioned earlier, it has been estimated 
that IL-lra is required in approximately 10-100-fold excess to effectively reduce the 
activity of IL-lp by 50% (Arend et al., 1990).
5.3.1: Healthy compared with rheumatoid cells (general trends)
Rheumatoid blasts (NSAID treatment) initially induced similar or slightly greater IL-ip 
release from THP-1 cells than healthy cells, but this had declined significantly with day 6 
rheumatoid blasts, inducing approximately only 50% of the IL-ip release induced by 
healthy 6-day blasts. This pattern was also observed with fixed cells. Both day 3 and day 
6 rheumatoid blasts generally induced less IL-lra release than healthy blasts.
The rheumatoid blasts themselves initially released greater quantities of IL-lp than the 
healthy cells, but this release had also fallen below the levels released from healthy cells by 
day 6 of blast culture. Interestingly, rheumatoid blasts also initially released greater levels 
of IL-lra than the healthy cells, but this also decreased in a similar manner to IL-lp 
release.
The ratio of EL-1 p to IL-lra release induced from THP-1 cells by both day 3 and day 6 
SEA blasts (Figure 5.14) showed little difference between rheumatoid (NSAID) and 
healthy cells, except when considering fixed cells (in the absence of LPS). Healthy fixed 
cells appeared to induce an anti-inflammatory cytokine profile capable of nullifying the 
activity of IL-ip, and although NSAID cells showed only a slightly more inflammatory 
profile, samples from DMARD groups showed profiles favouring IL-ip activity. It is 
important to be aware that NSAID data in these graphs are based on only 3 samples, and so 
are more susceptible to variation due to differences between individual samples.
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Cultured healthy PBMC generally released more IL-ip than rheumatoid PBMC, although 
without the addition of LPS the levels of IL-lp released from all samples were low 
(<200pg/ml). Basal levels of EL-Ira release from healthy PBMC were generally slightly 
lower than those from rheumatoid PBMC, with NSAID PBMC responding to activated 
fixed J16 cells and LPS with larger increases in IL-lra release than healthy cells. 
Unstimulated healthy and rheumatoid (NSAID) PBMC exhibited a similar ratio of IL-ip to 
EL-lra release (Figure 5.15), although when stimulated with activated fixed J16 cells the 
healthy cells favoured greater IL-lp activity. Again, the numbers of NSAID samples were 
small in comparison with other groups (n=5, compared to n=12 for healthy samples), so 
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Figure 5.14: Ratio of IL-ip release to IL -lra  release from THP-1 cells in coculture 
with SEA blasts from healthy controls/patient groups
Panel A: Ratio of IL-ip release to IL-lra release from THP-1 cells in coculture for 48h 
with unfixed/fixed SEA blast cells (day 3) from healthy controls/patient groups, stimulated 
with O.lpg/ml LPS. (n=3-9±sem).
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Figure 5.15: Ratio of IL-lp release to IL -lra release of PBMC from healthy and 
patient groups
Ratio of IL -ip release to IL-lra release from PBMC from healthy and patient groups 
cultured for 48h with fixed activated (PDBu/ionomycin, 18h) J16 cells, plastic-bound 
human IgG or LPS. (n=5-21±sem, * indicates p<0.05 using Mann-Whitney U-test against 
healthy control values).
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5.3.2: Healthy/NSAID rheumatoid controls compared with DMARD groups
This section summarises the various similarities and differences between the healthy and 
specific patient groups examined in the coculture experiments. In a large number of cases 
there was little difference between sample groups, so the focus will be primarily upon the 
general trends, and the more substantial differences observed.
There was little difference observed in the IL-ip release induced from THP-1 by day 3 
SEA blasts, although some general trends were evident. Unfixed SEA blasts from 
DMARD groups induced greater release of IL-ip than those from NSAID or healthy 
groups. Both unfixed and fixed SEA blasts from DMARD and NSAID groups tended to 
induce lower levels of IL-lra release than healthy cells. The ratio of IL-lp to IL-lra 
release from THP-1 cells stimulated with day 3 SEA blasts varied little between sample 
groups except when using fixed blasts. Fixed healthy blasts possessed anti-inflammatory 
effects on THP-1 cells, altering the ratio of IL-lp and IL-lra to a point at which (based on 
the literature (Arend et al., 1990)) IL-lp effects would be substantially reduced. This 
appeared to be mirrored in NSAID samples (although sample numbers might have affected 
this result). However, while SPZ blasts had little effect on the ratio of IL-ip to IL-lra 
release, MTX blasts retained pro-inflammatory activity while fixed, favouring the 
production of IL-lp relative to IL-lra.
Day 6 blasts from both DMARD and NSAID groups induced substantially less (50%) IL- 
lp release from THP-1 cells than healthy blasts. There was little difference in IL-lra 
release between the groups, although IL-lra release induced by SPZ blasts was lower than 
that from healthy or other DMARD groups. The only other major differences were 
observed in the limited numbers of D-Pen samples, which (when unfixed) exhibited 
reduced induction of IL-lp release, and also retained greater levels of IL-lra induction than 
other DMARD samples with day 6 blasts. There was also a dramatic retention of IL-ip 
and EL-Ira release from the D-Pen blasts themselves, even after day 6 of blast culture. Day 
6 blasts overall (in the absence of LPS) showed a reduction in inflammatory profile, with 
only MTX blasts still provoking an increased IL-lp release (relative to IL-lra release) over 
the baseline production of THP-1 cells. Fixed blasts from all groups examined (NSAID 
numbers were too low in this case) exhibited anti-inflammatory activity, favouring IL-lra 
release. This was a 10-fold relative increase in IL-lra release when involving healthy
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blasts (compared to basal THP-1 release), but there was still a relative 3-fold increase in 
IL-lra release due to both SPZ and MTX blasts.
Basal release of IL-lp from all PBMC groups was very low, rarely above 200pg/ml. 
Release of IL-lra was also similar from all groups, although greater from SPZ and NSAID 
PBMC. The ratio of basal IL-ip to IL-lra differed little between groups, except that MTX 
PBMC favoured more IL-1 p release.
Stimulation with activated fixed J16 cells induced IL-lp release from all samples except 
HCQ PBMC. However, this was most evident in the increase in IL-lp release from MTX 
cells. Healthy cells responded to J16 cells with an upregulation in IL-lra release, but there 
were greater increases from all rheumatoid groups, especially SPZ PBMC. Both healthy 
and MTX PBMC released EL-Ira at only a 10-fold greater concentration than IL-lp, while 
NSAID and SPZ PBMC exhibited a more anti-inflammatory profile, releasing IL-lra at a 
100-fold greater concentration than IL-lp (SPZ PBMC showing a significant reduction in 
comparison to healthy cells (p<0.05)).
PBMC stimulated with human IgG exhibited very little increase in IL-lp release above the 
low levels of IL-lp release already detected. However, there were definite increases in the 
IL-lra release from all PBMC, with a minimum increase of 100%, confirming IgG as a 
potent inducer of IL-lra release. Greater increases in IL-lra release were exhibited from 
SPZ and HCQ PBMC. The ratio of IL-lp to IL-lra was unreliable due to the low levels of 
IL-lp release following stimulation with IgG, and no significant differences were 
observed.
Stimulation with LPS resulted in considerable increases in IL-1 p release from all PBMC 
groups. Healthy cells responded the least, with increasing release of EL-ip from NSAID, 
MTX and SPZ PBMC in that order. IL-lra release from healthy cells was unaffected by 
the addition of LPS. PBMC from all disease groups responded to LPS stimulation with 
some (generally 50-100%) upregulation of IL-lra release, although SPZ PBMC exhibited a 
greater release than the other disease groups (approximately 200% increase). Stimulation 
of PBMC with LPS resulted in considerable increase in the release of IL-1 p, such that the 




The previous section has already consolidated and summarised the data collected for this 
chapter, however, there are several items requiring further discussion (Chapter 6).
Considering the stimuli used to trigger PBMC cytokine release, it is apparent that fixed, 
activated J16 cells are capable of inducing IL-lp from all patient and control PBMC, but 
that release of IL-lra is greater from rheumatoid PBMC. IgG can act as a potent inducer of 
IL-lra release from PBMC, and while LPS can also induce IL-lra, it is by far more 
effective at stimulating the release of IL-lp.
The coculture system is already complex, but even when combined with additional factors 
such as individual SEA blast cultures from patients receiving different drug treatments, it is 
still possible to distinguish certain trends. In the absence of LPS, day 3 RA SEA blasts 
generally induce greater IL-lp release from THP-1 cells than healthy SEA blasts, with the 
reverse being true for IL-lra release. Other general differences include healthy day 6 SEA 
blasts retaining the ability to induce EL-ip release from THP-1 cells with or without LPS, 
while day 6 rheumatoid SEA blasts induce substantially less IL-lp, particularly in the 
presence of LPS. However, healthy PBMC stimulated with LPS released less IL-ip than 
rheumatoid PBMC.
With regard to drug effects upon the T-cell blasts in the coculture, MTX SEA blasts 
specifically showed greater capacity to induce IL-lra release from THP-1 cells, compared 
to other rheumatoid samples. This difference between the samples was reduced following 
fixation of the blasts, suggesting the activity of a soluble factor induced from MTX treated 
cells. The other DMARD with noticeable effects upon T-cells was D-Pen, even though 
only a few samples were available. D-Pen SEA blasts were capable of inducing substantial 
IL-lra release from THP-1 cells. In addition, in the D-Pen SEA blast culture there was 
substantial SEA culture production of both IL-lp and IL-lra, suggesting increased survival 
or retention of activity of monocytes remaining in the culture.
The only significant anti-inflammatory trend observed between drug treatments on PBMC 
was from patients receiving SPZ. Whether SPZ PBMC were stimulated with fixed, 
activated J16, human IgG or LPS, SPZ PBMC were capable of inducing greater release of
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IL-lra than all other samples, rheumatoid or control (except HCQ PBMC triggered with 
IgG). In addition, when cultured with activated, fixed J16 cells, SPZ PBMC demonstrated 
a statistically significant decrease (p<0.05) in IL-lp:IL-lra ratio, corresponding to an anti­
inflammatory trend. The substantial IL-lp release of MTX PBMC in response to 





The primary aim of this thesis was to investigate T-lymphocyte/monocyte interactions 
resulting in the release of IL-1 P and IL-lra. The role of IL-1 p as a major pro-inflammatory 
mediator has been well established, but better understanding of the mechanisms controlling 
the release of both IL-lp and the specific receptor antagonist, IL-lra, could enable the 
development of more effective treatments for RA, especially in light of the initial success 
of trials using IL-lra as a therapeutic agent (Bresnihan et al., 1998).
It had previously been demonstrated that T-cells could induce “membrane-bound” EL-1 
(probably IL-1 a) production on macrophages (Weaver et al., 1989; Weaver & Unanue, 
1986), and that this activation of macrophages required both soluble factor and cell-cell 
contact interactions, with cell-cell contact being important for substantial IL-1 mRNA 
transcription (Landis et al., 1991). A similar line of research was followed by Dayer et al.
(1992), who investigated specifically the role of cell-cell contact between T-cells and 
monocytes. In this and subsequent work, it was demonstrated that direct cell-cell contact 
between T-lymphocytes and monocytes (both freshly isolated or “model” cell lines) could 
not only induce IL-lp, IL-lra, TNFa and IL-6 release from monocytes (Vey et al., 1992; 
Vey et al., 1997), but also stimulate the release of MMPs (Lacraz et al., 1994). Given the 
substantial induction of pro-inflammatory cytokines following T-cell/monocyte 
interactions, it was decided to utilise and manipulate a variant of this system to further 
investigate the mechanisms controlling EL-ip and IL-lra release.
6.1: Development of a Model Coculture System
There are a number of both similarities and differences between the work carried out for 
this thesis and that of Dayer et al. When using only cell lines J16 and THP-1 
(l,25(OH)2D3 cultured for 48h), there was low-level induction of IL-lp, which was 
retained following fixation of the J16 cells. Activation of the J16s with PDBu/ionomycin 
resulted in a slight increase in IL-lp release from the monocytes, although fixing the 
activated J16 resulted in reductions of IL-lp release. Unfixed J16 cells (whether activated 
or not) had little effect upon IL-lra release, although when fixed there was a slight increase 
in IL-lra release. In comparison, Dayer et al., determined that activation of T-cells was 
required for stimulation of IL-lp release, and that isolated cell membranes were capable of
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inducing both IL-1 P and IL-lra release (Vey et al., 1997). Dayer et al. also used Hut-78 
cells as their T-cell model (an alternate leukaemic T-cell line), which could account for 
some discrepancies (Vey et al., 1997). There is some agreement between the results, as 
fixed J16 cells were capable of inducing slight increases in IL-lp and IL-lra release from 
THP-1 cells, although at lower levels. Overall, J16 cells alone showed only limited ability 
to induce effects from THP-1 cells, not perhaps that surprising given that both are 
immortalised cell lines, and might well be deficient in certain signalling pathways or 
receptors (for example, lack of CD40 expression of THP-1 cells, or CD40L on Hut-78 cells 
(Gauchat et al., 1993; Vey et al., 1991)).
The use of LPS provided the coculture system with a means of magnifying IL-lp and IL- 
lra release from THP-1 cells, and thus perhaps allowing the detection of differences 
between treatments that would not otherwise have been observed. LPS is a potent 
stimulator of both monocytes and T-cells, and so could have potential effects on both cell 
types. One interesting discovery from this first set of data was that J16 cells were capable 
of interacting with an LPS stimulus, not only in the expected increase of induction of IL- 
lp, but also to inhibit LPS induced IL-lra release. This inhibition was mediated by a 
soluble factor released by J16 cells, as fixation of the J16 cells removed this inhibition, and 
we now possess evidence suggesting that IL-17 may possess a limited inhibitory influence 
of IL-lra release from PBMC or THP-1 cells.
Also of interest is an experiment carried out by Dayer et a l using freshly isolated cells 
(Vey et a l , 1997). Freshly purified monocytes were incubated with unstimulated or 
stimulated T-lymphocytes, either together or separated by a membrane, allowing mixing of 
soluble factors only. In all cases, stimulation of the T-lymphocytes resulted in greater IL- 
lp and IL-lra release (and was required for increases in IL-1 p release), and while soluble 
factors alone could strongly stimulate IL-lra and modestly stimulate IL-1 P release, the 
release of both (primarily IL-lp) was enhanced considerably in a mixed culture allowing 
cell-cell contact. This led to the hypothesis that cell-cell contact was a primary pro- 
inflammatory stimulus, while soluble factors were more anti-inflammatory in action.
However, what this experiment did not address, in a situation using isolated cells (as 
opposed to cell lines), was the effects of cell membranes alone on the monocyte cytokine 
release, and that an alternative hypothesis could be that both cell-cell contact and soluble
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factors act together to differentially control cytokine release. Following initial cell-cell 
contact, which can of course be a two-way process (June et al., 1994; Schiott et al., 1996; 
Schwartz, 1992), there might well be synthesis or expression of additional cell surface 
molecules or soluble factors. This hypothesis is supported by the stimulatory effect of J16 
cells upon freshly isolated PBMC or monocytes. Fixed J16 cells induce increased EL-ip 
release from monocytes/PBMC, but unfixed J16 do so to a greater extent. This difference 
is also apparent in the presence of LPS, although fixed J16 cells induce little additional EL- 
ip release above that induced by LPS itself. There are distinct differential patterns in IL- 
lra release, with unfixed J16 cells inhibiting IL-lra release from PBMC/monocytes, and 
removal of this inhibition following fixation of the J16 cells. This concept is supported by 
the induction of cytokine release from THP-1 cells by SEA T-cell blasts, in which unfixed 
blasts stimulate substantially greater IL-lp and IL-lra release than fixed cells, and 
synergise more effectively with LPS for the induction of IL-lp.
An alternative reason for the difference between results obtained in this study and those of 
Dayer et al. is the mechanism of T-cell activation. Dayer et al. activated T-cells with a 
mixture of phytohaemagglutinin (PHA) and PMA, whereas the standard T-cell activation 
in this study was performed with either SEA or PDBu/ionomycin. SEA can certainly 
activate T-cells in a pro-inflammatory fashion, as demonstrated by day 3 SEA blasts 
induction of IL-lp from THP-1 (from negligible to approximately 2800pg/ml) relative to 
the increase in IL-lra release (approximately 6-fold to 17,000pg/ml), far below the level 
required for effective inhibition of the effects of IL-lp. The potential for differential 
activation of T-lymphocytes (by PDBu/ionomycin or SEA) to affect monocyte cytokine 
release in subsequent coculture and the kinetics of SEA blast cultures were investigated 
through the use of time-courses of blast cultures, with samples being transferred to 
coculture on a daily basis. SEA stimulates T-cells directly through the TCR/CD3 complex 
with CD28 co-stimulation (from the corresponding APC), while PDBu and ionomycin 
stimulate PKC and calcium signalling directly, simulating the activation of phospholipases 
(specifically PLCy), which although involved in TCR/CD3 signalling, do not represent the 
entire range of signalling cascades activated. Activation of the T-cells with SEA appears 
to induce a stronger pro-inflammatory signal than with PDBu/ionomycin, as although 
levels of EL-Ira release are comparable between the stimuli, the induction of EL-ip (in the 
absence of LPS) is approximately 4 times greater. Fixed blasts stimulated by either
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method induce little IL-1 p (although greater for SEA blasts), and similar levels of IL-lra, 
which again supports the hypothesis that cell-cell interactions provide only a proportion of 
the pro-inflammatory signals during the induction of monocyte-produced cytokines.
One point of interest was the substantial induction of IL-lra in the PDBu/ionomycin blast 
culture, which was of a similar level or (in the later stages) greater than that induced by 
SEA blasts from THP-1 cells. There was also a sudden increase in IL-lra release from 
THP-1 cell cocultures between day 5 and day 6 of PDBu/ionomycin blast culture. 
Certainly this demonstrates that PDBu/ionomycin activated T-cells are not as strongly pro- 
inflammatory (or for as long duration) as those stimulated with SEA. The sudden increase 
in IL-lra release has yet to be explained, perhaps due to the induction of some form of 
response to continual activation, or alternatively the down regulation of expression of a 
pro-inflammatory stimulus. A more likely explanation is that as the PDBu/ionomycin 
blasts return to a more “resting” state following activation, there is a tendency of the cells 
to revert to a more anti-inflammatory profile of cytokine release or surface molecule 
expression, and that day 6 is the approximate point at which this reversion becomes 
detectable.
There is currently only weak evidence linking CD69 expression and cytokine release, 
except when fixed cells are incubated with LPS, for which the expression of CD69 and IL- 
lp release show similar patterns. There have already been studies demonstrating that 
blocking of CD69 with antibody can partially inhibit contact induction of cytokine release 
during coculture, although other, uncharacterised surface proteins are also required for 
contact activation (Isler et al., 1993). These data in combination with the induction of IL- 
1 p release from COS-69 transfectants in the presence of LPS strengthen the evidence for 
an accessory role of CD69 in the induction of IL-1 p release by cell-cell contact, although 
the presence of additional pro-inflammatory triggers is required.
RA is considered an autoimmune disease, with evidence implicating the inappropriate 
activation of a subset of T-cells due to the activity of an autoantigen (Baeten et al., 
1998a/b; Feldmann et al., 1996; Gregersen et al., 1987; Kirkpatrick et al., 1997; Panayi et 
al., 1999), and subsequent stimulation of an inflammatory response and joint destruction. 
In keeping with the pro-inflammatory nature of RA, and a desire to obtain conditions 
within the coculture approximating the “m vzvo” situation, it was decided that a “more
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complete” activation of isolated T-lymphocytes through TCR/CD3 and CD28 utilising 
SEA would be preferable for further use in this study.
6.2: Manipulation of the Coculture System 
6.2.1: Hypoxia and Oxidative Stress
The role of hypoxia and oxidative stress in RA has been well documented (reviewed by 
Mapp et a l, 1995), and it has been hypothesised that one reason for the 
hyporesponsiveness of T-cells in the rheumatoid synovium is the action of ROS. RA T- 
cells exhibit a depressed response to activation by either crosslinked anti-CD3 mAh or 
mitogens, including decreases in proliferation and cytokine release (Emery et al., 1988; 
Maurice et al., 1997; Maurice et al., 1998; Verwilghen et al., 1990). It has also been 
demonstrated that these downregulated responses can be related to both a depression of the 
intracellular calcium flux triggered following activation, and also due to deficiencies in 
PTK activity on rheumatoid T-cells (Allen et al., 1995; Ritter et al., 1997). This decrease 
in PTK activity, and a decrease in expression of the critical PTK Fyn, can be mimicked by 
incubation of T-cells with H2O2, and isolation of RA T-cells in the presence of catalase 
leads to partial restoration of PTK activity (Ritter et al., 1997). In light of this information, 
it was considered appropriate to investigate the capability of T-cells undergoing regular 
episodes of oxidative stress to induce cytokine release from monocytes, through the 
development of cell lines treated regularly with increasing concentrations of H2O2. These 
cells could then be characterised in terms of oxidative stress tolerance, expression of 
surface markers, proliferative response to mitogens, and induction of monocyte cytokine 
release in the coculture system.
Following consecutive treatments with increasing concentrations of H2O2, the HJ16 cell 
line was determined to be approximately 10-fold more tolerant to H2O2 than the original 
cell line, J16. There was a statistically significant (p<0.05) decrease in CD3 expression, 
which coupled with the lack of inhibitory proliferative response to PDBu/ionomycin 
suggests similarities to the hyporesponsive characteristics of RA T-cells outlined above. 
As PDBu alone is insufficient to affect proliferation of normal J16 cells, a depletion of 
calcium response in HJ16 cells could certainly account for the lack of proliferative 
response to PDBu/ionomycin. HJ16 cells exhibit an increase in resistance to apoptosis 
induced by CH11 anti-Fas mAh, along with an increase in intracellular GSH levels. This
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shows similarities to apoptotic T-cells rescued through the action of stromal cells, which 
also possess increased GSH and are quiescent (Akbar & Salmon, 1997; Salmon et al., 
1997). Interestingly, freshly isolated synovial T-cells and monocytes are highly 
susceptible to anti-Fas mAb, although these cells appear to be divided into susceptible and 
resistant populations providing evidence for selective apoptosis that could be contributory 
to the inflammatory response (Nishioka et al., 1998). HJ16 cells also exhibited a 
significant (p<0.05) increase in CD69 expression and show a small increase in total 
ATPase activity relative to J16 cells, mirroring trends from RA PBMC in comparison with 
healthy cells (Chapter 5, Figures 5.1, 5.5).
However, HJ16 cells displayed certain characteristics not associated with RA synovial T- 
cells. HJ16 cells exhibit decreased CD3 expression and response to activation but 
increased GSH, while responsiveness of T-cells to signals via CD3 is decreased in 
conditions of depleted GSH (Maurice et al., 1998). It has been demonstrated that levels of 
GSH are reduced in erythrocytes from RA patients (Chilles et al., 1990), and that reduced 
GSH may be responsible for the differentiation of T-cells towards a Thl phenotype 
(Peterson et al., 1998). So whereas these cells share certain characteristics with 
rheumatoid synovial T-cells, there are also certain discrepancies, as the increased GSH 
levels detected in HJ16 cells do not seem so consistent with other observed characteristics.
Some differences between J16 and HJ16 cells induction of cytokine release from THP-1 
cells were identified. The major differences were that in the absence of LPS, HJ16 cells 
induce greater IL-lp release than J16 cells (although at very low levels), although unfixed 
J16 cells synergised more effectively with LPS to induce IL-lp release (possibly as a side 
effect of decreased HJ16 cell response to activation stimuli). When fixed however, HJ16 
cells induce more IL-lp in combination with LPS, perhaps due to increases in CD69 
expression. There was little difference in IL-lra induction between “resting” J16 and HJ16 
cells when unfixed, and a similar pattern when activated, except that unfixed HJ16 cells 
more severely inhibited IL-lra release from THP-1 cells. Differences between the cells 
types were generally small however, likely due to the limited stimulatory effect of J16 cells 
upon THP-1 cytokine release.
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6.2.2: Interleukin-17
Data outlined earlier demonstrated that soluble factors possess a substantial role in the 
induction of cytokine release from monocytes. IL-17, a T-lymphocyte derived cytokine 
with potential pro-inflammatory activity, was assessed for any capability to induce 
cytokine release in the coculture system. Previous studies determined that IL-17 is 
produced spontaneously in the rheumatoid synovium, and solely by memory T- 
lymphocytes (Chabaud et al., 1999; Fossiez et al., 1996). Additional studies have shown 
that IL-17 is in fact produced only by CD4+ ThO/Thl cells, and is not synthesised in cells 
expressing a Th2 phenotype (Aarvak et al., 1999a). Firstly, the cytokine release of PBMC 
or THP-1 cells cultured with IL-17 was determined, to obtain an indication of pro- 
inflammatory stimulation and ensure that THP-1 cells were capable of reacting to IL-17, 
after which cocultures were performed utilising blocking anti-IL-17 antibody, to 
demonstrate that IL-17 release from T-lymphocytes could directly affect cytokine release 
from monocytic cells.
Stimulation of PBMC and THP-1 with rhIL-17 induced increases in IL-1 p release, 
although this required the presence of LPS for THP-1 cells, and also for PBMC except at 
the highest concentration of rhIL-17 (lOOng/ml). This was in agreement with work carried 
out by Jovanovic et al. (1998), who also observed release of IL-6, PGE2, IL-10, IL-12 and 
IL-lra at similar concentrations of IL-17 with adhered human macrophages. In this study 
however, no increase in IL-lra release was observed due to the effects of rhIL-17, although 
Fossiez et al. (1996) observed no induction of a number of cytokines (IL-4, IL-6, IL-10 or 
IFNy) by IL-17 on PBMC, while obtaining cytokine release (GM-CSF, IL-6, IL-8) from 
cultured synoviocytes. This would suggest the requirement of additional signals (probably 
including TNFa) or activation of cells for the induction of certain cytokines, as only a 
combination of rhIL-17 and TNFa (as opposed to these cytokines used singularly) was 
capable of inducing GM-CSF release from cultured synovial fibroblasts (Fossiez et al., 
1996).
Data obtained using anti-IL-17 antibody were obscured due to unexpected induction of IL- 
1 p release by the antibody itself. However, with the use of appropriate controls including 
mouse IgG2b it was possible to determine several trends. THP-1 cells either in coculture
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with J16 cells, or cultured with J16 culture supernatant exhibited a dose-dependent 
decrease in IL-lp release with increasing anti-IL-17 mAh, and a specific corresponding 
dose dependent increase in IL-lra release. This implies the inhibition of IL-1 p release and 
stimulation of IL-lra release through the blocking of IL-17 signalling. Similar results were 
observed for the inhibition of IL-1 P release from cultured PBMC, although no trends for 
the induction of IL-lra were observed. The difference between the IL-lra release from 
PBMC and THP-1 could be as a result of the simplicity of the system. THP-1 cocultures 
included merely model monocytes and a source of T-cell cytokines, and results from this 
system were noticeably more variable when J16 cells were used as opposed to J16 culture 
supernatant. PBMC, although including monocytes and T-lymphocytes, also contain a 
range of other cell types and associated secreted factors. Taking this into consideration, it 
is possible that IL-ip is quite strongly regulated by IL-17, and so is affected to only a 
limited degree by the presence of other cellular signals, while IL-lra production and 
release is only regulated by IL-17 to a limited degree, and its inhibition by IL-17 can be 
overridden by other cellular signals.
6.2.3: Na,K-ATPase Effects on THP-1 Cytokine Release
Briefly, the effect of inhibition of the Na,K-ATPase on THP-1 cells was not substantial, 
with only slight indication that a small additional induction of IL-lp release occurred in the 
presence of LPS, and that a slight release of IL-lp occurred in the absence of LPS at high 
concentrations of ouabain. However, induction of IL-1 p transcription and release from 
PMBC following the impairment of Na,K-ATPase has been demonstrated (Foey et al., 
1997; Matsumori et al., 2000), leading to speculation about the importance and activity of 
the Na,K-ATPase on rheumatoid PBMC. This particular point will be discussed later, with 
relevance to data obtained using the biochemical determination of ATPase activity on RA 
PBMC. One consideration not covered in these papers is the toxic potential of ouabain, 
which is certainly the reason for the rapid decrease in IL-lp and IL-lra release observed in 
cells treated with lpM  ouabain (data not shown), the concentration used as standard by 
Matsumori et al. This is also most likely the cause of the low level IL-1 p release in the 
absence of LPS.
6.2.4: Manipulation of Thl/Th2 balance
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It had been previously demonstrated that isolated membranes of T-cell clones cultured with 
Thl or Th2 specific stimuli could induce differential release of IL-lp and IL-lra from 
THP-1 cells, with Thl clones inducing increased IL-lp and decreased IL-lra release, and 
Th2 clones the opposite (Chizzolini et al., 1997). Two methods were utilised in an attempt 
to develop Thl and Th2-like cells to investigate further the role of both surface proteins 
and soluble factors on monocyte cytokine release.
CD4+ T-lymphocytes were blast-cultured using SEA bound to the surface of fixed CHO- 
B7 cells, in the presence of IL-4 (Th2-inducing) or IL-12 (Thl-inducing) conditions. 
EMSA using STAT4 and STAT6 consensus sequence oligonucleotides was however 
unable to determine any difference between Thl- or Th2- induced cells, due to the low 
level induction of both STAT4 and STAT6 that was constitutive in these cultures. The 
second attempt utilised SEA and CD3/B7 blast cultures developed from PBMC, cultured 
with either IL-4 and anti-IL-12 mAb or IL-12 and anti-EL-4 mAb, and attempted to detect 
shifts in CCR3 and CCR5 expression. CCR3 and CCR5 are chemokine receptors, and are 
expressed at only a low density on T-lymphocytes. Even in cultures showing distinct 
tendencies towards a Thl phenotype, the expression of CCR5 was only slightly 
upregulated, although this shift was detectable using flow cytometry. Apart from 
occasional samples, it proved very difficult to alter the Thl/Th2 phenotype of SEA or 
CD3/B7 blast cultures substantially.
A recent paper (Aarvak et al., 1999b) suggests that the differential effects observed in 
cultures incubated with IL-4 and IL-12 and appropriate blocking antibodies may not be 
entirely due to shifts in Th cell phenotype. Using T-cell clones developed from synovial 
tissue, the shift from Th2 cells to Thl/ThO can be achieved using these cytokines, while 
Thl cells appear to possess a more stable phenotype. In addition, a substantial proportion 
of differentiation occurring is of the CD8+ cytotoxic T-cells, giving rise to Tel and Tc2 
phenotypes, and it is suggested that differentiation towards a “Th2” phenotype may be due 
to an increase in the proportion of Tc2 cells. This increased relevance of CD8+ cytotoxic 
T-cells could also partially account for the limited efficacy of CD4+ depletion treatments 
for RA (Choy et al., 1992; Moreland et al., 1993), as depletion of CD4+ cells would still 
leave the remaining cells capable of stimulating a pro-inflammatory process. The use of 
blocking antibodies, combined with the use of both CD4+ and CD8+ T-cells (as opposed to 
the CD8+ depleted T-cells used in the initial experiment) could at least partially explain the
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increase in success at differentiation observed in the second round of Thl/Th2 cultures. 
The other possible reason for the lack of differentiation detected towards Thl or Th2 could 
be due to the duration of the blast cultures. T-cell clones developed using Thl 
(mycobacterial protein derivative) or Th2 (tetanus toxoid) specific stimuli (Chizzolini et 
al., 1997), or developed utilising cytokines and blocking antibodies (Aarvak et al., 19996) 
were both cultured for 14 days before further use. Blast cultures utilised in these 
experiments were incubated for only 9 and 6 days respectively, only allowing a short time 
period for differentiation to occur in comparison.
6.3: Studies Utilising T-lymphocytes and Monocytes from Rheumatoid Patients 
6.3.1: Total ATPase and Na,K-ATPase Activity on Rheumatoid PBMC
Both total and Na,K-ATPase activity were significantly increased when measured in ES 
(p<0.005, p<0.05 respectively) and RA (p<0.005, total ATPase only) groups. Although 
the percentage Na,K-ATPase (as a proportion of total ATPase) was reduced slightly in ES 
PBMC, and to a greater extent in RA PBMC, these results were not statistically significant. 
Both total ATPase and Na,K-ATPase activity were significantly greater (p<0.05) on 
isolated monocytes, as opposed to T-cells and PBMC, but the proportions of CD14+ 
monocytes were not significantly increased in either ES or RA PBMC.
Certain of these data would appear to contradict earlier results obtained by Maubach et al.
(1993) who demonstrated downregulation of both total and Na,K-ATPase activity on 
rheumatoid PBMC, and also of Testa et al. (1987) who demonstrated decreased Na,K- 
ATPase activity on erythrocyte membranes from RA patients. However, there are a 
number of differences between the techniques utilised in this study and the studies 
mentioned above. Maubach et al. used a cytochemical assay, involving the deposition of 
PBMC onto poly-L-lysine coated microscope slides, followed by detection of ATPase 
activity using a cytochemical technique coupled with microdensitometry, in the absence or 
presence of ouabain. The adhesion of the cells to the microscope slide could have resulted 
in changes to both the activation state and survival of the isolated PBMC, and in addition, 
the percentage of Na,K-ATPase detected in healthy control samples using the cytochemical 
method (approximately 30%) was far above that detected using the biochemical assay 
(approximately 7%). However, the stimulatory effect of ouabain or calcium ionophore 
A23187 on EL-lp release from PBMC (Foey et al., 1997) and the increase of intracellular
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calcium following Na,K-ATPase inhibition in rat vascular smooth muscle cells (Zhu et al., 
1994) both suggest that IL-1 p release from rheumatoid monocytes could well be induced 
due to a decrease in Na,K-ATPase activity.
The disparity between the assays remains unresolved, although this might be accounted for 
by technical factors. The fixation of the cells to the microscope slide during the 
cytochemical assay could possibly lead to reduction in ATPase activity, especially if 
enzymes from rheumatoid cells were to prove more susceptible to loss of activity during 
this procedure. The requirement for membrane coherency to maintain effective enzyme 
conformation and activity will certainly vary between ATPases, and should non-Na,K- 
ATPase enzymes prove more susceptible to this inactivation this could account for the 
increased percentage of Na,K-ATPase observed. The biochemical assay meanwhile 
provides the cells with near optimum conditions for ATPase activity, with an excess of 
ATP and Na+/K+ ions. The increased ATPase activity detected on RA PBMC in this study 
is likely due to cells upregulating ATPase expression during a general cellular activation 
(Averdunk & Lauf, 1975) during the immune response. In the rheumatoid joint, there is 
likely to be a severe shortage of ATP due to the hypoxic conditions, preventing optimal 
Na,K-ATPase activity, and thus leading to induction of IL-1 p release. Another mechanism 
by which IL-lp release could be upregulated in the rheumatoid synovium is through 
inhibition of sodium pump activity due to the action of ROS. This theory is strengthened 
by the work of Maubach et al. (1993) who demonstrated that use of the thiol blocking 
agent joHMPSA (p-hydroxy-mercuriphenylsulphonate) can inhibit PBMC ATPase activity, 
and Guzman et al. (1995) who demonstrated inhibition of Na,K-ATPase in mouse 
epithelial cells by NO.
6.3.2: Cocultures Utilising Isolated Healthy and Rheumatoid Leukocytes
The aim of these experiments was to firstly obtain data regarding the effects of various 
DMARDs upon the T-lymphocytes or monocytes of rheumatoid patients, as measured by 
monocyte cytokine release, and also to investigate whether DMARD treatment affected the 
cytokine release of monocytes cultured with various basic activating stimuli.
One shortcoming in the results is the small number of “disease control” subjects from the 
NSAID group, which makes it difficult to assess changes due specifically to the action of
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DMARDs relative to an appropriate control group. Nevertheless, some results from the 
NSAID group were obtained, and it was possible to draw some conclusions from careful 
comparison with DMARD patient groups as a whole and the healthy control subjects.
In general, SEA T-cell blasts from rheumatoid patients induced greater LL-1 p and less IL- 
lra release from THP-1 cells than SEA blasts from healthy subjects, simulating the 
increased Thl-like phenotype of T-cells from the rheumatoid synovium (Brauer et al., 
1996); Dolhain et al., 1996; Qin et al., 1998; Yin et al., 1997). This in itself suggests a 
role for T-cells in the maintenance of the chronic inflammatory condition present in the 
rheumatoid synovium. Once again, fixation of SEA blasts resulted in a substantial 
decrease in the induction of both IL-lp and IL-lra from THP-1 cells, supporting the 
requirement for live T-cells or T-cell produced soluble factors for the induction of cytokine 
release. LPS acted as a potent stimulus for IL-lp release from THP-1 cells, although of 
interest is the inability of 6-day SEA blasts from RA patients to synergise with LPS as 
strongly as healthy SEA blasts for the induction of IL-lp release. This suggests an 
inability to maintain certain signalling cascades or cytokine release. Rheumatoid T-cells 
have been shown to possess a reduced response to activation due to downregulation of 
calcium and PKC signalling (Allen et al., 1995; Ritter et al., 1997), and if the T-cell blasts’ 
overall response to activation was impaired, this could result in a reduction of ability to 
synergise with LPS, especially as the cells return towards a more resting state. This theory 
is strengthened by the fact that HJ16 cells possess a deficiency in calcium signalling 
(demonstrated by a lack of proliferative inhibition in response to PDBu plus ionomycin), 
and synergise with LPS less effectively than J16 cells to induce IL-ip release from THP-1 
cells.
In comparison, IL-1 p release from healthy PBMC was often equivalent to or greater than 
that from a number of the rheumatoid groups, although the levels of LL-1 P produced were 
very low without additional stimuli (<100pg/ml). PDBu/ionomycin activated, fixed J16 
cells provided a weak pro-inflammatory stimulus, increasing IL-lp release from PBMC by 
between 2-10fold from most samples, but also inducing a modest increase in IL-lra 
release. IgG favoured an anti-inflammatory cytokine profile, increasing IL-lra release 
substantially, while inducing a maximum IL-lp release of only 200pg/ml. LPS potently 
induced IL-lp release from PBMC while only inducing a slight increase in IL-lra release 
(if at all), leading to a strong pro-inflammatory cytokine profile.
233
The effects of MTX on any aspect of coculture were marginal at best, with perhaps some 
indication of increased IL-lra induction by SEA blasts in the absence of LPS. MTX 
PBMC showed very little release of IL-1 p and induced increased IL-lra release in response 
to IgG in comparison with healthy controls or NSAID PBMC. MTX cells did however 
show a very strong release of IL-lp in response to both activated, fixed J16 cells and LPS. 
This lack of definite effect is perhaps not surprising considering the modes of action 
already determined for MTX. MTX is associated with a rapid remission in symptoms, but 
is also responsible for rapid flares of disease activity upon removal of treatment (Kremer et 
al., 1987; Segal et al., 1990). Given the low quantity of residual MTX that would remain 
in SEA blast culture at least, there may be insufficient MTX to exert an effect, and that in 
the absence of the drug cells are prone to rapidly revert to pro-inflammatory activity. The 
mode of action of MTX has been described as anti-inflammatory as much as 
immunoregulatory, with inhibitory effects upon the action and release of pro- 
inflammatory cytokines such as IL-lp, TNFa and IL-8 (Chang et al., 1992; Hu et al., 1988; 
Seitz et al., 1992). However, if this effect was due to a direct anti-inflammatory 
mechanism as opposed to a more long-term disease modifying mechanism, then in the 
absence of exogenous MTX no anti-inflammatory effect would be observed with regard to 
cytokine release. This is not to suggest that MTX is ineffective as a treatment for RA, as it 
possesses a wide range of disease modifying effects including effects on neutrophil 
function, downregulation of adhesion molecules, and inducing release of sTNFR and IL- 
lra in vivo (Seitz et al., 1995). However, based upon evidence obtained for this study, it 
would appear that the effects of MTX upon IL-1 p and IL-lra release are at least partially 
due to short-term anti-inflammatory processes as opposed to long-term immunomodulatory 
effects.
Overall, the major effect observed on cells isolated from patients receiving SPZ treatment 
was that SPZ appears to enhance IL-lra release from PBMC, to levels greater than those 
from either healthy or NSAID PBMC. This was most obvious when the SPZ PBMC were 
stimulated with IgG or activated, fixed J16 cells, as although there was also a substantial 
increase in IL-lra release when stimulated with LPS, there was a correspondingly greater 
increase in IL-lp release. In addition, SPZ PBMC stimulated with activated, fixed J16 
cells were the only set of results that were statistically significant with regard to the ratio 
IL-1 p:IL-Ira, relative to healthy cells. Of the attributed modes of action of SPZ, there are
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some that might be important for this observed activity in PBMC. Certainly, the 
maintenance of an effect throughout the coculture, following isolation of the PBMC, 
promotes the likelihood of a disease-modifying effect over an anti-inflammatory one. The 
inhibition of release of IL-lp, IFNy, EL-2, TNFa and IL-6 could certainly have relevance in 
the coculture system, except that no significant decrease in IL-lp release was observed. 
The inhibition of EL-12 release could certainly have acted to decrease any differentiation of 
T-cells within the PBMC towards a Thl phenotype, and thus promote a more anti­
inflammatory cytokine profile of release from the monocytes. SPZ also acts to strongly 
inhibit the activity of NFkB (Wahl et al., 1998), and inhibition of NFkB activity has been 
shown to exert significant inhibitory effects upon pro-inflammatory cytokine release, while 
having no substantial effect upon the release of anti-inflammatory cytokines such as IL- 
lra. Whereas this does not specifically suggest a mechanism whereby SPZ could actively 
induce IL-lra release, it does indicate a method by which SPZ could tip the balance of IL- 
lp/IL-lra in an anti-inflammatory direction, as supported by the data in this report.
Although it is difficult to make any firm conclusions about the activity of D-Pen due to the 
limited number of samples obtained, there were still some distinct trends observed. 
Specifically, D-Pen SEA blasts induced less EL-ip release from THP-1 cells than other 
blasts from either healthy or rheumatoid subjects, and also displayed tendencies for a 
greater IL-lra release. However, the most striking characteristic of SEA blasts was the 
retention of cytokine release, especially EL-Ira release. This could indicate an ability of D- 
Pen to retain the potential for cytokine release in residual monocytes, which otherwise 
decreases over the course of SEA blast culture (with IL-lp release decreasing to negligible 
levels by day 3 and IL-lra release decreasing by half between days 3 and 6). These results 
correspond to a certain degree with earlier work investigating the mechanism of action of 
D-Pen. D-Pen has been shown to possess inhibitory effects upon T-helper cell function 
(Lipsky & Ziff, 1980). This could certainly account for the reduced EL-ip release from 
THP-1 cells incubated with D-Pen SEA blasts, with these data indicating more specifically 
how D-Pen exerts a therapeutic effect. Also, D-Pen can act to maintain free sulphydryl 
groups on the surface of monocytes (and corresponding monocyte accessory function), 
which could therefore contribute to the retention of monocyte cytokine release. As this 
effect was mimicked with the addition of the anti-oxidant 2-mercaptoethanol (McKeown et
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al., 1984), D-Pen is also likely to possess more wide ranging protective effects against 
oxidative stress, leading to a corresponding decrease in joint degradation.
The effects of HCQ in the coculture system were varied. HCQ SEA blasts induced 
increased release of IL-lra relative to NSAID, MTX and SPZ blasts, especially on day 6 of 
blast culture. This difference was not evident with fixed SEA blasts, indicating the likely 
role of a soluble factor. This could indicate that SEA blasts treated with HCQ revert to 
induction of a more anti-inflammatory cytokine profile more rapidly than other RA cells. 
Certainly, possible reported activities of HCQ are inhibition of IL-1 release, along with 
inhibition of lysosomal enzyme release and protection of cartilage (Brooks, 1992; Tett et 
al., 1990). Reduction of IL-1 p release was observed in HCQ PBMC relative to other RA 
groups (to a lesser or greater degree depending on specific stimuli), although apart from 
the response to IgG stimulation, IL-lra release from HCQ cells was often lower as well, 
perhaps suggesting a general downregulatory effect on monocytes as opposed to just on 
IL-ip release. However, this could be due to anti-inflammatory effects of HCQ on T-cells 
within the PBMC culture.
6.4: SUMMARY & CONCLUSIONS
A model system for the investigation of T-lymphocyte/monocyte interactions was 
developed, and used to investigate the release of IL-ip and IL-lra release as a result of 
manipulation of these interactions. This coculture technique is a very flexible system, and 
could be used to investigate a wide range of factors acting upon either T-lymphocytes or 
monocytes. With the use of different readout techniques, the system could be expanded to 
quantify not only other released cytokines (released by either T-cell or monocyte), but also 
other secreted factors such as MMPs.
Cytokine release from monocytes is susceptible to a range of factors acting upon 
monocytes directly, including LPS, IgG, cytokines, cell surface interactions and 
intracellular ion concentrations. Likewise, the effects of T-lymphocytes upon cytokine 
release from monocytes, whether by cell-cell surface interactions or due to released soluble 
factors, are susceptible to stimuli acting upon the T-lymphocyte. The coculture system 
provided a tool with which the differential release of IL-1 P and IL-lra in response to a
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range of stimuli acting upon either T-lymphocyte or monocyte could be investigated and 
assessed for relevance to the cytokine imbalance observed in the rheumatoid synovium.
Initial investigations into the coculture system determined that although cell-cell surface 
interactions could induce the release of both IL-ip and IL-lra, a far greater degree of 
cytokine release could be achieved through incubation of the monocytes with live, unfixed 
T-lymphocytes, and that the effect of these interactions was much more easily detected 
when using freshly isolated cells as . either monocyte or T-lymphocyte as opposed to 
cultured cell lines. Data also demonstrated that a major proportion of the signal inducing 
cytokine release from monocytes was due to either a soluble factor, or the interaction of 
soluble factors and cell-cell surface interactions. It was later demonstrated that IL-17 
could act as a pro-inflammatory constituent of this soluble factor, acting as a strong 
inducer of IL-ip release, and a weak inhibitor of IL-lra release.
Investigation of the role of hypoxia and oxidative stress upon T-lymphocytes in the 
rheumatoid synovium involved the development of a T-cell line tolerant to episodes of 
oxidative stress. These cells exhibited reduced response to activation stimuli, with 
deficiencies in both CD3 expression and calcium signalling, similar to those present in 
rheumatoid synovial T-cells. They were also more resistant to pro-apoptotic signals 
perhaps as a result of increased intracellular defences against oxidative stress, specifically 
GSH. These cells induced little IL-ip in the absence of additional stimuli, and also 
exhibited reduced synergy with LPS to induce monocyte IL-ip release, suggesting that 
hyporesponsive T-cells in the rheumatoid synovium are unlikely to be responsible for 
directly stimulating IL-ip release from monocytes (although data suggesting this role for a 
small, active proportion (0.1-0.3%) of the T-cell population are still valid). Additional data 
imply that this is likely to be due to a deficiency in the production of a pro-inflammatory 
soluble factor.
There was some concern as to the differences in total ATPase and Na,K-ATPase activity 
observed on rheumatoid PBMC by biochemical or cytochemical methods, although several 
possible explanations are available. Upregulation of Na,K-ATPase activity on rheumatoid 
PBMC was observed in these studies, but it must be remembered that in the rheumatoid 
synovium, this activity is likely to be reduced due to the susceptibility of the Na,K-ATPase 
to oxidative stress. This situation could then account for both the increases in IL-ip release
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following ouabain-mediated inhibition of the Na,K-ATPase, and the suggested link 
between the reduced Na,K-ATPase activity in the rheumatoid synovial joint and the 
upregulation of IL-lp release observed there.
SEA blasts cultured from the PBMC of rheumatoid patients were capable of inducing 
increased IL-ip release from THP-1 cells relative to SEA blasts from healthy subjects. It 
must be remembered that these cells were cultured from peripheral blood, and so would 
not be in the same hyporesponsive state as most T-lymphocytes present in the rheumatoid 
synovium. It is therefore possible that T-cells infiltrating the rheumatoid synovial joint are 
capable of inducing a pro-inflammatory reaction for a short period of time before 
succumbing to an anergic state, due in part to the effects of ROS. In effect, the 0.1-0.3% 
of “active” T-cells detected in the synovial joint could be those cells that have recently 
infiltrated the joint, and have thus not sustained substantial oxidative damage.
Additional information was also obtained regarding the mechanism of action of certain 
DMARDs. MTX had little effect upon the coculture system, although this was consistent 
with existing knowledge on the pharmacology of this drug. SPZ meanwhile can act as a 
potent inhibitor of NFkB activity (Wahl et aL, 1998), acting to inhibit pro-inflammatory 
cytokine release while leaving anti-inflammatory cytokine release (including IL-lra) 
unaffected, demonstrated by the anti-inflammatory improvement in the ratio of IL-ipTL- 
lra release from rheumatoid PBMC observed in this report.
6.5: FURTHER WORK
The work described in this report has provided a variety of avenues that might warrant 
additional investigation. The work utilising J16 and HJ16 cells provided some interesting 
initial insights into the effects of oxidative stress upon T-cell activation, but if  these cells 
were used in a coculture system with PBMC instead of THP-1 cells it is likely that greater 
(or more subtle) differences could be determined between the cell types. Also, as the 
artificial manipulation of GSH levels can be used to manipulate T-cell cytokine release 
including IL-2 (Maurice et al., 1997), it would be of interest to assess the effects of similar 
manipulations upon IL-lp and IL-lra release using both J16 and HJ16 cells.
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Further investigation of the T-lymphocyte soluble factor could also be highly productive. 
Firstly, the use of anti-IL-17 blocking antibody could be used in coculture systems to 
investigate the effects of IL-17 release from rheumatoid T-cells relative to healthy T-cells, 
and the degree of effect that inhibition of this signal would have on the pro-inflammatory 
effects of rheumatoid T-cells on monocytes. In addition, it has been previously shown 
(Albanesi et al., 1999; Broxmeyer, 1996) that IL-17 has far greater effects on the release of 
certain cytokines (IL-8, GM-CSF) in synergy with other cytokines, specifically TNFa. 
Another useful experiment would be to investigate any additive effects of incubation of 
monocytes with combinations of IL-17 and TNFa, and also to determine if rheumatoid 
PBMC react more strongly to such stimulation than healthy PBMC.
The coculture system could also be used to further investigate the mechanisms of action of 
DMARDs upon rheumatoid cells, either utilising additional stimuli, effects on the release 
of alternative cytokines, or through addition of the drug exogenously (especially in the case 
of MTX). The effects of SPZ upon the release of IL-ip and IL-lra from rheumatoid 
PBMC were particularly interesting, and could warrant additional investigation to identify 




CULTURE MEDIA, SOLUTIONS AND BUFFERS
RPM I1640 (THP-1, J16, H9 and PBMC/T-cell culture)
Milli-Q H20 400ml
RPMI 1640(1 Ox) 50ml
FCS 50ml
Penicillin (1000IU ml"1 )/Streptomycin (1 OOOpg ml"1) 5ml
Sodium Bicarbonate (7.5% w/v) 15ml
L-Glutamine (200mM) 5ml
Sodium Hydroxide (10M) 800pl
Dulbecco’s Modified Eagle Medium (DMEM) (COS cells)
DMEM (lx) 500ml
FCS 55ml
Penicillin (1000IU ml'^/Streptomycin (lOOOpg ml'1) 5ml







Glutamine-free DMEM (CHO cells)
As above, omitting L-Glutamine.
Phosphate Buffered Saline (PBS)
NaCl 70. lg
NaH2P 0 4.H20  4.4g
Na2H P04.H20  12.8g
KC1 2g
Milli-Q H20  10 litres








0.05M carbonate-bicarbonate buffer, pH 9.6 
1% BSA, 5% sucrose in PBS, pH 7.4 
0.05% Tween 20 in PBS, pH 7.4
0.05% Tween 20, 0.1% BSA in Tris saline (20mM Trizma base, 










Dissolved in Milli-Q H20 , pH 7.4 
Dispensed into 10ml aliquots and stored at -20°C.
GSH assay cocktail (in PBS)
40pM monochlorobimane (Stock lOmM in 70% ethanol) 
0.1 units ml-1 GSH-S-transferase
















In Milli-Q H20 , pH 7.9 with KOH.
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Electromobilitv Shift Assay (EMSA)
5% non-denaturing polyacrylamide gel
1 Ox TBE buffer (Tris Borate EDTA) 1.5ml
Acrylamide (30% w/v, Kramel Biotech) 5.0ml
Fresh 10% Ammonium Persulphate (APS) 300pl
TEMED 25pl
Milli-Q H20  21ml
Milli-Q water, Acrylamide and TBE were combined, and then APS and TEMED added 
(with thorough mixing) to initiate polymerisation.
Binding Mix
























Aarvak, T., Chabaud, M., Miossec, P., and Natvig, J.B. (1999a) IL-17 is produced by some 
proinflammatory Thl/ThO cells but not by Th2 cells. Journal O f Immunology 162, 
1246-1251.
Aarvak, T., Chabaud, M., Kallberg, E., Miossec, P., and Natvig, J.B. (19996) Change in the 
Thl/Th2 phenotype of memory T-cell clones from rheumatoid arthritis synovium. 
Scandinavian Journal O f Immunology 50, 1-9.
Abe, E., Miyaura, C., Sakagami, H., Takeda, M., Konno, K., Yamazaki, T., Yoshiki, S., and 
Suda, T. (1981) Differentiation of mouse myeloid-leukemia cells induced by 1- 
alpha,25-dihydroxyvitamin-d3. Proceedings O f The National Academy O f Sciences Of 
The United States O f America-Biological Sciences 78, 4990-4994.
Abrahams, V.M., Cambridge, J., Lydyard, P.M.L., and Edwards, J.C.W. (1998) Fc-gamma- 
RJIIa mediates tumour necrosis factor alpha secretion by human monocytes. Arthritis 
And Rheumatism 41, 1873(Abstract)
Abramson, S.L. and Gallin, J.I. (1990) IL-4 inhibits superoxide production by human 
mononuclear phagocytes. Journal O f Immunology 144, 625-630.
Abrink, M., Gobi, A.E., Huang, R.Y., Nilsson, K., and Heilman, L. (1994) Human cell-lines 
U937,THP-1 and mono-mac-6 represent relatively immature cells of the monocyte­
macrophagecell lineage. Leukemia 8, 1579-1584.
Afeltra, A., Galeazzi, M., Sebastiani, G.D., Ferri, G.M., Caccavo, D., Addessi, M.A.,
Marcolongo, R., and Bonomo, L. (1997) Coexpression of CD69 and HLADR activation 
markers on synovial fluid T lymphocytes of patients affected by rheumatoid arthritis: a 
three- colour cytometric analysis. International Journal O f Experimental Pathology 78, 
331-336.
Ahn, H.J., Tomura, M., Yu, W.G., Iwasaki, M., Park, W.R., Hamaoka, T., and Fujiwara, H.
(1998) Requirement for distinct Janus kinases and STAT proteins in T cell proliferation 
versus IFN-gamma production following IL-12 stimulation. Journal O f Immunology 
161, 5893-5900.
Akahoshi, T., Oppenheim, J.J., and Matsushima, K. (1988) Interleukin-1 stimulates its own 
receptor expression on human fibroblasts through the endogenous production of 
prostaglandin(s). Journal O f Clinical Investigation 82, 1219-1224.
Akashi, K., Kondo, M., von Freeden Jeffry, U., Murray, R., and Weissman, I.L. (1997) Bcl-2 
rescues T lymphopoiesis in interleukin-7 receptor-deficient mice. Cell 89, 1033-1041.
Akbar, A.N., Terry, L., Timms, A., Beverley, P.C.L., and Janossy, G. (1988) Loss of CD45R 
and gain of UCHL1 reactivity is a feature of primed T-cells. Journal O f Immunology 
140,2171-2178.
Akbar, A.N. and Salmon, M. (1997) Cellular environments and apoptosis: Tissue
microenvironments control activated T-cell death. Immunology Today 18, 72-76.
245
Albanesi, C., Cavani, A., and Girolomoni, G. (1999) IL-17 is produced by nickel-specific T 
lymphocytes and regulates ICAM-1 expression and chemokine production in human 
keratinocytes: Synergistic or antagonist effects with IFN-gamma and TNF-alpha. 
Journal O f Immunology 162, 494-502.
Allard, S.A., Muirden, K.D., Camplejohn, K.L., and Maini, R.N. (1987) Chondrocyte-derived 
cells and matrix at the rheumatoid cartilage- pannus junction identified with 
monoclonal-antibodies. Rheumatology International 1, 153-159.
Allen, J.B., Wong, H.L., Costa, G.L., Bienkowski, M.J., and Wahl, S.M. (1993) Suppression of 
monocyte function and differential regulation of IL-1 and IL-lra by IL-4 contribute to 
resolution of experimental arthritis. Journal O f Immunology 151, 4344-4351.
Allen, J.E. and Maizels, R.M. (1997) Thl-Th2: reliable paradigm or dangerous dogma? 
Immunology Today 18, 387-392.
Allen, R.E., Blake, D.R., Nazhat, N.B., and Jones, P. (1989) Superoxide radical generation by 
inflamed human synovium after hypoxia. Lancet 2, 282-283.
Alnemri, E.S., Livingston, D.J., Nicholson, D.W., Salvesen, G., Thomberry, N.A., Wong,
W.W., and Yuan, J.Y. (1996) Human ICE/ced-3 protease nomenclature. Cell 87, 171- 
171.
Alvaro-gracia, J.M., Zvaifler, N.J., and Firestein, G.S. (1989) Cytokines in chronic
inflammatory arthritis .4. granulocyte macrophage colony-stimulating factor-mediated 
induction of class- II MHC antigen on human-monocytes - a possible role in 
rheumatoid- arthritis. Journal O f Experimental Medicine 170, 865-875.
Alvaro-gracia, J.M., Zvaifler, N.J., Brown, C.B., Kaushansky, K., and Firestein, G.S. (1991)
Cytokines in chronic inflammatory arthritis .6. analysis of the synovial-cells involved in 
granulocyte-macrophage colony- stimulating factor production and gene-expression in 
rheumatoid- arthritis and its regulation by IL-1 and tumor-necrosis-factor- alpha. 
Journal O f Immunology 146, 3365-3371.
Amento, E.P., Bhalla, A.K., Kumick, J.T., Kradin, R.L., Clemens, T.L., Holick, S.A., Holick, 
M.F., and Krane, S.M. (1984) 1-Alpha,25-dihydroxyvitamin-d3 induces maturation of 
the human monocyte cell-line U937, and, in association with a factor from human 
lymphocytes-T, augments production of the monokine, mononuclear cell factor.
Journal O f Clinical Investigation 73, 731-739.
Amigorena, S., Salamero, J., Davoust, J., Fridman, W.H., and Bonnerot, C. (1992) Tyrosine- 
containing motif that transduces cell activation signals also determines internalization 
and antigen presentation via type-III receptors for IgG. Nature 358, 337-341.
Amos, R.S. and Mcconkey, B. (1981) Non-invasive assessment of drug-action in rheumatoid- 
arthritis and related disorders. Pharmacology & Therapeutics 14, 477-492.
Antonysamy, M.A., Fanslow, W.C., Fu, F.M., Li, W., Qian, S.G., Troutt, A.B., and Thomson, 
A.W. (1999) Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes 
the functional differentiation of dendritic cell progenitors. Journal O f Immunology 162, 
577-584.
246
Arend, W.P., Joslin, F.G., and Massoni, R.J. (1985) Stimulation of production of interleukin-1 
and an interleukin-1 inhibitor in human-monocytes. British Journal O f Rheumatology 
24, 175-178.
Arend, W.P., Welgus, H.G., Thompson, R.C., and Eisenberg, S.P. (1990) Biological properties 
of recombinant human monocyte-derived interleukin-1 receptor antagonist. Journal Of 
Clinical Investigation 85, 1694-1697.
Arend, W.P., Smith, M.F., Janson, R.W., and Joslin, F.G. (1991) IL-1 receptor antagonist and 
IL-1-beta production in human monocytes are regulated differently. Journal O f 
Immunology 147, 1530-1536.
Arend, W.P., Janson, R.W., Malyak, M., Kutsch, C., Jenkins, J.K., Gahring, L.C., and Smith, 
M.F. (1993) IL-1 receptor antagonist - production and role in biology. Journal Of 
Cellular Biochemistry 54-54.
Arend, W.P., Malyak, M., Smith, M.F., Whisenand, T.D., Slack, J.L., Sims, J.E., Giri, J.G., and 
Dower, S.K. (1994) Binding of IL-1-alpha, IL-1-beta, and IL-1 receptor antagonist by 
soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial-fluids. Journal 
Of Immunology 153, 4766-4774.
Arend, W.P. and Dayer, J.M. (1995) Inhibition of the production and effects of interleukin-1
and tumor- necrosis-factor-alpha in rheumatoid-arthritis. Arthritis And Rheumatism 38, 
151-160.
Arend, W.P., Malyak, M., Guthridge, C.J., and Gabay, C. (1998) Interleukin-1 receptor 
antagonist: role in biology. Annual Review O f Immunology 16, 27-55.
Arias-Negrete, S., Keller, K., and Chadee, K. (1995) Proinflammatory cytokines regulate
cyclooxygenase-2, messenger-RNA expression in human macrophages. Biochemical 
And Biophysical Research Communications 208,582-589.
Auphan, N., Didonato, J.A., Rosette, C., Helmberg, A., and Karin, M. (1995)
Immunosuppression by glucocorticoids - inhibition of NF-kappa-B activity through 
induction of I-kappa-B synthesis. Science 270, 286-290.
Azam, M., Erdjumentbromage, H., Kreider, B.L., Xia, M., Quelle, F., Basu, R., Saris, C.,
Tempst, P., Ihle, J.N., and Schindler, C. (1995) Interleukin-3 signals through multiple 
isoforms of STAT5. Embo Journal 14, 1402-1411.
Bach, M.K., Brashler, J.R., and Johnson, M.A. (1985) Inhibition by sulfasalazine of ltc
synthetase and of rat-liver glutathione s-transferases. Biochemical Pharmacology 34, 
2695-2704.
Baeten, D., DeKeyser, F., Steenbakkers, P., Verheijden, F.G., Bos, E.S., Rijnders, A.M.W., 
Verbruggen, G., Boots, A.M.H., and Veys, E.M. (1998a) HC gp-39 is expressed by 
peripheral blood mononuclear cells in RA. Arthritis And Rheumatism 41, 1723
Baeten, D., DeKeyser, F., Elewaut, D., Rijnders, A.M.W., Verheijden, G.F., Miltenburg,
A.M.W., Steenbakkers, P., Verbruggen, G., Bocts, A.M.H., and Veys, E.M. (19986) HC
247
gp-39 expression in synovial lining is correlated with joint destruction in RA. Arthritis 
And Rheumatism 41, 1998
Baeuerle, P.A. and Henkel, T. (1994) Function and activation of NF-kappa-B in the immune- 
system. Annual Review O f Immunology 12, 141-179.
Baeuerle, P.A. (1998) Pro-inflammatory signaling: Last pieces in the NF-kappa B puzzle. 
Current Biology 8, R19-R22
Balavoine, J.F., Derochemonteix, B., Cruchaud, A., and Dayer, J.M. (1985) Evidence of
interleukin-1 (IL-1) activity and of an exhibition of this activity in urine in a case of 
acute monoblastic leukemia. Schweizerische Medizinische Wochenschrift 53-53.
Bandara, G., Mueller, G.M., Galealauri, J., Tindal, M.H., Georgescu, H.I., Suchanek, M.K., 
Hung, G.L., Glorioso, J.C., Robbins, P.D., and Evans, C.H. (1993) Intraarticular 
expression of biologically-active interleukin-1 receptor-antagonist protein by ex-vivo 
gene-transfer. Proceedings O f The National Academy O f Sciences O f The United States 
OfAmerica9Q, 10764-10768.
Barbulescu, K., Becker, C., Schlaak, J.F., Schmitt, E., Zumbuschenfelde, K.H.M., and Neurath, 
M.F. (1998) Cutting edge: IL-12 and IL-18 differentially regulate the transcriptional 
activity of the human IFN-gamma promoter in primary CD4(+) T lymphocytes. Journal 
O f Immunology 160, 3642-3647.
Bamaba, V., Watts, C., deBoer, M., Lane, P., and Lanzavecchia, A. (1994) Professional
presentation of antigen by activated human t-cells. European Journal Of Immunology 
24,71-75.
Bar-Shavit, Z., Teitelbaum, S.L., Reitsma, P., Hall, A., Pegg, L.E., Trial, J., and Kahn, A.J. 
(1983) Induction of monocytic differentiation and bone-resorption by 1,25- 
dihydroxyvitamin-d3. Proceedings O f The National Academy O f Sciences O f The 
United States O f America-Biological Sciences 80, 5907-5911.
Barthel, H.R., StuhlmUller, B., Lorenz, H.M., Grunke, M., and Burmester, G.R. (1996)
Thrombospondin - An inhibitor of angiogenesis - Is over-expressed by monocytes and 
peripheral blood mononuclear cells in patients with rheumatoid arthritis. Arthritis And 
Rheumatism 39, R6
Bavelloni, A., Santi, S., Sirri, A., Riccio, M., Faenza, I., Zini, N., Cecchi, S., Ferri, A., Auron, 
P., Maraldi, N.M., and Marmiroli, S. (1999) Phosphatidylinositol 3-kinase translocation 
to the nucleus is induced by interleukin 1 and prevented by mutation of interleukin 1 
receptor in human osteosarcoma Saos-2 cells. Journal O f Cell Science 112, 631-640.
Bax, B.E., Alam, A.S.M.T., Baneiji, B., Bax, C.M.R., Bevis, P.J.R., Stevens, C.R., Moonga,
B.S., Blake, D.R., and Zaidi, M. (1992) Stimulation of osteoclastic bone-resorption by 
hydrogen-peroxide. Biochemical And Biophysical Research Communications 183, 
1153-1158.
Beaulieu, A.D. and McColl, S.R. (1994) Differential expression of 2 major cytokines produced 
by neutrophils, interleukin-8 and the interleukin-1 receptor antagonist, in neutrophils
248
isolated from the synovial-fluid and peripheral-blood of patients with rheumatoid- 
arthritis. Arthritis And Rheumatism 37, 855-859.
Beekhuizen, H., Blokland, I., Corselvantilburg, A.J., Koning, F., and Van Furth, R. (1991)
CD 14 contributes to the adherence of human monocytes to cytokine- stimulated 
endothelial-cells. Journal O f Immunology 147, 3761-3767.
Belvin, M.P. and Anderson, K.V. (1996) A conserved signaling pathway: The Drosophila Toll- 
Dorsal pathway. Annual Review Of Cell And Developmental Biology 12, 393-416.
Benbemou, N., Esnault, S., Shin, H.C.K., Fekkar, H., and Guenounou, M. (1997) Differential 
regulation of IFN-gamma, IL-10 and inducible nitric oxide synthase in human T cells by 
cyclic AMP-dependent signal transduction. Immunology 91, 361-368.
Bergroth, V., Zvaifler, N.J., and Firestein, G.S. (1989) Cytokines in chronic inflammatory 
arthritis .3. rheumatoid- arthritis monocytes are not unusually sensitive to gamma- 
interferon, but have defective gamma-interferon-mediated HLA-DQ and HLA-DR 
induction. Arthritis And Rheumatism 32, 1074-1079.
Bernardo, J., Billingslea, A.M., Blumenthal, R.L., Seetoo, K.F., Simons, E.R., and Fenton, MJ.
(1998) Differential responses of human mononuclear phagocytes to mycobacterial 
lipoarabinomannans: role of CD 14 and the mannose receptor. Infection And Immunity 
66, 28-35.
Berry, N., Ase, K., Kikkawa, U., Kishimoto, A., and Nishizuka, Y. (1989) Human T-cell
activation by phorbol esters and diacylglycerol analogs. Journal O f Immunology 143, 
1407-1413.
Bertolini, D.R., Nedwin, G.E., Bringman, T.S., Smith, D.D., and Mundy, G.R. (1986)
Stimulation of bone-resorption and inhibition of bone-formation invitro by human- 
tumor necrosis factors. Nature 319, 516-518.
Beuscher, H.U., Fallon, R.J., and Colten, H.R. (1987) Macrophage membrane interleukin-1 
regulates the expression of acute phase proteins in human hepatoma hep-3b-cells. 
Journal Of Immunology 139, 1896-1901.
Bienkowski, M.J., Eessalu, T.E., Berger, A.E., Truesdell, S.E., Shelly, J.A., Laborde, A.L., 
Zurchemeely, H.A., Reardon, I.M., Heinrikson, R.L., Chosay, J.G., and Tracey, D.E. 
(1990) Purification and characterization of interleukin-1 receptor level antagonist 
proteins from THP-1 cells. Journal O f Biological Chemistry 265, 14505-14511.
Black, R.A., Kronheim, S.R., and Sleath, P.R. (1989) Activation of interleukin-1-beta by a co­
induced protease. Febs Letters 247, 386-390.
Blake, D.R., Hall, N.D., Treby, D.A., Halliwell, B., and Gutteridge, J.M.C. (1981) Protection 
against superoxide and hydrogen-peroxide in synovial-fluid from rheumatoid patients. 
Clinical Science 61, 483-486.
Blake, D.R., Merry, P., Unsworth, J., Kidd, B.L., Outhwaite, J.M., Ballard, R., Morris, C.J.,
Gray, L., and Lunec, J. (1989) Hypoxic-reperfusion injury in the inflamed human joint. 
Lancet 1, 289-293.
249
Bondeson, J., Browne, K.A., Brennan, F.M., Foxwell, B.M.J., and Feldmann, M. (1999) 
Selective regulation of cytokine induction by adenoviral gene transfer of I kappa B 
alpha into human macrophages: Lipopolysaccharide-induced, but not zymosan-induced, 
proinflammatory cytokines are inhibited, but IL-10 is nuclear Factor-kappa B 
independent. Journal O f Immunology 162, 2939-2945.
Bonecchi, R., Bianchi, G., Bordignon, P.P., D’Ambrosio, D., Lang, R., Borsatti, A., Sozzani,
S., Allavena, P., Gray, P.A., Mantovani, A., and Sinigaglia, F. (1998) Differential 
expression of chemokine receptors and chemotactic responsiveness of type 1 T helper 
cells (This) and Th2s. Journal O f Experimental Medicine 187, 129-134.
Boots, A.M.H., Verheijden, G.F.M., Schoningh, R., vanStaveren, C.J., Bos, E., Elewaut, D., 
DeKeyser, F., Veys, E., Joosten, I., and Rijnders, A.W.M. (1997) Selection of self­
reactive peptides within human aggrecan by use of a HLA-DRB 1*0401 peptide binding 
motif. Journal O f Autoimmunity 10, 569-578.
Bom, T.L., Thomassen, E., Bird, T.A., and Sims, J.E. (1998) Cloning of a novel receptor
subunit, AcPL, required for interleukin- 18 signaling. Journal O f Biological Chemistry 
273, 29445-29450.
Borrego, F., Robertson, M.J., Ritz, J., Pena, J., and Solana, R. (1999) CD69 is a stimulatory 
receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory 
receptor. Immunology 91, 159-165.
Boumpas, D.T., Chrousos, G.P., Wilder, R.L., Cupps, T.R., and Balow, J.E. (1993)
Glucocorticoid therapy for immune-mediated diseases - basic and clinical correlates. 
Annals O f Internal Medicine 119, 1198-1208.
Box, S. A. and Pullar, T. (1997) Sulphasalazine in the treatment of rheumatoid arthritis. British 
Journal O f Rheumatology 36, 382-386.
Brakebusch, C., Varfolomeev, E.E., Batkin, M., and Wallach, D. (1994) Structural
requirements for inducible shedding of the p55 tumor- necrosis-factor receptor. Journal 
O f Biological Chemistry 269, 32488-32496.
Brauer, R., Austmp, F., Hamann, A., Hersmann, G.H.W., Petrow, P.K., and Katenkamp, D. 
(1996) Different trafficking of Thl and Th2 CD4(+) lymphocytes into arthritic joints. 
Arthritis And Rheumatism 39, 1658-1658.
Brennan, F.M., Jackson, A., Chantry, D., Maini, R., and Feldmann, M. (1989) Inhibitory effect 
of TNF-alpha antibodies on synovial cell interleukin-1 production in rheumatoid- 
arthritis. Lancet 2, 244-247.
Brennan, F.M., Chantry, D., Turner, M., Foxwell, B., Maini, R., and Feldmann, M. (1990)
Detection of transforming growth-factor-beta in rheumatoid- arthritis synovial tissue - 
lack of effect on spontaneous cytokine production in joint cell-cultures. Clinical And 
Experimental Immunology 81, 278-285.
Brennan, F.M., Cope, A.P., Katsikis, P., Gibbons, D.L., Maini, R.N., and Feldmann, M. (1995) 
Selective immunosuppression of tumor-necrosis-factor-alpha in rheumatoid-arthritis. 
Chemical Immunology 60, 48-60.
250
Brennan, P. and Oneill, L.A.J. (1995) Effects of oxidants and antioxidants on nuclear factor 
kappa-b activation in 3 different cell-lines - evidence against a universal hypothesis 
involving oxygen radicals. Biochimica Et Biophysica Acta-Gene Structure And 
Expression 1260, 167-175.
Bresnihan, B., Alvaro-gracia, J.M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., 
Pavelka, K., Rau, R., Rozman, B., Watt, I., Williams, B., Aitchison, R., McCabe, D., 
and Musikic, P. (1998) Treatment of rheumatoid arthritis with recombinant human 
interleukin- 1 receptor antagonist. Arthritis And Rheumatism 41, 2196-2204.
Breyer, M.D. (1999) Cox2 selective NSAIDs and renal function: Gain without pain? Kidney 
International 55, 738-739.
Brooks, P.M. and Day, R.O. (1991) Drug-therapy - nonsteroidal antiinflammatory drugs - 
differences and similarities. New England Journal O f Medicine 324, 1716-1725.
Brooks, P.M. (1993) Clinical management of rheumatoid-arthritis. Lancet 341, 286-290.
Buchner, J. (1996) Supervising the fold: Functional principles of molecular chaperones. Faseb 
Journal 10, 10-19.
Bunch, T.W., Oduffy, J.D., Tompkins, R.B., and Ofallon, W.M. (1984) Controlled trial of
hydroxychloroquine and D-penicillamine singly and in combination in the treatment of 
rheumatoid-arthritis. Arthritis And Rheumatism 27, 267-276.
Buras, J.A., Reenstra, W.R., and Fenton, M.J. (1995) Nf beta a, a factor required for maximal 
interleukin-l,beta gene expression is identical to the ets family member PU.l. evidence 
for structural alteration following LPS activation (vol 32, pg 541, 1995). Molecular 
Immunology'S2, 1175-1175.
Burger, D. and Dayer, J.M. (1998) Interactions between T cell plasma membranes and
monocytes. In: T Cells in Arthritis, 111-128. Edited by Miossec, P., Vandenberg, W.B., 
and Firestein, G.S., Basel, Switzerland, Birkhauser Verlag.
Burmester, G.R., Stuhlmuller, B., Keyszer, G., and Kinne, R.W. (1997) Mononuclear
phagocytes and rheumatoid synovitis - Mastermind or workhorse in arthritis? Arthritis 
And Rheumatism 40, 5-18.
Buscher, D., Hipskind, R.A., Krautwald, S., Reimann, T., and Baccarini, M. (1995) Ras-
dependent and ras-independent pathways target the mitogen- activated protein-kinase 
network in macrophages. Molecular And Cellular Biology 15, 466-475.
Butler, D.M., Malfait, A.M., Mason, L.J., Warden, P.J., Kollias, G., Maini, R.N., Feldmann,
M., and Brennan, F.M. (1997) DBA/1 mice expressing the human TNF-alpha transgene 
develop a severe, erosive arthritis - Characterization of the cytokine cascade and cellular 
composition. Journal O f Immunology 159, 2867-2876.
Cambier, J.C., Pleiman, C.M., and Clark, M.R. (1994) Signal-transduction by the B-cell antigen 
receptor and its coreceptors. Annual Review O f Immunology 12, 457-486.
251
Cantoma, M.T., Hayes, C.E., and Deluca, H.F. (1996) 1,25-dihydroxyvitamin D-3 reversibly 
blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. 
Proceedings O f The National Academy O f Sciences O f The United States OfAmerica 
93, 7861-7864.
Cantoma, M.T., Hayes, C.E., and Deluca, H.F. (1998) 1,25-dihydroxycholecalciferol inhibits 
the progression of arthritis in murine models of human arthritis. Journal O f Nutrition 
128, 68-72.
Cao, Z.D., Xiong, J., Takeuchi, M., Kurama, T., and Goeddel, D.V. (1996) TARF6 is a signal 
transducer for interleukin-1. Nature 383, 443-446.
Carlin, G., Djursater, R., Smedegard, G., and Gerdin, B. (1985) Effect of anti-inflammatory 
drugs on xanthine-oxidase and xanthine- oxidase induced depolymerization of 
hyaluronic-acid. Agents And Actions 16,377-384.
Carlin, G., Djursater, R., and Smedegard, G. (1992) Sulfasalazine inhibition of human
granulocyte activation by inhibition of 2nd messenger compounds. Annals O f The 
Rheumatic Diseases 51, 1230-1236.
Carroll, R.G., Riley, J.L., Levine, B.L., Feng, Y., Kaushal, S., Ritchey, D.W., Bernstein, W., 
Weislow, O.S., Brown, C.R., Berger, E.A., June, C.H., and StLouis, D.C. (1997) 
Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of 
CD4(+) T cells. Science 276, 273-276.
Carter, D.B., Deibel, M.R., Dunn, C.J., Tomich, C.S.C., Laborde, A.L., Slightom, J.L., Berger, 
A.E., Bienkowski, M.J., Sun, F.F., Mcewan, R.N., Harris, P.K.W., Yem, A.W., Waszak, 
G.A., Chosay, J.G., Sieu, L.C., Hardee, M.M., Zurchemeely, H.A., Reardon, I.M., 
Heinrikson, R.L., Truesdell, S.E., Shelly, J.A., Eessalu, T.E., Taylor, B.M., and Tracey, 
D.E. (1990) Purification, cloning, expression and biological characterization of an 
interleukin-1 receptor antagonist protein. Nature 344, 633-638.
Cerretti, D.P., Kozlosky, C.J., Mosley, B., Nelson, N., Vanness, K., Greenstreet, T.A., March,
C.J., Kronheim, S.R., Dmck, T., Cannizzaro, L.A., Huebner, K., and Black, R.A. (1992) 
Molecular-cloning of the interleukin-1-beta converting enzyme. Science 256, 97-100.
Chabaud, M., Durand, J.M., Buchs, N., Fossiez, F., Page, G., Frappart, L., and Miossec, P.
(1999) Human interleukin-17 -A T  cell-derived proinflammatory cytokine produced by 
the rheumatoid synovium. Arthritis And Rheumatism 42, 963-970.
Chabner, B.A., Allegra, C.J., Curt, G.A., Clendeninn, N.J., Baram, J., Koizumi, S., Drake, J.C., 
and Jolivet, J. (1985) Polyglutamation of methotrexate - is methotrexate a prodrug. 
Journal O f Clinical Investigation 76, 907-912.
Champion, G.D., Graham, G.G., and Ziegler, J.B. (1990) The gold complexes. Baillieres 
Clinical Rheumatology 4, 491-534.
Chang, D.M., Weinblatt, M.E., and Schur, P.H. (1992) The effects of methotrexate on
interleukin-1 in patients with rheumatoid-arthritis. Journal O f Rheumatology 19, 1678- 
1682.
252
Chantry, D., Turner, M., Abney, E., and Feldmann, M. (1989) Modulation of cytokine
production by transforming growth factor-beta. Journal O f Immunology 142, 4295- 
4300.
Charles, P., Elliott, M.J., Davis, D., Potter, A., Kalden, J.R., Antoni, C., Breedveld, F.C., 
Smolen, J.S., Eberl, G., deWoody, K., Feldmann, M., and Maini, R.N. (1999) 
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti- 
TNF-alpha therapy in rheumatoid arthritis. Journal O f Immunology 163, 1521-1528.
Chaudhri, G., Hunt, N.H., Clark, I.A., and Ceredig, R. (1988) Antioxidants inhibit proliferation 
and cell-surface expression of receptors for interleukin-2 and transferrin in 
lymphocytes-t stimulated with phorbol-myristate acetate and ionomycin. Cellular 
Immunology 115, 204-213.
Chikanza, I.C., Kingsley, G., and Panayi, G.S. (1995) Peripheral-blood and synovial-fluid 
monocyte expression of interleukin-1-alpha and 1-beta during active rheumatoid- 
arthritis. Journal O f Rheumatology 22, 600-606.
Grilles, C., Mulheron, M., Mccrae, F.M., Reglinksi, J., Smith, W.E., Brzeski, M., and Sturrock, 
R.D. (1990) Concentration and reactivity of the sulfhydryl-group population on the 
membrane of intact erythrocytes in patients with rheumatoid- arthritis. Annals Of The 
Rheumatic Diseases 49,668-671.
Chizzolini, C., Chicheportiche, R., Burger, D., and Dayer, J.M. (1997) Human Thl cells 
preferentially induce interleukin (IL)-l beta while Th2 cells induce IL-1 receptor 
antagonist production upon cell/cell contact with monocytes. European Journal Of 
Immunology 27, 171-177.
Chizzonite, R., Truitt, T., Kilian, P.L., Stem, A.S., Nunes, P., Parker, K.P., Kaffka, K.L., Chua, 
A.O., Lugg, D.K., and Gubler, U. (1989) 2 High-affinity interleukin-1 receptors 
represent separate gene- products. Proceedings O f The National Academy O f Sciences 
O f The United States O f America 86, 8029-8033.
Cho, S.S., Bacon, C.M., Sudarshan, C., Rees, R.C., Finbloom, D., Pine, R., and Oshea, J.J.
(1996) Activation of STAT4 by IL-12 and IFN-alpha - evidence for the involvement of 
ligand-induced tyrosine and serine phosphorylation. Journal O f Immunology 157, 
4781-4789.
Choi, Y.W., Herman, A., Digiusto, D., Wade, T., Marrack, P., and Kappler, J. (1990) Residues 
of the variable region of the t-cell-receptor beta-chain that interact with s-aureus toxin 
superantigens. Nature 346, 471-473.
Chomarat, P., Vannier, E., Dechanet, J., Rissoan, M.C., Banchereau, J., Dinarello, C.A., and 
Miossec, P. (1995) Balance of IL-1 receptor antagonist/IL-l-beta in rheumatoid 
synovium and its regulation by IL-4 and IL-10. Journal O f Immunology 154, 1432- 
1439.
Chow, J.C., Young, D.W., Golenbock, D.T., Christ, W.J., and Gusovsky, F. (1999) Toll-like 
receptor-4 mediates lipopolysaccharide-induced signal transduction. JBiol Chem 274, 
10689-10692.
253
Choy, E.H.S., Chikanza, I.C., Kingsley, G.H., Bijl, H., Sanders, M.E., and Panayi, G.S. (1992) 
Chimeric anti-CD4 monoclonal-antibody in rheumatoid-arthritis. British Journal Of 
Rheumatology'S1, 102-102.
Choy, E.H.S., Kingsley, G.H., and Panayi, G.S. (1998) Anti-CD4 monoclonal antibodies in 
rheumatoid arthritis. Springer Seminars In Immunopathology 20, 261-273.
Chu, C.Q., Field, M., Feldmann, M., and Maini, R.N. (1991) Localization of tumor-necrosis- 
factor-alpha in synovial tissues and at the cartilage pannus junction in patients with 
rheumatoid- arthritis. Arthritis And Rheumatism 34, 1125-1132.
Clark, S.C. and Kamen, R. (1987) The human hematopoietic colony-stimulating factors. 
Science 236, 1229-1237.
Clegg, D.O., Furst, D.E., Tolman, K.G., and Pogue, R. (1989) Acute, reversible hepatic-failure 
associated with methotrexate treatment of rheumatoid-arthritis. Journal O f 
Rheumatology 16, 1123-1126.
Clive, D.M. and Stoff, J.S. (1984) Renal syndromes associated with nonsteroidal 
antiinflammatory drugs. New England Journal O f Medicine 310, 563-572.
Coccia, E.M., DelRusso, N., Stellacci, E., Testa, U., Marziali, G., and Battistini, A. (1999)
ST ATI activation during monocyte to macrophage maturation: role of adhesion 
molecules. International Immunology 11, 1075-1083.
Coffman, R.L., Lebman, D.A., and Shrader, B. (1989) Transforming growth factor-beta 
specifically enhances iga production by lipopolysaccharide-stimulated murine 
lymphocytes-b. Journal O f Experimental Medicine 170, 1039-1044.
Cogswell, J.P., Godlevski, M.M., Wisely, G.B., Clay, W.C., Leesnitzer, L.M., Ways, J.P., and 
Gray, J.G. (1994) Nf-kappa-b regulates IL-1-beta transcription through a consensus nf- 
kappa-b binding-site and a nonconsensus cre-like site. Journal O f Immunology 153, 
712-723.
Cohen, J. and Glauser, M.P. (1991) Septic shock - treatment. Lancet 338, 736-739.
Cohen, J.J. (1993) Programmed cell-death and apoptosis in lymphocyte development and 
function. Chest 103, S99-S101
Colotta, F., Re, F., Muzio, M., Bertini, R., Polentarutti, N., Sironi, M., Giri, J.G., Dower, S.K., 
Sims, J.E., and Mantovani, A. (1993) Interleukin-1 type-II receptor - a decoy target for 
IL-1 that is regulated by IL-4. Science 261, 472-475.
Comer, S.S. and Jasin, H.E. (1988) Invitro immunomodulatory effects of sulfasalazine and its 
metabolites. Journal O f Rheumatology 15, 580-586.
Constant, S.L. and Bottomly, K. (1997) Induction of Thl and Th2 CD4+ T cell responses: the 
alternative approaches. Annual Review Of Immunology 15, 297-322.
Cope, A.P., Gibbons, D.L., Aderka, D., Foxwell, B.M., Wallach, D., Maini, R.N., Feldmann,
M., and Brennan, F.M. (1993) Differential regulation of tumor-necrosis-factor receptors
254
(TNF-R) By IL-4, up-regulation of p55 and p75 TNF-R on synovial joint mononuclear- 
cells. Cytokine 5, 205-212.
Cornwell, W.D. and Rogers, T.J. (1999) Role of interleukin-2 in superantigen-induced T-cell 
anergy. Immunology 96, 193-201.
Coso, O.A., Chiariello, R., Kalinec, G., Kyriakis, J.M., Woodgett, J., and Gutkind, J.S. (1995) 
Transforming G-protein-coupled receptors potently activate jnk (Sapk) - Evidence for a 
divergence from the tyrosine kinase signaling pathway. Journal O f Biological 
Chemistry 270, 5620-5624.
Creasey, A.A., Chang, A.C.K., Feigen, L., Wun, T.C., Taylor, F.B., and Hinshaw, L.B. (1993) 
Tissue factor pathway inhibitor reduces mortality from escherichia- coli septic shock. 
Journal O f Clinical Investigation 91, 2850-2860.
Crilly, A., Capell, H.A., Watson, J., and Madhok, R. (1995) The effect of auranofin and 
sulfasalazine therapy on circulating levels of interleukin-6 in rheumatoid-arthritis 
patients. Clinical Rheumatology 14, 561-565.
Cronstein, B.N., Eberle, M.A., Gruber, H., and Levin, R.I. (1991) A novel antiinflammatory 
action of methotrexate (MTX) - MTX increases adenosine release from connective- 
tissue cells and, thereby, inhibits neutrophil (PMN) Function. Faseb Journal 5, A510
Croston, G.E., Cao, Z.D., and Goeddel, D.V. (1995) Nf-kappa-b activation by interleukin-1 (IL- 
1) Requires an IL-1 receptor-associated protein-kinase activity. Journal O f Biological 
Chemistry 270, 16514-16517.
Czemiecki, B.J., Carter, C., Rivoltini, L., Koski, G.K., Kim, H.I., Weng, D.E., Roros, J.G.,
Hijazi, Y.M., Xu, S.W., Rosenberg, S.A., and Cohen, P.A. (1997) Calcium ionophore- 
treated peripheral blood monocytes and dendritic cells rapidly display characteristics of 
activated dendritic cells. Journal O f Immunology 159, 3823-3837.
Daeron, M., Malbec, O., Bonnerot, C., Latour, S., Segal, D.M., and Fridman, W.H. (1994)
Tyrosine-containing activation motif-dependent phagocytosis in mast- cells. Journal O f 
Immunology 152, 783-792.
Daeron, M., Latour, S., Malbec, O., Espinosa, E., Pina, P., Pasmans, S., and Fridman, W.H.
(1995) The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc- 
gamma-RIIB, regulates negatively BCR-dependent, TCR- dependent, and FCR- 
dependent cell activation. Immunity 3, 635-646.
Daeron, M. (1997) Fc receptor biology. Annual Review O f Immunology 15, 203-234.
D’Ambrosio, D., Cantrell, D.A., Frati, L., Santoni, A., and Testi, R. (1994) Involvement of 
p21 (ras) activation in t-cell cd69 expression. European Journal O f Immunology 24, 
616-620.
Danis, V.A., Franic, G.M., and Brooks, P.M. (1991) The effect of slow-acting antirheumatic 
drugs (Saards) And combinations of saards on monokine production in vitro. Drugs 
Under Experimental And Clinical Research 17, 549-554.
255
Darby, C., Geahlen, R.L., and Schreiber, A.D. (1994) Stimulation of macrophage Fc-gamma- 
RIIIA activates the receptor- associated protein-tyrosine kinase syk and induces 
phosphorylation of multiple proteins including p95vav and p62 gap- associated protein. 
Journal O f Immunology 152, 5429-5437.
Davis, E.C., Broekelmann, T.J., Ozawa, Y., and Mecham, R.P. (1998) Identification of
tropoelastin as a ligand for the 65-kD FK506- binding protein, FKBP65, in the secretory 
pathway. Journal O f Cell Biology 140, 295-303.
Davis, K., Boros, P., Keltz, M., Unkeless, J.C., and Fleischmajer, R. (1995) Circulating Fc-
gamma receptor-specific autoantibodies in localized and systemic scleroderma. Journal 
O f The American Academy Of Dermatology 33, 612-616.
Dayer, J.M. and Fenner, H. (1992) The role of cytokines and their inhibitors in arthritis. 
Baillieres Clinical Rheumatology 6, 485-516.
Dayer, J.M. (1999) Interleukin-18, rheumatoid arthritis, and tissue destruction. Journal Of 
Clinical Investigation 104, 1337-1339.
Dean, N.M., Mckay, R., Condon, T.P., and Bennett, C.F. (1994) Inhibition of protein-kinase c- 
alpha expression in human a549 cells by antisense oligonucleotides inhibits induction of 
intercellular- adhesion molecule-1 (Icam-1) Messenger-RNA by phorbol esters.
Journal O f Biological Chemistry 269, 16416-16424.
Deans, J.P., Serra, H.M., Shaw, J., Shen, Y.J., Torres, R.M., and Pilarski, L.M. (1992)
Transient accumulation and subsequent rapid loss of messenger-RNA encoding high 
molecular mass cd45 isoforms after t-cell activation. Journal O f Immunology 148, 
1898-1905.
De Benedetti, F., Pignatti, P., Massa, M., Sartirana, P., Ravelli, A., and Martini, A. (1995) 
Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in 
systemic juvenile chronic arthritis. Clinical And Experimental Rheumatology 13, 779- 
784.
Della Corte, E. and Stirpe, F. (1972) The regulation of rat liver xanthine oxidase. Involvement 
of thiol groups in the conversion of the enzyme activity from dehydrogenase (type D) 
into oxidase (type O) and purification of the enzyme. Biochemical Journal 126, 739- 
745.
Dellabona, P., Peccoud, J., Kappler, J., Marrack, P., Benoist, C., and Mathis, D. (1990)
Superantigens interact with MHC class-II molecules outside of the antigen groove. Cell 
62, 1115-1121.
Den Broeder, A.A., van Gestel, A.M., and van Riel, P.L.C.M. (1999) Evaluation of the disease 
activity in patients with RA during longterm treatment with Anti-TNF. Arthritis And 
Rheumatism 42, 389
Devitt, A., Moffatt, O.D., Raykundalia, C., Capra, J.D., Simmons, D.L., and Gregory, C.D.
(1998) Human CD 14 mediates recognition and phagocytosis of apoptotic cells. Nature 
392, 505-509.
256
Digiovine, F.S., Nuki, G., and Duff, G.W. (1988) Tumor necrosis factor in synovial exudates. 
Annals O f The Rheumatic Diseases 47, 768-772.
Dinarello, C.A., Mamoy, S.O., and Rosenwasser, L.J. (1983) Role of arachidonate metabolism 
in the immunoregulatory function of human leukocytic pyrogen lymphocyte-activating 
factor interleukin-1. Journal O f Immunology 130, 890-895.
Dinarello, C.A. (1984) Interleukin-1. Review’s Of Infectious Diseases 6, 51-95.
Dinarello, C.A. (1992) Role of interleukin-1 in infectious-diseases. Immunological Reviews 
127, 119-146.
Dinarello, C.A. (1996) Biologic basis for interleukin-1 in disease. Blood 87, 2095-2147.
Dolhain, R.J.E.M., van der Heiden, A.N., ter Haar, N.T., Breedveld, F.C., and Miltenburg,
A.M.M. (1996) Shift toward t lymphocytes with a T helper 1 cytokine-secretion profile 
in the joints of patients with rheumatoid arthritis. Arthritis And Rheumatism 39, 1961- 
1969.
Dolhain, R.J.E.M., Tak, P.P., Dijkmans, B.A.C., De Kuiper, P., Breedveld, F.C., and 
Miltenburg, A.M.M. (1998) Methotrexate reduces inflammatory cell numbers, 
expression of monokines and of adhesion molecules in synovial tissue of patients with 
rheumatoid arthritis. British Journal O f Rheumatology 37, 502-508.
Donovan, S., Hawley, S., MacCarthy, J., and Scott, D.L. (1990) Tolerability of enteric-coated 
sulfasalazine in rheumatoid-arthritis - results of a cooperating clinics study. British 
Journal O f Rheumatology 29, 201-204.
Dowd, J.E., Karr, R.W., and Karp, D.R. (1996) Functional activity of Staphylococcal
enterotoxin A requires interactions with both the alpha and beta chains of HLA-DR. 
Molecular Immunology 33, 1267-1274.
Dower, S.K., Kronheim, S.R., March, C.J., Conlon, P.J., Hopp, T.P., Gillis, S., and Urdal, D.L. 
(1985) Detection and characterization of high-affinity plasma-membrane receptors for 
human interleukin-1. Journal O f Experimental Medicine 162, 501-515.
Dower, S.K., Kronheim, S.R., Hopp, T.P., Cantrell, M., Deeley, M., Gillis, S., Henney, C.S., 
and Urdal, D.L. (1986) The cell-surface receptors for interleukin-1-alpha and 
interleukin-1- beta are identical. Nature 324, 266-268.
Downward, J. (1994) Signal-transduction - regulating s6 kinase. Nature 371, 378-379.
Duby, A.D., Sinclair, A.K., Osbome-Lawrence, S.L., Zeldes, W., Kan, L., and Fox, D.A.
(1989) Clonal heterogeneity of synovial-fluid lymphocytes-t from patients with 
rheumatoid-arthritis. Proceedings O f The National Academy O f Sciences O f The United 
States O f America 86, 6206-6210.
Durum, S.K., Schmidt, J.A., and Oppenheim, J.J. (1985) Interleukin-1 - an immunological 
perspective. Annual Review O f Immunology 3, 263-287.
257
Eastgate, J.A., Wood, N.C., Digiovine, F.S., Symons, J.A., Grinlinton, F.M., and Duff, G.W. 
(1988) Correlation of plasma interleukin-1 levels with disease-activity in rheumatoid- 
arthritis. Lancet 2, 706-709.
Edberg, J.C., Lin, C.T., Lau, D., Unkeless, J.C., and Kimberly, R.P. (1995) The Ca2+
dependence of human Fc-gamma receptor-initiated phagocytosis. Journal O f Biological 
Chemistry 270, 22301-22307.
Edwards, S.W. and Hallett, M.B. (1997) Seeing the wood for the trees: The forgotten role of 
neutrophils in rheumatoid arthritis. Immunology Today 18, 320-324.
Eisenberg, S.P., Evans, R.J., Arend, W.P., Verderber, E., Brewer, M.T., Hannum, C.H., and 
Thompson, R.C. (1990) Primary structure and functional expression from 
complementary- DNA of a human interleukin-1 receptor antagonist. Nature 343, 341- 
346.
El Gabalawy, H., Gallatin, M., Vazeux, R., Peterman, G., and Wilkins, J. (1994) Expression of 
ICAM-R (ICAM-3), a novel counter-receptor for LFA- 1, in rheumatoid and 
nonrheumatoid synovium - comparison with other adhesion molecules. Arthritis And 
Rheumatism 37, 846-854.
Elices, M.J., Osborn, L., Takada, Y., Crouse, C., Luhowskyj, S., Hemler, M.E., and Lobb, R.R.
(1990) VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 
at a site distinct from the VLA-4 fibronectin binding-site. Cell 60, 577-584.
Elliott, M.J., Maini, R.N., Feldmann, M., Longfox, A., Charles, P., Katsikis, P., Brennan, F.M., 
Walker, J., Bijl, H., Ghrayeb, J., and Woody, J.N. (1993) Treatment of rheumatoid- 
arthritis with chimeric monoclonal-antibodies to tumor-necrosis-factor-alpha. Arthritis 
And Rheumatism 36, 1681-1690.
Elliott, M.J., Maini, R.N., Feldmann, M., Kalden, J.R., Antoni, C., Smolen, J.S., Leeb, B., 
Breedveld, F.C., Macfarlane, J.D., Bijl, H., and Woody, J.N. (1994a) Randomized 
double-blind comparison of chimeric monoclonal-antibody to tumor-necrosis-factor- 
alpha (Ca2) Versus placebo in rheumatoid- arthritis. Lancet 344, 1105-1110.
Elliott, M.J., Maini, R.N., Feldmann, M., Longfox, A., Charles, P., Bijl, H., and Woody, J.N. 
(19946) Repeated therapy with monoclonal-antibody to tumor-necrosis-factor- alpha 
(Ca2) In patients with rheumatoid-arthritis. Lancet 344, 1125-1127.
Emery, P., Wood, N., Gentry, K., Stockman, A., Mackay, I.R., and Bernard, O. (1988) High- 
affinity interleukin-2 receptors on blood-lymphocytes are decreased during active 
rheumatoid-arthritis. Arthritis And Rheumatism 31, 1176-1181.
Engelmann, H., Aderka, D., Rubinstein, M., Rotman, D., and Wallach, D. (1989) A tumor
necrosis factor-binding protein purified to homogeneity from human-urine protects cells 
from tumor necrosis factor toxicity. Journal O f Biological Chemistry 264, 11974- 
11980.
Ernst, L.K., Duchemin, A.M., and Anderson, C.L. (1993) Association of the high-affinity 
receptor for IgG (Fc-gamma-RI) With the gamma-subunit of the IgE receptor.
258
Proceedings O f The National Academy O f Sciences O f The United States OfAmerica 
90, 6023-6027.
Essner, R., Rhoades, K., McBride, W.H., Morton, D.L., and Economou, J.S. (1989) IL-4 down- 
regulates IL-1 and TNF gene-expression in human- monocytes. Journal O f 
Immunology 142, 3857-3861.
Fairbum, K., Stevens, C.R., Winyard, P.G., Kus, M., Ward, R.J., Cunningham, J., Zaidi, M., 
and Blake, D.R. (1993) Oxidative stress and its control - a pathogenetic role in 
inflammatory joint disease. Biochemical Society Transactions 21, 371-375.
Farr, M., Brodrick, A., and Bacon, P.A. (1985) Plasma and synovial-fluid concentrations of 
sulphasalazine and 2 of its metabolites in rheumatoid-arthritis. Rheumatology 
International 5, 247-251.
Farr, M., Tunn, E.J., Symmons, D.P.M., Scott, D.G.I., and Bacon, P.A. (1989) Sulphasalazine 
in rheumatoid-arthritis - hematological problems and changes in hematological indexes 
associated with therapy. British Journal O f Rheumatology 28, 134-138.
Fava, R.A., Mckanna, J., and Cohen, S. (1989) Lipocortin-I (P35) is abundant in a restricted 
number of differentiated cell-types in adult organs. Journal O f Cellular Physiology 
141,284-293.
Feams, C., Thinnes, T., Roegner, K., Kravchenko, V., Ulevitch, R.J., and Loskutoff, D.J.
(1994) Murine CD 14-gene expression in-vivo - tissue distribution and regulation by 
lipopolysaccharide (LPS). Faseb Journal 8, A1019
Feldmann, M., Brennan, F.M., and Maini, R.N. (1996) Role of cytokines in rheumatoid 
arthritis. Annual Review O f Immunology 14, 397-440.
Feng, L., Xia, Y.Y., Garcia, G.E., Hwang, D., and Wilson, C.B. (1995) Involvement of reactive 
oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor- 
necrosis-factor-alpha, and lipopolysaccharide. Journal O f Clinical Investigation 95, 
1669-1675.
Fenton, M.J., Vermeulen, M.W., Clark, B.D., Webb, A.C., and Auron, P.E. (1988) Human pro- 
IL-l-beta gene-expression in monocytic cells is regulated by 2 distinct pathways. 
Journal O f Immunology 140, 2267-2273.
Finazzi-Agro, A., Conti, P., Hofmann, M., Angeletti, P.U., and Rotilio, G. (1980) Activation of 
Lymphocytes by H202. AAS 7, 220-223.
Firestein, G.S., Xu, W.D., Townsend, K., Broide, D., Alvarogracia, J., Glasebrook, A., and
Zvaifler, N.J. (1988) Cytokines in chronic inflammatory arthritis .1. Failure to detect T- 
cell lymphokines (interleukin-2 and interleukin-3) and presence of macrophage colony- 
stimulating factor (CSF-1) and a novel mast-cell growth-factor in rheumatoid synovitis. 
Journal O f Experimental Medicine 168, 1573-1586.
Firestein, G.S., Roeder, W.D., Laxer, J.A., Townsend, K.S., Weaver, C.T., Horn, J.T., Linton,
J., Torbett, B.E., and Glasebrook, A.L. (1989) A new murine cd4+ t-cell subset with an 
unrestricted cytokine profile. Journal O f Immunology 143, 518-525.
259
Firestein, G.S., Alvarogarcia, J.M., and Maki, R. (1990) Quantitative-analysis of cytokine gene- 
expression in rheumatoid- arthritis. Journal O f Immunology 144, 3347-3353.
Firestein, G.S. and Zvaifler, N.J. (1990) How important are t-cells in chronic rheumatoid 
synovitis. Arthritis And Rheumatism 33, 768-773.
Firestein, G.S., Paine, M.M., Boyle, D.L., Zvaifler, C.Y.N.J., and Arend, W.P. (1992) IL-lra- 
IL-1 balance in rheumatoid-arthritis (ra) and osteoarthritis (oa) synovial-cells. Arthritis 
And Rheumatism 35, SI43
Firestein, G.S., Boyle, D.L., Yu, C., Paine, M.M., Whisenand, T.D., Zvaifler, N.J., and Arend, 
W.P. (1994a) Synovial interleukin-1 receptor antagonist and interleukin-1 balance in 
rheumatoid-arthritis. Arthritis And Rheumatism 37, 644-652.
Firestein, G.S., Paine, M.M., and Boyle, D.L. (19946) Mechanisms of methotrexate action in 
rheumatoid-arthritis - selective decrease in synovial collagenase gene-expression. 
Arthritis And Rheumatism 37, 193-200.
Fischman, C.M., Udey, M.C., Kurtz, M., and Wedner, H.J. (1981) Inhibition of lectin-induced 
lymphocyte-activation by 2-cyclohexene- 1-one - decreased intracellular glutathione 
inhibits an early event in the activation sequence. Journal O f Immunology 127, 2257- 
2262.
Flower, R.J. and Rothwell, N.J. (1994) Lipocortin-1 - cellular mechanisms and clinical 
relevance. Trends In Pharmacological Sciences 15, 71-76.
Foey, A.D., Crawford, A., and Hall, N.D. (1996) Dysfunctional Na,K-ATPase activity in
rheumatoid synovial lining cells results in a defect in fas-mediated apoptosis. Arthritis 
And Rheumatism 39, 628-628.
Foey, A.D., Crawford, A., and Hall, N.D. (1997) Modulation of cytokine production by human 
mononuclear cells following impairment of Na, K-ATPase activity. Biochim Biophys 
Acta 1355, 43-49.
Fossiez, F., Djossou, O., Chomarat, P., Floresromo, L., Aityahia, S., Maat, C., Pin, J.J.,
Garrone, P., Garcia, E., Saeland, S., Blanchard, D., Gaillard, C., Das Mahapatra, B., 
Rouvier, E., Golstein, P., Banchereau, J., and Lebecque, S. (1996) T cell interleukin-17 
induces stromal cells to produce proinflammatory and hematopoietic cytokines. Journal 
O f Experimental Medicine 183, 2593-2603.
Foxwell, B., Browne, K., Bondeson, J., Clarke, C., De Martin, R., Brennan, F., and Feldmann, 
M. (1998) Efficient adenoviral infection with I kappa B alpha reveals that macrophage 
tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappa B dependent. 
Proceedings O f The National Academy O f Sciences O f The United States O f America 
95, 8211-8215.
Franklin, C.M. (1999) Clinical experience with soluble TNF p75 receptor in rheumatoid 
arthritis. Seminars In Arthritis And Rheumatism 29, 172-181.
260
Frey, E.A., Miller, D.S., Jahr, T.G., Sundan, A., Bazil, V., Espevik, T., Finlay, B.B., and 
Wright, S.D. (1992) Soluble CD 14 participates in the response of cells to 
lipopolysaccharide. Journal O f Experimental Medicine 176, 1665-1671.
Fridman, W.H. (1991) Fc-receptors and immunoglobulin binding-factors. Faseb Journal 5, 
2684-2690.
Fujikawa, Y., Shingu, M., Torisu, T., and Masumi, S. (1995) Interleukin-1 receptor antagonist 
production in cultured synovial- cells from patients with rheumatoid-arthritis and 
osteoarthritis. Annals O f The Rheumatic Diseases 54, 318-320.
Funk, C.D., Funk, L.B., Kennedy, M.E., Pong, A.S., and Fitzgerald, G.A. (1991) Human
platelet erythroleukemia cell prostaglandin g/h synthase - cDNA cloning, expression, 
and gene chromosomal assignment. Faseb Journal 5, 2304-2312.
Gabay, C., Gaycroisier, F., Rouxlombard, P., Meyer, O., Maineti, C., Gueme, P.A., Vischer, T., 
and Dayer, J.M. (1994) Elevated serum levels of interleukin-1 receptor antagonist in 
polymyositis/dermatomyositis - a biologic marker of disease- activity with a possible 
role in the lack of acute-phase protein response. Arthritis And Rheumatism 37, 1744- 
1751.
Galon, J., Bouchard, C., Fridman, W.H., and Sautes, C. (1995) Ligands and biological-activities 
of soluble fc-gamma receptors. Immunology Letters 44, 175-181.
Gangloff, S.C. and Goyert, S.M. (1999) Structural requirements for the induction of the acute 
phase response by LPS. Faseb Journal 13, A840
Garrison, L. and McDonnell, N.D. (1999) Etanercept: therapeutic use in patients with 
rheumatoid arthritis. Annals O f The Rheumatic Diseases 58, 65-69.
Gately, M.K., Renzetti, L.M., Magram, J., Stem, A.S., Adorini, L., Gubler, U., and Presky,
D.H. (1998) The interleukin-12/interleukin-12-receptor system: Role in normal and 
pathologic immune responses. Annual Review O f Immunology 16, 495-521.
Gauchat, J.F., Aubry, J.P., Mazzei, G., Life, P., Jomotte, T., Elson, G., and Bonnefoy, J.Y.
(1993) Human CD40-ligand - molecular-cloning, cellular-distribution and regulation of 
expression by factors controlling IgE production. Febs Letters 315, 259-266.
Ghayur, T., Baneijee, S., Hugunin, M., Butler, D., Herzog, L., Carter, A., Quintal, L., Sekut, L., 
Talanian, R., Paskind, M., Wong, W., Kamen, R., Tracey, D., and Allen, H. (1997) 
Caspase-1 processes IFN-gamma-inducing factor and regulates LPS- induced IFN- 
gamma production. Nature 386, 619-623.
Ghezzi, P., Bertini, R., Bianchi, M., Erroi, A., Villa, P., and Mantovani, A. (1987) Interleukin-1 
and tumor-necrosis-factor depress cytochrome-p-450- dependent liver drug-metabolism 
in mice. Journal O f Leukocyte Biology 42, 617
Giambartolomei, G.H., Dennis, V.A., Lasater, B.L., and Philipp, M.T. (1999) Induction of pro- 
and anti-inflammatory cytokines by Borrelia burgdorferi lipoproteins in monocytes is 
mediated by CD 14. Infection And Immunity 67, 140-147.
261
Giant, T.T., Mikecz, K., Arzoumanian, A., and Poole, A.R. (1987) Proteoglycan-induced
arthritis in balb/c mice - clinical-features and histopathology. Arthritis And Rheumatism 
30, 201-212.
Glauser, M.P., Zanetti, G., Baumgartner, J.D., and Cohen, J. (1991) Septic shock - 
pathogenesis. Lancet 338, 732-736.
Goldstone, S.D. and Hunt, N.H. (1997) Redox regulation of the mitogen-activated protein 
kinase pathway during lymphocyte activation. Biochimica Et Biophysica Acta- 
Molecular Cell Research 1355, 353-360.
Goulding, N.J., Godolphin, J.L., Sharland, P.R., Peers, S.H., Sampson, M., Maddison, PJ., and 
Flower, R.J. (1990) Antiinflammatory lipocortin-1 production by peripheral-blood 
leukocytes in response to hydrocortisone. Lancet 335, 1416-1418.
Goulding, N.J., Pan, L.Y., Wardwell, K., Guyre, V.C., and Guyre, P.M. (1996) Evidence for 
specific annexin I-binding proteins on human monocytes. Biochemical Journal 316, 
593-597.
Gracie, J.A., Forsey, R.J., Chan, W.L., Gilmour, A., Leung, B.P., Greer, M.R., Kennedy, K., 
Carter, R., Wei, X.Q., Xu, D.M., Field, M., Foulis, A., Liew, F.Y., and Mclnnes, I.B.
(1999) A proinflammatory role for IL-18 in rheumatoid arthritis. Journal Of Clinical 
Investigation 104, 1393-1401.
Granowitz, E.V., Porat, R., Mier, J.W., Orencole, S.F., Kaplanski, G., Lynch, E.A., Ye, K.,
Vannier, E., Wolff, S.M., and Dinarello, C.A. (1993) Intravenous endotoxin suppresses 
the cytokine response of peripheral- blood mononuclear-cells of healthy humans. 
Journal Of Immunology 151, 1637-1645.
Greenfeder, S.A., Nunes, P., Kwee, L., Labow, M., Chizzonite, P.A., and Ju, G. (1995)
Molecular-cloning and characterization of a 2nd subunit of the interleukin-1 receptor 
complex. Journal Of Biological Chemistry 270, 13757-13765.
Gregersen, P.K., Silver, J., and Winchester, R.J. (1987) The shared epitope hypothesis - an 
approach to understanding the molecular-genetics of susceptibility to rheumatoid- 
arthritis. Arthritis And Rheumatism US, 1205-1213.
Gronberg, A. (1994) Inhibitory effect of sulphasalazine on production of IL-lp, IL-6 and 
TNFa. Arthritis And Rheumatism 37, S3 83
Grube, B.J., Cochane, C.G., Ye, R.D., Green, C.E., Mcphail, M.E., Ulevitch, R.J., and Tobias, 
P.S. (1994) Lipopolysaccharide-binding protein expression in primary human 
hepatocytes and hepg2 hepatoma-cells. Journal O f Biological Chemistry 269, 8477- 
8482.
Grusby, M.J. (1997) STAT4- and STAT6-deficient mice as models for manipulating T helper 
cell responses. Biochemical Society Transactions 25, 359-360.
Guinan, E.C., Gribben, J.G., Boussiotis, V.A., Freeman, G.J., andNadler, L.M. (1994) Pivotal 
role of the b7-CD28 pathway in transplantation tolerance and tumor-immunity. Blood 
84, 3261-3282.
262
Guzman, N.J., Fang, M.Z., Tang, S.S., Ingelfinger, J.R., and Garg, L.C. (1995) Autocrine
inhibition of Na+/K+-ATPase by nitric-oxide in mouse proximal tubule epithelial-cells. 
Journal O f Clinical Investigation 95, 2083-2088.
Hahn, W.C., Burakoff, S.J., and Bierer, B.E. (1993) Signal transduction pathways involved in t- 
cell receptor-induced regulation of CD2 avidity for CD58. Journal O f Immunology 150, 
2607-2619.
Hakala, B.E., White, C., and Recklies, A.D. (1993) Human cartilage gp-39, a major secretory 
product of articular chondrocytes and synovial-cells, is a mammalian member of a 
chitinase protein family. Journal O f Biological Chemistry 268, 25803-25810.
Hambleton, J., Weinstein, S.L., Lem, L., and DeFranco, A.L. (1996) Activation of c-jun n-
terminal kinase in bacterial lipopolysaccharide-stimulated macrophages. Proceedings 
O f The National Academy O f Sciences O f The United States O f America 93, 2774-2778.
Hannum, C.H., Wilcox, C.J., Arend, W.P., Joslin, F.G., Dripps, D.J., Heimdal, P.L., Armes, 
L.G., Sommer, A., Eisenberg, S.P., and Thompson, R.C. (1990) Interleukin-1 receptor 
antagonist activity of a human interleukin-1 inhibitor. Nature 343, 336-340.
Hare, B.J., Wyss, D.F., Osbume, M.S., Kern, P.S., Reinherz, E.L., and Wagner, G. (1999) 
Structure, specificity and CDR mobility of a class II restricted single-chain T-cell 
receptor. Nature Structural Biology 6, 574-581.
Harriman, G., Harper, L.K., and Schaible, T.F. (1999) Summary of clinical trials in rheumatoid 
arthritis using infliximab, an anti-TNF alpha treatment. Annals O f The Rheumatic 
Diseases 58, 61-64.
Harris, E.D. (1990) Mechanisms of disease - rheumatoid-arthritis - pathophysiology and 
implications for therapy. New England Journal Of Medicine 322, 1277-1289.
Harrison, P.T., Davis, W., Norman, J.C., Hockaday, A.R., and Allen, J.M. (1994) Binding of 
monomeric immunoglobulin-g triggers fc-gamma-ri-mediated endocytosis. Journal Of 
Biological Chemistry 269, 24396-24402.
Hart, P.H., Vitti, G.F., Burgess, D.R., Whitty, G.A., Piccoli, D.S., and Hamilton, J.A. (1989) 
Potential antiinflammatory effects of interleukin-4 - suppression of human monocyte 
tumor necrosis factor-alpha, interleukin-1, and prostaglandin-e2. Proceedings Of The 
National Academy O f Sciences O f The United States O f America 86, 3803-3807.
Harth, M., Keown, P.A., and Orange, J.F. (1983) Monocyte dependent excited oxygen radical 
generation in rheumatoid- arthritis - inhibition by gold sodium thiomalate. Journal Of 
Rheumatology 10, 701-707.
Harvath, L., Yancey, K.B., and Katz, S.I. (1986) Selective-inhibition of human neutrophil 
chemotaxis to n-formyl- methionyl-leucyl-phenylalanine by sulfones. Journal Of 
Immunology 137, 1305-1311.
Haskill, S., Martin, G., Vanle, L., Morris, J., Peace, A., Bigler, C.F., Jaffe, G.J., Hammerberg,
C., Spom, S.A., Fong, S., Arend, W.P., and Ralph, P. (1991) cDNA cloning of an 
intracellular form of the human interleukin-1 receptor antagonist associated with
263
epithelium. Proceedings O f The National Academy O f Sciences O f The United States 
Of America 88, 3681-3685.
Hawkins, P.T., Eguinoa, A., Qiu, R.G., Stokoe, D., Cooke, F.T., Walters, R., Wennstrom, S.,
Claessonwelsh, L., Evans, T., Symons, M., and Stephens, L. (1995) PDGF stimulates an 
increase in GTP-rac via activation of phosphoinositide 3-kinase. Current Biology 5, 
393-403.
Haworth, C., Brennan, F.M., Chantry, D., Turner, M., Maini, R.N., and Feldmann, M. (1991)
Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid-arthritis 
- regulation by tumor-necrosis-factor- alpha. European Journal O f Immunology 21, 
2575-2579.
Haziot, A., Rong, G.W., Bazil, V., Silver, J., and Goyert, S.M. (1994) Recombinant soluble 
cdl4 inhibits LPS-induced tumor-necrosis-factor- alpha production by cells in whole- 
blood. Journal O f Immunology 152,5868-5876.
Haziot, A., Lin, X.Y., Zhang, F., and Goyert, S.M. (1998) Cutting edge: the induction of acute 
phase proteins by lipopolysaccharide uses a novel pathway that is cd 14-independent. 
Journal O f Immunology 160, 2570-2572.
Hazuda, D., Webb, R.L., Simon, P., and Young, P. (1989) Purification and characterization of 
human recombinant precursor interleukin-1-beta. Journal O f Biological Chemistry 264 
, 1689-1693.
Hazuda, D.J., Strickler, J., Kueppers, F., Simon, P.L., and Young, P.R. (1990) Processing of 
precursor interleukin-1-beta and inflammatory disease. Journal O f Biological 
Chemistry 265, 6318-6322.
Helle, M., Boeije, L., Degroot, E., Devos, A., and Aarden, L. (1991) Sensitive ELISA for
interleukin-6 - detection of IL-6 in biological- fluids - synovial-fluids and sera. Journal 
O f Immunological Methods 138, 47-56.
Hemler, M.E. (1990) Via proteins in the integrin family - structures, functions, and their role on 
leukocytes. Annual Review O f Immunology 8, 365-400.
Herrera-Velit, P. and Reiner, N.E. (1996) Bacterial lipopolysaccharide induces the association 
and coordinate activation of p53/56(lyn) and phosphatidylinositol 3-kinase in human 
monocytes. Journal O f Immunology 156, 1157-1165.
Hiepe, F., Volk, H.D., Apostoloff, E., Von Baehr, R., and Emmrich, F. (1991) Treatment of 
severe systemic lupus-erythematosus with anti-cd4 monoclonal-antibody. Lancet 338, 
1529-1530.
Hilkens, C.M.U., Kalinski, P., de Boer, M., and Kapsenberg, M.L. (1997) Human dendritic 
cells require exogenous interleukin-12-inducing factors to direct the development of 
naive T-helper cells toward the Thl phenotype. Blood 90, 1920-1926.
Hirano, T. (1992) Interleukin-6 and its relation to inflammation and disease. Clinical 
Immunology And Immunopathology 62, S60-S65
264
Hirohata, S., Yanagida, T., Hashimoto, H., Tomita, T., and Ochi, T. (1999) Suppressive
influences of methotrexate on the generation of CD14(+) monocyte-lineage cells from 
bone marrow of patients with rheumatoid arthritis [Full text delivery]. Clinical 
Immunology 91, 84-89.
Hollenberg, S.M., Weinberger, C., Ong, E.S., Cerelli, G., Oro, A., Lebo, R., Thompson, E.B., 
Rosenfeld, M.G., and Evans, R.M. (1985) Primary structure and expression of a 
functional human glucocorticoid receptor cdna. Nature 318, 635-641.
Holtmann, H. and Wallach, D. (1987) Down regulation of the receptors for tumor-necrosis- 
factor by interleukin-1 and 4-beta-phorbol-12-myristate-13-acetate. Journal Of 
Immunology 139, 1161-1167.
Homeff, G., Emmrich, F., Kalden, J.R., and Burmester, G.R. (1991) Suppression of monocyte- 
macrophage activation induced by anti-cd4 treatment in rheumatoid-arthritis. Immunitat 
Und Infektion 19, 55-56.
Homeff, G., Sack, U., Kalden, J.R., Emmrich, F., and Burmester, G.R. (1993) Reduction of
monocyte-macrophage activation markers upon anti-cd4 treatment - decreased levels of 
IL-1, IL-6, neopterin and soluble cdl4 in patients with rheumatoid-arthritis. Clinical 
And Experimental Immunology 91, 207-213.
Hou, J.Z., Schindler, U., Henzel, W.J., Ho, T.C., Brasseur, M., and Mcknight, S.L. (1994) An 
interleukin-4-induced transcription factor - IL-4 stat. Science 265, 1701-1706.
Hoult, J.R.S. and Moore, P.K. (1980) Effects of sulfasalazine and its metabolites on
prostaglandin synthesis, inactivation and actions on smooth muscle. British Journal o f 
Pharmacology 68, 719-730.
Houssiau, F.A., Devogelaer, J.P., Vandamme, J., Dedeuxchaisnes, C.N., and Vansnick, J.
(1988) Interleukin-6 in synovial-fluid and serum of patients with rheumatoid-arthritis 
and other inflammatory arthritides. Arthritis And Rheumatism 31, 784-788.
Hsieh, C.S., Heimberger, A.B., Gold, J.S., Ogarra, A., and Murphy, K.M. (1992) Differential 
regulation of t-helper phenotype development by interleukin-4 and interleukin-10 in an 
alpha-beta-t-cell-receptor transgenic system. Proceedings O f The National Academy O f 
Sciences O f The United States O f America 89, 6065-6069.
Hu, S.K., Mitcho, Y.L., Oronsky, A.L., and Kerwar, S.S. (1988) Studies on the effect of 
methotrexate on macrophage function. Journal O f Rheumatology 15, 206-209.
Huang, H., HuLi, J., Chen, H.J., BenSasson, S.Z., and Paul, W.E. (1997) IL-4 and IL-13
production in differentiated t helper type 2 cells is not IL-4 dependent. Journal Of 
Immunology 159, 3731-3738.
Huang, J.N., Gao, X., Li, S., and Cao, Z.D. (1997) Recruitment of IRAK to the interleukin 1
receptor complex requires interleukin 1 receptor accessory protein. Proceedings Of The 
National Academy O f Sciences O f The United States O f America 94, 12829-12832.
265
Hudson, K.R., Tiedemann, R.E., Urban, R.G., Lowe, S.C., Strominger, J.L., and Fraser, J.D. 
(1995) Staphylococcal-enterotoxin-a has 2 cooperative binding-sites on major 
histocompatibility complex class-ii. Journal O f Experimental Medicine 182, 711-720.
Hulett, M.D. and Hogarth, P.M. (1994) Molecular-basis of fc receptor function. Advances In 
Immunology 57, 1-127.
Hume, D.A., Robinson, A.P., Macpherson, G.G., and Gordon, S. (1983) The mononuclear 
phagocyte system of the mouse defined by immunohistochemical localization of 
antigen-f4/80 - relationship between macrophages, langerhans cells, reticular cells, and 
dendritic cells in lymphoid and hematopoietic organs. Journal O f Experimental 
Medicine 158, 1522-1536.
Hurst, N.P., Bell, A.L., and Nuki, G. (1986) Studies of the effect of d-penicillamine and sodium 
aurothiomalate therapy on superoxide anion production by monocytes from patients 
with rheumatoid-arthritis - evidence for in vivo stimulation of monocytes. Annals Of 
The Rheumatic Diseases 45, 37-43.
Iho, S., Takahashi, T., Kura, F., Sugiyama, H., and Hoshino, T. (1986) The effect of 1,25-
dihydroxyvitamin-d3 on in vitro immunoglobulin production in human B-cells. Journal 
O f Immunology 136, 4427-4431.
Imai, F., Suzuki, T., Ishibashi, T., Tanaka, M., Akiyama, Y., and Dohi, Y. (1994) Effect of
sulfasalazine on B-cell hyperactivity in patients with rheumatoid-arthritis. Journal Of 
Rheumatology 21, 612-615.
Isaacs, J.D., Greer, S., Symmons, D., Sharma, S., Hale, G., Waldmann, H., and Hazleman, B. 
(1998) Survival of patients after lymphocytotoxic monoclonal antibody therapy for RA. 
Arthritis And Rheumatism 41, 141
Ishikawa, H. and Ziff, M. (1976) Electron microscopic observations of immunoreactive cells in 
the rheumatoid synovial membrane. Arthritis And Rheumatism 19, 1-14.
Isler, P., Vey, E., Zhang, J.H., and Dayer, J.M. (1993) Cell-surface glycoproteins expressed on 
activated human t-cells induce production of interleukin-1-beta by monocytic cells - a 
possible role of CD69. European Cytokine Network 4, 15-23.
Jacobson, N.G., Szabo, S.J., Webemordt, R.M., Zhong, Z., Schreiber, R.D., Darnell, J.E., and 
Murphy, K.M. (1995) Interleukin-12 signaling in T-helper type-1 (Thl) cells involves 
tyrosine phosphorylation of signal transducer and activator of transcription (STAT)3 
and STAT4. Journal O f Experimental Medicine 181, 1755-1762.
Jaffe, I. A. (1990) Combination therapy of rheumatoid-arthritis - rationale and overview.
Journal O f Rheumatology 17, 24-27.
Janossy, G., Duke, O., Poulter, L.W., Panayi, G., Bofill, M., and Goldstein, G. (1981)
Rheumatoid-arthritis - a disease of lymphocyte-t-macrophage immunoregulation.
Lancet 2, 839-842.
266
Janson, R.W., Hance, K.R., and Arend, W.P. (1991) Production of IL-1-receptor antagonist by 
human in vitro-dehved macrophages - effects of lipopolysaccharide and granulocyte- 
macrophage colony-stimulating factor. Journal O f Immunology 147, 4218-4223.
Jasin, H.E. and Taurog, J.D. (1991) Mechanisms of disruption of the articular-cartilage surface 
in inflammation - neutrophil elastase increases availability of collagen type-II epitopes 
for binding with antibody on the surface of articular-cartilage. Journal O f Clinical 
Investigation 87, 1531-1536.
Johansen, J.S., Jensen, H.S., and Price, P. A. (1993) A new biochemical marker for joint injury - 
analysis of ykl-40 in serum and synovial-fluid. British Journal O f Rheumatology 32, 
949-955.
Jouvenne, P., Vannier, E., Dinarello, C.A., and Miossec, P. (1998) Elevated levels of soluble 
interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with 
chronic arthritis - correlations with markers of inflammation and joint destruction. 
Arthritis And Rheumatism 41, 1083-1089.
Jovanovic, D.V., Di Battista, J.A., Martel-Pelletier, J., Jolicoeur, F.C., He, Y., Zhang, M.,
Mineau, F., and Pelletier, J.P. (1998) IL-17 stimulates the production and expression of 
proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J  
Immunol 160, 3513-3521.
June, C.H., Bluestone, J.A., Nadler, L.M., and Thompson, C.B. (1994) The b7 and CD28 
receptor families. Immunology Today 15, 321-331.
Kanakaraj, P., Schafer, P.H., Cavender, D.E., Wu, Y., Ngo, K., Grealish, P.F., Wadsworth,
S.A., Peterson, P.A., Siekierka, J.J., Harris, C.A., and FungLeung, W.P. (1998) 
Interleukin (IL)-l receptor-associated kinase (IRAK) requirement for optimal induction 
of multiple IL-1 signaling pathways and IL-6 production. Journal O f Experimental 
Medicine 187, 2073-2079.
Kanerud, L., Engstrom, G.N., and Tarkowski, A. (1995) Evidence for differential-effects of
sulfasalazine on systemic and mucosal immunity in rheumatoid-arthritis. Annals O f The 
Rheumatic Diseases 54, 256-262.
Kang, B.Y., Chung, S.W., Im, S.Y., Choe, Y.K., and Kim, T.S. (1999) Sulfasalazine prevents 
T-helper 1 immune response by suppressing interleukin-12 production in macrophages. 
Immunology 98, 98-103.
Kapeller, R. and Cantley, L.C. (1994) Phosphatidylinositol 3-kinase. Bioessays 16, 565-576.
Kaplan, M.H., Sun, Y.L., Hoey, T., and Grusby, M.J. (1996) Impaired EL-12 responses and 
enhanced development of Th2 cells in STAT4-deflcient mice. Nature 382, 174-177.
Kaplan, M.H., Wurster, A.L., and Grusby, M.J. (1998) A signal transducer and activator of 
transcription (STAT)4- independent pathway for the development of T helper type 1 
cells. Journal O f Experimental Medicine 188, 1191-1196.
Kasama, T., Strieter, R.M., Lukacs, N.W., Lincoln, P.M., Burdick, M.D., and Kunkel, S.L.
(1995) Interleukin-10 expression and chemokine regulation during the evolution of
267
murine type-ii collagen-induced arthritis. Journal O f Clinical Investigation 95, 2868- 
2876.
Katsikis, P.D., Chu, C.Q., Brennan, F.M., Maini, R.N., and Feldmann, M. (1994)
Immunoregulatory role of interleukin-10 in rheumatoid-arthritis. Journal O f 
Experimental Medicine 179, 1517-1527.
Keffer, J., Probert, L., Cazlaris, H., Georgopoulos, S., Kaslaris, E., Kioussis, D., and Kollias, G.
(1991) Transgenic mice expressing human tumor-necrosis-factor - a predictive genetic 
model of arthritis. Embo Journal 10, 4025-4031.
Kehrl, J.H., Roberts, A.B., Wakefield, L.M., Jakowlew, S., Spom, M.B., and Fauci, A.S. (1986) 
Production of transforming growth-factor-beta (TGF-beta) By human lymphocytes-t. 
Clinical Research 34, A497
Kelso, A. (1995) Thl and th2 subsets - paradigms lost. Immunology Today 16, 374-379.
Kerstens, P.J.S.M., Boerbooms, A.M.T., Jeurissen, M.E.C., Fast, J.H., Assmann, K.J.M., and 
Van De Putte, L.B.A. (1992) Accelerated nodulosis during low-dose methotrexate 
therapy for rheumatoid-arthritis - an analysis of 10 cases. Journal O f Rheumatology 19, 
867-871.
Keystone, E.C., Minden, M., Klock, R., Poplonski, L., Zalcberg, J., Takadera, T., and Mak,
T.W. (1988) Structure of T-cell antigen receptor beta-chain in synovial-fluid cells from 
patients with rheumatoid-arthritis. Arthritis And Rheumatism 31, 1555-1557.
Khalil, N., Bereznay, O., Spom, M., and Greenberg, A.H. (1989) Macrophage production of
transforming growth factor-beta and fibroblast collagen-synthesis in chronic pulmonary 
inflammation. Journal O f Experimental Medicine 170, 727-737.
Kienzle, G. and von Kempis, J. (2000) CD 137 (ILA/4-1BB), expressed by primary human 
monocytes, induces monocyte activation and apoptosis of B lymphocytes [Full text 
delivery]. International Immunology 12, 73-82.
Kinne, R.W., Palombo-Kinne, E., and Emmrich, F. (1997) T-cells in the pathogenesis of 
rheumatoid arthritis - Villains or accomplices? Biochimica Et Biophysica Acta- 
Molecular Basis O f Disease 1360, 109-141.
Kirkpatrick, R.B., Emery, J.G., Connor, J.R., Dodds, R., Lysko, P.G., and Rosenberg, M.
(1997) Induction and expression of human cartilage glycoprotein 39 in rheumatoid 
inflammatory and peripheral blood monocyte-derived macrophages. Experimental Cell 
Research 237, 46-54.
Kitchens, R.L. and Munford, R.S. (1998) Cd 14-dependent internalization of bacterial
lipopolysaccharide (LPS) is strongly influenced by LPS aggregation but not by cellular 
responses to LPS. Journal Of Immunology 160, 1920-1928.
Klareskog, L., Forsum, U., Wigren, A., and Wigzell, H. (1982) Relationships between HLA- 
DR-expressing cells and lymphocytes-t of different subsets in rheumatoid synovial 
tissue. Scandinavian Journal O f Immunology 15, 501-507.
268
Klimiuk, P.A., Yang, H., Goronzy, J.J., and Weyand, C.M. (1999) Production of cytokines and 
metalloproteinases in rheumatoid synovitis is T cell dependent. Clin Immunol 90, 65- 
78.
Kobayashi, Y., Yamamoto, K., Saido, T., Kawasaki, H., Oppenheim, J.J., and Matsushima, K.
(1990) Identification of calcium-activated neutral protease as a processing enzyme of 
human interleukin-1-alpha. Proceedings O f The National Academy O f Sciences O f The 
United States O f America 87, 5548-5552.
Koch, A.E., Kunkel, S.L., Harlow, L.A., Johnson, B., Evanoff, H.L., Haines, G.K., Burdick, 
M.D., Pope, R.M., and Strieter, R.M. (1992) Enhanced production of monocyte 
chemoattractant protein-1 in rheumatoid-arthritis. Journal O f Clinical Investigation 90, 
772-779.
Koeffler, H.P., Amatruda, T., Ikekawa, N., Kobayashi, Y., and Deluca, H.F. (1984) Induction 
of macrophage differentiation of human normal and leukemic myeloid stem-cells by
1,25-dihydroxyvitamin-d3 and its fluorinated analogs. Cancer Research 44, 5624-5628.
Kono, K., SalazarOnffay, F., Petersson, M., Hansson, J., Masucci, G., Wasserman, K.,
Nakazawa, T., Anderson, P., and Kiessling, R. (1996) Hydrogen peroxide secreted by 
tumor-derived macrophages down- modulates signal-transducing zeta molecules and 
inhibits tumor- specific T cell- and natural killer cell-mediated cytotoxicity. European 
Journal Of Immunology 26, 1308-1313.
Kostura, M.J., Tocci, M.J., Limjuco, G., Chin, J., Cameron, P., Hillman, A.G., Chartrain, N.A., 
and Schmidt, J.A. (1989) Identification of a monocyte specific pre-interleukin 1-beta 
convertase activity. Proceedings O f The National Academy O f Sciences O f The United 
States O f America 86, 5227-5231.
Kotzin, B.L., Falta, M.T., Crawford, F., Rosloniec, E.F., Bill, J., Marrack, P., and Kappler, J. 
(2000) Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for 
cartilage antigens in patients with rheumatoid arthritis. Proceedings O f The National 
Academy O f Sciences O f The United States O f America 97, 291-296.
Kowanko, I.C., Ferrante, A., Harvey, D.P., and Carman, K.L. (1991) Granulocyte-macrophage 
colony-stimulating factor augments neutrophil killing of torulopsis-glabrata and 
stimulates neutrophil respiratory burst and degranulation. Clinical And Experimental 
Immunology 83, 225-230.
Kremer, J.M., Rynes, R.I., and Bartholomew, L.E. (1987) Severe flare of rheumatoid-arthritis 
after discontinuation of long- term methotrexate therapy - double-blind-study.
American Journal O f Medicine 82, 781-786.
Kremer, J.M. and Lee, J.K. (1988) A long-term prospective-study of the use of methotrexate in 
rheumatoid-arthritis - update after a mean of 53 months. Arthritis And Rheumatism 31, 
577-584.
Kremer, J.M. and Phelps, C.T. (1992) Long-term prospective-study of the use of methotrexate 
in the treatment of rheumatoid-arthritis - update after a mean of 90 months. Arthritis 
And Rheumatism 35, 138-145.
269
Krummel, M.F. and Allison, J.P. (1996) CTLA-4 engagement inhibits IL-2 accumulation and 
cell cycle progression upon activation of resting T cells. Journal O f Experimental 
Medicine 183, 2533-2540.
Kumar, S., Minnich, M.D., and Young, P.R. (1995) St2/tl protein functionally binds to 2
secreted proteins from balb/c 3t3 and human umbilical vein endothelial-cells but does 
not bind interleukin-1. Journal O f Biological Chemistry 270, 27905-27913.
Kunz, D., Miihl, H., Walker, G., and Pfeilschifter, J. (1994) 2 Distinct signaling pathways 
trigger the expression of inducible nitric-oxide synthase in rat renal mesangial cells. 
Proceedings O f The National Academy O f Sciences O f The United States O f America 
91,5387-5391.
Kurosaka, K., Watanabe, N., and Kobayashi, Y. (1998) Production of proinflammatory
cytokines by phorbol myristate acetate- treated THP-1 cells and monocyte-derived 
macrophages after phagocytosis of apoptotic CTLL-2 cells. Journal O f Immunology 
161, 6245-6249.
Kvien, T.K., Hoyeraal, H.M., and Sandstad, B. (1985) Slow acting antirheumatic drugs in 
patients with juvenile rheumatoid- arthritis - evaluated in a randomized, parallel 50- 
week clinical- trial. Journal O f Rheumatology 12, 533-539.
Lacraz, S., Isler, P., Vey, E., Welgus, H.G., and Dayer, J.M. (1994) Direct-contact between t- 
lymphocytes and monocytes is a major pathway for induction of metalloproteinase 
expression. Journal O f Biological Chemistry 269, 22027-22033.
Lafyatis, R., Thompson, N.L., Remmers, E.F., Flanders, K.C., Roche, N.S., Kim, S.J., Case,
J.P., Spom, M.B., Roberts, A.B., and Wilder, R.L. (1989) Transforming growth factor- 
beta production by synovial tissues from rheumatoid patients and streptococcal cell-wall 
arthritic rats - studies on secretion by synovial fibroblast-like cells and 
immunohistologic localization. Journal O f Immunology 143, 1142-1148.
Lagasse, E. and Weissman, I.L. (1997) Enforced expression of Bcl-2 in monocytes rescues 
macrophages and partially reverses osteopetrosis in op/op mice. Cell 89, 1021-1031.
Lai, J.H. and Tan, T.H. (1994) Cd28 signaling causes a sustained down-regulation of i-kappa-b- 
alpha which can be prevented by the immunosuppressant rapamycin. Journal Of 
Biological Chemistry 269, 30077-30080.
Lander, H.M., Ogiste, J.S., Teng, K.K., and Novogrodsky, A. (1995) P21(Ras) As a common
signaling target of reactive free-radicals and cellular redox stress. Journal O f Biological 
Chemistry 270, 21195-21198.
Lander, H.M., Jacovina, A.T., Davis, R.J., and Tauras, J.M. (1996) Differential activation of
mitogen-activated protein kinases by nitric oxide-related species. Journal O f Biological 
Chemistry 111, 19705-19709.
Landis, R.C., Friedman, M.L., Fisher, R.I., and Ellis, T.M. (1991) Induction of human
monocyte IL-1 messenger-ma and secretion during anti-CD3 mitogenesis requires 2 
distinct T-cell-derived signals. Journal O f Immunology 146, 128-135.
270
Landmann, R., Link, S., Sansano, S., Rajacic, Z., and Zimmerli, W. (1998) Soluble CD 14
activates monocytic cells independently of lipopolysaccharide. Infection And Immunity 
66, 2264-2271.
Lando, P.A., Dohlsten, M., Hedlund, G., Brodin, T., Sansom, D., and Kalland, T. (1993) Co­
stimulation with b7 and targeted superantigen is required for mhc class ii-independent t- 
cell proliferation but not cytotoxicity. Immunology 80, 236-241.
Langstein, J., Michel, J., Fritsche, J., Kreutz, M., Andreesen, R., and Schwarz, H. (1998)
CD 137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte 
activation via bidirectional signaling. Journal O f Immunology 160, 2488-2494.
Le Barillec, K., SiTahar, M., Balloy, V., and Chignard, M. (1999) Proteolysis of monocyte
CD 14 by human leukocyte elastase inhibits lipopolysaccharide-mediated cell activation. 
Journal O f Clinical Investigation 103, 1039-1046.
Lee, S.H., Soyoola, E., Chanmugam, P., Hart, S., Sun, W.Q., Zhong, H., Liou, S., Simmons, D., 
and Hwang, D. (1992) Selective expression of mitogen-inducible cyclooxygenase in 
macrophages stimulated with lipopolysaccharide. Journal O f Biological Chemistry 267, 
25934-25938.
Lemire, J.M., Adams, J.S., Kermaniarab, V., Bakke, A.C., Sakai, R., and Jordan, S.C. (1985)
l,25-Dihydroxyvitamin-d3 suppresses human T-helper inducer lymphocyte activity in 
vitro. Journal O f Immunology 134, 3032-3035.
Leonard, W.J. and O’Shea, J.J. (1998) JAKS AND STATS: Biological implications. Annual 
Review O f Immunology 16, 293-322.
Levine, B.L., Bernstein, W.B., Connors, M., Craighead, N., Lindsten, T., Thompson, C.B., and 
June, C.H. (1997) Effects of CD28 costimulation on long-term proliferation of CD4(+)
T cells in the absence of exogenous feeder cells. Journal O f Immunology 159, 5921- 
5930.
Li, J.M., Isler, P., Dayer, J.M., and Burger, D. (1995) Contact-dependent stimulation of
monocytic cells and neutrophils by stimulated human T-cell clones. Immunology 84, 
571-576.
Lindsey, J.W., Hodgkinson, S., Mehta, R., Mitchell, D., Enzmann, D., and Steinman, L. (1994) 
Repeated treatment with chimeric anti-CD4 antibody in multiple- sclerosis. Annals O f 
Neurology 36, 183-189.
Lingrel, J.B. and Kuntzweiler, T. (1994) Na+,K+-atpase. Journal O f Biological Chemistry 269, 
19659-19662.
Linsley, P.S. and Golstein, P. (1996) Lymphocyte activation: T-cell regulation by CTLA-4. 
CurrBiol 6, 398-400.
Liote, F., BovalBoizard, B., Weill, D., Kuntz, D., and Wautier, J.L. (1996) Blood monocyte 
activation in rheumatoid arthritis: Increased monocyte adhesiveness, integrin 
expression, and cytokine release. Clinical And Experimental Immunology 106, 13-19.
271
Lipsky, P.E. and Ziff, M. (1977) Inhibition of antigen and mitogen-induced human lymphocyte 
proliferation by gold compounds. Journal O f Clinical Investigation 59, 455-466.
Liu, M.F., Kohsaka, H., Sakurai, H., Azuma, M., Okumura, K., Saito, I., and Miyasaka, N.
(1996) The presence of costimulatory molecules cd86 and cd28 in rheumatoid arthritis 
synovium. Arthritis And Rheumatism 39, 110-114.
Loetscher, H., Gentz, R., Zulauf, M., Lustig, A., Tabuchi, H., Schlaeger, E.J., Brockhaus, M., 
Gallati, H., Manneberg, M., and Lesslauer, W. (1991) Recombinant 55-kda tumor- 
necrosis-factor (TNF) Receptor - stoichiometry of binding to TNF-alpha and TNF-beta 
and inhibition of TNF activity. Journal O f Biological Chemistry 266, 18324-18329.
Lohmander, L.S., Hoermer, L.A., Dahlberg, L., Roos, H., Bjomsson, S., and Lark, M.W.
(1993) Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments 
in human knee-joint fluid after injury. Journal O f Rheumatology 20, 1362-1368.
Londei, M., Savill, C.M., Verhoef, A., Brennan, F., Leech, Z.A., Duance, V., Maini, R.N., and 
Feldmann, M. (1989) Persistence of collagen type 11-specific T-cell clones in the 
synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U SA  86, 
636-640.
Lorber, A., Halter, D., and Simon, T. (1981) Diphasic lymphocyte mitogen response observed 
during early systemic gold therapy. Clinical Pharmacology & Therapeutics 29, 261- 
262.
Lotz, M., Kekow, J., and Carson, D.A. (1990) Transforming growth-factor-beta and cellular 
immune-responses in synovial-fluids. Journal O f Immunology 144, 4189-4194.
Lu, L.N., Qian, S.G., Hershberger, P.A., Rudert, W.A., Lynch, D.H., and Thomson, A.W.
(1997) Fas ligand (CD95L) and B7 expression on dendritic cells provide counter- 
regulatory signals for T cell survival and proliferation. Journal O f Immunology 158, 
5676-5684.
Lue, K.H., Lauener, R.P., Winchester, R.J., Geha, R.S., and Vercelli, D. (1991) Engagement of 
cdl4 on human monocytes terminates t-cell proliferation by delivering a negative signal 
tot-cells. Journal O f Immunology 147, 1134-1138.
Lunec, J., Blake, D.R., Mccleary, S J., Brailsford, S., and Bacon, P.A. (1985) Self-perpetuating 
mechanisms of immunoglobulin-g aggregation in rheumatoid inflammation. Journal Of 
Clinical Investigation 76, 2084-2090.
Luqmani, R., Gordon, C., and Bacon, P. (1994) Clinical-pharmacology and modification of 
autoimmunity and inflammation in rheumatoid disease. Drugs 47, 259-285.
MacKichan, M.L. and DeFranco, A.L. (1999) Role of ceramide in lipopolysaccharide (LPS)- 
induced signaling - LPS increases ceramide rather than acting as a structural homolog. 
Journal O f Biological Chemistry 274, 1767-1775.
Maini, R.N., Elliott, M., Brennan, F.M., Williams, R.O., and Feldmann, M. (1997) TNF
blockade in rheumatoid arthritis: Implications for therapy and pathogenesis. Apmis 105, 
257-263.
272
Maini, R.N., Taylor, P.C., Paleolog, E., Charles, P., Ballara, S., Brennan, F.M., and Feldmann, 
M. (1999) Anti-tumour necrosis factor specific antibody (infliximab) treatment provides 
insights into the pathophysiology of rheumatoid arthritis. Annals O f The Rheumatic 
Diseases 58, 56-60.
Malefyt, R.D., Abrams, J.S., deVries, J.E., and Yssel, H. (1994) IL-13, an IL-4-like cytokine 
that has no t-cell stimulating activities, is produced by human CD4+ and CD8+ t-cells 
and CD4+ ThO, Thl and Th2 T-cell clones. Journal O f Cellular Biochemistry 353-353.
Malefyt, R.D. (1997) The role of type I interferons in the differentiation and function of Thl 
and Th2 cells. Seminars In Oncology 24, 994-998.
Malyak, M., Swaney, R.E., and Arend, W.P. (1993) Levels of synovial-fluid interleukin-1 
receptor antagonist in rheumatoid-arthritis and other arthropathies - potential 
contribution from synovial-fluid neutrophils. Arthritis And Rheumatism 36, 781-789.
Malyak, M., Smith, M.F., Abel, A.A., Hance, K.R., and Arend, W.P. (1998a) The differential 
production of three forms of IL-1 receptor antagonist by human neutrophils and 
monocytes. Journal O f Immunology 161, 2004-2010.
Malyak, M., Guthridge, J.M., Hance, K.R., Dower, S.K., Freed, J.H., and Arend, W.P. (19986) 
Characterization of a low molecular weight isoform of IL-1 receptor antagonist.
Journal O f Immunology 161, 1997-2003.
Manie, S., Kubar, J., Limouse, M., Ferrua, B., Ticchioni, M., Breittmayer, J.P., Peyron, J.F., 
Schaffar, L., and Rossi, B. (1993) CD3-stimulated Jurkat T-cells mediate IL-1-beta 
production in monocytic THP-1 cells - role of LFA-1 molecule and participation of 
CD69 T-cell antigen. European Cytokine Network 4, 7-13.
Mapp, P.I., Grootveld, M.C., and Blake, D.R. (1995) Hypoxia, oxidative stress and rheumatoid- 
arthritis. British Medical Bulletin 51, 419-436.
Maraskovsky, E., Pulendran, B., Brasel, K., Teepe, M., Roux, E.R., Shortman, K., Lyman,
S.D., and McKenna, H.J. (1997) Dramatic numerical increase of functionally mature 
dendritic cells in FLT3 ligand-treated mice. Advances In Experimental Medicine And 
Biology 417, 33-40.
Marie, C. and Cavaillon, J.M. (1997) Negative feedback in inflammation: the role of 
antiinflammatory cytokines. Bulletin De L Institut Pasteur 95, 41-54.
Marinova-Mutafchieva, L., Williams, R.O., Mauri, C., Mason, L.J., Walmsley, M.J., Taylor, 
P.C., and Feldmann, M. (2000) A comparative study into the mechanisms of action of 
anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor 
alpha/anti-CD4 treatment in early collagen-induced arthritis. Arthritis And Rheumatism 
43, 638-644.
Marrack, P. and Kappler, J. (1997) Positive selection of thymocytes bearing alpha beta T cell 
receptors. Current Opinion In Immunology 9, 250-255.
Martin, S.J., Reutelingsperger, C.P.M., Mcgahon, A.J., Rader, J.A., Vanschie, R.C.A.A.,
Laface, D.M., and Green, D.R. (1995) Early redistribution of plasma-membrane
273
phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus - 
inhibition by overexpression of bcl-2 and abl. Journal O f Experimental Medicine 182, 
1545-1556.
Marzio, R., Mauel, J., and BetzCorradin, S. (1999) CD69 and regulation of the immune 
function. Immunopharmacology AndImmunotoxicology 21, 565-582.
Masferrer, J.L., Reddy, S.T., Zweifel, B.S., Seibert, K., Needleman, P., Gilbert, R.S., and 
Herschman, H.R. (1994) In-vivo glucocorticoids regulate cyclooxygenase-2 but not 
cyclooxygenase-1 in peritoneal-macrophages. Journal O f Pharmacology And 
Experimental Therapeutics 270, 1340-1344.
Massague, J. (1987) The TGF-beta family of growth and differentiation factors. Cell 49, 437- 
438.
Matsumori, A., Ono, K., Nishio, R., Igata, H., Shioi, T., Matsui, S., Furukawa, Y., Iwasaki, A., 
Nose, Y., and Sasayama, S. (1997) Modulation of cytokine production and protection 
against lethal endotoxemia by the cardiac glycoside ouabain. Circulation 96, 1501- 
1506.
Matsumori, A., Ono, K., Nishio, R., Nose, Y., and Sasayama, S. (2000) Amlodipine inhibits the 
production of cytokines induced by ouabain [Full text delivery]. Cytokine 12, 294-297.
Matsuno, R., Aramaki, Y., Arima, H., Adachi, Y., Ohno, N., Yadomae, T., and Tsuchiya, S.
(1998) Contribution of CR3 to nitric oxide production from macrophages stimulated 
with high-dose of LPS. Biochemical And Biophysical Research Communications 244, 
115-119.
Matsushima, K. and Oppenheim, J.J. (1985) Calcium ionophore (A23187) increases
interleukin-1 (IL-1) production by human peripheral-blood monocytes and interacts 
synergistically with IL-1 to augment concanavalin-a stimulated thymocyte proliferation. 
Cellular Immunology 90,226-233.
Mattem, T., Thanhauser, A., Reiling, N., Toellner, K.M., Duchrow, M., Kusumoto, S.,
Rietschel, E.T., Ernst, M., Brade, H., and Flad, H.D. (1994) Endotoxin and lipid A 
stimulate proliferation of human T cells in the presence of autologous monocytes. J  
Immunol 153, 2996-3004.
Mattem, T., Flad, H.D., Brade, L., Rietschel, E.T., and Ulmer, A.J. (1998) Stimulation of 
human t lymphocytes by lps is mhc unrestricted, but strongly dependent on b7 
interactions. Journal O f Immunology 160,3412-3418.
Maubach, K., Foey, A.D., and Hall, N.D. (1993) Impaired activity of thiol-dependent atpases in 
rheumatoid mononuclear cell-membranes. Agents And Actions 39, C107-C109
Maurice, M.M., Nakamura, H., vanderVoort, E.A.M., vanVliet, A.I., Staal, F.J.T., Tak, P.P.,
Breedveld, F.C., and Verweij, C.L. (1997) Evidence for the role of an altered redox state 
in hyporesponsiveness of synovial T cells in rheumatoid arthritis. Journal O f 
Immunology 158, 1458-1465.
274
Maurice, M.M., Nakamura, H., vanderVoort, E.A.M., Leow, A., Versandaal, J., Yodoi, J., Tak, 
P.P., Breedveld, F.C., and Verweij, C.L. (1998) Increased expression of thioredoxin in 
rheumatoid arthritis. Arthritis And Rheumatism 41, 1722
Mclnnes, I.B., Leung, B.P., Forsey, R.J., Hack, E., Liew, F.Y., and Tak, R.P. (1997)
Interleukin-15 (IL-15) induces granzyme synthesis by rheumatoid arthritis (RA) 
synovial T cells. Arthritis And Rheumatism 40, 1458
McKeown, M.J., Hall, N.D., and Corvalan, J.R.F. (1984) Defective monocyte accessory
function due to surface sulfhydryl (SH) Oxidation in rheumatoid-arthritis. Clinical And 
Experimental Immunology 56, 607-613.
McLeod, J.D., Walker, L.S.K., Patel, Y.I., Boulougouris, G., and Sansom, D.M. (1998)
Activation of human T cells with superantigen (Staphylococcal enterotoxin B) and 
CD28 confers resistance to apoptosis via CD95. Journal O f Immunology 160, 2072- 
2079.
Medvedev, A.E., Flo, T., Ingalls, R.R., Golenbock, D.T., Teti, G., Vogel, S.N., and Espevik, T.
(1998) Involvement of CD 14 and complement receptors CR3 and CR4 in nuclear 
factor-kappa b activation and TNF production induced by lipopolysaccharide and group 
b streptococcal cell walls. Journal O f Immunology 160, 4535-4542.
Meng, F.Y. and Lowell, C.A. (1997) Lipopolysaccharide (LPS)-induced macrophage activation 
and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn. Journal 
O f Experimental Medicine 185, 1661-1670.
Merino, F., Alvarezmon, M., Delahera, A., Ales, J.E., Bonilla, F., and Durantez, A. (1989) 
Regulation of natural-killer cyto-toxicity by 1,25-dihydroxyvitamin d3. Cellular 
Immunology 118, 328-336.
Metcalf, D. (1992) Hematopoietic regulators. Trends In Biochemical Sciences 17, 286-289.
Metz, C.N., Brunner, G., Choimuira, N.H., Nguyen, H., Gabrilove, J., Caras, I.W., Altszuler,
N., Rifkin, D.B., Wilson, E.L., and Davitz, M.A. (1994) Release of GPI-anchored 
membrane-proteins by a cell-associated GPI- specific phospholipase-d. Embo Journal 
13, 1741-1751.
Miller, G.A., Demayo, T., and Hutter, J. (1994) Production of interleukin-1 by
polymorphonuclear leukocytes present in inflammatory periradicular tissues. Faseb 
Journal 8, A996
Miltenburg, A.M., van Laar, J.M., de Kuiper, R., Daha, M.R., and Breedveld, F.C. (1992) T
cells cloned from human rheumatoid synovial membrane functionally represent the Thl 
subset. Scand J  Immunol 35, 603-610.
Miltenburg, A.M.M., Lacraz, S., Welgus, H.G., and Dayer, J.M. (1995) Immobilized anti-CD3 
antibody activates t-cell clones to induce the production of interstitial collagenase, but 
not tissue inhibitor of metalloproteinases, in monocytic THP-1 cells and dermal 
fibroblasts. Journal O f Immunology 154, 2655-2667.
275
Miossec, P., Naviliat, M., Dangeac, A.D., Sany, J., and Banchereau, J. (1990) Low-levels of 
interleukin-4 and high-levels of transforming growth- factor-beta in rheumatoid 
synovitis. Arthritis And Rheumatism 33, 1180-1187.
Miossec, P., Briolay, J., Dechanet, J., Wijdenes, J., Martinezvaldez, H., and Banchereau, J.
(1992) Inhibition of the production of proinflammatory cytokines and immunoglobulins 
by interleukin-4 in an ex vivo model of rheumatoid synovitis. Arthritis And Rheumatism 
35, 874-883.
Miossec, P. and vandenBerg, W. (1997) Thl/th2 cytokine balance in arthritis. Arthritis And 
Rheumatism 40, 2105-2115.
Modlin, R.L., Melanconkaplan, J., Young, S.M.M., Pirmez, C., Kino, H., Convit, J., Rea, T.H., 
and Bloom, B.R. (1988) Learning from lesions - patterns of tissue inflammation in 
leprosy. Proceedings O f The National Academy O f Sciences O f The United States Of 
America 85, 1213-1217.
Moots, R.J. and Wucherpfennig, K.W. (1998) The role of T cells in autoimmunity. In:
Immunological aspects o f rheumatic disease., Edited by Gaston, J.S.H., Cambridge, 
Cambridge University Press.
Moreland, L.W., Bucy, R.P., Jackson, B., Feldman, J., and Koopman, W.J. (1993) Long-term 
follow-up (30 Months) Of rheumatoid-arthritis patients treated with a chimeric anti- 
CD4 monoclonal-antibody (CmAb). Arthritis And Rheumatism 36, S129
Moreland, L.W., Baumgartner, S.W., Schiff, M.H., Tindall, E.A., Fleischmann, R.M., Weaver, 
A.L., Ettlinger, R.E., Cohen, S., Koopman, W.J., Mohler, K., Widmer, M.B., and 
Blosch, C.M. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor 
necrosis factor receptor (p75)-Fc fusion protein. New England Journal O f Medicine 
337, 141-147.
Morgan, S.L., Baggott, J.E., Vaughn, W.H., Young, P.K., Austin, J.V., Krumdieck, C.L., and 
Alarcon, G.S. (1990) The effect of folic-acid supplementation on the toxicity of low- 
dose methotrexate in patients with rheumatoid-arthritis. Arthritis And Rheumatism 33, 
9-18.
Moriggl, R., Kristofic, C., Kinzel, B., Volarevic, S., Groner, B., and Brinkmann, V. (1998)
Activation of ST AT proteins and cytokine genes in human Thl and Th2 cells generated 
in the absence of IL-12 and IL-4. Journal O f Immunology 160, 3385-3392.
Morita, Y., Yamamura, M., Harada, S., Okamoto, H., Inoue, H., and Makino, H. (1996) A role 
of interleukin-12 in perpetuating Thl cell-mediated immune responses in rheumatoid 
arthritis. Arthritis And Rheumatism 39, 607
Morita, Y., Yamamura, M., Kawashima, M., Harada, S., Tsuji, K., Shibuya, K., Maruyama, K., 
and Makino, H. (1998) Flow cytometric single-cell analysis of cytokine production by 
CD4+ T cells in synovial tissue, and peripheral blood from patients with rheumatoid 
arthritis. Arthritis And Rheumatism 41, 1669-1676.
Mosley, B., Dower, S.K., Gillis, S., and Cosman, D. (1987) Determination of the minimum
polypeptide lengths of the functionally active-sites of human interleukins 1-alpha and 1-
276
beta. Proceedings O f The National Academy O f Sciences O f The United States Of 
America 84, 4572-4576.
Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A., and Coffman, R.L. (1986) 2
Types of murine helper t-cell clone .1. Definition according to profiles of lymphokine 
activities and secreted proteins. Journal O f Immunology 136, 2348-2357.
Mosmann, T.R., Wieringa, E.A., van Kooten, C., Vanlier, R., Beverley, P.C.L., Schraven, B., 
Olive, D., Lea, T., and Reinherz, E. (1991) Functional-aspects of t-helper subsets. 
Research In Immunology 142, 843-844.
Mosmann, T.R. and Sad, S. (1996) The expanding universe of T-cell subsets: Thl, Th2 and 
more. Immunology Today 17, 138-146.
Mueller, D.L., Jenkins, M.K., and Schwartz, R.H. (1989) Clonal expansion versus functional 
clonal inactivation - a costimulatory signaling pathway determines the outcome of t-cell 
antigen receptor occupancy. Annual Review O f Immunology 7, 445-480.
Miihl, H. and Pfeilschifter, J. (1994) Possible role of protein-kinase c-epsilon isoenzyme in
inhibition of interleukin-1-beta induction of nitric-oxide synthase in rat renal mesangial 
cells. Biochemical Journal 303, 607-612.
Mulherin, D., FitzGerald, O., and Bresnihan, B. (1996) Synovial tissue macrophage populations 
and articular damage in rheumatoid arthritis. Arthritis And Rheumatism 39, 115-124.
Muller, K.P. and Kyewski, B.A. (1993) T-cell receptor targeting to thymic cortical epithelial- 
cells in-vivo induces survival, activation and differentiation of immature thymocytes. 
European Journal Of Immunology 23, 1661-1670.
Muzio, M., Ni, J., Feng, P., and Dixit, V.M. (1997) IRAK (Pelle) family member IRAK-2 and 
MyD88 as proximal mediators of IL-1 signaling. Science 278, 1612-1615.
Nagarajan, S., Chesla, S., Cobem, L., Anderson, P., Zhu, C., and Selvaraj, P. (1995) Ligand- 
binding and phagocytosis by cdl6 (Fc-gamma receptor-III) Isoforms - phagocytic 
signaling by associated zeta-subunits and gamma-subunits in chinese-hamster ovary 
cells. Journal O f Biological Chemistry 270, 25762-25770.
Neal, T.M., Winterboum, C.C., and Vissers, M.C.M. (1987) Inhibition of neutrophil 
degranulation and superoxide production by sulfasalazine - comparison with 5- 
aminosalicylic acid, sulfapyridine and olsalazine. Biochemical Pharmacology 36, 2765- 
2768.
Nepom, G.T. and Erlich, H. (1991) MHC class-II molecules and autoimmunity. Annual Review 
O f Immunology 9, 493-525.
Neumann, V.C., Shinebaum, R., Cooke, E.M., and Wright, V. (1987) Effects of sulfasalazine 
on fecal flora in patients with rheumatoid- arthritis - a comparison with penicillamine. 
British Journal O f Rheumatology 26, 334-337.
277
Newton, R.C. (1990) The production of IL-lbeta by blood monocytes. In: Cytokines and 
Lipocortins in Inflammation and Differentiation., 217-228. Edited by Melli, M. and 
Parente, L., New York, Wiley.
Nilsson, H., Bjork, P., Dohlsten, M., and Antonsson, P. (1999) Staphylococcal enterotoxin H 
displays unique MHC class II-binding properties. Journal O f Immunology 163, 6686- 
6693.
Nishioka, K., Hasunuma, T., Kato, T., Sumida, T., and Kobata, T. (1998) Apoptosis in
rheumatoid arthritis - A novel pathway in the regulation of synovial tissue. Arthritis 
And Rheumatism 41, 1-9.
Novick, D., Kim, S.H., Fantuzzi, G., Reznikov, L.L., Dinarello, C.A., and Rubinstein, M.
(1999) Interleukin-18 binding protein: A novel modulator of the Thl cytokine response. 
Immunity 10, 127-136.
Novogrodsky, A., Ravid, A., Rubin, A.L., and Stenzel, K.H. (1982) Hydroxyl radical
scavengers inhibit lymphocyte mitogenesis. Proceedings O f The National Academy Of 
Sciences O f The United States O f America-Biological Sciences 79, 1171-1174.
Novotny, W.F., Palmier, M., Wun, T.C., Broze, G.J., and Miletich, J.P. (1991) Purification and 
properties of heparin-releasable lipoprotein- associated coagulation inhibitor. Blood 78, 
394-400.
Nykanen, P., Bergroth, V., Raunio, P., Nordstrom, D., and Konttinen, Y.T. (1986) Phenotypic 
characterization of thymidine-h-3 incorporating cells in rheumatoid-arthritis synovial- 
membrane. Rheumatology International 6, 269-271.
Obeid, L.M., Okazaki, T., Karolak, L.A., and Hannun, Y.A. (1990) Transcriptional regulation 
of protein kinase-c by 1,25- dihydroxyvitamin-d3 in hl-60 cells. Journal O f Biological 
Chemistry 265, 2370-2374.
O’Byme, E.M., Blancuzzi, V., Wilson, D.E., Wong, M., and Jeng, A.Y. (1990) Elevated 
substance-p and accelerated cartilage degradation in rabbit knees injected with 
interleukin-1 and tumor-necrosis-factor. Arthritis And Rheumatism 33, 1023-1028.
Ohmori, Y., Smith, M.F., and Hamilton, T.A. (1996) IL-4-induced expression of the IL-1
receptor antagonist gene is mediated by stat6. Journal O f Immunology 157, 2058-2065.
Okazaki, T., Bell, R.M., and Hannun, Y.A. (1989) Sphingomyelin turnover induced by vitamin- 
d3 in hl-60 cells - role in cell-differentiation. Journal O f Biological Chemistry 264 , 
19076-19080.
Olee, T., Hashimoto, S., Quach, J., and Lotz, M. (1999) IL-18 is produced by articular 
chondrocytes and induces proinflammatory and catabolic responses. Journal O f 
Immunology 162, 1096-1100.
Openshaw, P., Murphy, E.E., Hosken, N.A., Maino, V., Davis, K., Murphy, K., and Ogarra, A.
(1995) Heterogeneity of intracellular cytokine synthesis at the single-cell level in 
polarized T-helper-1 and T-helper-2 populations. Journal O f Experimental Medicine 
182, 1357-1367.
278
Ortiz, A.M., GarciaVicuna, R., Sabando, P., and GonzalezAlvaro, I. (1999) Correlation
between lymphocytic CD69 expression and IL15 concentration in synovial fluids from 
inflammatory arthropaties. Arthritis And Rheumatism 42, 755
Pahan, K., Raymond, J.S., and Singh, I. (1999) Inhibition of phosphatidylinositol 3-kinase is 
necessary for the induction of nitric oxide synthase in C6 glial cells. Journal Of 
Neurochemistry 72, S69
Pai, S.Y., Calvo, V., Wood, M., and Bierer, B.E. (1993) Cross-linking CD28 leads to activation 
of 70 kda s6 kinase. Blood 82, A188
Palmer, D.G. (1995) The anatomy of the rheumatoid lesion. British Medical Bulletin 51, 286- 
295.
Panayi, G.S., Lanchbury, J.S., and Kingsley, G.H. (1992) The importance of the T-cell in
initiating and maintaining the chronic synovitis of rheumatoid-arthritis. Arthritis And 
Rheumatism 35, 729-735.
Panayi, G.S., Corrigall, V., BodmanSmith, M., Fife, M., Pappin, D., and Lanchbury, J. (1999)
The p78 putative rheumatoid arthritis T cell auto-antigen. Arthritis And Rheumatism 42, 
105
Park, C.T., Creasey, A.A., and Wright, S.D. (1997) Tissue factor pathway inhibitor blocks 
cellular effects of endotoxin by binding to endotoxin and interfering with transfer to 
cdl4. Blood 89, 4268-4274.
Park, S., Marshall, M.S., Gibbs, J.B., and Jove, R. (1992) Reconstitution of interactions
between the src tyrosine kinases and ras GTPase-activating protein using a baculovirus 
expression system. Journal O f Biological Chemistry 267, 11612-11618.
Parker, D.C. (1993) T-cell - dependent b-cell activation. Annual Review O f Immunology 11, 
331-360.
Pamet, P., Garka, K.E., Bonnert, T.P., Dower, S.K., and Sims, J.E. (1996) IL-lRrp is a novel 
receptor-like molecule similar to the type I interleukin-1 receptor and its homologues 
T1/ST2 and IL-1R AcP. Journal O f Biological Chemistry 271, 3967-3970.
Pedron, T., Girard, R., and Chaby, R. (1995) Variation of LPS-binding capacity, epitope
expression, and shedding of membrane-bound CD 14 during differentiation of human 
monocytes. Journal O f Immunology 155, 1460-1471.
Peeva, E., Fishman, A.D., Goddard, G., Wadler, S., and Barland, P. (2000) Rheumatoid arthritis 
exacerbation caused by exogenous interleukin-12. Arthritis And Rheumatism 43, 461- 
463.
Pellegrini, S. and DusanterFourt, I. (1997) The structure, regulation and function of the Janus 
kinases (JAKs) and the signal transducers and activators of transcription (STATs). 
European Journal O f Biochemistry 248, 615-633.
279
Perlmutter, R.M., Levin, S.D., Appleby, M.W., Anderson, S.J., and Alberolaila, J. (1993) 
Regulation of lymphocyte function by protein-phosphorylation. Annual Review Of 
Immunology 11, 451-499.
Perretti, M., Croxtall, J.D., Wheller, S.K., Goulding, N.J., Hannon, R., and Flower, R.J. (1996a) 
Mobilizing lipocortin 1 in adherent human leukocytes downregulates their 
transmigration. Nature Medicine 2, 1259-1262.
Perretti, M., Wheller, S.K., Harris, J.G., and Flower, R.J. (19966) Modulation of ICAM-1 levels 
on U-937 cells and mouse macrophages by interleukin-1 beta and dexamethasone. 
Biochemical And Biophysical Research Communications 223, 112-117.
Peterson, J.D., Herzenberg, L.A., Vasquez, K., and Waltenbaugh, C. (1998) Glutathione levels 
in antigen-presenting cells modulate Thl versus Th2 response patterns. Proceedings O f 
The National Academy O f Sciences O f The United States O f America 95, 3071-3076.
Poe, J.C., Wagner, D.H., Miller, R.W., Stout, R.D., and Suttles, J. (1997) IL-4 and IL-10
modulation of CD40-mediated signaling of monocyte IL-1 beta synthesis and rescue 
from apoptosis. Journal O f Immunology 159, 846-852.
Poltorak, A., Smirnova, I., He, X.L., Liu, M.Y., VanHuffel, C., Birdwell, D., Alejos, E., Silva, 
M., Du, X., Thompson, P., Chan, E.F.L., Ledesma, J., Roe, B., Clifton, S., Vogel, S., 
and Beutler, B. (1998) Genetic and physical mapping of the Lps locus: Identification of 
the Toll-4 receptor as a candidate gene in the critical region. Blood Cells Molecules 
And Diseases 24, 340-355.
Postigo, A.A., GarciaVicuna, R., Diazgonzalez, F., Arroyo, A.G., Delandazuri, M.O., Chirosso, 
G., Lobb, R.R., Laffon, A., and Sanchezmadrid, F. (1992) Increased binding of synovial 
lymphocytes-t from rheumatoid-arthritis to endothelial-leukocyte adhesion molecule-1 
(ELAM-1) And vascular cell-adhesion molecule-1 (VCAM-1). Journal O f Clinical 
Investigation 89, 1445-1452.
Prasad, K.V.S., Cai, Y.C., Raab, M., Duckworth, B., Cantley, L., Shoelson, S.E., and Rudd,
C.E. (1994) T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3- 
kinase by a cytoplasmic tyr(P)-Met-xaa-met motif. Proceedings O f The National 
Academy O f Sciences O f The United States O f America 91, 2834-2838.
Prevoo, M.L.L., Vanthof, M.A., Kuper, H.H., Vanleeuwen, M.A., Vandeputte, L.B.A., and
vanRiel, P.L.C.M. (1995) Modified disease-activity scores that include 28-joint counts - 
development and validation in a prospective longitudinal-study of patients with 
rheumatoid-arthritis. Arthritis And Rheumatism 38, 44-48.
Prieur, A.M., Kaufmann, M.T., Griscelli, C., and Dayer, J.M. (1987) Specific interleukin-1
inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 
2, 1240-1242.
Probert, L., Akassoglou, K., Pasparakis, M., Kontogeorgos, G., and Kollias, G. (1995)
Spontaneous inflammatory demyelinating disease in transgenic mice showing central 
nervous system-specific expression of tumor-necrosis- factor-alpha. Proceedings Of 
The National Academy O f Sciences O f The United States O f America 92, 11294-11298.
280
Procyk, K.J., Kovarik, P., vonGabain, A., and Baccarini, M. (1999) Salmonella typhimurium 
and lipopolysaccharide stimulate extracellularly regulated kinase activation in 
macrophages by a mechanism involving phosphatidylinositol 3-kinase and 
phospholipase D as novel intermediates. Infection And Immunity 67, 1011-1017.
Prowedini, D.M., Tsoukas, C.D., Deftos, L.J., and Manolagas, S.C. (1983) 1,25-
Dihydroxyvitamin d3 receptors in human-leukocytes. Science 221, 1181-1182.
Pugin, J., Schurermaly, C.C., Leturcq, D., Moriarty, A., Ulevitch, R.J., and Tobias, P.S. (1993) 
Soluble cdl4 and lipopolysaccharide binding-protein mediate epithelial-cell responses 
to lipopolysaccharides. Faseb Journal 7, A142
Pugin, J., Kravchenko, V.V., Lee, J.D., Kline, L., Ulevitch, R.J., and Tobias, P.S. (1998) Cell 
activation mediated by glycosylphosphatidylinositol- anchored or transmembrane forms 
ofcdl4. Infection And Immunity 66, 1174-1180.
Pullar, T., Hunter, J.A., and Capell, H.A. (1987) Effect of sulfasalazine on the radiological 
progression of rheumatoid-arthritis. Annals O f The Rheumatic Diseases 46, 398-402.
Putz, E.F. and Mannel, D.N. (1996) A role for L-selectin in monocyte activation by Jurkat 
tumour cells. Scandinavian Journal O f Immunology 44, 556-564.
Qin, S.X., Rottman, J.B., Myers, P., Kassam, N., Weinblatt, M., Loetscher, M., Koch, A.E.,
Moser, B., and Mackay, C.R. (1998) The chemokine receptors CXCR3 and CCR5 mark 
subsets of T cells associated with certain inflammatory reactions. Journal O f Clinical 
Investigation 101, 746-754.
Qiu, W.Q., Debruin, D., Brownstein, B.H., Pearse, R., and Ravetch, J.V. (1990) Organization 
of the human and mouse low-affinity fc-gamma-r genes - duplication and 
recombination. Science 248, 732-735.
Quelle, F.W., Shimoda, K., Thierfelder, W., Fischer, C., Kim, A., Ruben, S.M., Cleveland, J.L., 
Pierce, J.H., Keegan, A.D., Nelms, K., Paul, W.E., and Ihle, J.N. (1995) Cloning of 
murine STAT6 and human ST AT 6, STAT proteins that are tyrosine-phosphorylated in 
responses to IL-4 and IL-3 but are not required for mitogenesis. Molecular And 
Cellular Biology 15, 3336-3343.
Raghavan, M. and Bjorkman, PJ. (1996) Fc receptors and their interactions with
immunoglobulins. Annual Review O f Cell And Developmental Biology 12, 181-220.
Ramadori, G., Sipe, J.D., Dinarello, C.A., Mizel, S.B., and Colten, H.R. (1985) Pretranslational 
modulation of acute phase hepatic protein-synthesis by murine recombinant interleukin- 
1 (IL-1) And purified human IL-1. Journal O f Experimental Medicine 162, 930-942.
Ranges, G.E., Figari, I.S., Espevik, T., and Palladino, M.A. (1987) Inhibition of cytotoxic t-cell 
development by transforming growth- factor-beta and reversal by recombinant tumor- 
necrosis-factor-alpha. Journal O f Experimental Medicine 166, 991-998.
Ranheim, E.A. and Kipps, T.J. (1994) Elevated expression of CD80 (b7/bbl) and other
accessory molecules on synovial-fluid mononuclear cell subsets in rheumatoid-arthritis. 
Arthritis And Rheumatism 37, 1637-1646.
281
Rankin, E.C.C., Choy, E.H.S., Kassimos, D., Kingsley, G.H., Sopwith, A.M., Isenberg, D.A., 
and Panayi, G.S. (1995) The therapeutic effects of an engineered human antitumor 
necrosis factor-alpha antibody (Cdp571) In rheumatoid-arthritis. British Journal O f 
Rheumatology 34, 334-342.
Rao, G.N., Baas, A.S., Glasgow, W.C., Eling, T.E., Runge, M.S., and Alexander, R.W. (1994) 
Activation of mitogen-activated protein-kinases by arachidonic-acid and its metabolites 
in vascular smooth-muscle cells. Journal O f Biological Chemistry 269, 32586-32591.
Reid, C.D.L., Stackpoole, A., Meager, A., and Tikerpae, J. (1992) Interactions of tumor- 
necrosis-factor with granulocyte- macrophage colony-stimulating factor and other 
cytokines in the regulation of dendritic cell-growth in vitro from early bipotent cd34+ 
progenitors in human bone-marrow. Journal O f Immunology 149, 2681-2688.
Remvig, L. and Andersen, B. (1990) Salicylazosulfapyridine (Salazopyrin) Effect on
endotoxin-induced production of interleukin-1-like factor from human monocytes 
invitro. Scandinavian Journal O f Rheumatology 19, 11-16.
Rep, M.H.G., van Oosten, B.W., Roos, M.T.L., Ader, H.J., Polman, C.H., and van Lier, R.A.W.
(1997) Treatment with depleting CD4 monoclonal antibody results in a preferential loss 
of circulating naive T cells but does not affect IFN-gamma secreting Thl cells in 
humans. Journal O f Clinical Investigation 99, 2225-2231.
Rezzonico, R., Burger, D., and Dayer, J.M. (1998) Direct contact between t lymphocytes and 
human dermal fibroblasts or synoviocytes down-regulates types I and III collagen 
production via cell-associated cytokines. Journal O f Biological Chemistry 273, 18720- 
18728.
Rietschel, E.T., Kirikae, T., Schade, F.U., Mamat, U., Schmidt, G., Loppnow, H., Ulmer, A.J., 
Zahringer, U., Seydel, U., Dipadova, F., Schreier, M., and Brade, H. (1994) Bacterial, 
endotoxin - molecular relationships of structure to activity and function. Faseh Journal 
8,217-225.
Rigby, W.F.C., Stacy, T., and Fanger, M.W. (1984) Inhibition of lymphocyte-t mitogenesis by
l,25-dihydroxyvitamin-d-3 (Calcitriol). Journal O f Clinical Investigation 74, 1451- 
1455.
Rigby, W.F.C., Denome, S., and Fanger, M.W. (1987) Regulation of lymphokine production
and human lymphocyte-t activation by l,25-dihydroxyvitamin-d3 - specific-inhibition at 
the level of messenger-RNA. Journal O f Clinical Investigation 79, 1659-1664.
Rincon, M. and Flavell, R.A. (1994) AP-1 transcriptional activity requires both T-cell receptor- 
mediated and costimulatory signals in primary t-lymphocytes. Embo Journal 13, 4370- 
4381.
Rincon, M., Anguita, J., Nakamura, T., Fikrig, E., and Flavell, R.A. (1997) Interleukin (IL)-6 
directs the differentiation of IL-4-producing CD4(+) T cells. Journal O f Experimental 
Medicine 185, 461-469.
282
Rittig, M.G., Krause, A., Haupl, T., Schaible, U.E., Modolell, M., Kramer, M.D., Lutjendrecoll, 
E., Simon, M.M., and Burmester, G.R. (1992) Coiling phagocytosis is the preferential 
phagocytic mechanism for borrelia-burgdorferi. Infection And Immunity 60, 4205-4212.
Rittig, M.G., Haupl, T., and Burmester, G.R. (1994) Coiling phagocytosis - a way for mhc 
class-i presentation of bacterial-antigens. International Archives O f Allergy And 
Immunology 103, 4-10.
Roberts, A.B., Spom, M.B., Assoian, R.K., Smith, J.M., Roche, N.S., Wakefield, L.M., Heine, 
U.I., Liotta, L.A., Falanga, V., Kehrl, J.H., and Fauci, A.S. (1986) Transforming 
growth-factor type-beta - rapid induction of fibrosis and angiogenesis in vivo and 
stimulation of collagen formation in vitro. Proceedings O f The National Academy Of 
Sciences O f The United States O f America 83, 4167-4171.
Rock, F.L., Hardiman, G., Timans, J.C., Kastelein, R.A., and Bazan, J.F. (1998) A family of 
human receptors structurally related to Drosophila Toll. Proceedings O f The National 
Academy O f Sciences O f The United States O f America 95, 588-593.
Rocken, M., Bonomo, A., Levine, A., Shevach, E.M., and Racke, M. (1994) Cytokine therapy 
for a thl-mediated autoimmune-disease. Journal O f Investigative Dermatology 102,
557
Rodenburg, R.J.T., vandenHoogen, F.H.J., Vandeputte, L.B.A., and vanVenrooij, WJ. (1998) 
Peripheral blood monocytes of rheumatoid arthritis patients do not express elevated 
TNF alpha, IL-1 beta, and IL-8 mRNA levels. A comparison of monocyte isolation 
procedures. Journal O f Immunological Methods 221, 169-175.
Roessler, B J . and Davidson, B.L. (1993) Genetic-modification of synoviocytes in vivo using 
recombinant adenoviral vectors. Journal O f Cellular Biochemistry 240
Romagnani, S. (1994) Human Thl and Th2 cells - mechanisms of regulation and role in 
diseases. Aids Research And Human Retroviruses 10, S 70-S 70
Ross, T.K., Darwish, H.M., and Deluca, H.F. (1994) Molecular-biology of vitamin-d action. 
Vitamins And Hormones-Advances In Research And Applications 49, 281-326.
Roth, J., Goebeler, M., Vandenbos, C., and Sorg, C. (1993) Expression of calcium-binding
proteins mrp8 and mrpl4 is associated with distinct monocytic differentiation pathways 
in HL-60 cells. Biochemical And Biophysical Research Communications 191, 565-570.
Rowley, D., Gutteridge, J.M.C., Blake, D., Farr, M., and Halliwell, B. (1984) Lipid-
peroxidation in rheumatoid-arthritis - thiobarbituric acid- reactive material and catalytic 
iron salts in synovial-fluid from rheumatoid patients. Clinical Science 66, 691-695.
Russell, A.S., Johnston, C., Chew, C., and Maksymowych, W.P. (1997) Evidence for reduced 
Thl function in normal pregnancy: A hypothesis for the remission of rheumatoid 
arthritis. Journal Of Rheumatology 24, 1045-1050.
Sakkas, L.I., Johanson, N.A., Scanzello, C.R., and Platsoucas, C.D. (1998) Interleukin-12 is 
expressed by infiltrating macrophages and synovial lining cells in rheumatoid arthritis 
and osteoarthritis. Cellular Immunology 188, 105-110.
283
Sallusto, F. and Lanzavecchia, A. (1994) Efficient presentation of soluble-antigen by cultured 
human dendritic cells is maintained by granulocyte-macrophage colony- stimulating 
factor plus interleukin-4 and down-regulated by tumor- necrosis- factor-alpha. Journal 
O f Experimental Medicine 179, 1109-1118.
Sallusto, F., Lanzavecchia, A., and Mackay, C.R. (1998) Chemokines and chemokine receptors 
in T-cell priming and Thl/Th2- mediated responses. Immunology Today 19, 568-574.
Salmon, M., Scheel-Toellner, D., Huissoon, A.P., Pilling, D., Shamsadeen, N., Hyde, H.,
DAngeac, A.D., Bacon, P.A., Emery, P., and Akbar, A.N. (1997) Inhibition of T cell 
apoptosis in the rheumatoid synovium. J  Clin Invest 99, 439-446.
Sanghera, J.S., Weinstein, S.L., Aluwalia, M., Gim, J., and Pelech, S.L. (1996) Activation of 
multiple proline-directed kinases by bacterial lipopolysaccharide in murine 
macrophages. Journal O f Immunology 156, 4457-4465.
Saxne, T., Palladino, M.A., Heinegard, D., Talal, N., and Wollheim, F.A. (1988) Detection of 
tumor necrosis factor-alpha but not tumor necrosis factor-beta in rheumatoid-arthritis 
synovial-fluid and serum. Arthritis And Rheumatism 31, 1041-1045.
Schafer, P.H., Wang, L.W., Wadsworth, S.A., Davis, J.E., and Siekierka, J.J. (1999) T cell
activation signals up-regulate p38 mitogen-activated protein kinase activity and induce 
TNF-alpha production in a manner distinct from LPS activation of monocytes. Journal 
O f Immunology 162, 659-668.
Schall, T.J., Lewis, M., Koller, K.J., Lee, A., Rice, G.C., Wong, G.H.W., Gatanaga, T.,
Granger, G.A., Lentz, R., Raab, H., Kohr, W.J., and Goeddel, D.V. (1990) Molecular- 
cloning and expression of a receptor for human tumor- necrosis-factor. Cell 61, 361- 
370.
Schattenkirchner, M., Kruger, K., Sander, O., Rau, R., Kroot, E.J., vanRiel, P.L.C.M.,
vandePutte, L., Fenner, H., Kempeni, J., and Kupper, H. (1998) Efficacy and tolerability 
of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in 
patients with rheumatoid arthritis - Results of a phase I study. Arthritis And 
Rheumatism 41, 149
Scheinberg, M.A., Santos, L.M.B., and Finkelstein, A.E. (1982) The effect of auranofin and 
sodium aurothiomalate on peripheral-blood monocytes. Journal O f Rheumatology 9, 
366-369.
Schindler, C. and Darnell, J.E. (1995) Transcriptional responses to polypeptipe ligands - the 
jak-stat pathway. Annual Review O f Biochemistry 64, 621 -651.
Schindler, R., Gelfand, J.A., and Dinarello, C.A. (1990a) Recombinant c5a stimulates
transcription rather than translation of interleukin-1 (IL-1) and tumor-necrosis-factor - 
translational signal provided by lipopolysaccharide or IL-1 itself. Blood 76, 1631-1638.
Schindler, R., Clark, B.D., and Dinarello, C.A. (19906) Dissociation between interleukin-1-beta 
messenger-ma and protein- synthesis in human peripheral-blood mononuclear-cells. 
Journal Of Biological Chemistry 265, 10232-10237.
284
Schindler, R., Mancilla, J., Endres, S., Ghorbani, R., Clark, S.C., and Dinarello, C.A. (1990c) 
Correlations and interactions in the production of interleukin-6 (IL- 6), IL-1, and tumor 
necrosis factor (tnf) in human-blood mononuclear- cells - IL-6 suppresses IL-1 and tnf. 
Blood 75, 40-47.
Schonbeck, U., Mach, F., Bonnefoy, J.Y., Loppnow, H., Flad, H.D., and Libby, P. (1997)
Ligation of CD40 activates interleukin 1 beta-converting enzyme (caspase-1) activity in 
vascular smooth muscle and endothelial cells and promotes elaboration of active 
interleukin 1 beta. Journal Of Biological Chemistry 272, 19569-19574.
Schroder, A.E., Greiner, A., Seyfert, C., and Berek, C. (1996) Differentiation of B cells in the 
nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. 
Proceedings O f The National Academy O f Sciences O f The United States O f America 
93, 221-225.
SchulzeKoops, H., Lipsky, P.E., Kavanaugh, A.F., and Davis, L.S. (1995) Elevated thl- or thO- 
like cytokine messenger-RNA in peripheral- circulation of patients with rheumatoid- 
arthritis - modulation by treatment with anti-ICAM-1 correlates with clinical benefit. 
Journal O f Immunology 155, 5029-5037.
Schumann, R.R., Lamping, N., Hoess, A., Yu, B., Park, T., Kirschning, C., Pfeil, D., Reuter, 
D., Wright, S.D., and Herrmann, F. (1996) Functional characterization of the 
lipopolysaccharide (LPS) binding site of LPS binding protein (LBP) by site-directed 
mutagenesis. British Journal O f Haematology 93, 1172
Schumann, R.R., Belka, C., Reuter, D., Lamping, N., Kirschning, C.J., Weber, J.R., and Pfeil,
D. (1998) Lipopolysaccharide activates caspase-1 (interleukin-1-converting enzyme) in 
cultured monocytic and endothelial cells. Blood 91, 577-584.
Scully, C.J., Anderson, C.J., and Cannon, G.W. (1991) Long-term methotrexate therapy for 
rheumatoid-arthritis. Seminars In Arthritis And Rheumatism 20, 317-331.
Sebbag, M., Parry, S.L., Brennan, F.M., and Feldmann, M. (1997) Cytokine stimulation of T 
lymphocytes regulates their capacity to induce monocyte production of tumor necrosis 
factor-alpha, but not interleukin-10: Possible relevance to pathophysiology of 
rheumatoid arthritis. European Journal O f Immunology 27, 624-632.
Seckinger, P., Isaaz, S., and Dayer, J.M. (1989) Purification and biologic characterization of a 
specific tumor necrosis factor-alpha inhibitor. Journal O f Biological Chemistry 264, 
11966-11973.
Seder, R.A. and Paul, W.E. (1994) Acquisition of lymphokine-producing phenotype by cd4+1- 
cells. Annual Review O f Immunology 12, 635-673.
Segal, R., Yaron, M., and Tartakovsky, B. (1990) Methotrexate - mechanism of action in 
rheumatoid-arthritis. Seminars In Arthritis And Rheumatism 20, 190-199.
Seitz, M. and Hunstein, W. (1985) Enhanced prostanoid release from monocytes of patients 
with rheumatoid-arthritis and active systemic lupus-erythematosus. Annals O f The 
Rheumatic Diseases 44,438-445.
285
Seitz, M., Dewald, B., Ceska, M., Gerber, N., and Baggiolini, M. (1992) Interleukin-8 in
inflammatory rheumatic diseases - synovial-fluid levels, relation to rheumatoid factors, 
production by mononuclear- cells, and effects of gold sodium thiomalate and 
methotrexate. Rheumatology International 12, 159-164.
Seitz, M., Loetscher, P., Dewald, B., Towbin, H., Ceska, M., and Baggiolini, M. (1994)
Production of interleukin-1 receptor antagonist, inflammatory chemotactic proteins, and 
prostaglandin-e by rheumatoid and osteoarthritic synoviocytes - regulation by ifn- 
gamma and IL-4. Journal O f Immunology 152, 2060-2065.
Seitz, M., Loetscher, P., Dewald, B., Towbin, H., Rordorf, C., Gallati, H., Baggiolini, M., and 
Gerber, N.J. (1995) Methotrexate action in rheumatoid-arthritis - stimulation of cytokine 
inhibitor and inhibition of chemokine production by peripheral-blood mononuclear- 
cells. British Journal O f Rheumatology 34, 602-609.
Seitz, M., Loetscher, P., Dewald, B., Towbin, H., Rordorf, C., Gallati, H., and Gerber, N.J.
(1996) Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, 
IL-1 beta, and IL-8 - markers of remission in rheumatoid arthritis during treatment with 
methotrexate. Journal O f Rheumatology 23, 1512-1516.
Sengupta, T.K., Chen, A., Zhong, Z., Darnell, J.E., and Ivashkiv, L.B. (1995) Activation of 
monocyte effector genes and ST AT family transcription factors by inflammatory 
synovial-fluid is independent of interferon- gamma. Journal O f Experimental Medicine 
181, 1015-1025.
Sewell, K.L. and Trentham, D.E. (1993) Pathogenesis of rheumatoid-arthritis. Lancet 341, 
283-286.
Shalom-Barak, T., Quach, J., and Lotz, M. (1998) Interleukin- 17-induced gene expression in
articular chondrocytes is associated with activation of mitogen-activated protein kinases 
andNF-kappa B. Journal O f Biological Chemistry 273, 27467-27473.
Sharkey, N.A. and Blumberg, P.M. (1985) Highly lipophilic phorbol esters as inhibitors of 
specific [H-3] Phorbol 12,13-dibutyrate binding. Cancer Research 45, 19-24.
Shimoda, K., Vandeursen, J., Sangster, M.Y., Sarawar, S.R., Carson, R.T., Tripp, R.A., Chu,
C., Quelle, F.W., Nosaka, T., Vignali, D.A.A., Doherty, P.C., Grosveld, G., Paul, W.E., 
and Ihle, J.N. (1996) Lack of IL-4-induced Th2 response and IgE class switching in 
mice with disrupted stat6 gene. Nature 380, 630-633.
Shingu, M., Fujikawa, Y., Wada, T., Nonaka, S., and Nobunaga, M. (1995) Increased IL-1 
receptor antagonist (IL-lra) production and decreased IL-1-beta/IL-lra ratio in 
mononuclear-cells from rheumatoid-arthritis patients. British Journal O f Rheumatology 
34, 24-30.
Shirakawa, F., Saito, K., Bonagura, C.A., Galson, D.L., Fenton, M.J., Webb, A.C., and Auron, 
P.E. (1993) The human prointerleukin-1-beta gene requires DNA-sequences both 
proximal and distal to the transcription start site for tissue- specific induction.
Molecular And Cellular Biology 13, 1332-1344.
286
Sims, J.E., Acres, R.B., Grubin, C.E., Mcmahan, C.J., Wignall, J.M., March, C.J., and Dower, 
S.K. (1989) Cloning the interleukin-1 receptor from human t-cells. Proceedings O f The 
National Academy Of Sciences O f The United States O f America 86, 8946-8950.
Sims, J.E., Giri, J.G., and Dower, S.K. (1994) 2 Interleukin-1 receptors play different roles in 
IL-1 actions. Clinical Immunology And Immunopathology 72, 9-14.
Sircar, J.C., Schwender, C.F., and Carethers, M.E. (1983) Inhibition of soybean lipoxygenase 
by sulfasalazine and 5- aminosalicylic acid - a possible mode of action in ulcerative- 
colitis. Biochemical Pharmacology 32, 170-172.
Skapenko, A.L., Kalden, J.R., Wendler, J., Davis, L.S., Lipsky, P.E., and SchulzeKoops, H.
(1998) Impaired Th2 cell differentiation in rheumatoid arthritis. Arthritis And 
Rheumatism 41, 1996
Smedegard, G. and Bjork, J. (1995) Sulfasalazine - mechanism of action in rheumatoid- 
arthritis. British Journal O f Rheumatology 34, 7-15.
Smith, M.F., Eidlen, D., Arend, W.P., and Gutierrez-Hartmann, A. (1994) Lps-induced 
expression of the human IL-1 receptor antagonist gene is controlled by multiple 
interacting promoter elements. Journal O f Immunology 153, 3584-3593.
Smith, M.F., Carl, V.S., Lodie, T., and Fenton, M.J. (1998) Secretory interleukin-1 receptor 
antagonist gene expression requires both a pu.l and a novel composite NF-kappa 
B/pu.l/ga- binding protein binding site. Journal O f Biological Chemistry 273, 24272- 
24279.
Smolen, J.S., TohidastAkrad, M., Gal, A., Kunaver, M., Eberl, G., Zenz, P., Falus, A., and 
Steiner, G. (1996) The role of T-lymphocytes and cytokines in rheumatoid arthritis. 
Scandinavian Journal Of Rheumatology 25, 1-4.
So, A.K.L., Peskett, S.A., and Webster, A.D.B. (1984) Hypogammaglobulinemia associated 
with gold therapy. Annals Of The Rheumatic Diseases 43, 581-582.
Socolovsky, M., DusanterFourt, I., and Lodish, H.F. (1997) The prolactin receptor and severely 
truncated erythropoietin receptors support differentiation of erythroid progenitors. 
Journal O f Biological Chemistry 111, 14009-14012.
Socolovsky, M., Lodish, H.F., and Daley, G.Q. (1998) Control of hematopoietic differentiation: 
Lack of specificity in signaling by cytokine receptors. Proceedings O f The National 
Academy O f Sciences O f The United States O f America 95, 6573-6575.
Soden, M., Rooney, M., Whelan, A., Feighery, C., and Bresnihan, B. (1991)
Immunohistological analysis of the synovial-membrane - search for predictors of the 
clinical course in rheumatoid-arthritis. Annals O f The Rheumatic Diseases 50, 673-676.
Spangler, R.S. (1996) Cyclooxygenase 1 and 2 in rheumatic disease: Implications for
nonsteroidal anti-inflammatory drug therapy. Seminars In Arthritis And Rheumatism 
26, 435-446.
287
Sperling, R.I., Benincaso, A.I., Anderson, R.J., Coblyn, J.S., Austen, K.F., and Weinblatt, M.E. 
(1992) Acute and chronic suppression of leukotriene-b4 synthesis exvivo in neutrophils 
from patients with rheumatoid-arthritis beginning treatment with methotrexate.
Arthritis And Rheumatism 35, 376-384.
Staal, F.J.T., Anderson, M.T., Staal, G.E.J., Herzenberg, L.A., and Gitler, C. (1994) Redox 
regulation of signal-transduction - tyrosine phosphorylation and calcium influx. 
Proceedings O f The National Academy O f Sciences O f The United States O f America 
91, 3619-3622.
Steiner, G., Tohidast-Akrad, M., Witzmann, G., Vesely, M., Studnicka-Benke, A., Gal, A.,
Kunaver, M., Zenz, P., and Smolen, J.S. (1999) Cytokine production by synovial T cells 
in rheumatoid arthritis. Rheumatology 38, 202-213.
Stenson, W.F. and Lobos, E. (1982) Sulfasalazine inhibits the synthesis of chemotactic lipids 
by neutrophils. Journal O f Clinical Investigation 69, 494-497.
Steven, M.M., Lafeber, G.J.M., Devries, E., and Cats, A. (1984) Stimulation of synovial tissue 
and peripheral-blood mononuclear- cells by autologous tissue and by pokeweed 
mitogen. British Journal O f Rheumatology 23, 128-129.
Stevens, C.R., Williams, R.B., Farrell, A.J., and Blake, D.R. (1991) Hypoxia and inflammatory 
synovitis - observations and speculation. Annals O f The Rheumatic Diseases 50, 124- 
132.
Stoeck, M., Wamcke, U., Brennecke, M., and Resch, K. (1987) Induction of responsiveness to 
interleukin-2 in mouse lymphocytes by synergistic action of ionophore a-23187 and 
diacylglycerol. Scandinavian Journal O f Immunology 26, 85-89.
Stylianou, E., O’Neill, L.A.J., Rawlinson, L., Edbrooke, M.R., Woo, P., and Saklatvala, J.
(1992) Interleukin-1 induces nf-kappa-b through its type-i but not its type- ii receptor in 
lymphocytes. Journal Of Biological Chemistry 267, 15836-15841.
Su, G.L., Freeswick, P.D., Geller, D.A., Wang, Q., Shapiro, R.A., Wan, Y.H., Billiar, T.R., 
Tweardy, D.J., Simmons, R.L., and Wang, S.C. (1994) Molecular-cloning, 
characterization, and tissue distribution of rat lipopolysaccharide-binding protein - 
evidence for extrahepatic expression. Journal O f Immunology 153, 743-752.
Sun, J.P., Olsson, T., Wang, W.Z., Xiao, B.G., Kostulas, V., Fredrikson, S., Ekre, H.P., and
Link, H. (1991) Autoreactive t-cell and b-cell responding to myelin proteolipid protein 
in multiple-sclerosis and controls. European Journal O f Immunology 21, 1461-1468.
Sutton, B.J. and Gould, H.J. (1993) The human ige network. Nature 366, 421-428.
Suzuki, H., Takemura, H., and Kashiwagi, H. (1995) IL-1 receptor antagonist (IL-1 ra) in 
patients with systemic lupus- erythematosus (sle). Faseb Journal 9, A1029
Swain, S., Croft, M., Haynes, L., and Zhang, X.H. (1994) Generation of thl and th2 memory. 
Faseb Journal 8, A1002-A1002
288
Tacchini, L., Pogliaghi, G., Radice, L., Anzon, E., and Bemellizazzera, A. (1995) Differential 
activation of heat-shock and oxidation-specific stress genes in chemically-induced 
oxidative stress. Biochemical Journal 309, 453-459.
Takada, H. and Kotani, S. (1989) Structural requirements of lipid-a for endotoxicity and other 
biological-activities. Crc Critical Reviews In Microbiology 16, 477-523.
Takeda, K., Tanaka, T., Shi, W., Matsumoto, M., Minami, M., Kashiwamura, S., Nakanishi, K., 
Yoshida, N., Kishimoto, T., and Akira, S. (1996) Essential role of stat6 in IL-4 
signaling. Nature 380, 627-630.
Tanaka, C., Kamata, H., Takeshita, H., Yagisawa, H., and Hirata, H. (1997) Redox regulation 
of lipopolysaccharide (LPS)-induced interleukin-8 (IL-8) gene expression mediated by 
NF kappa B and AP-1 in human astrocytoma U373 cells. Biochemical And Biophysical 
Research Communications 232, 568-573.
Tarkowski, A., Klareskog, L., Carlsten, H., Herberts, P., and Koopman, W.J. (1989) Secretion 
of antibodies to type-i and type-ii collagen by synovial tissue-cells in patients with 
rheumatoid-arthritis. Arthritis And Rheumatism'll, 1087-1092.
Tartaglia, L.A., Weber, R.F., Figari, I.S., Reynolds, C., Palladino, M.A., and Goeddel, D.V. 
(1991) The 2 different receptors for tumor-necrosis-factor mediate distinct cellular- 
responses. Proceedings O f The National Academy O f Sciences O f The United States Of 
America 88, 9292-9296.
Taylor, P.C., Chapman, P., Elliott, M.J., Schaible, T.F., Peters, A.M., Feldmann, M., and Maini, 
R.N. (1997) Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints 
following anti-TNF alpha therapy. Arthritis And Rheumatism 40, 297
Testa, I., Rabini, R.A., Corvetta, A., and Danieli, G. (1987) Decreased Na+, K+-ATPase 
activity in erythrocyte-membrane from rheumatoid-arthritis patients. Scandinavian 
Journal O f Rheumatology 16, 301-305.
Tett, S.E., Cutler, D.J., and Day, R.O. (1990) Hydroxychloroquine concentrations and clinical 
effects in rheumatoid- arthritis patients. European Journal O f Pharmacology 183, 1035
Tetta, C., Camussi, G., Modena, V., Divittorio, C., and Baglioni, C. (1990) Tumor-necrosis- 
factor in serum and synovial-fluid of patients with active and severe rheumatoid- 
arthritis. Annals O f The Rheumatic Diseases 49, 665-667.
Thierfelder, W.E., Vandeursen, J.M., Yamamoto, K., Tripp, R.A., Sarawar, S.R., Carson, R.T., 
Sangster, M.Y., Vignali, D.A.A., Doherty, P.C., Grosveld, G.C., and Ihle, J.N. (1996) 
Requirement for stat4 in interleukin-12-mediated responses of natural-killer and t-cells. 
Nature 382, 171-174.
Thomas, R. and Lipsky, P.E. (1994) Human peripheral-blood dendritic cell subsets - isolation 
and characterization of precursor and mature antigen-presenting cells. Journal Of 
Immunology 153, 4016-4028.
Thomberry, N.A., Bull, H.G., Calaycay, J.R., Chapman, K.T., Howard, A.D., Kostura, M.J., 
Miller, D.K., Molineaux, S.M., Weidner, J.R., Aunins, J., Elliston, K.O., Ayala, J.M.,
289
Casano, F.J., Chin, J., Ding, G.J.F., Egger, L.A., Gaffney, E.P., Limjuco, G., Palyha, 
O.C., Raju, S.M., Rolando, A.M., Salley, J.P., Yamin, T.T., Lee, T.D., Shively, J.E., 
Maccross, M., Mumford, R.A.and Tocci, M.J. (1992) A novel heterodimeric cysteine 
protease is required for interleukin- 1-beta processing in monocytes. Nature 356, 768- 
774.
Thomberry, N.A. (1994) Interleukin-1-beta converting-enzyme. Journal O f Cellular 
Biochemistry 122
Tiedemann, R.E. and Fraser, J.D. (1996) Cross-linking of MHC class II molecules by 
Staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell 
activation. Journal O f Immunology 157, 3958-3966.
Tivol, E.A., Boyd, S.D., McKeon, S., Borriello, F., Nickerson, P., Strom, T.B., and Sharpe,
A.H. (1997) CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue 
destruction in CTLA-4-deficient mice. Journal O f Immunology 158, 5091-5094.
Toker, A., Meyer, M., Reddy, K.K., Falck, J.R., Aneja, R., Aneja, S., Parra, A., Bums, D J., 
Balias, L.M., and Cantley, L.C. (1994) Activation of protein-kinase-c family members 
by the novel polyphosphoinositides ptdins-3,4-p-2 and ptdins-3,4,5-p-3. Journal Of 
Biological Chemistry 269, 32358-32367.
Torigoe, K., Ushio, S., Okura, T., Kobayashi, S., Taniai, M., Kunikata, T., Murakami, T.,
Sanou, O., Kojima, H., Fujii, M., Ohta, T., Ikeda, M., Ikegami, H., and Kurimoto, M. 
(1997) Purification and characterization of the human interleukin-18 receptor. Journal 
Of Biological Chemistry 212, 25737-25742.
Tomhamre, S., Edenius, C., Smedegard, G., Sjoquist, B., and Lindgren, J.A. (1989) Effects of 
sulfasalazine and a sulfasalazine analog on the formation of lipoxygenase and 
cyclooxygenase products. European Journal O f Pharmacology 169, 225-234.
Torsteinsdottir, I., Arvidson, N.G., Hallgren, R., and Hakansson, L. (1999) Monocyte activation 
in rheumatoid arthritis (RA): increased integrin, Fc gamma and complement receptor 
expression and the effect of glucocorticoids. Clinical And Experimental Immunology 
115, 554-560.
Truneh, A., Albert, F., Golstein, P., and Schmittverhulst, A.M. (1985) Calcium ionophore plus 
phorbol ester can substitute for antigen in the induction of cytolytic lymphocytes-t from 
specifically primed precursors. Journal O f Immunology 135, 2262-2267.
Tseng, Y.H. and Schuler, L.A. (1998) Transcriptional regulation of interleukin-1 beta gene by 
interleukin- 1 beta itself is mediated in part by oct-1 in thymic stromal cells. Journal Of 
Biological Chemistry 273, 12633-12641.
Tsitsikov, E.N., Fuleihan, R., Mcintosh, K., Scholl, P.R., and Geha, R.S. (1995) Cross-linking 
of Fc-gamma receptors activates hiv-1 long terminal repeat-driven transcription in 
human monocytes. International Immunology 7, 1665-1670.
Tsukada, J., Saito, K., Waterman, W.R., Webb, A.C., and Auron, P.E. (1994) Transcription
factors NF-IL6 and creb recognize a common essential site in the human prointerleukin 
1-beta gene. Molecular And Cellular Biology 14, 7285-7297.
290
Tsukada, J., Waterman, W.R., Koyama, Y., Misago, M., Eto, S., Webb, A.C., and Auron, P.E. 
(1996a) Lps, IL-1 and IL-6 signaling is mediated by a novel stat-like factor which 
recognizes a gas-like element in the human proIL-1 beta gene. Experimental 
Hematology 24, 482-482.
Tsukada, J., Waterman, W.R., Koyama, Y., Webb, A.C., and Auron, P.E. (19966) A novel stat- 
like factor mediates lipopolysaccharide, interleukin 1 (IL-1), and IL-6 signaling and 
recognizes a gamma interferon activation site-like element in the ILlb gene. Molecular 
And Cellular Biology 16, 2183-2194.
Ulevitch, R.J. and Tobias, P.S. (1994) Recognition of endotoxin by cells leading to 
transmembrane signaling. Current Opinion In Immunology 6, 125-130.
Ushio, S., Namba, M., Okura, T., Hattori, K., Nukada, Y., Akita, K., Tanabe, F., Konishi, K., 
Micallef, M., Fujii, M., Torigoe, K., Tanimoto, T., Fukuda, S., Ikeda, M., Okamura, H., 
and Kurimoto, M. (1996) Cloning of the cDNA for human IFN-gamma-lnducing factor, 
expression in Escherichia coli, and studies on the biologic activities of the protein. 
Journal O f Immunology 156, 4274-4279.
Van de Loo, F.A.J., Joosten, L.A.B., Vanlent, P.L.E.M., Amtz, O.J., and Vandenberg, W.B.
(1995) Role of interleukin-1, tumor-necrosis-factor-alpha, and interleukin-6 in cartilage 
proteoglycan metabolism and destruction - effect of in- situ blocking in murine antigen- 
induced and zymosan-induced arthritis. Arthritis And Rheumatism 38, 164-172.
Van de Putte, L.B.A., van Riel, P.L.C.M., den Broeder, A., Sander, O., Rau, R., Binder, C.,
Kruger, K., Schattenkircher, M., Fenner, H., Salfeld, J., Bankmann, Y., Kupper, H., and 
Kempeni, J. (1998) A single dose placebo controlled phase 1 study of the fully human 
anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis And 
Rheumatism 41, 148
Van der Graaff, W.L., Prins, A.P.A., Dijkmans, B.A.C., and vanLier, R.A.W. (1998) Prognostic 
value of the Thl/Th2 ratio in rheumatoid arthritis. Arthritis And Rheumatism 41, 5-5.
Van der Graaff, W.L., Prins, A.P.A., Niers, T.M.H., Dijkmans, B.A.C., and van Lier, R.A.W.
(1999) Quantitation of interferon gamma- and interleukin-4-producing T cells in 
synovial fluid and peripheral blood of arthritis patients. Rheumatology 38, 214-220.
Van de Winkel, J.GJ. and Anderson, C.L. (1991) Biology of human immunoglobulin-G Fc- 
receptors. Journal O f Leukocyte Biology 49, 511-524.
Vane, J.R., Mitchell, J.A., Appleton, I., Tomlinson, A., Bishopbailey, D., Croxtall, J., and 
Willoughby, D.A. (1994) Inducible isoforms of cyclooxygenase and nitric-oxide 
synthase in inflammation. Proceedings O f The National Academy O f Sciences O f The 
United States O f America 91, 2046-2050.
Vane, J.R., Bakhle, Y.S., and Botting, R.M. (1998) Cyclooxygenases 1 and 2. Annual Review 
O f Pharmacology And Toxicology 38, 97-120.
Van Roon, J.A.G., Vanroy, J.L.A.M., Duits, A., Lafeber, F.P.J.G., and Bijlsma, J.W. (1995)
Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial
291
t-helper-1 activation is inhibited by interleukin-4. Annals O f The Rheumatic Diseases 
54, 836-840.
Van Roon, J.A.G., Verhoef, C.M., Vanroy, J.L.A.M., GmeligMeyling, F.H.J., HuberBruning,
O., Lafeber, F.P.J.G., and Bijlsma, J.W.J. (1997) Decrease in peripheral type 1 over type 
2 T cell cytokine production in patients with rheumatoid arthritis correlates with an 
increase in severity of disease. Annals O f The Rheumatic Diseases 56, 656-660.
Vasselon, T., Pironkova, R., and Detmers, P. A. (1997) Sensitive responses of leukocytes to
lipopolysaccharide require a protein distinct from cdl4 at the cell surface. Journal Of 
Immunology 159, 4498-4505.
Veale, D.J., Kirk, G., Mclaren, M., and Belch, J.J.F. (1993) Elevation of circulating soluble 
icam-1 in response to venous occlusion in patients with systemic-sclerosis and their 
relatives. Arthritis And Rheumatism 36, S271
Veale, D.J., Reece, R.J., Parsons, W., Radjenovic, A., OConnor, P.J., Orgies, C.S., Berry, E., 
Ridgway, J.P., Mason, U., Boylston, A.W., Gibbon, W., and Emery, P. (1999) Intra- 
articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of 
combined arthroscopy, magnetic resonance imaging, and histology. Annals O f The 
Rheumatic Diseases 58, 342-349.
Verheijden, G.F.M., Rijnders, A.W.M., Bos, E., Deroo, C.J.J.C., vanStaveren, C.J., Miltenburg, 
A.M.M., Meijerink, J.H., Elewaut, D., DeKeyser, F., Veys, E., and Boots, A.M.H.
(1997) Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid 
arthritis. Arthritis And Rheumatism 40, 1115-1125.
Verwilghen, J., Vertessen, S., Stevens, E.A.M., Dequeker, J., and Ceuppens, J.L. (1990) 
Depressed T-cell reactivity to recall antigens in rheumatoid- arthritis. Journal Of 
Clinical Immunology 10, 90-98.
Vey, E., Zhang, J.H., and Dayer, J.M. (1992) EFN-gamma and l,25(oh)2d3 induce on THP-1 
cells distinct patterns of cell-surface antigen expression, cytokine production, and 
responsiveness to contact with activated t-cells. Journal O f Immunology 149, 2040- 
2046.
Vey, E., Dayer, J.M., and Burger, D. (1997) Direct contact with stimulated t cells induces the 
expression of IL-1 beta and IL-1 receptor antagonist in human monocytes, involvement 
of serine/threonine phosphatases in differential regulation. Cytokine 9, 480-487.
Vilcek, J. and Lee, T.H. (1991) Tumor-necrosis-factor - new insights into the molecular
mechanisms of its multiple actions. Journal O f Biological Chemistry 266, 7313-7316.
Vincenti, M.P., Coon, C.I., Lee, O., and Brinckerhoff, C.E. (1994) Regulation of collagenase 
gene-expression by IL-1-beta requires transcriptional and posttranscriptional 
mechanisms. Nucleic Acids Research 22, 4818-4827.
Von Boehmer, H. (1995) Control of T-cell development by the Pre-T and alpha beta T-cell. 
Annals O f The New York Academy O f Sciences 166, 52-61.
292
Vreugdenhil, A.C.E., Dentener, M.A., Snoek, A.M.P., Greve, and Buurman, W.A.
(1999) Lipopolysaccharide binding protein and serum amyloid a secretion by human 
intestinal epithelial cells during the acute phase response. Journal O f Immunology 163, 
2792-2798.
Wagner, D.H., Stout, R.D., and Suttles, J. (1994) Role of the CD40-CD40 ligand interaction in 
CD4(+) T-cell contact- dependent activation of monocyte interleukin-1 synthesis. 
European Journal O f Immunology 24, 3148-3154.
Wahl, C., Liptay, S., Adler, G., and Schmid, R.M. (1998) Sulfasalazine: a potent and specific 
inhibitor of nuclear factor kappa B. J  Clin Invest 101, 1163-1174.
Wakabayashi, G., Gelfand, J.A., Jung, W.K., Connolly, R.J., Burke, J.F., and Dinarello, C.A.
(1991) Staphylococcus-epidermidis induces complement activation, tumor- necrosis- 
factor and interleukin-1, a shock-like state and tissue- injury in rabbits without 
endotoxemia - comparison to escherichia- coli. Journal O f Clinical Investigation 87, 
1925-1935.
Walev, I., Reske, K., Palmer, M., Valeva, A., and Bhakdi, S. (1995) Potassium-inhibited 
processing of EL-l-beta in human monocytes. Embo Journal 14, 1607-1614.
Wang, P.Y., Kitchens, R.L., and Munford, R.S. (1998) Phosphatidylinositides bind to plasma 
membrane cdl4 and can prevent monocyte activation by bacterial lipopolysaccharide. 
Journal O f Biological Chemistry 273, 24309-24313.
Waterhouse, P., Penninger, J.M., Timms, E., Wakeham, A., Shahinian, A., Lee, K.P.,
Thompson, C.B., Griesser, H., and Mak, T.W. (1995) Lymphoproliferative disorders 
with early lethality in mice deficient in ctla-4. Science 270, 985-988.
Watrous, D.A. and Andrews, B.S. (1989) The metabolism and immunology of bone. Seminars 
In Arthritis And Rheumatism 19, 45-65.
Weaver, C.T. and Unanue, E.R. (1986) T-cell induction of membrane-IL-1 on macrophages. 
Journal O f Immunology 137, 3868-3873.
Weaver, C.T., Duncan, L.M., and Unanue, E.R. (1989) T-cell induction of macrophage IL-1
during antigen presentation - characterization of a lymphokine mediator and comparison 
of thl and th2 subsets. Journal O f Immunology 142, 3469-3476.
Weinblatt, M.E., Weissman, B.N., Holdsworth, D.E., Fraser, P.A., Maier, A.L., Falchuk, K.R., 
and Coblyn, J.S. (1992) Long-term prospective-study of methotrexate in the treatment 
of rheumatoid-arthritis - 84-month update. Arthritis And Rheumatism 35, 129-137.
Weinstein, S.L., Sanghera, J.S., Lemke, K., DeFranco, A.L., and Pelech, S.L. (1992) Bacterial 
lipopolysaccharide induces tyrosine phosphorylation and activation of mitogen- 
activated protein-kinases in macrophages. Journal O f Biological Chemistry 267, 
14955-14962.
Weinstein, S.L., June, C.H., and DeFranco, A.L. (1993) Lipopolysaccharide-inducedprotein- 
tyrosine phosphorylation in human macrophages is mediated by cdl4. Journal Of 
Immunology 151, 3829-3838.
293
Weiss, M.J., Daley, J.F., Hodgdon, J.C., and Reinherz, E.L. (1984) Calcium dependency of 
antigen-specific (T3-ti) And alternative (Til) Pathways of human t-cell activation. 
Proceedings O f The National Academy O f Sciences O f The United States O f America- 
Biological Sciences 81, 6836-6840.
Weng, Q.P., Andrabi, K., Klippel, A., Kozlowski, M.T., Williams, L.T., and Avruch, J. (1995) 
Phosphatidylinositol 3-kinase signals activation of p70 s6 kinase in- situ through site- 
specific p70 phosphorylation. Proceedings O f The National Academy O f Sciences O f 
The United States O f America 92, 5744-5748.
Wenger, M.E., Alexander, S., Bland, J.H., and Blechman, W.J. (1983) Auranofin versus
placebo in the treatment of rheumatoid-arthritis. American Journal O f Medicine 75, 
123-127.
Wesche, H., Korherr, C., Kracht, M., Falk, W., Resch, K., and Martin, M.U. (1997a) The 
interleukin-1 receptor accessory protein (IL-lracp) is essential for IL-1-induced 
activation of interleukin-1 receptor- associated kinase (irak) and stress-activated protein 
kinases (sap kinases). Journal O f Biological Chemistry 272, 7727-7731.
Wesche, H., Henzel, W.J., Shillinglaw, W., Li, S., and Cao, Z.D. (19976) MyD88: An adapter 
that recruits IRAK to the IL-1 receptor complex. Immunity 7, 837-847.
Westacott, C.I., Whicher, J.T., Barnes, I.C., Thompson, D., Swan, A.J., and Dieppe, P.A.
(1990) Synovial-fluid concentration of 5 different cytokines in rheumatic diseases. 
Annals O f The Rheumatic Diseases 49, 676-681.
Whisler, R.L., Goyette, M.A., Grants, I.S., andNewhouse, Y.G. (1995) Sublethal levels of 
oxidant stress stimulate multiple serine threonine kinases and suppress protein 
phosphatases in Jurkat T-cells. Archives O f Biochemistry And Biophysics 319, 23-35.
William, R., Watson, G., Rotstein, O.D., Parodo, J., Bitar, R., and Marshall, J.C. (1998) The IL- 
1 beta-converting enzyme (caspase-1) inhibits apoptosis of inflammatory neutrophils 
through activation of IL-1 beta. Journal O f Immunology 161, 957-962.
Wilson, L., Butcher, C.J., and Kellie, S. (1993) Calcium ionophore A23187 induces interleukin- 
8 gene-expression and protein secretion in human monocytic cells. Febs Letters 325, 
295-298.
Woods, J.M., Haines, G.K., Shah, M.R., and Koch, A.E. (1996) Interleukin-13 in synovial fluid 
and tissue of patients with rheumatoid arthritis. Arthritis And Rheumatism 39, 611
Wooten, R.M., Morrison, T.B., Weis, J.H., Wright, S.D., Thieringer, R., and Weis, J.J. (1998) 
The role of CD 14 in signaling mediated by outer membrane lipoproteins of borrelia 
burgdorferi. Journal O f Immunology 160, 5485-5492.
Wright, J.K., Cawston, T.E., and Hazleman, B.L. (1991) Transforming growth-factor-beta
stimulates the production of the tissue inhibitor of metalloproteinases (timp) by human 
synovial and skin fibroblasts. Biochimica Et Biophysica Acta 1094, 207-210.
294
Wright, S.D., Ramos, R.A., Tobias, P.S., Ulevitch, R.J., and Mathison, J.C. (1990) CD14, a 
receptor for complexes of lipopolysaccharide (Lps) And lps binding-protein. Science 
249, 1431-1433.
Wurfel, M.M., Lichenstein, H., and Wright, S.D. (1994) Binding and neutralization of 
lipopolysaccharide by lipoproteins is blocked by soluble CD 14 and LBP. Faseb 
Journal 8, A316
Xu, W.D., Firestein, G.S., Taetle, R., Kaushansky, K., and Zvaifler, N.J. (1989) Cytokines in 
chronic inflammatory arthritis .2. granulocyte- macrophage colony-stimulating factor in 
rheumatoid synovial effusions. Journal O f Clinical Investigation 83, 876-882.
Yamagata, N., Kobayashi, K., Kasama, T., Fukushima, T., Tabata, M., Yoneya, I., Shikama, Y., 
Kaga, S., Hashimoto, M., Yoshida, K., Sekine, F., Negishi, M., Ide, H., Mori, Y., and 
Takahashi, T. (1988) Multiple cytokine activities and loss of interleukin-2 inhibitor in 
synovial-fluids of patients with rheumatoid-arthritis. Journal O f Rheumatology 15, 
1623-1627.
Yamamoto, K., Quelle, F.W., Thierfelder, W.E., Kreider, B.L., Gilbert, D.J., Jenkins, N.A., 
Copeland, N.G., Silvennoinen, O., and Ihle, J.N. (1994) STAT4, a novel gamma- 
interferon activation site-binding protein expressed in early myeloid differentiation. 
Molecular And Cellular Biology 14, 4342-4349.
Yamin, T.T., Ayala, J.M., and Miller, D.K. (1996) Activation of the native 45-kDa precursor 
form of interleukin-1- converting enzyme. Journal O f Biological Chemistry 271, 
13273-13282.
Yamin, T.T. and Miller, D.K. (1997) The interleukin-1 receptor-associated kinase is degraded 
by proteasomes following its phosphorylation. Journal O f Biological Chemistry 272 , 
21540-21547.
Yao, Z.B., Painter, S.L., Fanslow, W.C., Ulrich, D., Macduff, B.M., Spriggs, M.K., and
Armitage, R.J. (1995) Human IL-17 - a novel cytokine derived from T-cells. Journal 
O f Immunology 155, 5483-5486.
Ye, K., Dinarello, C.A., and Clark, B.D. (1993) Identification of the promoter region of human 
interleukin-1 type-I receptor gene - multiple initiation sites, high G+C content, and 
constitutive expression. Proceedings O f The National Academy O f Sciences O f The 
United States O f America 90, 2295-2299.
Yin, Z.H., Braun, J., Neure, L., Wu, P.H., Liu, L.Z., Eggens, U., and Sieper, J. (1997) Crucial 
role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper 
cytokine response in reactive arthritis. Arthritis And Rheumatism 40, 1788-1797.
Yokoyama, C. and Tanabe, T. (1989) Cloning of human-gene encoding prostaglandin 
endoperoxide synthase and primary structure of the enzyme. Biochemical And 
Biophysical Research Communications 165, 888-894.
Yu, C.R., Kirken, R.A., Malabarba, M.G., Young, H.A., and Ortaldo, J.R. (1998) Differential 
regulation of the j anus kinase stat pathway and biologic function of IL-13 in primary
295
human NK acid T cells: a comparative study with IL-4. Journal O f Immunology 161 , 
218-227.
Zhang, F.X., Kirschning, C,J., Mancinelli, R., Xu, X.P., Jin, Y.P., Faure, E., Mantovani, A., 
Rothe, M., Muzio, M., and Arditi, M. (1999) Bacterial lipopolysaccharide activates 
nuclear factor-kappa B through interleukin-1 signaling mediators in cultured human 
dermal endothelial cells and mononuclear phagocytes. Journal O f Biological Chemistry 
274, 7611-7614.
Zhong, Z., Wen, Z.L., and Darnell, J.E. (1994a) STAT 3 - a STAT family member activated by 
tyrosine phosphorylation in response to epidermal growth-factor and interleukin-6. 
Science 264, 95-98.
Zhong, Z., Wen, Z.L., and Darnell, J.E. (19946) STAT3 and STAT 4 - members of the family 
of signal transducers and activators of transcription. Proceedings O f The National 
Academy O f Sciences O f The United States O f America 91, 4806-4810.
Ziff, M. (1991) Role of the endothelium in chronic inflammatory synovitis. Arthritis And 
Rheumatism 34, 1345-1352.
Zubiaga, A.M., Munoz, E., and Huber, B.T. (1991) Production of IL-1-alpha by activated Th
type-2 cells - its role as an autocrine growth-factor. Journal O f Immunology 146, 3849- 
3856.
Zuniga-Pflucker, J.C., Jiang, D., and Lenardo, M.J. (1995) Requirement for TNF-alpha and IL- 
1-alpha in fetal thymocyte commitment and differentiation. Science 268, 1906-1909.
296
